SS.SR-(D3Arb14-D3Mco36)(D7Mco19-D7Mco7)/Mco |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 28 days) then controlled sodium content diet (4 %) (between 46 and 48 days) |
Cicila GT, et al., Hypertension. 2009 Apr;53(4):725-32. Epub 2009 Mar 2. |
body mass |
male |
114 days-118 days |
6 |
|
|
384.2 |
g |
7.3 |
17.88 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65098 |
283 |
SS/Jr |
body weight |
controlled sodium content diet (4 %) (for 28 days) |
Garrett MR, et al., Physiol Genomics 2000 Jun 29;3(1):33-8. |
body mass |
male |
53 days-81 days |
10 |
|
|
344.0 |
g |
5.1 |
16.13 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
66109 |
691 |
F344/NSlc |
body weight |
fasting (between 16 and 18 hours) |
Kose H, et al., Exp Anim. 2008 Apr;57(2):135-8. |
body mass |
male |
210 days
| 9 |
|
|
387.4 |
g |
10.3 |
30.9 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
66178 |
716 |
SS.LEW-(D5Mit9-D5Mco10)/Jr |
body weight |
controlled sodium content diet (2 %) (between 24 and 27 days) |
Garrett MR, et al., Genome Res 1998 Jul;8(7):711-23 |
body mass |
not specified |
64 days-71 days |
40 |
|
|
282.0 |
g |
1.8 |
11.38 |
body weighing method |
0 |
|
0 |
|
|
|
|
4 rats per cage, 2 SR/Jr 2 LEW/NCrl |
64717 |
222 |
SS/JrSeac |
body weight |
controlled sodium content diet (0.3 %) (for 35 days) |
Fukushima K, et al., Nucl Med Biol. 2010 Nov;37(8):1005-12. Epub 2010 Sep 1. |
body mass |
not specified |
77 days
| 5 |
|
|
247.0 |
g |
7.6 |
17.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67253 |
733 |
SHRSP/Izm |
body weight |
control condition |
Yao H, et al., Physiol Genomics. 2007 Feb 27;. |
body mass |
male |
150 days
| 17 |
|
|
315.0 |
g |
7.28 |
30.0 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65509 |
567 |
BN.GK-(D8Got302-D8Got130)/Ox |
body weight |
control condition |
Wallis RH, et al., Diabetologia 2004 Jun;47(6):1096-106. Epub 2004 May 26 |
body mass |
male |
168 days
| 12 |
|
|
345.0 |
g |
11.0 |
38.11 |
body weighing method |
|
|
0 |
|
|
|
|
|
11294 |
66 |
F344.GK-(D1Mgh10-D1Rat119)/Swe |
body weight |
control condition (for 65 days) |
Galli J, et al., Diabetes 1999 Dec;48(12):2463-70. |
body mass |
male |
65 days
| 11 |
|
|
228.0 |
g |
4.0 |
13.27 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
11466 |
85 |
GH/Omr |
body weight |
angiotensin II (5-50 ng/kg/min) (between 0.2 and 1 hours) then norepinephrine (0.1-1 ug/kg/min) (between 0.2 and 1 hours) then phenylephrine (4 ug/kg) (between 0 and 0 hours) |
Bilusic M, et al., Croat Med J. 2008 Oct;49(5):586-99. |
body mass |
male |
132 days-146 days |
21 |
|
|
365.4 |
g |
3.71 |
17.0 |
body weighing method |
|
|
0 |
|
|
|
|
|
11527 |
101 |
LEW/CrlCrlj |
body weight |
control condition |
Tsujita Y, et al., Am J Physiol Heart Circ Physiol 2000 Nov;279(5):H2062-7 |
body mass |
male |
168 days
| 5 |
|
|
417.0 |
g |
8.5 |
19.0 |
body weighing method |
|
|
0 |
|
|
|
|
|
11578 |
103 |
WKY/NHsd |
body weight |
fasting (for 16 hours) |
Solberg Woods LC, et al., Mamm Genome. 2009 Aug 22 |
body mass |
male |
119 days
| 10 |
|
|
352.0 |
g |
4.5 |
14.23 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
11608 |
107 |
F344/NSlc |
body weight |
specific pathogen-free condition then fasting (for 16 hours) |
Fuse M, et al., Physiol Genomics. 2008 Jul 8;. |
body mass |
male |
420 days
| 7 |
|
|
470.3 |
g |
9.59 |
25.37 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
11607 |
106 |
F344/NHsd |
body weight |
fasting (for 16 hours) |
Solberg Woods LC, et al., Mamm Genome. 2009 Aug 22 |
body mass |
female |
119 days
| 10 |
|
|
221.0 |
g |
3.8 |
12.02 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
11611 |
107 |
SS/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 24 and 27 days) |
Cicila GT, et al., Genomics 2001 Feb 15;72(1):51-60. |
body mass |
male |
68 days-70 days |
20 |
|
|
298.2 |
g |
4.2 |
18.78 |
body weighing method |
|
|
0 |
|
|
|
|
|
11799 |
147 |
SS/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 24 and 27 days) |
Cicila GT, et al., Genomics 2001 Feb 15;72(1):51-60. |
body mass |
male |
68 days-70 days |
20 |
|
|
289.8 |
g |
3.2 |
14.31 |
body weighing method |
|
|
0 |
|
|
|
|
|
11817 |
147 |
SS.SR-(D7Rat16-D7Rat189)/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 24 and 27 days) |
Cicila GT, et al., Genomics 2001 Feb 15;72(1):51-60. |
body mass |
male |
68 days-70 days |
20 |
|
|
296.3 |
g |
3.0 |
13.42 |
body weighing method |
|
|
0 |
|
|
|
|
|
11806 |
147 |
SDT/Jcl |
body weight |
specific pathogen-free condition then fasting (for 16 hours) |
Fuse M, et al., Physiol Genomics. 2008 Jul 8;. |
body mass |
male |
420 days
| 5 |
|
|
334.2 |
g |
7.6 |
16.99 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
11605 |
106 |
SS/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 24 days) |
Saad Y, et al., Hypertension. 2007 |
body mass |
male |
64 days-66 days |
0 |
|
|
310.0 |
g |
2.38 |
|
body weighing method |
|
|
0 |
|
|
|
|
|
11976 |
205 |
SS.LEW-(D10Mco113-D10Got93)/Mco |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 24 days) |
Saad Y, et al., Hypertension. 2007 |
body mass |
male |
64 days-66 days |
0 |
|
|
337.0 |
g |
2.09 |
|
body weighing method |
|
|
0 |
|
|
|
|
|
11977 |
205 |
SS.LEW-(D10Mco84-D10Mco143)/Mco |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 24 days) |
Saad Y, et al., Hypertension. 2007 |
body mass |
male |
64 days-66 days |
0 |
|
|
335.0 |
g |
3.0 |
|
body weighing method |
|
|
0 |
|
|
|
|
|
11979 |
205 |
SS.LEW-(D10Mco84-D10Rat58)/Mco |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 24 days) |
Saad Y, et al., Hypertension. 2007 |
body mass |
male |
64 days-66 days |
0 |
|
|
311.0 |
g |
4.21 |
|
body weighing method |
|
|
0 |
|
|
|
|
|
11980 |
205 |
SS.LEW-(D10Mco84-D10Mco129)/Mco |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 24 days) |
Saad Y, et al., Hypertension. 2007 |
body mass |
male |
64 days-66 days |
0 |
|
|
308.0 |
g |
5.3 |
|
body weighing method |
|
|
0 |
|
|
|
|
|
11981 |
205 |
F344.OLETF-(D7Mgh16-D7Mgh20)/Tj |
body weight |
fasting (for 16 hours) |
Kose H, et al., Mamm Genome 2002 Oct;13(10):558-62. |
body mass |
male |
210 days
| 16 |
|
|
366.8 |
g |
4.2 |
16.8 |
body weighing method |
|
|
0 |
|
|
|
|
|
11985 |
230 |
F344.OLETF-(D8Rat54-D8Mgh17)/2Tj |
body weight |
fasting (for 16 hours) |
Kose H, et al., Mamm Genome 2002 Oct;13(10):558-62. |
body mass |
male |
210 days
| 19 |
|
|
398.6 |
g |
4.9 |
21.36 |
body weighing method |
|
|
0 |
|
|
|
|
|
11997 |
230 |
F344.OLETF-(D11Mgh4-D11Mgh1)/2Tj |
body weight |
fasting (for 16 hours) |
Kose H, et al., Mamm Genome 2002 Oct;13(10):558-62. |
body mass |
male |
210 days
| 13 |
|
|
411.2 |
g |
4.2 |
15.14 |
body weighing method |
|
|
0 |
|
|
|
|
|
12000 |
230 |
SS.LEW-(D3Got33-D3Chm68)/Ayd |
body weight |
controlled sodium content diet (2 %) (between 35 and 98 days) |
Duong C, et al., Mamm Genome 2006; 17(12): 1147-1161 |
body mass |
male |
98 days
| 10 |
|
|
389.0 |
g |
6.0 |
18.97 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12042 |
226 |
F344.OLETF-(D9Mgh8-D9Mit2)/2Tj |
body weight |
fasting (for 16 hours) |
Kose H, et al., Mamm Genome 2002 Oct;13(10):558-62. |
body mass |
male |
210 days
| 8 |
|
|
365.5 |
g |
7.0 |
19.8 |
body weighing method |
|
|
0 |
|
|
|
|
|
12052 |
230 |
SS.LEW-(D10Chm10-D10Rat11)/Ayd |
body weight |
controlled sodium content diet (2 %) (between 35 and 98 days) |
Duong C, et al., Mamm Genome 2006; 17(12): 1147-1161 |
body mass |
male |
98 days
| 7 |
|
|
375.0 |
g |
5.0 |
13.23 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12061 |
226 |
SS.LEW-(D10Rat27-Igfbp4)/Ayd |
body weight |
controlled sodium content diet (2 %) (between 35 and 98 days) |
Duong C, et al., Mamm Genome 2006; 17(12): 1147-1161 |
body mass |
male |
98 days
| 7 |
|
|
388.0 |
g |
6.0 |
15.87 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12058 |
226 |
SS.LEW-(D10Chm128-D10Chm169)/Ayd |
body weight |
controlled sodium content diet (2 %) (between 35 and 98 days) |
Duong C, et al., Mamm Genome 2006; 17(12): 1147-1161 |
body mass |
male |
98 days
| 8 |
|
|
369.0 |
g |
6.0 |
16.97 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12063 |
226 |
SS.LEW-(D17Chm14-D17Rat181)/Ayd |
body weight |
controlled sodium content diet (2 %) (between 35 and 98 days) |
Duong C, et al., Mamm Genome 2006; 17(12): 1147-1161 |
body mass |
male |
98 days
| 5 |
|
|
377.0 |
g |
9.0 |
20.12 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12069 |
226 |
SS.LEW-(D18Chm41-D18Rat92)/Ayd |
body weight |
controlled sodium content diet (2 %) (between 35 and 98 days) |
Duong C, et al., Mamm Genome 2006; 17(12): 1147-1161 |
body mass |
male |
98 days
| 5 |
|
|
386.0 |
g |
5.0 |
11.18 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12076 |
226 |
SS.LEW-(D18Chm91-D18Rat67)/Ayd |
body weight |
controlled sodium content diet (2 %) (between 35 and 98 days) |
Duong C, et al., Mamm Genome 2006; 17(12): 1147-1161 |
body mass |
male |
98 days
| 5 |
|
|
389.0 |
g |
8.0 |
17.89 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12077 |
226 |
F344.OLETF-(D14Rat8-D14Rat26)/Tj |
body weight |
fasting (for 16 hours) |
Kose H, et al., Mamm Genome 2002 Oct;13(10):558-62. |
body mass |
male |
210 days
| 14 |
|
|
392.2 |
g |
5.2 |
19.46 |
body weighing method |
|
|
0 |
|
|
|
|
|
12074 |
230 |
SS.LEW-(D10Chm224-D10Chm6)/Ayd |
body weight |
controlled sodium content diet (2 %) (between 35 and 98 days) |
Duong C, et al., Mamm Genome 2006; 17(12): 1147-1161 |
body mass |
male |
98 days
| 11 |
|
|
382.0 |
g |
6.0 |
19.9 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12082 |
226 |
SR/Jr |
body weight |
controlled sodium content diet (0.2 %) (for 56 days) |
Garrett MR, et al., Genome Res 1998 Jul;8(7):711-23 |
body mass |
male |
91 days
| 10 |
|
|
313.0 |
g |
4.8 |
15.18 |
body weighing method |
0 |
|
0 |
|
|
|
|
4 rats per cage, 2 SR/Jr 2 LEW/NCrl |
12181 |
222 |
SR/Jr |
body weight |
controlled sodium content diet (0.2 %) (for 5 days) then controlled sodium content diet (8 %) (for 168 days) |
Garrett MR, et al., Genome Res 1998 Jul;8(7):711-23 |
body mass |
male |
203 days
| 10 |
|
|
407.0 |
g |
5.7 |
18.02 |
body weighing method |
0 |
|
0 |
|
|
|
|
4 rats per cage, 2 SR/Jr 2 LEW/NCrl |
12189 |
222 |
LEW/NCrl |
body weight |
controlled sodium content diet (0.2 %) (for 5 days) then controlled sodium content diet (8 %) (for 112 days) |
Garrett MR, et al., Genome Res 1998 Jul;8(7):711-23 |
body mass |
male |
147 days
| 8 |
|
|
409.0 |
g |
5.1 |
14.42 |
body weighing method |
0 |
|
0 |
|
|
|
|
4 rats per cage, 2 SR/Jr 2 LEW/NCrl |
12199 |
222 |
SS.SR-(D3Mco78-D3Got130)/Jr |
body weight |
controlled sodium content diet (0.4 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 24 and 28 days) |
Lee SJ, et al., Genetics 2006 Dec;174(4):2203-13. |
body mass |
male |
70 days-72 days |
20 |
|
|
296.3 |
g |
3.0 |
13.42 |
body weighing method |
|
|
0 |
|
|
|
|
|
12288 |
237 |
SS.SR-(D3Mco24-D3Got130)/Jr |
body weight |
controlled sodium content diet (0.4 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 24 and 28 days) |
Lee SJ, et al., Genetics 2006 Dec;174(4):2203-13. |
body mass |
male |
70 days-72 days |
19 |
|
|
307.7 |
g |
1.9 |
8.28 |
body weighing method |
|
|
0 |
|
|
|
|
|
12297 |
237 |
WKY/NCruk |
body weight |
control condition |
Aitman TJ, et al., Nat Genet 1997 Jun;16(2):197-201 |
body mass |
not specified |
107 days
| 23 |
|
|
314.0 |
g |
2.88 |
13.8 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
11922 |
223 |
P.NP-(D4Rat119-D4Rat55)/Iusm |
body weight |
control condition |
Alam I, et al., J Bone Miner Res. 2010 Jan 8. |
body mass |
male |
180 days
| 8 |
|
|
597.0 |
g |
8.49 |
24.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
12757 |
308 |
SS/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 28 days) |
Saad Y, et al., Physiol Genomics 2001 Jan 19;4(3):201-14. |
body mass |
male |
68 days-70 days |
20 |
|
|
314.0 |
g |
1.72 |
7.69 |
body weighing method |
|
|
0 |
|
|
|
|
|
12486 |
266 |
SS/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 28 days) |
Saad Y, et al., Physiol Genomics 2001 Jan 19;4(3):201-14. |
body mass |
male |
68 days-70 days |
20 |
|
|
308.0 |
g |
1.68 |
7.51 |
body weighing method |
|
|
0 |
|
|
|
|
|
12489 |
266 |
SS.LEW-(D1Rat35-D1Rat49)/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 28 days) |
Saad Y, et al., Physiol Genomics 2001 Jan 19;4(3):201-14. |
body mass |
male |
68 days-70 days |
20 |
|
|
304.0 |
g |
2.97 |
13.28 |
body weighing method |
|
|
0 |
|
|
|
|
|
12496 |
266 |
SS.LEW-(D1Rat196-D1Mgh7)/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 28 days) |
Saad Y, et al., Physiol Genomics 2001 Jan 19;4(3):201-14. |
body mass |
male |
68 days-70 days |
20 |
|
|
294.0 |
g |
3.72 |
16.64 |
body weighing method |
|
|
0 |
|
|
|
|
|
12501 |
266 |
SS.LEW-(D1Rat196-D1Mco36)/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 28 days) |
Saad Y, et al., Physiol Genomics 2001 Jan 19;4(3):201-14. |
body mass |
male |
68 days-70 days |
20 |
|
|
303.0 |
g |
2.91 |
13.01 |
body weighing method |
|
|
0 |
|
|
|
|
|
12502 |
266 |
SS.LEW-(D1Uia8-D1Rat124)/Mco |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 28 days) |
Saad Y, et al., Physiol Genomics 2001 Jan 19;4(3):201-14. |
body mass |
male |
68 days-70 days |
20 |
|
|
298.0 |
g |
2.53 |
11.31 |
body weighing method |
|
|
0 |
|
|
|
|
|
12506 |
266 |
SS/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 24 days) |
Toland EJ, et al., Mamm Genome. 2008 Mar;19(3):209-18. Epub 2008 Mar 7. |
body mass |
male |
64 days-66 days |
20 |
|
|
314.0 |
g |
2.23 |
9.97 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
12863 |
313 |
SS.LEW-(D1Mco36-D1Rat131)/1Mco |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 24 days) |
Toland EJ, et al., Mamm Genome. 2008 Mar;19(3):209-18. Epub 2008 Mar 7. |
body mass |
male |
64 days-66 days |
20 |
|
|
305.0 |
g |
2.4 |
10.73 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12873 |
313 |
SS.LEW-(D1Mco85-D1Rat49)/Mco |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 24 days) |
Toland EJ, et al., Mamm Genome. 2008 Mar;19(3):209-18. Epub 2008 Mar 7. |
body mass |
male |
64 days-66 days |
20 |
|
|
316.0 |
g |
2.87 |
12.84 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12878 |
313 |
F344/DuCrlCrlj |
body weight |
control condition |
Muramatsu Y, et al., Biochem Biophys Res Commun 2005 Jun 17;331(4):1270-6. |
body mass |
male |
245 days
| 12 |
|
|
393.6 |
g |
5.31 |
18.4 |
body weighing method |
|
|
0 |
|
|
|
|
|
12431 |
262 |
LEW/OlaHsd |
body weight |
controlled olive oil content diet (5 %) (for 30 days) and controlled cholesterol content diet (2 %) (for 30 days) |
de Wolf ID, et al., Exp Biol Med (Maywood) 2002 Jul;227(7):529-34. |
body mass |
female |
77 days
| 4 |
|
|
224.0 |
g |
6.0 |
12.0 |
body weighing method |
|
|
0 |
|
|
|
|
|
12538 |
267 |
WKY |
body weight |
controlled sodium content diet (0.4 %) (for 122 days) then controlled sodium content diet (1.4 %) (for 210 days) |
Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81. |
body mass |
female |
360 days
| 4 |
|
|
200.8 |
g |
3.45 |
6.9 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12589 |
268 |
SHR/Mol |
body weight |
control condition |
Kovacs P, et al., Mamm Genome 1998 Apr;9(4):294-6. |
body mass |
male |
98 days
| 12 |
|
|
293.0 |
g |
3.46 |
12.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
12917 |
322 |
SHR/Mol |
body weight |
control condition |
Kloting I, et al., Biochem Biophys Res Commun 2001 Jun 29;284(5):1126-33. |
body mass |
female |
21 days
| 12 |
|
|
30.0 |
g |
1.44 |
5.0 |
body weighing method |
|
|
0 |
|
Kent Scientific Corp |
|
|
|
12937 |
323 |
SHR/Mol |
body weight |
control condition |
Kloting I, et al., Biochem Biophys Res Commun 2001 Jun 29;284(5):1126-33. |
body mass |
female |
70 days
| 12 |
|
|
171.0 |
g |
2.02 |
7.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
12939 |
323 |
SS/Jr |
body weight |
controlled sodium content diet (2 %) (for 28 days) |
Toland EJ, et al., J Hypertens. 2008 Nov;26(11):2134-41. |
body mass |
male |
68 days-70 days |
20 |
|
|
311.0 |
g |
1.63 |
7.29 |
body weighing method |
|
|
0 |
|
|
|
|
|
12944 |
305 |
SS/Jr |
body weight |
controlled sodium content diet (2 %) (for 28 days) |
Toland EJ, et al., J Hypertens. 2008 Nov;26(11):2134-41. |
body mass |
male |
68 days-70 days |
20 |
|
|
339.0 |
g |
3.0 |
13.42 |
body weighing method |
|
|
0 |
|
|
|
|
|
12945 |
305 |
SS/Jr |
body weight |
controlled sodium content diet (2 %) (for 28 days) |
Toland EJ, et al., J Hypertens. 2008 Nov;26(11):2134-41. |
body mass |
male |
68 days-70 days |
20 |
|
|
316.0 |
g |
3.93 |
17.58 |
body weighing method |
|
|
0 |
|
|
|
|
|
12942 |
305 |
SS/Jr |
body weight |
controlled sodium content diet (2 %) (for 28 days) |
Toland EJ, et al., J Hypertens. 2008 Nov;26(11):2134-41. |
body mass |
male |
68 days-70 days |
20 |
|
|
318.0 |
g |
2.09 |
9.35 |
body weighing method |
|
|
0 |
|
|
|
|
|
12947 |
305 |
SS.SHR-(D9Mco74-D9Rat64)/Mco |
body weight |
controlled sodium content diet (2 %) (for 28 days) |
Toland EJ, et al., J Hypertens. 2008 Nov;26(11):2134-41. |
body mass |
male |
68 days-70 days |
20 |
|
|
321.0 |
g |
6.99 |
31.26 |
body weighing method |
|
|
0 |
|
|
|
|
|
12955 |
305 |
OLETF |
body weight |
fasting (for 18 hours) |
Ogino T, et al., Mamm Genome 2003 Dec;14(12):839-44. |
body mass |
male |
246 days
| 23 |
|
|
641.0 |
g |
6.92 |
33.21 |
body weighing method |
|
|
0 |
|
|
|
|
|
12363 |
248 |
MWF-Chr 6SHR/Rkb |
body weight |
control condition |
Schulz A, et al., Clin Sci (Lond). 2007 Oct 22;. |
body mass |
female |
168 days
| 20 |
|
|
214.4 |
g |
5.2 |
23.26 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
12759 |
309 |
F344.OLETF-(D7Mgh16-D7Mgh20)/Tj |
body weight |
specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) |
Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. |
body mass |
male |
211 days
| 7 |
|
|
368.7 |
g |
8.7 |
23.02 |
body weighing method |
|
oral glucose |
0 |
min |
|
|
|
|
12791 |
311 |
ACI/Eur |
body weight |
controlled hydrogen ion content drinking water (2.4-2.8 pH) |
Van Dijk SJ, et al., Nephron Exp Nephrol 2005 Jun 20;101(2):e59-e66. |
body mass |
male |
173 days-180 days |
8 |
|
|
315.0 |
g |
6.0 |
16.97 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67499 |
751 |
SS/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 25 and 28 days) |
Kumarasamy S, et al., Hypertens Res. 2011 Dec;34(12):1263-70. doi: 10.1038/hr.2011.116. Epub 2011 Aug 4. |
body mass |
not specified |
0 days
| 0 |
|
|
353.0 |
g |
6.24 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67537 |
749 |
SS/HsdMcwiCrl |
body weight to tibia length ratio |
controlled carbohydrate content diet (69 %) (for 91 days) and controlled fat content diet (12 %) (for 91 days) and controlled protein content diet (19 %) (for 91 days) |
Spradley FT, et al., Am J Physiol Regul Integr Comp Physiol. 2012 Jan 1;302(1):R150-8. Epub 2011 Oct 26. |
body mass |
male |
112 days
| 6 |
|
|
96.12 |
g/cm |
1.28 |
3.14 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67616 |
735 |
ACI.FHH-(D17Rat117-D17Arb5)(D17Rat180-D17Rat51)/Eur |
body weight |
controlled NG-nitroarginine methyl ester content in acidified drinking water (8-13 mg/kg/d) (for 126 days) |
Van Dijk SJ, et al., Nephron Exp Nephrol 2005 Jun 20;101(2):e59-e66. |
body mass |
male |
173 days-180 days |
9 |
|
|
296.0 |
g |
8.0 |
24.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67676 |
751 |
ACI.FHH-(D1Rat324-D1Rat156)/Eur |
body weight |
controlled NG-nitroarginine methyl ester content in acidified drinking water (8-13 mg/kg/d) (for 126 days) |
Van Dijk SJ, et al., Nephron Exp Nephrol 2005 Jun 20;101(2):e59-e66. |
body mass |
male |
173 days-180 days |
7 |
|
|
293.0 |
g |
6.0 |
15.87 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67677 |
751 |
SS.LEW-(D18Chm41-D18Rat92)/Ayd |
body weight |
controlled sodium content diet (0.2 %) (for 14 days) then controlled sodium content diet (2 %) (for 35 days) |
Deng AY, et al., J Hypertens. 2008 Oct;26(10):1935-1943. |
body mass |
male |
77 days
| 8 |
|
|
326.1 |
g |
3.22 |
9.1 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65007 |
542 |
SHR.BN-(D2Rat114-D2Rat123)/Jk |
body weight |
controlled sodium content diet (1 %) (for 14 days) |
Aneas I, et al., Physiol Genomics. 2009 Mar 3;37(1):52-7. Epub 2009 Jan 6. |
body mass |
male |
87 days
| 23 |
|
|
273.0 |
g |
7.0 |
33.57 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65431 |
306 |
SHR.BN-(D16Rat87-D16Mgh1)/Jk |
body weight |
controlled sodium content diet (1 %) (for 14 days) |
Aneas I, et al., Physiol Genomics. 2009 Mar 3;37(1):52-7. Epub 2009 Jan 6. |
body mass |
male |
87 days
| 23 |
|
|
271.0 |
g |
5.0 |
23.98 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65437 |
306 |
SHRSP.WKY-(Klk1-D1Rat116)/Izm |
body weight |
control condition (0 null) |
Kato N, et al., Hypertension 2003 DXCO;42(6):1191-7. |
body mass |
male |
91 days
| 5 |
|
|
226.0 |
g |
2.81 |
6.28 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
64829 |
115 |
SHR/NHsd |
body weight |
control condition |
Garrett MR, et al., J Am Soc Nephrol 2003 May;14(5):1175-87 |
body mass |
male |
56 days-57 days |
6 |
|
|
203.0 |
g |
6.0 |
14.7 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65441 |
104 |
F344/NHsd |
body weight |
controlled air oxygen content (10 %) (for 21 days) |
Zhao L et al., 2001, Circulation, 103(3), 442-7 |
body mass |
male |
105 days
| 23 |
|
median |
238.0 |
g |
|
|
body weighing method |
0 |
|
0 |
|
|
|
|
|
66124 |
102 |
SS-Chr 19SHR/Rkb |
body weight |
controlled sodium content diet (0.2 %) (for 56 days) |
Wendt N, et al., J Hypertens. 2007 Jan;25(1):95-102. |
body mass |
male |
98 days
| 20 |
|
|
355.0 |
g |
8.0 |
35.78 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
66084 |
669 |
SS-Chr 19SHR/Rkb |
body weight |
controlled sodium content diet (4 %) (for 56 days) |
Wendt N, et al., J Hypertens. 2007 Jan;25(1):95-102. |
body mass |
male |
98 days
| 20 |
|
|
355.0 |
g |
9.0 |
40.25 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
66085 |
669 |
SS/Hsd |
cubic root of body weight to nasoanal length ratio |
controlled sodium content diet (0.3 %) then fasting (for 16 hours) |
Herrera VL, et al., Circ Res 2004 Mar 5; 94(4):446-52 |
body mass |
male |
180 days
| 20 |
|
|
315.4 |
g/mm x 10000 |
1.87 |
8.36 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67893 |
204 |
BN/Crl |
body weight |
fasting (between 16 and 18 hours) |
Finlay C, et al., Mamm Genome. 2010 Oct;21(9-10):499-508. Epub 2010 Sep 29. |
body mass |
male |
60 days
| 6 |
|
|
191.0 |
g |
4.0 |
9.8 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
68768 |
1012 |
BN/Crl |
body weight |
fasting (between 16 and 18 hours) |
Finlay C, et al., Mamm Genome. 2010 Oct;21(9-10):499-508. Epub 2010 Sep 29. |
body mass |
female |
60 days
| 6 |
|
|
155.0 |
g |
6.0 |
14.7 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
68769 |
1012 |
BN/Cub |
body weight |
controlled sucrose content diet (for 7 days) |
Seda O, et al., Physiol Genomics. 2005 Apr 14;21(2):243-52. Epub 2005 Feb 22. |
body mass |
male |
307 days
| 6 |
|
|
291.1 |
g |
10.29 |
25.2 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
70208 |
1318 |
DA/ZtmKini |
maximum body weight loss to initial body weight ratio |
myelin oligodendrocyte glycoprotein (20 ug) |
Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. |
body mass |
male |
103 days-131 days |
10 |
|
|
3.5 |
% |
1.49 |
4.7 |
body weighing method |
0.0 |
intradermal injection |
40 |
days |
from before p.i. |
|
|
|
68708 |
839 |
DA/ZtmKini |
maximum body weight loss to initial body weight ratio |
myelin oligodendrocyte glycoprotein (20 ug) |
Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. |
body mass |
male |
103 days-131 days |
12 |
|
|
1.0 |
% |
0.78 |
2.7 |
body weighing method |
0.0 |
intradermal injection |
40 |
days |
from before p.i. |
|
|
|
68712 |
839 |
ACI.FHH-(D1Rat384-D1Rat156)/Eur |
body weight |
specific pathogen-free condition |
van Dijk SJ, et al., Nephron Exp Nephrol. 2006;104(3):e96-e102. Epub 2006 Jul 12. |
body mass |
not specified |
168 days-175 days |
12 |
|
|
312.0 |
g |
6.0 |
20.78 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67904 |
832 |
ACI.FHH-(D1Rat298-D1Rat90)/Eur |
body weight |
NG-nitroarginine methyl ester (50-150 mg/l) |
Van Dijk SJ, et al., Kidney Int. 2006 |
body mass |
male |
168 days-175 days |
12 |
|
|
328.0 |
g |
3.0 |
10.39 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67702 |
62 |
COP.DA-(D3Rat233-D3Mgh14)/Mco |
body weight |
control condition |
Ways JA, et al., Physiol Genomics. 2006 Dec 19;. |
body mass |
not specified |
105 days
| 18 |
|
|
252.6 |
g |
4.6 |
19.52 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
68488 |
933 |
WKY.SHRSP-(D1Wox29-D1Arb21)/Izm |
body weight |
control condition |
Cui ZH, et al., J Hypertens 2004 Nov;22(11):2103-9. |
body mass |
not specified |
112 days
| 10 |
|
|
393.0 |
g |
5.66 |
17.9 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
68692 |
971 |
DA.PVG.1AV1-(D4Rat155-D4Rat84) |
maximum body weight loss to initial body weight ratio |
squalene (200 ul) |
Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. |
body mass |
both |
120 days-200 days |
11 |
|
|
9.6 |
% |
1.4 |
4.64 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
69795 |
1162 |
DA/Ztm |
maximum body weight loss to initial body weight ratio |
type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) |
Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. |
body mass |
both |
120 days-200 days |
12 |
|
|
13.4 |
% |
1.4 |
4.85 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
69798 |
1162 |
DA.PVG.1AV1-(D4Mgh17-D4Rat56) |
maximum body weight loss to initial body weight ratio |
type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) |
Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. |
body mass |
both |
120 days-200 days |
11 |
|
|
0.7 |
% |
1.6 |
5.31 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
69801 |
1162 |
DA.PVG.1AV1-(D4Rat63-D4Rat203) |
maximum body weight loss to initial body weight ratio |
pristane (150 ul) |
Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. |
body mass |
both |
120 days-200 days |
10 |
|
|
12.6 |
% |
2.7 |
8.54 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
69812 |
1162 |
Crl:CD(SD) |
body weight |
standard diet then acetaminophen (500 mg/kg) (for 35 days) |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
105 days
| 8 |
|
|
472.0 |
g |
8.49 |
24.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85532 |
1604 |
W-LeprfaNin |
body weight |
controlled retinyl palmitate content diet (2.6 mg/kg) (between 36 and 42 days) then fasting (for 12 hours) |
Tiruvalluru M, et al., Nutrition. 2013 Jan;29(1):298-304. doi: 10.1016/j.nut.2012.06.006. Epub 2012 Oct 2. |
body mass |
male |
284 days
| 6 |
|
|
926.0 |
g |
56.2 |
137.66 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
96721 |
1660 |
Crl:CD(SD) |
body weight |
standard diet |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
147 days
| 19 |
|
|
563.0 |
g |
13.54 |
59.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85318 |
1604 |
Crl:CD(SD) |
body weight |
standard diet and restricted feeding (4 h) |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
105 days
| 19 |
|
|
374.0 |
g |
5.28 |
23.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85315 |
1604 |
Crl:CD(SD) |
body weight |
standard diet and restricted feeding (4 h) then acetaminophen (300 mg/kg) (for 35 days) |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
105 days
| 8 |
|
|
375.0 |
g |
12.73 |
36.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85534 |
1604 |
BluHsd:LE |
body weight |
controlled in utero environment (for 9 days) and bisphenol A (2.5 ug/kg) (for 30 days) then maternal milk (for 21 days) |
Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. |
body mass |
male |
70 days
| 8 |
|
|
339.6 |
g |
9.5 |
26.87 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
76146 |
1543 |
HanTac:WH |
body weight gain |
bisphenol A (0.025 mg/kg/d) (for 14 days) |
Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. |
body mass |
female |
0 days
| 21 |
|
|
91.2 |
g |
3.06 |
14.0 |
body weighing method |
0.0 |
|
0 |
|
|
G7-G21 |
|
|
76271 |
1559 |
F344/NHsd |
body weight |
control condition |
Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17. |
body mass |
male |
123 days-267 days |
8 |
|
|
379.3 |
g |
9.2 |
26.02 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84700 |
1599 |
F344/NHsd |
body weight |
control condition |
Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17. |
body mass |
male |
132 days-264 days |
5 |
|
|
381.2 |
g |
9.4 |
21.02 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84708 |
1599 |
SD |
body weight |
acetaminophen (1000 mg/kg) (for 22 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
male |
64 days-78 days |
6 |
|
|
252.7 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84792 |
1602 |
SD |
body weight |
acetaminophen (1000 mg/kg) (for 28 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
male |
70 days-84 days |
6 |
|
|
264.0 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84793 |
1602 |
SD |
body weight |
control condition |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
female |
70 days-84 days |
6 |
|
|
172.8 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84798 |
1602 |
SD |
body weight |
acetaminophen (250 mg/kg) (for 1 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
female |
42 days-56 days |
6 |
|
|
136.3 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84799 |
1602 |
SD |
body weight |
acetaminophen (500 mg/kg) (for 8 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
female |
50 days-64 days |
6 |
|
|
147.9 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84805 |
1602 |
SD |
body weight |
acetaminophen (1000 mg/kg) (for 1 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
female |
42 days-56 days |
6 |
|
|
134.2 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84809 |
1602 |
CrljJcl:SD |
body weight |
gestation (for 21 days) then lactation (for 14 days) |
Xu X, et al., Neurotoxicol Teratol. 2011 Jul-Aug;33(4):458-63. doi: 10.1016/j.ntt.2011.06.002. Epub 2011 Jun 17. |
body mass |
female |
0 days
| 6 |
|
|
264.54 |
g |
14.41 |
35.3 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
75904 |
1539 |
Crl:SD |
body weight |
controlled fructose content drinking water (5 %) and controlled bisphenol A content drinking water (0.025 mg/l) |
Ronn M, et al., Toxicology. 2013 Jan 7;303:125-32. doi: 10.1016/j.tox.2012.09.013. Epub 2012 Nov 8. |
body mass |
female |
35 days
| 12 |
|
|
84.7 |
g |
3.2 |
11.1 |
body weighing method |
0.0 |
|
0 |
|
|
week one |
|
|
75749 |
1538 |
W/Nin |
body weight |
controlled retinyl palmitate content diet (129 mg/kg) (between 36 and 42 days) then fasting (for 12 hours) |
Tiruvalluru M, et al., Nutrition. 2013 Jan;29(1):298-304. doi: 10.1016/j.nut.2012.06.006. Epub 2012 Oct 2. |
body mass |
male |
284 days
| 6 |
|
|
454.0 |
g |
13.3 |
32.58 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
96720 |
1660 |
Hsd:WI |
body weight |
vehicle control condition (for 10 days) |
Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90. |
body mass |
male |
0 days
| 6 |
|
|
140.6 |
g |
0.53 |
1.3 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
75951 |
1544 |
Hsd:WI |
body weight |
bisphenol A (125 mg/kg/d) (for 91 days) |
Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796. |
body mass |
male |
119 days-126 days |
6 |
|
|
314.83 |
g |
6.15 |
15.07 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
76042 |
1545 |
Crl:CD(SD) |
body weight |
standard diet |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
84 days
| 19 |
|
|
419.0 |
g |
8.72 |
38.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85312 |
1604 |
HanTac:WH |
body weight |
bisphenol A (5 mg/kg/d) (between 16 and 17 days) |
Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. |
body mass |
male |
16 days-17 days |
16 |
|
|
28.6 |
g |
0.75 |
3.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
96635 |
1559 |
Crl:SD |
body weight gain |
controlled fructose content drinking water (5 %) (for 70 days) and controlled bisphenol A content drinking water (0.025 mg/l) (for 70 days) |
Ronn M, et al., Toxicology. 2013 Jan 7;303:125-32. doi: 10.1016/j.tox.2012.09.013. Epub 2012 Nov 8. |
body mass |
female |
35 days-105 days |
12 |
|
|
88.3 |
g |
2.22 |
7.7 |
body weighing method |
0.0 |
|
0 |
|
|
week one |
|
|
75759 |
1538 |
SD |
body weight |
acetaminophen (1000 mg/kg) (for 28 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
female |
70 days-84 days |
6 |
|
|
166.7 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84813 |
1602 |
BluHsd:LE |
body weight |
controlled in utero environment (for 9 days) and bisphenol A (2.5 ug/kg) (for 30 days) then maternal milk (for 21 days) |
Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. |
body mass |
male |
98 days
| 8 |
|
|
442.5 |
g |
12.5 |
35.36 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
75963 |
1543 |
SHR-Ndufc2em1Mcwi+/+ |
body weight |
controlled protein content diet (19.7 %) (for 84 days) and controlled potassium content diet (6.3 mg/g) (for 84 days) and controlled sodium content diet (3.7 mg/g) (for 84 days) |
Rubattu S, et al., J Am Heart Assoc. 2016 Feb 17;5(2). pii: e002701. doi: 10.1161/JAHA.115.002701. |
body mass |
not specified |
126 days
| 10 |
|
|
309.0 |
g |
8.54 |
27.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97879 |
1938 |
SHR-Ndufc2em1Mcwi-/+ |
body weight |
controlled protein content diet (19.7 %) (for 84 days) and controlled potassium content diet (6.3 mg/g) (for 84 days) and controlled sodium content diet (3.7 mg/g) (for 84 days) |
Rubattu S, et al., J Am Heart Assoc. 2016 Feb 17;5(2). pii: e002701. doi: 10.1161/JAHA.115.002701. |
body mass |
not specified |
126 days
| 17 |
|
|
308.0 |
g |
5.09 |
21.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97897 |
1938 |
SHR-Ndufc2em2Mcwi-/+ |
body weight |
controlled protein content diet (19.7 %) (for 28 days) and controlled potassium content diet (6.3 mg/g) (for 28 days) and controlled sodium content diet (3.7 mg/g) (for 28 days) |
Rubattu S, et al., J Am Heart Assoc. 2016 Feb 17;5(2). pii: e002701. doi: 10.1161/JAHA.115.002701. |
body mass |
not specified |
70 days
| 26 |
|
|
237.0 |
g |
5.3 |
27.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97903 |
1938 |
SHR-Ndufc2em2Mcwi+/+ |
body weight |
controlled protein content diet (19.7 %) (for 84 days) and controlled potassium content diet (6.3 mg/g) (for 84 days) and controlled sodium content diet (3.7 mg/g) (for 84 days) |
Rubattu S, et al., J Am Heart Assoc. 2016 Feb 17;5(2). pii: e002701. doi: 10.1161/JAHA.115.002701. |
body mass |
not specified |
126 days
| 12 |
|
|
314.0 |
g |
14.15 |
49.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97902 |
1938 |
SHR/Bbb |
body weight |
controlled protein content diet (19.7 %) (for 28 days) and controlled potassium content diet (6.3 mg/g) (for 28 days) and controlled sodium content diet (3.7 mg/g) (for 28 days) |
Rubattu S, et al., J Am Heart Assoc. 2016 Feb 17;5(2). pii: e002701. doi: 10.1161/JAHA.115.002701. |
body mass |
not specified |
70 days
| 18 |
|
|
220.0 |
g |
3.06 |
13.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97906 |
1938 |
F344.OLETF-(D14Rat23-D14Rat12)/Tj |
body weight |
control condition |
Sasaki D, et al., Mamm Genome. 2015 Dec;26(11-12):619-29. doi: 10.1007/s00335-015-9597-4. Epub 2015 Aug 22. |
body mass |
male |
168 days-175 days |
22 |
|
|
301.64 |
g |
7.17 |
33.63 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97719 |
1918 |
MW |
body weight |
right nephrectomy (for 56 days) then angiotensin II receptor antagonist (20 mg/l) |
Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55. |
body mass |
male |
0 days
| 7 |
|
|
254.9 |
g |
14.1 |
37.31 |
body weighing method |
0.0 |
~5/6 to 7/8 nephrectomy |
56 |
days |
|
|
|
|
100804 |
2523 |
MW |
body weight |
right nephrectomy (for 56 days) then angiotensin II receptor antagonist (80 mg/l) |
Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55. |
body mass |
male |
0 days
| 5 |
|
|
257.0 |
g |
6.1 |
13.64 |
body weighing method |
0.0 |
~5/6 to 7/8 nephrectomy |
56 |
days |
|
|
|
|
100805 |
2523 |
WKY |
body weight |
0.9% sodium chloride solution (3 ml) |
Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. |
body mass |
male |
0 days
| 11 |
|
|
319.0 |
g |
5.0 |
16.58 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
100394 |
2479 |
WKY |
body weight |
controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) |
Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. |
body mass |
male |
0 days
| 12 |
|
|
312.0 |
g |
4.0 |
13.86 |
body weighing method |
0.0 |
PA IV 50mg/kg |
0 |
|
|
|
|
|
100396 |
2479 |
SS-Plod1em1Mcwi-/- |
body weight |
controlled sodium content diet (0.4 %) (between 56 and 63 days) then controlled sodium content diet (4 %) (for 12 days) |
Flister MJ, et al., Genome Res. 2013 Dec;23(12):1996-2002. doi: 10.1101/gr.160283.113. Epub 2013 Sep 4. |
body mass |
male |
60 days-69 days |
0 |
|
|
298.0 |
g |
6.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
98465 |
2059 |
SS-Nppbem2Mcwi-/- |
body weight |
control condition (for 168 days) |
Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. |
body mass |
male |
168 days
| 5 |
|
|
425.0 |
g |
22.0 |
49.19 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99550 |
2319 |
SS-Nppbem2Mcwi+/+ |
body weight |
control condition (for 252 days) |
Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. |
body mass |
male |
252 days
| 6 |
|
|
462.0 |
g |
19.0 |
46.54 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99551 |
2319 |
SS/JrHsd |
body weight |
controlled sodium chloride content diet (4 %) (for 14 days) then sham surgical control condition then peanut oil (0.2 ml) (for 14 days) |
Zheng W, et al., Am J Physiol Heart Circ Physiol. 2008 Apr;294(4):H1508-13. doi: 10.1152/ajpheart.01322.2007. Epub 2008 Feb 1. |
body mass |
female |
0 days
| 0 |
|
|
235.0 |
g |
13.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102190 |
2681 |
LL/Mav |
body weight |
vehicle control condition |
Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. |
body mass |
male |
56 days
| 9 |
|
|
231.0 |
g |
4.0 |
12.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102698 |
2721 |
FHH-Nr4a1m1Mcwi |
body weight |
control condition |
Westbrook L, et al., J Am Soc Nephrol. 2014 Nov;25(11):2499-510. doi: 10.1681/ASN.2013070786. Epub 2014 Apr 10. |
body mass |
male |
168 days
| 6 |
|
|
352.0 |
g |
14.0 |
34.29 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99456 |
2318 |
SR/NEisSlc |
body weight |
controlled sodium chloride content diet (8 %) (for 21 days) then 0.9% sodium chloride solution (for 21 days) |
Yoshihara F, et al., Regul Pept. 2005 May 15;128(1):7-13. |
body mass |
male |
77 days
| 19 |
|
|
370.0 |
g |
2.52 |
11.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102453 |
2689 |
SR/NEisSlc |
body weight |
controlled sodium chloride content diet (0.3 %) (for 42 days) then controlled sodium chloride content diet (8 %) (for 84 days) |
Horinaka S, et al., Int J Cardiol. 2003 Sep;91(1):25-35. |
body mass |
male |
126 days
| 10 |
|
|
483.0 |
g |
5.69 |
18.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102481 |
2690 |
SS |
body weight |
controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 42 days) |
Fujii N, et al., Am J Physiol Heart Circ Physiol. 2004 Aug;287(2):H760-6. doi: 10.1152/ajpheart.00734.2003. Epub 2004 Mar 18. |
body mass |
male |
84 days
| 7 |
|
|
287.0 |
g |
9.45 |
25.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103298 |
2803 |
WKY |
body weight |
controlled in utero environment (100 % of calories) (for 22 days) |
Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. |
body mass |
male |
112 days
| 17 |
|
|
454.0 |
g |
8.0 |
32.98 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99075 |
2218 |
SD |
body weight |
in utero condition (for 7 days) and corn oil (for 7 days) |
Jiang JT, et al., Toxicology. 2015 Dec 2;338:77-85. doi: 10.1016/j.tox.2015.10.006. Epub 2015 Oct 26. |
body mass |
male |
1 days
| 0 |
|
|
6.34 |
g |
|
0.34 |
body weighing method |
1.0 |
|
0 |
|
|
|
|
|
98736 |
2158 |
SR |
body weight |
controlled sodium content diet (6 %) (between 56 and 70 days) |
Kamei K, et al., Circ J. 2007 Mar;71(3):390-6. |
body mass |
male |
98 days-132 days |
7 |
|
|
405.0 |
g |
15.5 |
41.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103346 |
2804 |
LH/Mav |
body weight |
controlled sodium chloride content drinking water (2 %) (for 8 days) |
Naelten G, et al., J Cardiovasc Pharmacol. 2011 Feb;57(2):240-5. doi: 10.1097/FJC.0b013e318204bb7b. |
body mass |
male |
119 days
| 7 |
|
|
407.0 |
g |
9.0 |
23.81 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103404 |
2824 |
LH/Mav |
body weight |
control condition (for 84 days) |
Bertram D, et al., Am J Physiol Regul Integr Comp Physiol. 2002 Nov;283(5):R1041-5. doi: 10.1152/ajpregu.00620.2001. |
body mass |
male |
84 days
| 12 |
|
|
353.0 |
g |
8.0 |
27.71 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103424 |
2825 |
LH/Mav |
body weight |
controlled perindopril content drinking water (0.4 mg/kg/d) (for 63 days) |
Bertram D, et al., Am J Physiol Regul Integr Comp Physiol. 2002 Nov;283(5):R1041-5. doi: 10.1152/ajpregu.00620.2001. |
body mass |
male |
84 days
| 13 |
|
|
327.0 |
g |
7.0 |
25.24 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103426 |
2825 |
WF/Mol |
body weight gain |
vehicle control condition then sham surgical control condition (for 7 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 5 |
|
|
23.0 |
g |
3.0 |
6.71 |
body weighing method |
0.0 |
sham acf |
7 |
days |
|
change from surgery weight |
|
|
101343 |
2585 |
LH/Mav |
body weight |
control condition |
Egan EJ, et al., Acta Pharmacol Sin. 2008 Nov;29(11):1296-300. doi: 10.1111/j.1745-7254.2008.00862.x. |
body mass |
male |
161 days
| 8 |
|
|
442.0 |
g |
8.0 |
22.63 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102801 |
2723 |
LH/Mav |
body weight |
perindopril (0.4 mg/kg/d) (for 98 days) |
Egan EJ, et al., Acta Pharmacol Sin. 2008 Nov;29(11):1296-300. doi: 10.1111/j.1745-7254.2008.00862.x. |
body mass |
male |
161 days
| 8 |
|
|
459.0 |
g |
10.0 |
28.28 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102804 |
2723 |
LH/Mav |
body weight |
perindopril (0.04 mg/kg/d) (for 98 days) |
Egan EJ, et al., Acta Pharmacol Sin. 2008 Nov;29(11):1296-300. doi: 10.1111/j.1745-7254.2008.00862.x. |
body mass |
male |
161 days
| 6 |
|
|
457.0 |
g |
11.0 |
26.94 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102807 |
2723 |
SS-Nppbem2Mcwi-/- |
body weight |
gene transfer of the rat natriuretic peptide B gene using an adenovirus vector (100000000000 PFU) |
Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. |
body mass |
male |
84 days
| 6 |
|
|
347.0 |
g |
28.0 |
68.59 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99757 |
2319 |
SS-Nppbem2Mcwi-/- |
body weight |
gene transfer of the rat natriuretic peptide B gene using an adenovirus vector (100000000000 PFU) |
Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. |
body mass |
male |
252 days
| 6 |
|
|
446.0 |
g |
20.0 |
48.99 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99761 |
2319 |
SHRSP |
body weight |
controlled captopril content drinking water (100-400 mg/l) |
Ohashi H, et al., Jpn Circ J. 1986 Feb;50(2):140-6. |
body mass |
male |
245 days
| 6 |
|
|
310.5 |
g |
6.08 |
14.9 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99847 |
2338 |
SD |
body weight |
sham surgical control condition (between 12 and 14 days) |
Greene EL, et al., J Clin Invest. 1996 Aug 15;98(4):1063-8. |
body mass |
male |
0 days
| 6 |
|
|
336.0 |
g |
6.53 |
16.0 |
body weighing method |
0.0 |
sham unx |
13 |
days |
|
|
|
|
101535 |
2602 |
SD |
change in body weight |
unilateral nephrectomy (for 28 days) |
Greene EL, et al., J Clin Invest. 1996 Aug 15;98(4):1063-8. |
body mass |
male |
0 days
| 7 |
|
|
96.0 |
g |
15.12 |
40.0 |
body weighing method |
0.0 |
unx |
28 |
days |
|
change from surgery weight |
|
|
101576 |
2602 |
SD |
body weight |
unilateral nephrectomy (for 28 days) then spironolactone (5.56 mg/kg/d) (for 28 days) |
Greene EL, et al., J Clin Invest. 1996 Aug 15;98(4):1063-8. |
body mass |
male |
0 days
| 8 |
|
|
300.0 |
g |
10.96 |
31.0 |
body weighing method |
0.0 |
unx |
28 |
days |
|
|
|
|
101608 |
2602 |
SD |
body weight |
artificial aortocaval fistula (for 12 hours) |
Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. |
body mass |
male |
0 days
| 6 |
|
|
267.0 |
g |
4.0 |
9.8 |
body weighing method |
1.0 |
ACF |
720 |
min |
|
|
|
|
98771 |
2160 |
SD |
body weight |
artificial aortocaval fistula (for 5 days) |
Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. |
body mass |
male |
0 days
| 6 |
|
|
281.0 |
g |
4.0 |
9.8 |
body weighing method |
1.0 |
ACF |
5 |
days |
|
|
|
|
98775 |
2160 |
SS-Renem1Mcwi+/+ |
body weight |
controlled sodium content diet (0.4 %) (for 49 days) |
Moreno C, et al., Hypertension. 2011 Mar;57(3):614-9. doi: 10.1161/HYPERTENSIONAHA.110.163840. Epub 2011 Jan 17. |
body mass |
female |
70 days
| 8 |
|
|
204.5 |
g |
3.31 |
9.36 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
98292 |
2038 |
GK/CskCrljCrl |
body weight |
control condition |
Devanathan S, et al., PLoS One. 2013 Oct 21;8(10):e78477. doi: 10.1371/journal.pone.0078477. eCollection 2013. |
body mass |
male |
168 days
| 4 |
|
|
334.17 |
g |
8.89 |
17.78 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103088 |
2786 |
LL/Mav |
body weight |
vehicle control condition |
Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3. |
body mass |
male |
49 days-56 days |
13 |
|
|
219.0 |
g |
5.0 |
18.03 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102641 |
2703 |
SD |
body weight |
left nephrectomy then puromycin (100 mg/kg) then anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) then puromycin (40 mg/kg) |
Ma LJ, et al., Kidney Int. 2004 Jan;65(1):106-15. |
body mass |
male |
0 days
| 7 |
|
|
257.0 |
g |
4.0 |
10.58 |
body weighing method |
0.0 |
unx |
0 |
|
|
|
|
|
98926 |
2179 |
SD |
body weight |
control condition |
Jung FF, etal., J Am Soc Nephrol. 1995 Feb;5(8):1573-80. |
body mass |
male |
90 days
| 9 |
|
|
396.0 |
g |
7.6 |
22.8 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
101214 |
2582 |
LH/Mav |
body weight |
perindopril (0.1 mg/kg/d) (for 98 days) |
Egan EJ, et al., Acta Pharmacol Sin. 2008 Nov;29(11):1296-300. doi: 10.1111/j.1745-7254.2008.00862.x. |
body mass |
male |
112 days
| 8 |
|
|
404.0 |
g |
6.0 |
16.97 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102789 |
2723 |
GK/MolTac |
body weight |
running on treadmill (0-10 m/min) (between 0.1 and 0.2 hours) then running on treadmill (15 m/min) (for 0.5 hours) then running on treadmill (15 m/min) (for 0.8 hours) |
Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. |
body mass |
male |
147 days
| 0 |
|
|
374.0 |
g |
4.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103984 |
2885 |
SS/NEisSlc |
body weight |
controlled sodium chloride content diet (8 %) (for 21 days) |
Yoshihara F, et al., Regul Pept. 2005 May 15;128(1):7-13. |
body mass |
male |
77 days
| 8 |
|
|
342.0 |
g |
4.24 |
12.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102410 |
2689 |
WKY |
body weight |
puromycin aminonucleoside (50 mg/kg) |
Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. |
body mass |
male |
0 days
| 11 |
|
|
249.0 |
g |
11.0 |
36.48 |
body weighing method |
0.0 |
PA IV 50mg/kg |
15 |
days |
|
|
|
|
100392 |
2479 |
WKY |
body weight |
controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) |
Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. |
body mass |
male |
0 days
| 5 |
|
|
245.0 |
g |
12.0 |
26.83 |
body weighing method |
0.0 |
PA IV 50mg/kg |
15 |
days |
|
|
|
|
100429 |
2479 |
WKY |
body weight |
0.9% sodium chloride solution (3 ml) |
Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. |
body mass |
male |
0 days
| 8 |
|
|
317.0 |
g |
10.0 |
28.28 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
100430 |
2479 |
SD |
body weight |
sham surgical control condition (for 28 days) |
Lax CJ, et al., Clin Exp Pharmacol Physiol. 2004 Aug;31(8):512-7. |
body mass |
male |
77 days
| 6 |
|
|
378.1 |
g |
12.1 |
29.64 |
body weighing method |
0.0 |
sham lad occlusion |
28 |
days |
|
|
|
|
101076 |
2564 |
WF/Mol |
body weight |
controlled losartan content drinking water (10 mg/kg/d) (for 8 days) then sham surgical control condition (for 7 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 6 |
|
|
204.0 |
g |
2.0 |
4.9 |
body weighing method |
0.0 |
sham acf |
7 |
days |
|
|
|
|
101319 |
2585 |
WF/Mol |
body weight |
vehicle control condition then artificial aortocaval fistula (for 7 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 8 |
|
|
193.0 |
g |
2.0 |
5.66 |
body weighing method |
0.0 |
acf |
7 |
days |
|
|
|
|
101320 |
2585 |
SS/Jr |
body weight |
controlled sodium chloride content diet (0.3 %) (for 35 days) |
Vokurkov? M, et al., Hypertens Res. 2003 May;26(5):397-404. |
body mass |
male |
63 days
| 15 |
|
|
271.0 |
g |
10.0 |
38.73 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103236 |
2802 |
SR/Jr |
body weight |
controlled sodium chloride content diet (8 %) (for 35 days) |
Vokurkov? M, et al., Hypertens Res. 2003 May;26(5):397-404. |
body mass |
male |
63 days
| 13 |
|
|
225.0 |
g |
8.0 |
28.84 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103235 |
2802 |
WKY |
body weight |
unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 14 days) |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
body mass |
male |
0 days
| 8 |
|
|
236.0 |
g |
7.0 |
19.8 |
body weighing method |
0.0 |
unx |
28 |
days |
|
|
|
|
99937 |
2378 |
SD-Nfe2l2em1Mcwi-/- |
body weight |
controlled sodium content diet (0.4 %) (between 70 and 84 days) |
Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4. |
body mass |
male |
56 days-70 days |
4 |
|
|
287.0 |
g |
26.7 |
53.4 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
100732 |
2520 |
SD-Nfe2l2em1Mcwi+/+ |
body weight |
controlled sodium chloride content diet (0.4 %) (between 70 and 84 days) then controlled sodium chloride content diet (4 %) (for 3 days) then angiotensin II (100 ng/kg/min) (for 3 days) |
Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4. |
body mass |
male |
62 days-76 days |
6 |
|
|
291.0 |
g |
11.6 |
28.41 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
100735 |
2520 |
MW |
body weight |
right nephrectomy (for 84 days) then angiotensin II receptor antagonist (80 mg/l) (for 28 days) |
Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55. |
body mass |
male |
0 days
| 5 |
|
|
276.4 |
g |
4.9 |
10.96 |
body weighing method |
0.0 |
~5/6 to 7/8 nephrectomy |
84 |
days |
|
|
|
|
100826 |
2523 |
MW |
body weight |
right nephrectomy (for 112 days) |
Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55. |
body mass |
male |
0 days
| 6 |
|
|
283.2 |
g |
19.9 |
48.74 |
body weighing method |
0.0 |
~5/6 to 7/8 nephrectomy |
112 |
days |
|
|
|
|
100827 |
2523 |
MW |
body weight |
right nephrectomy (for 112 days) then lisinopril (10 mg/kg/d) (for 56 days) |
Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55. |
body mass |
male |
0 days
| 10 |
|
|
293.0 |
g |
14.2 |
44.9 |
body weighing method |
0.0 |
~5/6 to 7/8 nephrectomy |
112 |
days |
|
|
|
|
100831 |
2523 |
MW |
body weight |
right nephrectomy (for 112 days) then angiotensin II receptor antagonist (80 mg/l) (for 56 days) |
Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55. |
body mass |
male |
0 days
| 5 |
|
|
271.0 |
g |
14.1 |
31.53 |
body weighing method |
0.0 |
~5/6 to 7/8 nephrectomy |
112 |
days |
|
|
|
|
100833 |
2523 |
WI |
body weight |
swimming (for 0.2 hours) |
Ma Z, et al., Eur J Appl Physiol. 2013 Oct;113(10):2473-86. doi: 10.1007/s00421-013-2685-9. Epub 2013 Jun 28. |
body mass |
female |
0 days
| 16 |
|
|
274.8 |
g |
4.47 |
17.9 |
body weighing method |
1.0 |
|
0 |
|
following 8 wk protocol |
|
|
|
98748 |
2159 |
SS.BN-(D13Hmgc64-4582)/Mcwi |
body weight |
control condition |
Stodola TJ, et al., Physiol Genomics. 2011 Jul 14;43(13):808-17. doi: 10.1152/physiolgenomics.00171.2010. Epub 2011 Apr 26. |
body mass |
male |
49 days-63 days |
13 |
|
|
262.3 |
g |
9.8 |
35.33 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99001 |
2198 |
MHS |
body weight |
control condition |
Pugliese G, et al., Kidney Int. 2005 Apr;67(4):1440-52. doi: 10.1111/j.1523-1755.2005.00221.x. |
body mass |
male |
168 days
| 8 |
|
|
473.0 |
g |
17.68 |
50.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
104066 |
2907 |
MNS |
body weight |
standard diet |
Menini S, et al., J Hypertens. 2004 Nov;22(11):2185-92. |
body mass |
male |
63 days
| 10 |
|
|
270.8 |
g |
4.3 |
13.6 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
104192 |
2927 |
SS-Kcnj1em1Kasu+/+ |
body weight |
control condition (for 13 days) |
Zhou X, et al., Hypertension. 2013 Aug;62(2):288-94. doi: 10.1161/HYPERTENSIONAHA.111.01051. Epub 2013 Jun 10. |
body mass |
male |
13 days
| 6 |
|
|
29.5 |
g |
0.4 |
0.98 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
104415 |
2948 |
SS-Kcnj1em1Kasu-/- |
body weight |
control condition (for 13 days) |
Zhou X, et al., Hypertension. 2013 Aug;62(2):288-94. doi: 10.1161/HYPERTENSIONAHA.111.01051. Epub 2013 Jun 10. |
body mass |
male |
13 days
| 5 |
|
|
14.3 |
g |
0.2 |
0.45 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
104417 |
2948 |
SS/JrHsdMcwi |
body weight |
monocrotaline (40 mg/kg) |
Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. |
body mass |
male |
56 days
| 11 |
|
|
208.0 |
g |
4.1 |
13.6 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
106552 |
3032 |
WI-Mc4rm1Hubr |
body weight |
control condition |
Stepp DW, et al., Physiol Rep. 2013 Nov;1(6):e00146. doi: 10.1002/phy2.146. Epub 2013 Nov 13. |
body mass |
male |
70 days-140 days |
8 |
|
|
793.0 |
g |
95.0 |
268.7 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
105507 |
3017 |
SS-Plekha7em4Mcwi+/+ |
body weight |
controlled sodium content diet (0.4 %) (for 42 days) |
Endres BT, et al., Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):12817-22. doi: 10.1073/pnas.1410745111. Epub 2014 Aug 18. |
body mass |
male |
63 days
| 10 |
|
|
250.0 |
g |
8.0 |
25.3 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
105736 |
3022 |
SS-Plekha7em4Mcwi+/+ |
body weight |
controlled sodium content diet (8 %) (for 28 days) |
Endres BT, et al., Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):12817-22. doi: 10.1073/pnas.1410745111. Epub 2014 Aug 18. |
body mass |
male |
91 days
| 10 |
|
|
371.0 |
g |
5.0 |
15.81 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
105742 |
3022 |
Hsd:SD |
body weight |
control condition (for 84 days) |
Harrill JA, et al., Toxicol Appl Pharmacol. 2013 Oct 15;272(2):503-18. doi: 10.1016/j.taap.2013.06.024. Epub 2013 Jul 13. |
body mass |
female |
84 days
| 5 |
|
|
257.6 |
g |
27.2 |
60.82 |
body weighing method |
|
|
0 |
|
|
|
|
|
106440 |
3025 |
SBH/Ygl |
body weight |
controlled sodium chloride content diet (0.65 %) (for 98 days) |
Landau D, et al., J Endocrinol. 2008 Apr;197(1):75-83. doi: 10.1677/JOE-08-0040. |
body mass |
male |
98 days
| 7 |
|
|
295.0 |
g |
10.0 |
26.46 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
106700 |
3038 |
SBH/Ygl |
body weight |
controlled sodium chloride content diet (8 %) (for 42 days) then streptozotocin (60 mg/kg) then insulin (10 ul) (for 42 days) |
Landau D, et al., J Endocrinol. 2008 Apr;197(1):75-83. doi: 10.1677/JOE-08-0040. |
body mass |
male |
98 days
| 7 |
|
|
216.0 |
g |
13.0 |
34.39 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
106703 |
3038 |
SBN/Ygl |
body weight |
deoxycorticosterone acetate (75 mg) (for 56 days) and controlled sodium content drinking water (1 %) (for 56 days) |
Rothermund L, et al., Eur J Pharmacol. 2003 May 16;468(3):209-16. doi: 10.1016/s0014-2999(03)01714-x. |
body mass |
male |
16 days
| 8 |
|
|
319.0 |
g |
5.0 |
14.14 |
body weighing method |
0.0 |
|
0 |
|
|
n=8-15 |
|
|
106641 |
3035 |
SBN/Ygl |
body weight |
deoxycorticosterone acetate (75 mg) (for 56 days) and controlled sodium content drinking water (1 %) (for 56 days) and darusentan (50 mg/kg/d) (for 56 days) |
Rothermund L, et al., Eur J Pharmacol. 2003 May 16;468(3):209-16. doi: 10.1016/s0014-2999(03)01714-x. |
body mass |
male |
16 days
| 8 |
|
|
345.0 |
g |
6.9 |
19.52 |
body weighing method |
0.0 |
|
0 |
|
|
n=8-15 |
|
|
106642 |
3035 |
Crl:WI |
body weight |
vehicle control condition (for 28 days) |
Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275. |
body mass |
male |
112 days
| 10 |
|
|
391.8 |
g |
17.2 |
54.39 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109387 |
3140 |
F344/NHsd |
body weight |
azoxymethane (15 mg/kg) |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
male |
91 days-0 days |
4 |
|
|
386.0 |
g |
8.35 |
16.7 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
107008 |
3074 |
SHR/FubRkb |
fetal body weight |
control condition |
Schulte L, etal., J Hypertens. 2012 Oct;30(10):2031-8. doi: 10.1097/HJH.0b013e328356a60a. |
body mass |
not specified |
-5 days
| 10 |
|
|
0.25 |
g |
0.01 |
0.03 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109503 |
3145 |
LOU/MWsl |
change in body weight to initial body weight ratio |
rat IgM immunocytoma cells (1 x 10E4 cells) then doxorubicin (2 mg/kg) (for 14 days) |
van Hoesel QG, etal., Cancer Res. 1984 Sep;44(9):3698-705. |
body mass |
male |
105 days-119 days |
6 |
|
|
-40.0 |
% |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109579 |
3150 |
LN/MavRrrcAek |
body weight to body length (nose to rump) ratio |
standard rat chow (for 98 days) then controlled sodium chloride content diet (4 %) (for 14 days) |
Wang J, et al., Circ Cardiovasc Genet. 2015 Apr;8(2):316-26. doi: 10.1161/CIRCGENETICS.114.000520. Epub 2015 Jan 8. |
body mass |
male |
112 days
| 0 |
|
|
13.2 |
g/cm |
0.22 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
107401 |
3014 |
GK/MolTac |
body weight |
control condition |
Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. |
body mass |
female |
420 days
| 11 |
|
|
292.0 |
g |
6.0 |
19.9 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
106895 |
3071 |
SHRSP/A3NCrl |
body weight |
controlled sodium chloride content drinking water (1 %) (for 49 days) and controlled fat content diet (24.5 %) (for 49 days) then controlled BAY60-4552 content diet (3 mg/kg/d) (for 42 days) |
Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. |
body mass |
male |
134 days-141 days |
10 |
|
|
345.0 |
g |
14.0 |
44.27 |
body weighing method |
0.0 |
|
0 |
|
|
HSFD +3.0 mg/kg/day BAY 60-4552 |
|
|
106964 |
3073 |
SHRSP/A3NCrl |
body weight |
controlled sodium chloride content drinking water (1 %) (for 49 days) and controlled fat content diet (24.5 %) (for 49 days) then controlled BAY60-4552 content diet (0.3 mg/kg/d) (for 42 days) |
Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. |
body mass |
male |
134 days-141 days |
9 |
|
|
328.0 |
g |
6.0 |
18.0 |
body weighing method |
0.0 |
|
0 |
|
|
HSFD +0.3 mg/kg/day BAY 60-4552 |
|
|
106963 |
3073 |
F344/NHsd |
body weight |
0.9% sodium chloride solution (1 ml) |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
male |
91 days-0 days |
2 |
|
|
417.0 |
g |
17.47 |
24.7 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
107014 |
3074 |
BDIX/Orl |
body weight |
0.9% sodium chloride solution (1 ml) |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
male |
98 days-0 days |
2 |
|
|
358.0 |
g |
23.48 |
33.2 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
107012 |
3074 |
BN/HsdMcwiCrl |
body weight |
control condition |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
body mass |
male |
88 days-94 days |
11 |
|
|
276.0 |
g |
4.0 |
13.27 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
107347 |
3077 |
Crl:SD |
body weight |
control condition |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
body mass |
male |
88 days-94 days |
11 |
|
|
448.0 |
g |
8.0 |
26.53 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
107351 |
3077 |
LEW/SsNHsd |
body weight |
control condition |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
body mass |
male |
88 days-94 days |
9 |
|
|
302.0 |
g |
6.0 |
18.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
107356 |
3077 |
SHR/NHsd |
body weight |
control condition |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
body mass |
male |
88 days-94 days |
10 |
|
|
323.0 |
g |
4.0 |
12.65 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
107359 |
3077 |
SR/Hsd |
body weight |
control condition |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
body mass |
male |
88 days-94 days |
10 |
|
|
316.0 |
g |
8.0 |
25.3 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
107360 |
3077 |
SHRSP/A3N |
body weight |
control condition (for 42 days) |
Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. |
body mass |
male |
126 days-147 days |
0 |
|
|
293.0 |
g |
4.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
107526 |
3090 |
SHRSP/A3N |
body weight |
controlled sodium chloride content drinking water (1 %) (for 42 days) and controlled fat content diet (24.5 %) (for 42 days) and vehicle control condition (for 42 days) |
Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. |
body mass |
male |
126 days-147 days |
0 |
|
|
254.0 |
g |
7.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
107527 |
3090 |
WAG/RijCrl |
body weight |
CC531 cells (25 X 10E3) (for 28 days) then iron oxide nanoparticle (2.6 mg) (for 0.1 hours) |
Echevarria-Uraga JJ, et al., Int J Nanomedicine. 2012;7:2399-410. doi: 10.2147/IJN.S31302. Epub 2012 May 9. |
body mass |
male |
148 days
| 19 |
|
|
292.0 |
g |
8.81 |
38.4 |
body weighing method |
0.0 |
CC531 injection |
28 |
days |
|
|
|
|
107972 |
3104 |
GK/Jpe |
body weight gain |
control condition |
Sena CM, etal., Br J Pharmacol. 2008 Mar;153(5):894-906. doi: 10.1038/sj.bjp.0707474. Epub 2007 Oct 1. |
body mass |
male |
450 days-540 days |
20 |
|
|
1.5 |
g |
0.7 |
3.13 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108000 |
3108 |
GK/Jpe |
body weight gain |
controlled cholesterol content diet (1.25 %) (for 90 days) and controlled cocoa butter content diet (7.5 %) (for 90 days) |
Sena CM, etal., Br J Pharmacol. 2008 Mar;153(5):894-906. doi: 10.1038/sj.bjp.0707474. Epub 2007 Oct 1. |
body mass |
male |
450 days-540 days |
10 |
|
|
7.6 |
g |
2.6 |
8.22 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108001 |
3108 |
Slc:ZUC-Leprfa+ |
body weight |
control condition |
Mine T, etal., Biol Pharm Bull. 2002 Nov;25(11):1412-6. doi: 10.1248/bpb.25.1412. |
body mass |
male |
84 days-105 days |
9 |
|
|
342.7 |
g |
2.9 |
8.7 |
body weighing method |
0.0 |
|
0 |
|
|
slc:zuc-leprfa+ |
|
|
108663 |
3070 |
ACI/SegHsd |
volume of blood removed to total prehemorrhagic blood volume ratio |
arterial catheter implantation (between 1 and 1.2 days) then controlled hemorrhage (for 0.4 hours) |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
blood amount |
male |
89 days-95 days |
9 |
5.83 mL/100 g of body weight |
|
56.9 |
% |
0.5 |
1.5 |
body weighing method |
0.0 |
|
0 |
|
|
volume of blood removed to total prehemorrhagic blood volume ratio (CMO:0003663) |
|
|
109123 |
3077 |
MWF |
body weight |
castor oil (for 7 days) |
Fassi A, etal., Am J Kidney Dis. 1999 Feb;33(2):267-75. doi: 10.1016/s0272-6386(99)70299-4. |
body mass |
male |
132 days-146 days |
7 |
|
|
374.0 |
g |
13.61 |
36.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109994 |
3163 |
MNS |
body weight |
control condition |
Capasso G, etal., Am J Physiol Renal Physiol. 2008 Aug;295(2):F556-67. doi: 10.1152/ajprenal.00340.2007. Epub 2008 May 14. |
body mass |
not specified |
85 days-87 days |
11 |
|
|
350.0 |
g |
6.0 |
19.9 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110138 |
3164 |
MWF |
body weight |
control condition |
Eisenberger U, etal., Ren Physiol Biochem. 1995 Mar-Apr;18(2):89-96. doi: 10.1159/000173904. |
body mass |
female |
96 days-121 days |
10 |
|
|
190.0 |
g |
2.21 |
7.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110177 |
3166 |
WKY |
body weight |
unilateral nephrectomy (for 150 days) then vehicle control condition |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
body mass |
male |
0 days
| 11 |
|
|
408.0 |
g |
10.0 |
33.17 |
body weighing method |
0.0 |
unx |
150 |
days |
|
|
|
|
107445 |
2378 |
MWF/Fub |
body weight |
standard diet |
Kreutz R, etal., J Hypertens. 2000 Jun;18(6):777-82. doi: 10.1097/00004872-200018060-00017. |
body mass |
male |
104 days
| 8 |
|
|
319.0 |
g |
7.1 |
20.08 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109001 |
3134 |
F344/NHsd |
maximum body weight loss to initial body weight ratio |
arterial catheter implantation (for 1 days) |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
body mass |
male |
89 days-95 days |
10 |
|
|
5.7 |
% |
0.9 |
2.85 |
body weighing method |
0.0 |
arterial catheter implantation |
1 |
days |
|
|
|
|
107176 |
3077 |
HanTac:WH |
body weight |
control condition |
Kold-Petersen H, etal., J Vasc Res. 2012;49(3):267-78. doi: 10.1159/000335487. Epub 2012 Apr 11. |
body mass |
male |
112 days
| 0 |
|
|
375.0 |
g |
4.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108024 |
3109 |
DA/Bkl |
maximum body weight loss to initial body weight ratio |
arterial catheter implantation (for 1 days) |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
body mass |
male |
89 days-95 days |
9 |
|
|
4.7 |
% |
1.0 |
3.0 |
body weighing method |
0.0 |
arterial catheter implantation |
1 |
days |
|
|
|
|
107183 |
3077 |
GK/MolTac |
body weight |
control condition |
Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. |
body mass |
male |
112 days
| 9 |
|
|
345.8 |
g |
8.4 |
25.2 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110734 |
3183 |
SHR/NHsd |
volume of blood removed to total prehemorrhagic blood volume ratio |
arterial catheter implantation (for 1 days) then controlled hemorrhage (for 0.4 hours) |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
blood amount |
male |
89 days-95 days |
10 |
5.83 mL/100 g of body weight |
|
57.4 |
% |
0.7 |
2.21 |
body weighing method |
0.0 |
|
0 |
|
|
volume of blood removed to total prehemorrhagic blood volume ratio (CMO:0003663) |
|
|
109132 |
3077 |
WAG/Rij |
body weight |
0.9% sodium chloride solution (0.4 ml) |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
male |
56 days
| 2 |
|
|
178.0 |
g |
5.02 |
7.1 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
106986 |
3074 |
BDIX/Orl |
body weight |
azoxymethane (15 mg/kg) |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
male |
63 days
| 4 |
|
|
237.0 |
g |
4.65 |
9.3 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
106991 |
3074 |
SHRSP/A3N |
body weight |
control condition |
Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. |
body mass |
female |
120 days-140 days |
24 |
|
|
207.0 |
g |
4.0 |
19.6 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
107574 |
3093 |
WAG/Nov |
body weight |
control condition |
Ragaeva DS, et al., Physiol Behav. 2017 Jun 1;175:22-30. doi: 10.1016/j.physbeh.2017.03.026. Epub 2017 Mar 21. |
body mass |
male |
14 days
| 15 |
|
|
21.2 |
g |
1.6 |
6.2 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110674 |
3182 |
ISIAH |
body weight |
control condition |
Ragaeva DS, et al., Physiol Behav. 2017 Jun 1;175:22-30. doi: 10.1016/j.physbeh.2017.03.026. Epub 2017 Mar 21. |
body mass |
male |
25 days
| 13 |
|
|
51.1 |
g |
11.3 |
40.74 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110675 |
3182 |
ISIAH |
body weight |
control condition |
Ragaeva DS, et al., Physiol Behav. 2017 Jun 1;175:22-30. doi: 10.1016/j.physbeh.2017.03.026. Epub 2017 Mar 21. |
body mass |
male |
84 days-98 days |
13 |
|
|
324.85 |
g |
5.86 |
21.13 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110685 |
3182 |
BDIX/OrlCrl |
body weight |
control condition |
Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. |
body mass |
male |
0 days
| 3 |
|
|
205.0 |
g |
4.04 |
7.0 |
body weighing method |
0.0 |
|
0 |
|
|
sham surgical group |
|
|
111020 |
3195 |
WKY/NCrlCrlj |
body weight |
control condition |
Mine T, etal., Biol Pharm Bull. 2002 Nov;25(11):1412-6. doi: 10.1248/bpb.25.1412. |
body mass |
male |
224 days-238 days |
5 |
|
|
622.7 |
g |
31.7 |
70.88 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108091 |
3070 |
GK/Par |
body weight |
control condition |
Fourny N, et al., Nutrients. 2019 Jan 6;11(1). pii: nu11010105. doi: 10.3390/nu11010105. |
body mass |
female |
270 days-300 days |
14 |
|
|
284.6 |
g |
4.4 |
16.46 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109874 |
3159 |
GK/Jpe |
body weight |
controlled cocoa butter content diet (7.5 null) (for 90 days) and controlled cholesterol content diet (1.25 null) (for 90 days) and lipoic acid (50 mg/kg) |
Sena CM, etal., Int J Mol Sci. 2018 Sep 11;19(9). pii: ijms19092706. doi: 10.3390/ijms19092706. |
body mass |
male |
540 days
| 7 |
|
|
433.9 |
g |
10.9 |
28.84 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110849 |
3193 |
HanTac:WH |
body weight |
control condition |
Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. |
body mass |
female |
56 days
| 8 |
|
|
173.0 |
g |
6.0 |
16.97 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110241 |
3168 |
HanTac:WH |
body weight |
anti-rh-VEGF165 monoclonal antibody (1 mg) (for 28 days) |
Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. |
body mass |
female |
84 days
| 8 |
|
|
230.0 |
g |
4.0 |
11.31 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110250 |
3168 |
SHR/FubRkb |
body weight |
control condition |
Schulz A, etal., Physiol Genomics. 2008 Sep 17;35(1):30-5. Epub 2008 Jul 22. |
body mass |
female |
168 days
| 10 |
|
|
208.0 |
g |
5.5 |
17.39 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108917 |
3133 |
Hsd:WI |
fetal body weight |
control condition |
Rothermund L, etal., J Hypertens. 2006 Sep 24(9). |
body mass |
not specified |
-4 days
| 0 |
|
|
0.87 |
g |
0.01 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108071 |
3115 |
LEW/Mol |
body weight |
standard diet |
Kreutz R, etal., J Hypertens. 2000 Jun;18(6):777-82. doi: 10.1097/00004872-200018060-00017. |
body mass |
female |
104 days
| 8 |
|
|
193.0 |
g |
2.6 |
7.35 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108996 |
3134 |
MWF/Fub |
body weight |
standard diet |
Kreutz R, etal., J Hypertens. 2000 Jun;18(6):777-82. doi: 10.1097/00004872-200018060-00017. |
body mass |
female |
104 days
| 8 |
|
|
193.0 |
g |
2.8 |
7.92 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109000 |
3134 |
BDIX/OrlCrl |
body weight |
control condition |
Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. |
body mass |
male |
0 days
| 5 |
|
|
205.0 |
g |
6.71 |
15.0 |
body weighing method |
0.0 |
|
0 |
|
|
baseline group C |
|
|
111023 |
3195 |
BDIX/Nem |
fetal body weight |
control condition |
Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. |
body mass |
male |
-1 days
| 56 |
|
|
2.97 |
g |
0.02 |
0.16 |
body weighing method |
0.0 |
|
12 |
days |
|
|
|
|
111221 |
3199 |
BN/HsdMcwiCrl |
maximum body weight loss to initial body weight ratio |
arterial catheter implantation (for 1 days) |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
body mass |
male |
89 days-95 days |
11 |
|
|
1.5 |
% |
0.6 |
1.99 |
body weighing method |
0.0 |
arterial catheter implantation |
1 |
days |
|
|
|
|
107172 |
3077 |
MWF/FubRkb |
body weight |
control condition |
Schulz A, etal., Physiol Genomics. 2010 Jun. |
body mass |
male |
84 days
| 0 |
|
|
279.3 |
g |
5.5 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109039 |
3116 |
ACI/EurMcwi |
nose to tail body mass index |
control condition |
Keele GR, etal., Obesity (Silver Spring). 2018 Jan;26(1):213-222. doi: 10.1002/oby.22075. Epub 2017 Nov 28. |
body mass |
male |
119 days
| 18 |
|
|
1.91 |
(g/cm2) x 10 |
0.04 |
0.16 |
body weighing method |
|
|
0 |
|
|
|
|
|
138385 |
3200 |
BN/SsNHsd |
nose to rump body mass index |
control condition |
Keele GR, etal., Obesity (Silver Spring). 2018 Jan;26(1):213-222. doi: 10.1002/oby.22075. Epub 2017 Nov 28. |
body mass |
male |
119 days
| 10 |
|
|
7.63 |
(g/cm2) x 10 |
0.19 |
0.6 |
body weighing method |
|
|
0 |
|
|
|
|
|
138389 |
3200 |
WKY/NHsd |
body weight |
control condition |
Keele GR, etal., Obesity (Silver Spring). 2018 Jan;26(1):213-222. doi: 10.1002/oby.22075. Epub 2017 Nov 28. |
body mass |
male |
119 days
| 16 |
|
|
318.69 |
g |
9.83 |
39.31 |
body weighing method |
|
|
0 |
|
|
|
|
|
138413 |
3200 |
WKY/NHsd |
nose to rump body mass index |
control condition |
Keele GR, etal., Obesity (Silver Spring). 2018 Jan;26(1):213-222. doi: 10.1002/oby.22075. Epub 2017 Nov 28. |
body mass |
male |
119 days
| 16 |
|
|
7.9 |
(g/cm2) x 10 |
0.2 |
0.78 |
body weighing method |
|
|
0 |
|
|
|
|
|
138414 |
3200 |
SHR.BN-(D2Rat171-D2Arb24)/Ipcv |
body weight |
control condition |
Pravenec M, et al., J Hypertens 2001 Jun;19(6):1061-4. |
body mass |
male |
100 days
| 8 |
|
|
314.2 |
g |
4.8 |
13.58 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
11284 |
61 |
SS.SHR-(D9Rat7-D9Got111)/Mco |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 25 and 28 days) |
Kumarasamy S, et al., Hypertens Res. 2011 Dec;34(12):1263-70. doi: 10.1038/hr.2011.116. Epub 2011 Aug 4. |
body mass |
not specified |
0 days
| 0 |
|
|
347.0 |
g |
4.08 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67539 |
749 |
SS.SHR-(D9Mco72-D9Mco106)/Mco |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 25 and 28 days) |
Kumarasamy S, et al., Hypertens Res. 2011 Dec;34(12):1263-70. doi: 10.1038/hr.2011.116. Epub 2011 Aug 4. |
body mass |
not specified |
0 days
| 0 |
|
|
300.0 |
g |
4.41 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67536 |
749 |
ACI.FHH-(D1Rat475-D1Rat90)(D3Rat84-D3Rat59)/Eur |
body weight |
control condition |
Van Dijk SJ, et al., Kidney Int. 2006 |
body mass |
male |
168 days-175 days |
12 |
|
|
311.0 |
g |
3.0 |
10.39 |
body weighing method |
|
|
0 |
|
|
|
|
|
11944 |
62 |
F344.OLETF-(D12Wox5-D12Rat21)/Tj |
body weight |
fasting (for 16 hours) |
Kose H, et al., Mamm Genome 2002 Oct;13(10):558-62. |
body mass |
male |
210 days
| 13 |
|
|
367.2 |
g |
5.2 |
18.75 |
body weighing method |
|
|
0 |
|
|
|
|
|
12065 |
230 |
SS.MNS-(D10Mco62-D10Got99)/Mco |
body weight |
controlled sodium content diet (2 %) (for 24 days) |
Saad Y, et al., Mamm Genome. 2008 Jan 4 |
body mass |
male |
64 days-68 days |
20 |
|
|
304.0 |
g |
2.1 |
9.39 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12147 |
232 |
SS.SR-(D3Mco36-D3Got166)/Jr |
body weight |
controlled sodium content diet (0.4 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 24 and 28 days) |
Lee SJ, et al., Genetics 2006 Dec;174(4):2203-13. |
body mass |
male |
70 days-72 days |
40 |
|
|
303.9 |
g |
2.0 |
12.65 |
body weighing method |
|
|
0 |
|
|
|
|
|
12283 |
237 |
SHR/NHsd |
body weight |
controlled sodium content diet (0.3 %) |
Packard M, et al., Am J Physiol Renal Physiol. 2009 Apr;296(4):F839-46. Epub 2009 Jan 28. |
body mass |
male |
84 days
| 12 |
|
|
292.0 |
g |
3.6 |
12.47 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
12334 |
246 |
SS/Jr |
body weight |
controlled sodium content diet (0.3 %) |
Packard M, et al., Am J Physiol Renal Physiol. 2009 Apr;296(4):F839-46. Epub 2009 Jan 28. |
body mass |
male |
84 days
| 12 |
|
|
375.0 |
g |
6.0 |
20.78 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
12331 |
246 |
SS.LEW-(D17Mco3-D17Mco10)/Jr |
body weight |
controlled sodium content diet (2 %) (between 24 and 27 days) |
Garrett MR, et al., Genome Res 1998 Jul;8(7):711-23 |
body mass |
not specified |
64 days-71 days |
20 |
|
|
287.0 |
g |
2.2 |
9.84 |
body weighing method |
0 |
|
0 |
|
|
|
|
4 rats per cage, 2 SR/Jr 2 LEW/NCrl |
64730 |
222 |
SS.LEW-(D1Mco2-D1Mco35)/Jr |
body weight |
controlled sodium content diet (2 %) (between 24 and 27 days) |
Garrett MR, et al., Genome Res 1998 Jul;8(7):711-23 |
body mass |
not specified |
64 days-71 days |
39 |
|
|
300.0 |
g |
2.7 |
16.86 |
body weighing method |
0 |
|
0 |
|
|
|
|
4 rats per cage, 2 SR/Jr 2 LEW/NCrl |
64715 |
222 |
SHRSP.WKY-(D1Wox29-D1Arb21)/Izm |
body weight |
control condition |
Yao H, et al., Physiol Genomics. 2007 Feb 27;. |
body mass |
male |
150 days
| 15 |
|
|
390.0 |
g |
6.71 |
26.0 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65510 |
567 |
SS.LEW-(D1Mco36-D1Rat49)/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 28 days) |
Saad Y, et al., Physiol Genomics 2001 Jan 19;4(3):201-14. |
body mass |
male |
68 days-70 days |
20 |
|
|
307.0 |
g |
3.23 |
14.44 |
body weighing method |
|
|
0 |
|
|
|
|
|
12497 |
266 |
SS.LEW-(D1Uia2-D1Rat49)/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 28 days) |
Saad Y, et al., Physiol Genomics 2001 Jan 19;4(3):201-14. |
body mass |
male |
68 days-70 days |
20 |
|
|
307.0 |
g |
5.02 |
22.45 |
body weighing method |
|
|
0 |
|
|
|
|
|
12500 |
266 |
ACI/Eur |
body weight |
control condition |
Van Dijk SJ, et al., Kidney Int. 2006 |
body mass |
male |
168 days-175 days |
12 |
|
|
309.0 |
g |
4.0 |
13.86 |
body weighing method |
|
|
0 |
|
|
|
|
|
11285 |
62 |
BN.GK-(D8Rat29-D8Got130)/Ox |
body weight |
control condition |
Wallis RH, et al., Diabetologia 2004 Jun;47(6):1096-106. Epub 2004 May 26 |
body mass |
male |
168 days
| 13 |
|
|
309.0 |
g |
6.0 |
21.63 |
body weighing method |
|
|
0 |
|
|
|
|
|
11293 |
66 |
BN.GK-(D2Rat40-D2Wox35)/Ox |
body weight |
control condition |
Wallace KJ, et al., Physiol Genomics 2004 Sep 16;19(1):1-10. Epub 2004 Jul 20. |
body mass |
male |
90 days
| 11 |
|
|
238.0 |
g |
10.0 |
33.17 |
body weighing method |
|
|
0 |
|
|
|
|
|
11301 |
69 |
SS.LEW-(D1Mco36-D1Mco101)/Mco |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 24 days) |
Toland EJ, et al., Mamm Genome. 2008 Mar;19(3):209-18. Epub 2008 Mar 7. |
body mass |
male |
64 days-66 days |
30 |
|
|
323.0 |
g |
2.25 |
12.32 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12877 |
313 |
SS/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 24 days) |
Toland EJ, et al., Mamm Genome. 2008 Mar;19(3):209-18. Epub 2008 Mar 7. |
body mass |
male |
64 days-66 days |
20 |
|
|
309.0 |
g |
2.53 |
11.31 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12864 |
313 |
BN/CrlCrlj |
body weight |
controlled protein content diet |
Tsuji A, et al., Genomics 2001 Jun 15;74(3):365-9. |
body mass |
male |
120 days
| 5 |
|
|
248.0 |
g |
4.3 |
9.62 |
body weighing method |
|
|
0 |
|
|
|
|
|
12913 |
321 |
SHR/Mol |
body weight |
control condition |
Kloting I, et al., Biochem Biophys Res Commun 2001 Jun 29;284(5):1126-33. |
body mass |
male |
84 days
| 12 |
|
|
293.0 |
g |
3.46 |
12.0 |
body weighing method |
|
|
0 |
|
|
|
|
|
12930 |
323 |
F344/DuCrlCrlj |
body weight |
control condition (for 65 days) |
Galli J, et al., Diabetes 1999 Dec;48(12):2463-70. |
body mass |
male |
65 days
| 15 |
|
|
207.0 |
g |
3.0 |
11.62 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
11465 |
85 |
LEW |
body weight |
control condition |
Ueno T, et al., Physiol Genomics 2004 Mar 12;17(1):38-47. |
body mass |
female |
150 days-180 days |
10 |
|
|
212.7 |
g |
3.8 |
12.02 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
13154 |
120 |
MWF/FubRkb |
body weight |
control condition |
Schulz A, et al., Clin Sci (Lond). 2007 Oct 22;. |
body mass |
female |
168 days
| 18 |
|
|
207.2 |
g |
1.2 |
5.09 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
12760 |
309 |
F344/NHsd |
body weight |
fasting (for 16 hours) |
Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17. |
body mass |
male |
123 days-267 days |
8 |
|
|
371.3 |
g |
8.3 |
23.48 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84704 |
1599 |
ACI.FHH-(D1Rat475-D1Rat90)(D3Rat84-D3Rat59)/Eur |
body weight |
right nephrectomy then NG-nitroarginine methyl ester (50-150 mg/l) |
Van Dijk SJ, et al., Kidney Int. 2006 |
body mass |
male |
168 days-175 days |
5 |
|
|
263.0 |
g |
12.0 |
26.83 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67707 |
62 |
ACI/Eur |
body weight |
right nephrectomy then NG-nitroarginine methyl ester (50-150 mg/l) |
Van Dijk SJ, et al., Kidney Int. 2006 |
body mass |
male |
168 days-175 days |
12 |
|
|
314.0 |
g |
6.0 |
20.78 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67704 |
62 |
DA/Ztm |
maximum body weight loss to initial body weight ratio |
type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) |
Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. |
body mass |
male |
120 days-200 days |
9 |
|
|
7.5 |
% |
2.1 |
6.3 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
69802 |
1162 |
DA/Ztm |
maximum body weight loss to initial body weight ratio |
Freund's complete adjuvant (100 ul) |
Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. |
body mass |
both |
120 days-200 days |
16 |
|
|
3.2 |
% |
1.8 |
7.2 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
69796 |
1162 |
SS/JrHsdMcwi |
body weight |
controlled sodium content diet (0.4 %) (for 35 days) then controlled sodium content diet (0.1 %) (for 35 days) and controlled sodium content diet (8 %) (between 22 and 24 days) |
Moreno C, et al., Physiol Genomics 2003 Nov 11;15(3):243-57. |
body mass |
female |
84 days
| 28 |
|
|
221.0 |
g |
2.7 |
14.29 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
69442 |
151 |
ACI/Eur |
body weight |
controlled hydrogen ion content drinking water (2.4-2.8 pH) |
Van Dijk SJ, et al., Nephron Exp Nephrol 2005 Jun 20;101(2):e59-e66. |
body mass |
male |
98 days
| 15 |
|
|
269.0 |
g |
4.0 |
15.49 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
68032 |
751 |
HanTac:WH |
body weight gain |
bisphenol A (50 mg/kg/d) (for 14 days) |
Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. |
body mass |
female |
0 days
| 18 |
|
|
78.8 |
g |
4.03 |
17.1 |
body weighing method |
0.0 |
|
0 |
|
|
G7-G21 |
|
|
76274 |
1559 |
Crl:CD(SD) |
body weight |
standard diet then acetaminophen (300 mg/kg) (for 77 days) |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
147 days
| 8 |
|
|
557.0 |
g |
8.13 |
23.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85543 |
1604 |
DA/Ztm |
body weight gain |
spinal cord homogenate (10 mg) |
Bergsteinsdottir K, et al., J Immunol 2000 Feb 1;164(3):1564-8 |
body mass |
male |
56 days-103 days |
9 |
|
|
32.0 |
g |
8.33 |
25.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
69948 |
1258 |
DA/Slc |
body weight |
anti-glomerular basement membrane antibody (500 ul) |
Kose H, et al., Exp Anim. 2009 Apr;58(2):193-8. |
body mass |
female |
64 days
| 10 |
|
|
136.8 |
g |
|
|
body weighing method |
0.0 |
antibody injection |
8 |
days |
|
|
|
|
67689 |
307 |
Iusm:HAD2 |
body weight |
control condition |
Alam I, etal., Alcohol Clin Exp Res. 2005 Oct;29(10):1769-76. doi: 10.1097/01.alc.0000183005.28502.4f. |
body mass |
male |
120 days
| 16 |
|
geometric mean |
399.37 |
g |
12.22 |
48.88 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
138518 |
3202 |
SD |
body weight |
control condition |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
female |
64 days-78 days |
6 |
|
|
159.1 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84817 |
1602 |
SS/NEisSlc |
body weight |
controlled sodium content diet (8 %) (for 42 days) then cilazapril (10 mg/kg/d) (for 42 days) |
Otsuka F, et al., Am J Physiol. 1998 Jun;274(6 Pt 2):R1797-806. |
body mass |
male |
91 days
| 6 |
|
|
319.3 |
g |
7.49 |
18.35 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
100699 |
2519 |
SS.BN-(D13Hmgc64-RN34_13048990782)/Mcwi |
body weight |
control condition |
Stodola TJ, et al., Physiol Genomics. 2011 Jul 14;43(13):808-17. doi: 10.1152/physiolgenomics.00171.2010. Epub 2011 Apr 26. |
body mass |
male |
49 days-63 days |
9 |
|
|
273.3 |
g |
6.8 |
20.4 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
98997 |
2198 |
SS.BN-(D13Hmgc64-4582)/Mcwi |
body weight |
common peroneal nerve direct electrical stimulation (3 V) (for 8 hours) |
Stodola TJ, et al., Physiol Genomics. 2011 Jul 14;43(13):808-17. doi: 10.1152/physiolgenomics.00171.2010. Epub 2011 Apr 26. |
body mass |
male |
56 days-70 days |
13 |
|
|
285.4 |
g |
11.5 |
41.46 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99002 |
2198 |
SS.BN-(D13Hmgc64-D13Hmgc23)/Mcwi |
body weight |
common peroneal nerve direct electrical stimulation (3 V) (for 8 hours) |
Stodola TJ, et al., Physiol Genomics. 2011 Jul 14;43(13):808-17. doi: 10.1152/physiolgenomics.00171.2010. Epub 2011 Apr 26. |
body mass |
male |
56 days-70 days |
12 |
|
|
288.4 |
g |
7.4 |
25.63 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99000 |
2198 |
SS/JrHsdMcwi |
body weight |
common peroneal nerve direct electrical stimulation (3 V) (for 8 hours) |
Stodola TJ, et al., Physiol Genomics. 2011 Jul 14;43(13):808-17. doi: 10.1152/physiolgenomics.00171.2010. Epub 2011 Apr 26. |
body mass |
male |
56 days-70 days |
5 |
|
|
271.8 |
g |
13.4 |
29.96 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99012 |
2198 |
SD |
body weight |
artificial aortocaval fistula (for 6 hours) |
Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. |
body mass |
male |
0 days
| 6 |
|
|
302.0 |
g |
5.0 |
12.25 |
body weighing method |
1.0 |
ACF |
360 |
min |
|
|
|
|
98755 |
2160 |
Crl:CD(SD) |
body weight |
standard diet and restricted feeding (4 h) then acetaminophen (500 mg/kg) (for 77 days) |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
147 days
| 8 |
|
|
431.0 |
g |
8.49 |
24.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85547 |
1604 |
PXO5-2/Cub |
body weight |
controlled sucrose content diet (70 % of calories) (between 0 and 168 hours) and controlled protein content diet (19.6 % of calories) (between 0 and 168 hours) and controlled fat content diet (10.4 % of calories) (between 0 and 168 hours) then fasting (between 0 and 16 hours) |
Hodulova M, et al., PLoS One. 2014 Oct 8;9(10):e109983. doi: 10.1371/journal.pone.0109983. eCollection 2014. |
body mass |
male |
127 days
| 10 |
|
|
220.6 |
g |
3.3 |
10.44 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97157 |
1858 |
F344-Hsd11b2em1Jmul-/- |
body weight |
standard rat chow |
Mullins LJ, et al., Hypertension. 2015 Sep;66(3):667-73. doi: 10.1161/HYPERTENSIONAHA.115.05262. Epub 2015 Jun 15. |
body mass |
female |
98 days
| 5 |
|
|
166.2 |
g |
2.6 |
5.81 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
104991 |
3008 |
Iusm:LAD1 |
body weight |
control condition |
Alam I, etal., Alcohol Clin Exp Res. 2005 Oct;29(10):1769-76. doi: 10.1097/01.alc.0000183005.28502.4f. |
body mass |
male |
90 days
| 16 |
|
geometric mean |
305.65 |
g |
12.59 |
50.36 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
138485 |
3202 |
Iusm:HAD1 |
body weight |
control condition |
Alam I, etal., Alcohol Clin Exp Res. 2005 Oct;29(10):1769-76. doi: 10.1097/01.alc.0000183005.28502.4f. |
body mass |
male |
120 days
| 16 |
|
geometric mean |
342.25 |
g |
10.67 |
42.68 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
138516 |
3202 |
SHR.BN-(D8Mit5-D8Mgh6)/Ipcv |
body weight |
controlled sucrose content diet (70 % of calories) (between 0 and 168 hours) and controlled protein content diet (19.6 % of calories) (between 0 and 168 hours) and controlled fat content diet (10.4 % of calories) (between 0 and 168 hours) then fasting (between 0 and 16 hours) |
Hodulova M, et al., PLoS One. 2014 Oct 8;9(10):e109983. doi: 10.1371/journal.pone.0109983. eCollection 2014. |
body mass |
male |
127 days
| 13 |
|
|
328.0 |
g |
4.0 |
14.42 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97101 |
1858 |
MHS |
body weight |
standard diet |
Menini S, et al., J Hypertens. 2004 Nov;22(11):2185-92. |
body mass |
male |
270 days
| 10 |
|
|
538.6 |
g |
6.77 |
21.4 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
104196 |
2927 |
CrljJcl:SD |
body weight |
gestation (for 21 days) then controlled bisphenol A content drinking water (0.01 mg/l) (for 17 days) then lactation (for 7 days) |
Xu X, et al., Neurotoxicol Teratol. 2011 Jul-Aug;33(4):458-63. doi: 10.1016/j.ntt.2011.06.002. Epub 2011 Jun 17. |
body mass |
female |
0 days
| 8 |
|
|
260.16 |
g |
27.93 |
79.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
75908 |
1539 |
CrljJcl:SD |
body weight |
gestation (for 20 days) then controlled bisphenol A content drinking water (1 mg/l) (for 9 days) |
Xu X, et al., Neurotoxicol Teratol. 2011 Jul-Aug;33(4):458-63. doi: 10.1016/j.ntt.2011.06.002. Epub 2011 Jun 17. |
body mass |
female |
0 days
| 8 |
|
|
347.63 |
g |
30.6 |
86.55 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
75917 |
1539 |
CrljJcl:SD |
body weight |
gestation (for 20 days) then controlled bisphenol A content drinking water (0.1 mg/l) (for 9 days) |
Xu X, et al., Neurotoxicol Teratol. 2011 Jul-Aug;33(4):458-63. doi: 10.1016/j.ntt.2011.06.002. Epub 2011 Jun 17. |
body mass |
female |
0 days
| 8 |
|
|
363.35 |
g |
28.59 |
80.86 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
75912 |
1539 |
MW |
body weight |
right nephrectomy (for 84 days) |
Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55. |
body mass |
male |
0 days
| 6 |
|
|
294.0 |
g |
8.2 |
20.09 |
body weighing method |
0.0 |
~5/6 to 7/8 nephrectomy |
84 |
days |
|
|
|
|
100806 |
2523 |
Crl:WI(Han) |
body weight |
sham surgical control condition (for 24 days) |
Apaijai N, et al., Biosci Rep. 2017 Oct 17;37(5). pii: BSR20170886. doi: 10.1042/BSR20170886. Print 2017 Oct 31. |
body mass |
female |
87 days
| 6 |
|
|
292.0 |
g |
13.0 |
31.84 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102930 |
2782 |
HsdCpb:WU |
body weight |
sham surgical control condition |
Szymanski MK, etal., Basic Res Cardiol. 2012 Mar;107(2):242. doi: 10.1007/s00395-011-0242-4. Epub 2012 Jan 19. |
body mass |
male |
175 days
| 10 |
|
|
482.0 |
g |
11.0 |
34.79 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108787 |
3130 |
WAG/Rij |
body weight |
azoxymethane (15 mg/kg) |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
female |
91 days-0 days |
4 |
|
|
195.0 |
g |
6.25 |
12.5 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
107009 |
3074 |
WKY |
body weight |
left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days) |
Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. |
body mass |
male |
266 days-280 days |
32 |
|
|
574.0 |
g |
38.0 |
214.96 |
body weighing method |
0.0 |
lad occlusion |
210 |
days |
|
|
|
|
100275 |
2460 |
SD |
body weight |
controlled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then enalapril (25 mg/l) (for 90 days) |
Finch JL, et al., Am J Physiol Renal Physiol. 2011 Sep 28. |
body mass |
female |
0 days
| 12 |
|
|
281.9 |
g |
4.2 |
14.55 |
body weighing method |
0.0 |
unx |
97 |
days |
|
|
|
|
100633 |
2499 |
SR |
body weight |
controlled sodium content diet (0.3 %) (for 42 days) |
Fujii N, et al., Am J Physiol Heart Circ Physiol. 2004 Aug;287(2):H760-6. doi: 10.1152/ajpheart.00734.2003. Epub 2004 Mar 18. |
body mass |
male |
42 days
| 5 |
|
|
185.0 |
g |
7.16 |
16.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103297 |
2803 |
WKY |
body weight |
in utero condition (30 % of calories) (for 22 days) |
Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. |
body mass |
male |
112 days
| 18 |
|
|
436.0 |
g |
11.0 |
46.67 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99076 |
2218 |
LH/Mav |
body weight |
controlled perindopril content drinking water (3 mg/kg/d) (for 63 days) |
Bertram D, et al., Am J Physiol Regul Integr Comp Physiol. 2002 Nov;283(5):R1041-5. doi: 10.1152/ajpregu.00620.2001. |
body mass |
male |
84 days
| 12 |
|
|
318.0 |
g |
8.0 |
27.71 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103427 |
2825 |
LL/Mav |
body weight |
control condition (for 0 hours) |
Cerutti C, et al., Physiol Genomics. 2006 Nov 27;27(3):295-308. doi: 10.1152/physiolgenomics.00318.2005. Epub 2006 Aug 1. |
body mass |
male |
84 days
| 5 |
|
|
332.0 |
g |
8.0 |
17.89 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103478 |
2826 |
Iusm:HAD2 |
body weight |
control condition |
Alam I, etal., Alcohol Clin Exp Res. 2005 Oct;29(10):1769-76. doi: 10.1097/01.alc.0000183005.28502.4f. |
body mass |
male |
90 days
| 16 |
|
geometric mean |
318.36 |
g |
6.74 |
26.96 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
138488 |
3202 |
SHRSP |
body weight |
control condition |
Ohashi H, et al., Jpn Circ J. 1986 Feb;50(2):140-6. |
body mass |
male |
210 days
| 5 |
|
|
281.0 |
g |
10.06 |
22.5 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99846 |
2338 |
BluHsd:LE |
body weight gain |
controlled in utero environment (for 9 days) and bisphenol A (25 ug/kg) (for 30 days) then maternal milk (for 21 days) |
Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. |
body mass |
male |
71 days-98 days |
8 |
|
|
99.5 |
g |
5.1 |
14.42 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
75971 |
1543 |
SD |
body weight |
sham surgical control condition (for 12 hours) |
Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. |
body mass |
male |
0 days
| 6 |
|
|
271.0 |
g |
6.0 |
14.7 |
body weighing method |
1.0 |
sham ACF |
720 |
min |
|
|
|
|
98772 |
2160 |
SR/NEisSlc |
body weight |
controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) |
Ishikawa M, et al., Int Heart J. 2013;54(2):98-106. |
body mass |
male |
126 days
| 8 |
|
|
449.0 |
g |
6.0 |
16.97 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102310 |
2684 |
WF/Mol |
body weight |
vehicle control condition then sham surgical control condition (for 4 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 5 |
|
|
188.0 |
g |
1.0 |
2.24 |
body weighing method |
0.0 |
|
4 |
days |
|
|
|
|
101303 |
2585 |
WF/Mol |
body weight |
vehicle control condition then sham surgical control condition (for 7 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 5 |
|
|
180.0 |
g |
2.0 |
4.47 |
body weighing method |
0.0 |
|
7 |
days |
|
|
|
|
101307 |
2585 |
WF/Mol |
body weight |
vehicle control condition then sham surgical control condition (for 7 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 6 |
|
|
201.0 |
g |
3.0 |
7.35 |
body weighing method |
0.0 |
|
7 |
days |
|
|
|
|
101321 |
2585 |
WF/Mol |
body weight gain |
controlled ramipril content drinking water (3 mg/kg/d) (for 8 days) then artificial aortocaval fistula (for 7 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 7 |
|
|
4.0 |
g |
1.0 |
2.65 |
body weighing method |
0.0 |
acf |
7 |
days |
|
change from surgery weight |
|
|
101326 |
2585 |
SS/JrHsd |
body weight |
controlled sodium chloride content diet (4 %) (for 14 days) then bilateral ovariectomy then 17 beta-estradiol (10 ug/d) (for 14 days) |
Zheng W, et al., Am J Physiol Heart Circ Physiol. 2008 Apr;294(4):H1508-13. doi: 10.1152/ajpheart.01322.2007. Epub 2008 Feb 1. |
body mass |
female |
0 days
| 0 |
|
|
228.0 |
g |
6.1 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102194 |
2681 |
HanTac:WH |
body weight |
bisphenol A (0.25 mg/kg/d) (between 16 and 17 days) |
Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. |
body mass |
male |
16 days-17 days |
14 |
|
|
28.3 |
g |
0.61 |
2.3 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
96634 |
1559 |
HanTac:WH |
body weight |
bisphenol A (50 mg/kg/d) (between 16 and 17 days) |
Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. |
body mass |
male |
16 days-17 days |
17 |
|
|
28.7 |
g |
1.29 |
5.3 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
96636 |
1559 |
F344/StmMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 35 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
56 days
| 12 |
|
|
201.42 |
g |
4.14 |
14.33 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139567 |
3292 |
F344/StmMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 42 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
63 days
| 12 |
|
|
228.67 |
g |
3.75 |
13.0 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139568 |
3292 |
F344/StmMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 49 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
70 days
| 12 |
|
|
250.58 |
g |
3.55 |
12.3 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139569 |
3292 |
BN/NHsdMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 14 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
35 days
| 11 |
|
|
94.0 |
g |
2.31 |
7.67 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139048 |
3292 |
BN/NHsdMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 28 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
49 days
| 11 |
|
|
153.36 |
g |
3.02 |
10.03 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139050 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 28 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
49 days
| 12 |
|
|
163.25 |
g |
4.46 |
15.45 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139758 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
91 days
| 12 |
|
|
238.58 |
g |
6.19 |
21.43 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139764 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 14 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
35 days
| 12 |
|
|
102.17 |
g |
2.8 |
9.69 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139822 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 42 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
63 days
| 12 |
|
|
209.42 |
g |
4.27 |
14.8 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139826 |
3292 |
BUF/MnaMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 35 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
56 days
| 9 |
|
|
236.0 |
g |
3.22 |
9.67 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139243 |
3292 |
WKY/NCrl |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 21 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
42 days
| 15 |
|
|
125.0 |
g |
2.48 |
9.62 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
140015 |
3292 |
BUF/MnaMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 42 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
63 days
| 11 |
|
|
268.91 |
g |
2.83 |
9.39 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139310 |
3292 |
BUF/MnaMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 28 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
49 days
| 11 |
|
|
193.09 |
g |
2.1 |
6.95 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139308 |
3292 |
WKY/NCrl |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 49 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
70 days
| 15 |
|
|
243.33 |
g |
3.46 |
13.4 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
140085 |
3292 |
ACI/EurMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 35 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
56 days
| 13 |
|
|
169.38 |
g |
1.95 |
7.04 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138815 |
3292 |
F344/StmMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
7 days
| 12 |
|
|
9.97 |
g |
0.47 |
1.62 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139494 |
3292 |
BUF/MnaMcwi |
body mass index (BMI) |
controlled bisphenol F content drinking water (1.125 mg/l) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
91 days
| 11 |
|
|
0.62 |
g/cm2 |
0.0 |
0.01 |
body weighing method |
|
|
0 |
|
"weight scale, tape measure" |
Body Mass Index (BMI) |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139364 |
3292 |
F344/StmMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 56 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
77 days
| 12 |
|
|
267.0 |
g |
2.72 |
9.44 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139504 |
3292 |
ACI/EurMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
7 days
| 13 |
|
|
11.09 |
g |
0.3 |
1.08 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138808 |
3292 |
ACI/EurMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
21 days
| 13 |
|
|
33.08 |
g |
0.62 |
2.25 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138810 |
3292 |
BN/NHsdMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
14 days
| 10 |
|
|
26.1 |
g |
0.59 |
1.86 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138983 |
3292 |
ACI/EurMcwi |
body mass index (BMI) |
controlled bisphenol F content drinking water (1.125 mg/l) (between 49 and 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
91 days
| 13 |
|
|
0.48 |
g/cm2 |
0.01 |
0.02 |
body weighing method |
|
|
0 |
|
"weight scale, tape measure" |
Body Mass Index (BMI) |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138870 |
3292 |
BN/NHsdMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 49 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
70 days
| 10 |
|
|
218.0 |
g |
3.17 |
10.02 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138991 |
3292 |
BN/NHsdMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 56 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
77 days
| 10 |
|
|
223.8 |
g |
4.98 |
15.76 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138992 |
3292 |
ACI/EurMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 63 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
84 days
| 13 |
|
|
212.46 |
g |
2.87 |
10.36 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138819 |
3292 |
BN/NHsdMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 63 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
84 days
| 10 |
|
|
151.4 |
g |
2.65 |
8.37 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138882 |
3292 |
BN/NHsdMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
7 days
| 10 |
|
|
13.02 |
g |
0.25 |
0.8 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138928 |
3292 |
BN/NHsdMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
14 days
| 10 |
|
|
25.35 |
g |
0.58 |
1.84 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138929 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 14 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
35 days
| 11 |
|
|
88.55 |
g |
2.18 |
7.22 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139627 |
3292 |
BN/NHsdMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 42 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
63 days
| 10 |
|
|
134.5 |
g |
2.11 |
6.67 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138936 |
3292 |
ACI/EurMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 14 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
35 days
| 11 |
|
|
72.55 |
g |
2.29 |
7.58 |
body weighing method |
|
|
0 |
|
|
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138683 |
3292 |
BN/NHsdMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 63 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
84 days
| 11 |
|
|
238.45 |
g |
2.4 |
7.95 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139055 |
3292 |
BUF/MnaMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 63 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
84 days
| 10 |
|
|
202.0 |
g |
2.34 |
7.41 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139118 |
3292 |
BUF/MnaMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 49 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
70 days
| 10 |
|
|
187.9 |
g |
2.29 |
7.23 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139116 |
3292 |
BUF/MnaMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 42 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
63 days
| 10 |
|
|
179.7 |
g |
2.03 |
6.43 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139115 |
3292 |
BUF/MnaMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
91 days
| 10 |
|
|
204.6 |
g |
2.79 |
8.82 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139119 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 21 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
42 days
| 11 |
|
|
104.27 |
g |
1.92 |
6.36 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139628 |
3292 |
BUF/MnaMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
14 days
| 10 |
|
|
25.04 |
g |
0.48 |
1.53 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139174 |
3292 |
BUF/MnaMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 14 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
35 days
| 10 |
|
|
108.3 |
g |
1.65 |
5.23 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139240 |
3292 |
F344/StmMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 7 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
28 days
| 9 |
|
|
60.56 |
g |
1.57 |
4.72 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139368 |
3292 |
F344/StmMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 35 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
56 days
| 9 |
|
|
136.67 |
g |
2.27 |
6.8 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139372 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 7 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
28 days
| 9 |
|
|
64.78 |
g |
1.75 |
5.24 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139692 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 49 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
70 days
| 9 |
|
|
143.89 |
g |
2.3 |
6.9 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139698 |
3292 |
F344/StmMcwi |
body weight |
control condition (0 null) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
14 days
| 9 |
|
|
19.52 |
g |
0.55 |
1.65 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139432 |
3292 |
F344/StmMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 14 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
35 days
| 12 |
|
|
92.92 |
g |
3.08 |
10.67 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139498 |
3292 |
BUF/MnaMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
21 days
| 10 |
|
|
40.3 |
g |
0.75 |
2.36 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139175 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 7 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
28 days
| 11 |
|
|
66.36 |
g |
2.2 |
7.28 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139626 |
3292 |
F344/StmMcwi |
body mass index (BMI) |
controlled bisphenol F content drinking water (1.125 mg/l) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
91 days
| 12 |
|
|
0.55 |
g/cm2 |
0.01 |
0.02 |
body weighing method |
|
|
0 |
|
"weight scale, tape measure" |
Body Mass Index (BMI) |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139622 |
3292 |
F344/StmMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
7 days
| 9 |
|
|
8.89 |
g |
0.32 |
0.97 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139365 |
3292 |
F344/StmMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 21 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
42 days
| 9 |
|
|
106.0 |
g |
2.43 |
7.28 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139370 |
3292 |
WKY/NCrl |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 21 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
42 days
| 10 |
|
|
110.1 |
g |
1.74 |
5.51 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139886 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 63 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
84 days
| 12 |
|
|
235.33 |
g |
6.15 |
21.32 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139763 |
3292 |
WKY/NCrl |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 35 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
56 days
| 10 |
|
|
145.8 |
g |
2.24 |
7.07 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139888 |
3292 |
WKY/NCrl |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
7 days
| 10 |
|
|
9.88 |
g |
0.44 |
1.39 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139947 |
3292 |
WKY/NCrl |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 56 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
77 days
| 15 |
|
|
264.8 |
g |
3.7 |
14.34 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
140086 |
3292 |
WKY/NCrl |
body mass index (BMI) |
controlled bisphenol F content drinking water (1.125 mg/l) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
91 days
| 10 |
|
|
0.48 |
g/cm2 |
0.0 |
0.01 |
body weighing method |
|
|
0 |
|
"weight scale, tape measure" |
Body Mass Index (BMI) |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
140009 |
3292 |
BUF/MnaMcwi |
body mass index (BMI) |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
91 days
| 10 |
|
|
0.5 |
g/cm2 |
0.0 |
0.01 |
body weighing method |
|
|
0 |
|
"weight scale, tape measure" |
Body Mass Index (BMI) |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139172 |
3292 |
F344/StmMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
91 days
| 9 |
|
|
167.22 |
g |
2.52 |
7.55 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139377 |
3292 |
BN/NHsdMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
21 days
| 10 |
|
|
42.9 |
g |
1.75 |
5.55 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138873 |
3292 |
BN/NHsdMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 14 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
35 days
| 10 |
|
|
83.5 |
g |
1.77 |
5.58 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138875 |
3292 |
ACI/EurMcwi |
body mass index (BMI) |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
91 days
| 15 |
|
|
0.42 |
g/cm2 |
0.0 |
0.01 |
body weighing method |
|
|
0 |
|
"weight scale, tape measure" |
Body Mass Index (BMI) |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138678 |
3292 |
BN/NHsdMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 42 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
63 days
| 10 |
|
|
133.7 |
g |
1.89 |
5.96 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138879 |
3292 |
F344/StmMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
91 days
| 9 |
|
|
161.89 |
g |
2.72 |
8.16 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139443 |
3292 |
ACI/EurMcwi |
body mass index (BMI) |
controlled bisphenol F content drinking water (1.125 mg/l) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
91 days
| 11 |
|
|
0.42 |
g/cm2 |
0.0 |
0.01 |
body weighing method |
|
|
0 |
|
|
Body Mass Index (BMI) |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138741 |
3292 |
BN/NHsdMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 14 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
35 days
| 10 |
|
|
81.7 |
g |
2.01 |
6.36 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138932 |
3292 |
ACI/EurMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 14 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
35 days
| 15 |
|
|
74.67 |
g |
1.39 |
5.37 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138617 |
3292 |
ACI/EurMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 7 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
28 days
| 13 |
|
|
58.31 |
g |
0.96 |
3.45 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138811 |
3292 |
BB.SHR-(D6Rat184-D6Rat3)/K |
body weight |
control condition |
Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. |
body mass |
male |
84 days
| 17 |
|
|
324.0 |
g |
6.79 |
28.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
66144 |
324 |
BN/Crl |
body weight |
control condition |
Wallis RH, et al., Diabetologia 2004 Jun;47(6):1096-106. Epub 2004 May 26 |
body mass |
female |
168 days
| 23 |
|
|
200.0 |
g |
5.0 |
23.98 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67312 |
66 |
SS.LEW-(D10Mit10-D10Mgh1)/Jr |
body weight |
controlled sodium content diet (2 %) (between 24 and 27 days) |
Garrett MR, et al., Genome Res 1998 Jul;8(7):711-23 |
body mass |
not specified |
64 days-71 days |
20 |
|
|
292.0 |
g |
2.1 |
9.39 |
body weighing method |
0 |
|
0 |
|
|
|
|
4 rats per cage, 2 SR/Jr 2 LEW/NCrl |
64725 |
222 |
SS/JrSeac |
body weight |
controlled sodium content diet (8 %) (for 35 days) |
Fukushima K, et al., Nucl Med Biol. 2010 Nov;37(8):1005-12. Epub 2010 Sep 1. |
body mass |
not specified |
77 days
| 5 |
|
|
236.0 |
g |
7.16 |
16.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67254 |
733 |
BN.GK-(D8Got302-D8Got130)/Ox |
body weight |
control condition |
Wallis RH, et al., Diabetologia 2004 Jun;47(6):1096-106. Epub 2004 May 26 |
body mass |
female |
84 days
| 24 |
|
|
168.0 |
g |
3.0 |
14.7 |
body weighing method |
|
|
0 |
|
|
|
|
|
11297 |
66 |
BN/Crl |
body weight |
control condition |
Wallace KJ, et al., Physiol Genomics 2004 Sep 16;19(1):1-10. Epub 2004 Jul 20. |
body mass |
male |
90 days
| 28 |
|
|
236.0 |
g |
5.0 |
26.46 |
body weighing method |
|
|
0 |
|
|
|
|
|
11298 |
69 |
BN.GK-(D2Wox30-D2Wox68)/Ox |
body weight |
control condition |
Wallace KJ, et al., Physiol Genomics 2004 Sep 16;19(1):1-10. Epub 2004 Jul 20. |
body mass |
male |
90 days
| 16 |
|
|
250.0 |
g |
6.0 |
24.0 |
body weighing method |
|
|
0 |
|
|
|
|
|
11300 |
69 |
GK/KyoSwe |
body weight |
control condition |
Galli J, et al., NatGenet 1996 Jan;12(1):31-7. |
body mass |
not specified |
80 days
| 8 |
|
|
228.0 |
g |
19.0 |
53.74 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
11392 |
82 |
BN.GH-(D18Rat41-D18Mgh4)/Mcwi |
body weight |
angiotensin II (5-50 ng/kg/min) (between 0.2 and 1 hours) then norepinephrine (0.1-1 ug/kg/min) (between 0.2 and 1 hours) then phenylephrine (4 ug/kg) (between 0 and 0 hours) |
Bilusic M, et al., Croat Med J. 2008 Oct;49(5):586-99. |
body mass |
male |
132 days-146 days |
21 |
|
|
315.2 |
g |
5.24 |
24.0 |
body weighing method |
|
|
0 |
|
|
|
|
|
11548 |
101 |
F344/NHsd |
body weight |
fasting (for 16 hours) |
Solberg Woods LC, et al., Mamm Genome. 2009 Aug 22 |
body mass |
male |
119 days
| 10 |
|
|
345.0 |
g |
5.4 |
17.08 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
11609 |
107 |
WKY/NHsd |
body weight |
fasting (for 16 hours) |
Solberg Woods LC, et al., Mamm Genome. 2009 Aug 22 |
body mass |
female |
119 days
| 10 |
|
|
230.0 |
g |
3.2 |
10.12 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
11610 |
107 |
WKY/NCruk |
body weight |
control condition |
Clemitson JR, et al., Hypertension 2002 Sep;40(3):292-7 |
body mass |
male |
175 days
| 19 |
|
|
329.3 |
g |
5.62 |
24.5 |
body weighing method |
|
|
0 |
|
|
|
|
|
11641 |
110 |
SS.SR-(D7Mco7-D7Wox19)/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 24 and 27 days) |
Cicila GT, et al., Genomics 2001 Feb 15;72(1):51-60. |
body mass |
male |
68 days-70 days |
20 |
|
|
299.4 |
g |
2.8 |
12.52 |
body weighing method |
|
|
0 |
|
|
|
|
|
11824 |
147 |
SS/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 24 and 27 days) |
Cicila GT, et al., Genomics 2001 Feb 15;72(1):51-60. |
body mass |
male |
68 days-70 days |
19 |
|
|
302.3 |
g |
3.5 |
15.26 |
body weighing method |
|
|
0 |
|
|
|
|
|
11829 |
147 |
SS.SR-(D7Rat16-D7Mgh5)/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 24 and 27 days) |
Cicila GT, et al., Genomics 2001 Feb 15;72(1):51-60. |
body mass |
male |
68 days-70 days |
20 |
|
|
292.1 |
g |
2.2 |
9.84 |
body weighing method |
|
|
0 |
|
|
|
|
|
11800 |
147 |
SS.SR-(D7Uia1-D7Mco7)/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 24 and 27 days) |
Cicila GT, et al., Genomics 2001 Feb 15;72(1):51-60. |
body mass |
male |
68 days-70 days |
20 |
|
|
300.2 |
g |
2.6 |
11.63 |
body weighing method |
|
|
0 |
|
|
|
|
|
11818 |
147 |
SS.SR-(D7Mco7-D7Rat81)/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 24 and 27 days) |
Cicila GT, et al., Genomics 2001 Feb 15;72(1):51-60. |
body mass |
male |
68 days-70 days |
20 |
|
|
302.4 |
g |
2.3 |
10.29 |
body weighing method |
|
|
0 |
|
|
|
|
|
11812 |
147 |
F344.GK-(D1Arb42a-D1Rat90)/Swe |
body weight |
control condition (for 95 days) |
Galli J, et al., Diabetes 1999 Dec;48(12):2463-70. |
body mass |
male |
95 days
| 11 |
|
|
27.0 |
g |
6.0 |
19.9 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
11443 |
85 |
F344.GK-(D1Mgh10-D1Rat119)/Swe |
body weight |
control condition (for 95 days) |
Galli J, et al., Diabetes 1999 Dec;48(12):2463-70. |
body mass |
male |
95 days
| 11 |
|
|
305.0 |
g |
5.0 |
16.58 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
11445 |
85 |
ACI.FHH-(D3Wox2-D3Rat59)/Eur |
body weight |
right nephrectomy |
Van Dijk SJ, et al., Kidney Int. 2006 |
body mass |
male |
168 days-175 days |
12 |
|
|
311.0 |
g |
4.0 |
13.86 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
11948 |
62 |
SS.MNS-(D2Rat183-D2Chm113)/Ayd |
body weight |
controlled sodium content diet (2 %) (between 35 and 98 days) |
Duong C, et al., Mamm Genome 2006; 17(12): 1147-1161 |
body mass |
male |
98 days
| 8 |
|
|
415.0 |
g |
6.0 |
16.97 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12029 |
226 |
SS.MNS-(D2Chm25-D2Rat131)/Ayd |
body weight |
controlled sodium content diet (2 %) (between 35 and 98 days) |
Duong C, et al., Mamm Genome 2006; 17(12): 1147-1161 |
body mass |
male |
98 days
| 5 |
|
|
394.0 |
g |
0.8 |
1.79 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12031 |
226 |
F344.OLETF-(D5Mgh4-D5Rat21)/Tj |
body weight |
fasting (for 16 hours) |
Kose H, et al., Mamm Genome 2002 Oct;13(10):558-62. |
body mass |
male |
210 days
| 10 |
|
|
352.5 |
g |
4.4 |
13.91 |
body weighing method |
|
|
0 |
|
|
|
|
|
12034 |
230 |
SS.LEW-(D16Rat38-D16Chm66)/Ayd |
body weight |
controlled sodium content diet (2 %) (between 35 and 98 days) |
Duong C, et al., Mamm Genome 2006; 17(12): 1147-1161 |
body mass |
male |
98 days
| 8 |
|
|
360.0 |
g |
15.0 |
42.43 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12064 |
226 |
SS/Jr |
body weight |
controlled sodium content diet (0.4 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 24 and 28 days) |
Lee SJ, et al., Genetics 2006 Dec;174(4):2203-13. |
body mass |
male |
70 days-72 days |
41 |
|
|
326.2 |
g |
2.1 |
13.45 |
body weighing method |
|
|
0 |
|
|
|
|
|
12305 |
237 |
SS.MNS-(D10Mco30-D10Got112)/Mco |
body weight |
controlled sodium content diet (2 %) (for 24 days) |
Saad Y, et al., Mamm Genome. 2008 Jan 4 |
body mass |
male |
64 days-68 days |
20 |
|
|
299.0 |
g |
2.78 |
12.43 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12148 |
232 |
SS.MNS-(D10Mco30-D10Got91)/2Mco |
body weight |
controlled sodium content diet (2 %) (for 24 days) |
Saad Y, et al., Mamm Genome. 2008 Jan 4 |
body mass |
male |
64 days-68 days |
20 |
|
|
296.0 |
g |
3.6 |
16.1 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12151 |
232 |
SR/Jr |
body weight |
controlled sodium content diet (0.2 %) (for 5 days) then controlled sodium content diet (8 %) (for 28 days) |
Garrett MR, et al., Genome Res 1998 Jul;8(7):711-23 |
body mass |
male |
63 days
| 10 |
|
|
243.0 |
g |
5.5 |
17.39 |
body weighing method |
0 |
|
0 |
|
|
|
|
4 rats per cage, 2 SR/Jr 2 LEW/NCrl |
12184 |
222 |
SR/Jr |
body weight |
controlled sodium content diet (0.2 %) (for 5 days) then controlled sodium content diet (8 %) (for 56 days) |
Garrett MR, et al., Genome Res 1998 Jul;8(7):711-23 |
body mass |
male |
91 days
| 10 |
|
|
309.0 |
g |
6.3 |
19.92 |
body weighing method |
0 |
|
0 |
|
|
|
|
4 rats per cage, 2 SR/Jr 2 LEW/NCrl |
12186 |
222 |
SS/Jr |
body weight |
controlled sodium content diet (0.4 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 24 and 28 days) |
Lee SJ, et al., Genetics 2006 Dec;174(4):2203-13. |
body mass |
male |
70 days-72 days |
20 |
|
|
304.7 |
g |
2.1 |
9.39 |
body weighing method |
|
|
0 |
|
|
|
|
|
12299 |
237 |
SS.SHR-(D8Uia1-D8Rat90)/Mco |
body weight |
controlled sodium content diet (0.3 %) |
Packard M, et al., Am J Physiol Renal Physiol. 2009 Apr;296(4):F839-46. Epub 2009 Jan 28. |
body mass |
male |
84 days
| 12 |
|
|
366.0 |
g |
4.3 |
14.9 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12332 |
246 |
NP.P-(D4Rat119-D4Rat55)/Iusm |
body weight |
control condition |
Alam I, et al., J Bone Miner Res. 2010 Jan 8. |
body mass |
male |
180 days
| 8 |
|
|
609.0 |
g |
11.67 |
33.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
12756 |
308 |
SHR/N |
body weight |
control condition |
Ye P and West MJ, Clin Exp Pharmacol Physiol 2003 Dec;30(12):930-6. |
body mass |
male |
84 days
| 14 |
|
|
441.0 |
g |
26.0 |
97.28 |
body weighing method |
|
|
0 |
|
|
|
|
|
13046 |
327 |
F344.GK-(D1Mgh14-D1Rat90)/Swe |
body weight |
fasting (for 6 hours) |
Granhall C, et al., Genetics. 2006 Nov;174(3):1565-72. Epub 2006 Sep 1. |
body mass |
male |
95 days
| 24 |
|
|
286.0 |
g |
4.0 |
19.6 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
13104 |
330 |
F344.GK-(D1Rat83-D1Rat376)/Swe |
body weight |
fasting (for 6 hours) |
Granhall C, et al., Genetics. 2006 Nov;174(3):1565-72. Epub 2006 Sep 1. |
body mass |
male |
95 days
| 24 |
|
|
290.0 |
g |
5.0 |
24.49 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
13108 |
330 |
F344.GK-(D1Swe4-D1Rat85)/Swe |
body weight |
fasting (for 6 hours) |
Granhall C, et al., Genetics. 2006 Nov;174(3):1565-72. Epub 2006 Sep 1. |
body mass |
male |
95 days
| 24 |
|
|
279.0 |
g |
1.0 |
4.9 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
13112 |
330 |
F344.OLETF-(D1Rat166-D1Rat90)/Tj |
body weight |
control condition |
Muramatsu Y, et al., Biochem Biophys Res Commun 2005 Jun 17;331(4):1270-6. |
body mass |
male |
245 days
| 9 |
|
|
483.1 |
g |
6.8 |
20.4 |
body weighing method |
|
|
0 |
|
|
|
|
|
12442 |
262 |
SS.LEW-(D1Mco2-D1Rat49)/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 28 days) |
Saad Y, et al., Physiol Genomics 2001 Jan 19;4(3):201-14. |
body mass |
male |
68 days-70 days |
20 |
|
|
294.0 |
g |
2.63 |
11.76 |
body weighing method |
|
|
0 |
|
|
|
|
|
12493 |
266 |
SS.LEW-(D1Uia8-D1Rat213)/Mco |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 28 days) |
Saad Y, et al., Physiol Genomics 2001 Jan 19;4(3):201-14. |
body mass |
male |
68 days-70 days |
20 |
|
|
277.0 |
g |
5.53 |
24.73 |
body weighing method |
|
|
0 |
|
|
|
|
|
12507 |
266 |
BC/CpbU |
body weight |
control condition |
Bonne AC, et al., Arterioscler Thromb Vasc Biol 2002 Dec 1;22(12):2072-9. |
body mass |
male |
49 days
| 6 |
|
|
109.0 |
g |
5.31 |
13.0 |
body weighing method |
|
|
0 |
|
|
|
|
|
12598 |
271 |
LEW/OlaHsd |
body weight |
control condition |
Bonne AC, et al., Arterioscler Thromb Vasc Biol 2002 Dec 1;22(12):2072-9. |
body mass |
male |
49 days
| 6 |
|
|
217.0 |
g |
5.31 |
13.0 |
body weighing method |
|
|
0 |
|
|
|
|
|
12609 |
271 |
SS/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 24 days) |
Toland EJ, et al., Mamm Genome. 2008 Mar;19(3):209-18. Epub 2008 Mar 7. |
body mass |
male |
64 days-66 days |
30 |
|
|
328.0 |
g |
2.61 |
14.3 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12866 |
313 |
SHR/Mol |
body weight |
control condition |
Kovacs P, et al., Mamm Genome 1998 Apr;9(4):294-6. |
body mass |
female |
98 days
| 12 |
|
|
188.0 |
g |
1.73 |
6.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
12918 |
322 |
SHR/Mol |
body weight |
control condition |
Kloting I, et al., Biochem Biophys Res Commun 2001 Jun 29;284(5):1126-33. |
body mass |
male |
98 days
| 12 |
|
|
314.0 |
g |
3.46 |
12.0 |
body weighing method |
|
|
0 |
|
|
|
|
|
12931 |
323 |
LEW/Crlc |
body weight gain |
controlled sodium content diet (8 %) (between 8 and 10 days) |
Huang BS, et al., Hypertension. 2007 Apr 9;. |
body mass |
male |
43 days-52 days |
8 |
|
|
54.0 |
g |
3.0 |
8.49 |
body weighing method |
|
|
0 |
|
|
|
|
|
13315 |
344 |
SS/Jr |
body weight gain |
controlled sodium content diet (8 %) (between 8 and 10 days) |
Huang BS, et al., Hypertension. 2007 Apr 9;. |
body mass |
male |
43 days-52 days |
12 |
|
|
51.0 |
g |
2.0 |
6.93 |
body weighing method |
|
|
0 |
|
|
|
|
|
13318 |
344 |
DA/OlaHsd |
body weight |
running on inclined treadmill (10 m/min) (for 0.1 hours) |
Lee SJ, et al., Physiol Genomics 2005 Jul 20;. |
body mass |
male |
105 days
| 4 |
|
|
270.1 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
13336 |
345 |
ACI/SegHsd |
body weight |
control condition |
Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. |
body mass |
male |
900 days
| 12 |
|
null |
419.6 |
g |
|
|
body weighing method |
|
|
0 |
|
method not specified, assumed to be digital scale |
|
|
|
13301 |
341 |
ACI.FHH-(D1Rat324-D1Rat156)/Eur |
body weight |
controlled hydrogen ion content drinking water (2.4-2.8 pH) |
Van Dijk SJ, et al., Nephron Exp Nephrol 2005 Jun 20;101(2):e59-e66. |
body mass |
male |
173 days-180 days |
8 |
|
|
309.0 |
g |
3.0 |
8.49 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67501 |
751 |
SS.SHR-(D9Mco72-D9Mco109)/Mco |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 25 and 28 days) |
Kumarasamy S, et al., Hypertens Res. 2011 Dec;34(12):1263-70. doi: 10.1038/hr.2011.116. Epub 2011 Aug 4. |
body mass |
not specified |
0 days
| 0 |
|
|
307.0 |
g |
2.84 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67530 |
749 |
SS.LEW-(D16Chm36-D16Mit2)/Ayd |
body weight |
controlled sodium content diet (0.2 %) (for 14 days) then controlled sodium content diet (2 %) (for 35 days) |
Deng AY, et al., J Hypertens. 2008 Oct;26(10):1935-1943. |
body mass |
male |
77 days
| 18 |
|
|
319.8 |
g |
3.54 |
15.0 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65008 |
542 |
SHR |
body weight |
controlled sodium content diet (1 %) (for 14 days) |
Aneas I, et al., Physiol Genomics. 2009 Mar 3;37(1):52-7. Epub 2009 Jan 6. |
body mass |
male |
87 days
| 24 |
|
|
269.0 |
g |
6.0 |
29.39 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65429 |
306 |
LEW/Cub |
body weight |
losartan (10 mg/kg) (for 0.2 hours) then pentolinium (5 mg/kg) (for 0.1 hours) then NG-nitroarginine methyl ester (30 mg/kg) (for 0.3 hours) |
Ueno T, et al., Physiol Res 2003;52(6):689-700. |
body mass |
not specified |
0 days
| 9 |
|
serial mean |
300.2 |
g |
|
|
body weighing method |
0 |
|
0 |
|
|
|
|
|
65439 |
568 |
SHRSP.WKY-(Klk1-D1Rat116)/Izm |
body weight |
control condition (0 null) |
Kato N, et al., Hypertension 2003 DXCO;42(6):1191-7. |
body mass |
female |
91 days
| 5 |
|
|
158.48 |
g |
4.8 |
10.73 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
64832 |
115 |
WKY/Izm |
body weight |
control condition (0 null) |
Kato N, et al., Hypertension 2003 DXCO;42(6):1191-7. |
body mass |
female |
91 days
| 5 |
|
|
200.8 |
g |
3.1 |
6.93 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
64833 |
115 |
SS/JrRkb |
body weight |
controlled sodium content diet (0.2 %) (for 56 days) |
Wendt N, et al., J Hypertens. 2007 Jan;25(1):95-102. |
body mass |
male |
98 days
| 14 |
|
|
371.0 |
g |
5.0 |
18.71 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
66082 |
669 |
BB.SHR-(Acsm3-Igf2)/K |
body weight |
control condition |
Kovacs P, et al., Mamm Genome 1998 Apr;9(4):294-6. |
body mass |
male |
98 days
| 15 |
|
|
293.0 |
g |
7.49 |
29.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
66200 |
322 |
ACI.FHH-(D17Rat117-D17Arb5)(D17Rat180-D17Rat51)/Eur |
body weight |
unilateral nephrectomy then controlled NG-nitroarginine methyl ester content in acidified drinking water (11-15 mg/kg/d) (for 126 days) |
Van Dijk SJ, et al., Nephron Exp Nephrol 2005 Jun 20;101(2):e59-e66. |
body mass |
male |
173 days-180 days |
9 |
|
|
284.0 |
g |
6.0 |
18.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67682 |
751 |
SS/HsdMcwiCrl |
body weight to tibia length ratio |
controlled carbohydrate content diet (53 %) (for 91 days) and controlled fat content diet (14 %) (for 91 days) and controlled protein content diet (33 %) (for 91 days) |
Spradley FT, et al., Am J Physiol Regul Integr Comp Physiol. 2012 Jan 1;302(1):R150-8. Epub 2011 Oct 26. |
body mass |
male |
112 days
| 7 |
|
|
100.21 |
g/cm |
1.76 |
4.66 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67614 |
735 |
ACI.FHH-(D1Rat324-D1Rat156)/Eur |
body weight |
unilateral nephrectomy then controlled NG-nitroarginine methyl ester content in acidified drinking water (11-15 mg/kg/d) (for 126 days) |
Van Dijk SJ, et al., Nephron Exp Nephrol 2005 Jun 20;101(2):e59-e66. |
body mass |
male |
173 days-180 days |
8 |
|
|
235.0 |
g |
9.0 |
25.46 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67683 |
751 |
ACI.FHH-(D1Rat324-D1Rat156)/Eur |
body weight |
controlled hydrogen ion content drinking water (2.4-2.8 pH) |
Van Dijk SJ, et al., Nephron Exp Nephrol 2005 Jun 20;101(2):e59-e66. |
body mass |
male |
98 days
| 18 |
|
|
254.0 |
g |
4.0 |
16.97 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
68035 |
751 |
GK/Ox |
body weight |
fasting (between 16 and 18 hours) |
Finlay C, et al., Mamm Genome. 2010 Oct;21(9-10):499-508. Epub 2010 Sep 29. |
body mass |
male |
60 days
| 6 |
|
|
224.0 |
g |
7.0 |
17.15 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
68770 |
1012 |
DA/K |
body mass index (BMI) |
control condition |
Kovacs P, et al., Biochem Biophys Res Commun 2000 Mar 24;269(3):660-5. |
body mass |
not specified |
224 days
| 12 |
|
|
0.62 |
g/cm2 |
0.01 |
0.04 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
69111 |
1123 |
PD/Cub |
body weight |
control condition |
Seda O, et al., Physiol Genomics. 2005 Apr 14;21(2):243-52. Epub 2005 Feb 22. |
body mass |
male |
300 days
| 6 |
|
|
376.9 |
g |
3.02 |
7.4 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
70205 |
1318 |
PD/Cub |
body weight |
controlled sucrose content diet (for 7 days) then dexamethasone (0.03 mg/ml) (for 3 days) |
Seda O, et al., Physiol Genomics. 2005 Apr 14;21(2):243-52. Epub 2005 Feb 22. |
body mass |
male |
310 days
| 6 |
|
|
352.9 |
g |
1.55 |
3.8 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
70211 |
1318 |
F344/NRrrc |
body weight |
control condition |
Kanemoto N, et al., Mamm Genome 1998 Jun;9(6):419-25 |
body mass |
male |
210 days
| 7 |
|
|
374.1 |
g |
8.0 |
21.17 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
68067 |
836 |
ACI.FHH-(D1Rat384-D1Rat156)/Eur |
body weight |
NG-nitroarginine methyl ester (9-16 mg/kg/d) (for 126 days) |
van Dijk SJ, et al., Nephron Exp Nephrol. 2006;104(3):e96-e102. Epub 2006 Jul 12. |
body mass |
not specified |
168 days-175 days |
12 |
|
|
292.0 |
g |
5.0 |
17.32 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67936 |
832 |
DA/ZtmKini |
maximum body weight loss to initial body weight ratio |
myelin oligodendrocyte glycoprotein (20 ug) |
Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. |
body mass |
male |
103 days-131 days |
11 |
|
|
14.4 |
% |
2.47 |
8.2 |
body weighing method |
0.0 |
intradermal injection |
40 |
days |
from before p.i. |
CMO:0001400 |
|
|
68134 |
839 |
DA.ACI-(D10Rat2-D10Rat29)/Kini |
maximum body weight loss to initial body weight ratio |
myelin oligodendrocyte glycoprotein (20 ug) |
Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. |
body mass |
male |
103 days-131 days |
10 |
|
|
0.0 |
% |
0.0 |
0.0 |
body weighing method |
0.0 |
intradermal injection |
40 |
days |
from before p.i. |
|
|
|
68723 |
839 |
ACI.FHH-(D1Mit18-D1Mit8)(D14Mit11-D14Hmgc14b)(D14Rat65-D14Rat90)/Eur |
body weight |
unilateral nephrectomy |
van Dijk SJ, et al., Nephron Exp Nephrol. 2006;104(3):e96-e102. Epub 2006 Jul 12. |
body mass |
not specified |
168 days-175 days |
12 |
|
|
304.0 |
g |
2.0 |
6.93 |
body weighing method |
0.0 |
unilateral nephrectomy |
126 |
days |
|
|
|
|
67901 |
832 |
ACI.FHH-(D1Rat384-D1Rat156)/Eur |
body weight |
unilateral nephrectomy then NG-nitroarginine methyl ester (10-21 ml/kg/d) (for 126 days) |
van Dijk SJ, et al., Nephron Exp Nephrol. 2006;104(3):e96-e102. Epub 2006 Jul 12. |
body mass |
not specified |
168 days-175 days |
11 |
|
|
267.0 |
g |
11.0 |
36.48 |
body weighing method |
0.0 |
unilateral nephrectomy |
126 |
days |
|
|
|
|
67908 |
832 |
ACI.FHH-(D1Mit18-D1Mit8)(D14Mit11-D14Hmgc14b)(D14Rat65-D14Rat90)/Eur |
body weight |
unilateral nephrectomy then NG-nitroarginine methyl ester (10-21 ml/kg/d) (for 126 days) |
van Dijk SJ, et al., Nephron Exp Nephrol. 2006;104(3):e96-e102. Epub 2006 Jul 12. |
body mass |
not specified |
168 days-175 days |
2 |
|
|
286.0 |
g |
1.0 |
1.41 |
body weighing method |
0.0 |
unilateral nephrectomy |
126 |
days |
|
|
|
|
67909 |
832 |
WKY/NCruk |
body weight |
left nephrectomy and left kidney transplant then right nephrectomy |
Clemitson JR, et al., Hypertension 2002 Sep;40(3):292-7 |
body mass |
male |
175 days
| 20 |
|
|
338.8 |
g |
5.95 |
26.6 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67747 |
110 |
DA.PVG.1AV1-(D4Mgh17-D4Rat56) |
maximum body weight loss to initial body weight ratio |
type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) |
Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. |
body mass |
male |
120 days-200 days |
13 |
|
|
6.6 |
% |
1.3 |
4.69 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
69803 |
1162 |
DA.PVG.1AV1-(D4Rat63-D4Rat203) |
maximum body weight loss to initial body weight ratio |
squalene (200 ul) |
Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. |
body mass |
both |
120 days-200 days |
10 |
|
|
6.6 |
% |
2.5 |
7.91 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
69808 |
1162 |
BN/NHsdMcwi |
body weight |
controlled sodium content diet (0.4 %) (for 35 days) then controlled sodium content diet (0.1 %) (for 35 days) and controlled sodium content diet (8 %) (between 22 and 24 days) |
Moreno C, et al., Physiol Genomics 2003 Nov 11;15(3):243-57. |
body mass |
female |
84 days
| 33 |
|
|
167.0 |
g |
3.4 |
19.53 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
69441 |
151 |
Crl:CD(SD) |
body weight |
standard diet and restricted feeding (4 h) then acetaminophen (500 mg/kg) (for 1 days) |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
71 days
| 8 |
|
|
287.0 |
g |
5.3 |
15.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85523 |
1604 |
Crl:CD(SD) |
body weight |
standard diet then acetaminophen (500 mg/kg) (for 1 days) |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
71 days
| 8 |
|
|
375.0 |
g |
6.36 |
18.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85520 |
1604 |
Crl:CD(SD) |
body weight |
standard diet and restricted feeding (4 h) then acetaminophen (500 mg/kg) (for 98 days) |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
168 days
| 8 |
|
|
440.0 |
g |
9.19 |
26.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85553 |
1604 |
Crl:SD |
body weight |
controlled fructose content drinking water (5 %) (for 70 days) and controlled bisphenol A content drinking water (2.5 mg/l) (for 70 days) |
Ronn M, et al., Toxicology. 2013 Jan 7;303:125-32. doi: 10.1016/j.tox.2012.09.013. Epub 2012 Nov 8. |
body mass |
female |
105 days
| 12 |
|
|
175.1 |
g |
2.37 |
8.2 |
body weighing method |
0.0 |
|
0 |
|
|
week one |
|
|
75756 |
1538 |
Crl:SD |
body weight |
controlled fructose content drinking water (5 %) and controlled ethanol content drinking water (1 %) |
Ronn M, et al., Toxicology. 2013 Jan 7;303:125-32. doi: 10.1016/j.tox.2012.09.013. Epub 2012 Nov 8. |
body mass |
female |
35 days
| 12 |
|
|
87.8 |
g |
3.93 |
13.6 |
body weighing method |
0.0 |
|
0 |
|
|
week one |
|
|
75748 |
1538 |
BluHsd:LE |
body weight |
controlled in utero environment (for 9 days) and bisphenol A (25 ug/kg) (for 30 days) then maternal milk (for 21 days) |
Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. |
body mass |
male |
70 days
| 8 |
|
|
338.5 |
g |
8.3 |
23.48 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
76147 |
1543 |
BluHsd:LE |
body weight gain |
controlled in utero environment (for 9 days) and bisphenol A (25 ug/kg) (for 30 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days) |
Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. |
body mass |
male |
71 days-98 days |
8 |
|
|
150.1 |
g |
4.7 |
13.29 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
76163 |
1543 |
HanTac:WH |
body weight gain |
vehicle control condition (for 14 days) |
Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. |
body mass |
female |
0 days
| 18 |
|
|
82.4 |
g |
6.22 |
26.4 |
body weighing method |
0.0 |
|
0 |
|
|
G7-G21 |
|
|
76270 |
1559 |
SD |
body weight |
acetaminophen (250 mg/kg) (for 15 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
male |
57 days-71 days |
6 |
|
|
227.7 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84767 |
1602 |
SD |
body weight |
acetaminophen (1000 mg/kg) (for 8 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
male |
50 days-64 days |
6 |
|
|
208.8 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84790 |
1602 |
SD |
body weight |
control condition |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
female |
42 days-56 days |
6 |
|
|
136.2 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84794 |
1602 |
SD |
body weight |
acetaminophen (1000 mg/kg) (for 15 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
female |
57 days-71 days |
6 |
|
|
153.9 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84821 |
1602 |
CrljJcl:SD |
body weight |
gestation (for 14 days) then controlled bisphenol A content drinking water (0.01 mg/l) (for 3 days) |
Xu X, et al., Neurotoxicol Teratol. 2011 Jul-Aug;33(4):458-63. doi: 10.1016/j.ntt.2011.06.002. Epub 2011 Jun 17. |
body mass |
female |
0 days
| 8 |
|
|
290.3 |
g |
24.82 |
70.2 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
75906 |
1539 |
CrljJcl:SD |
body weight |
gestation (for 21 days) then controlled bisphenol A content drinking water (0.1 mg/l) (for 24 days) then lactation (for 14 days) |
Xu X, et al., Neurotoxicol Teratol. 2011 Jul-Aug;33(4):458-63. doi: 10.1016/j.ntt.2011.06.002. Epub 2011 Jun 17. |
body mass |
female |
0 days
| 8 |
|
|
264.83 |
g |
21.28 |
60.19 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
75914 |
1539 |
DA/OlaHsd |
body weight |
control condition |
Ways JA, et al., Genomics 2002 Jul;80(1):13-20. |
body mass |
male |
77 days-84 days |
0 |
|
|
231.0 |
g |
10.0 |
|
body weighing method |
0.0 |
|
0 |
|
timing method |
|
|
|
84623 |
932 |
Hsd:WI |
body weight |
1H-pyrazole (10 mg/kg/d) (for 10 days) then cisplatin (7.5 mg/kg) |
Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90. |
body mass |
male |
0 days
| 6 |
|
|
142.5 |
g |
0.73 |
1.8 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
75953 |
1544 |
SD |
body weight |
control condition |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
male |
57 days-71 days |
6 |
|
|
225.6 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84762 |
1602 |
Hsd:WI |
change in body weight to body weight ratio |
bisphenol A (125 mg/kg/d) (for 91 days) |
Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796. |
body mass |
male |
119 days-126 days |
6 |
|
|
201.5 |
% |
17.15 |
42.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
76066 |
1545 |
Hsd:WI |
change in body weight to body weight ratio |
octylphenol (125 mg/kg/d) (for 91 days) |
Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796. |
body mass |
male |
119 days-126 days |
6 |
|
|
242.2 |
% |
18.74 |
45.9 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
76068 |
1545 |
SD |
body weight |
control condition |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
male |
42 days-56 days |
6 |
|
|
184.1 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84781 |
1602 |
Crl:CD(SD) |
body weight |
standard diet then acetaminophen (300 mg/kg) (for 14 days) |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
84 days
| 8 |
|
|
418.0 |
g |
6.72 |
19.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85525 |
1604 |
W-LeprfaNin |
body weight |
controlled retinyl palmitate content diet (129 mg/kg) (between 36 and 42 days) then fasting (for 12 hours) |
Tiruvalluru M, et al., Nutrition. 2013 Jan;29(1):298-304. doi: 10.1016/j.nut.2012.06.006. Epub 2012 Oct 2. |
body mass |
male |
284 days
| 6 |
|
|
778.0 |
g |
23.8 |
58.3 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
96724 |
1660 |
PXO10/Cub |
body weight |
controlled sucrose content diet (70 % of calories) (between 0 and 168 hours) and controlled protein content diet (19.6 % of calories) (between 0 and 168 hours) and controlled fat content diet (10.4 % of calories) (between 0 and 168 hours) then fasting (between 0 and 16 hours) |
Hodulova M, et al., PLoS One. 2014 Oct 8;9(10):e109983. doi: 10.1371/journal.pone.0109983. eCollection 2014. |
body mass |
male |
127 days
| 12 |
|
|
295.6 |
g |
7.2 |
24.94 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97168 |
1858 |
SHR-Ndufc2em2Mcwi-/+ |
body weight |
controlled protein content diet (19.7 %) (for 84 days) and controlled potassium content diet (6.3 mg/g) (for 84 days) and controlled sodium content diet (3.7 mg/g) (for 84 days) |
Rubattu S, et al., J Am Heart Assoc. 2016 Feb 17;5(2). pii: e002701. doi: 10.1161/JAHA.115.002701. |
body mass |
not specified |
126 days
| 16 |
|
|
312.0 |
g |
9.0 |
36.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97905 |
1938 |
SHRSP/Bbb |
body weight |
controlled protein content diet (19.7 %) (for 49 days) and controlled potassium content diet (6.3 mg/g) (for 49 days) and controlled sodium content diet (3.7 mg/g) (for 49 days) |
Rubattu S, et al., J Am Heart Assoc. 2016 Feb 17;5(2). pii: e002701. doi: 10.1161/JAHA.115.002701. |
body mass |
not specified |
91 days
| 5 |
|
|
192.0 |
g |
2.68 |
6.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97910 |
1938 |
SS.LEW-(D1Rat200-D1Mco136)/Bj |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 24 days) |
Mell B, et al., Hypertens Res. 2015 Jan;38(1):61-7. doi: 10.1038/hr.2014.134. Epub 2014 Sep 18. |
body mass |
male |
73 days-75 days |
10 |
|
|
331.0 |
g |
5.0 |
15.81 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
96968 |
1778 |
MW |
body weight |
right nephrectomy (for 56 days) then enalapril (20 mg/kg/d) |
Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55. |
body mass |
male |
0 days
| 9 |
|
|
280.5 |
g |
1.1 |
3.3 |
body weighing method |
0.0 |
~5/6 to 7/8 nephrectomy |
56 |
days |
|
|
|
|
100802 |
2523 |
Crl:WI(WU) |
body weight |
sham surgical control condition |
Goetz RM and Holtz J, Clin Sci (Lond). 1999 Aug;97(2):165-74. |
body mass |
male |
91 days
| 14 |
|
|
334.0 |
g |
8.0 |
29.93 |
body weighing method |
0.0 |
sham surgery |
35 |
days |
|
|
|
|
100005 |
2398 |
Crl:WI(WU) |
body weight |
abdominal aorta constriction |
Goetz RM and Holtz J, Clin Sci (Lond). 1999 Aug;97(2):165-74. |
body mass |
male |
91 days
| 14 |
|
|
311.0 |
g |
9.0 |
33.67 |
body weighing method |
0.0 |
aorta coarctation |
35 |
days |
|
|
|
|
100006 |
2398 |
SS-Nppaem4Mcwi-/- |
body weight |
controlled sodium content diet (0.4 %) (between 56 and 63 days) then controlled sodium content diet (4 %) (for 12 days) |
Flister MJ, et al., Genome Res. 2013 Dec;23(12):1996-2002. doi: 10.1101/gr.160283.113. Epub 2013 Sep 4. |
body mass |
male |
60 days-69 days |
0 |
|
|
299.0 |
g |
5.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
98467 |
2059 |
SS-Nppbem2Mcwi+/+ |
body weight |
control condition (for 56 days) |
Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. |
body mass |
male |
56 days
| 5 |
|
|
267.0 |
g |
5.0 |
11.18 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99545 |
2319 |
SR/JrHsd |
body weight |
controlled sodium chloride content diet (0.4 %) (for 14 days) then bilateral ovariectomy then peanut oil (0.2 ml) (for 14 days) |
Zheng W, et al., Am J Physiol Heart Circ Physiol. 2008 Apr;294(4):H1508-13. doi: 10.1152/ajpheart.01322.2007. Epub 2008 Feb 1. |
body mass |
female |
0 days
| 0 |
|
|
276.0 |
g |
11.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102185 |
2681 |
LH/Mav |
body weight |
vehicle control condition |
Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. |
body mass |
male |
56 days
| 11 |
|
|
246.0 |
g |
4.0 |
13.27 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102700 |
2721 |
LL/Mav |
body weight |
streptozotocin (100 mg/kg) |
Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. |
body mass |
male |
112 days
| 18 |
|
|
331.0 |
g |
3.0 |
12.73 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102723 |
2721 |
OLETF |
body weight |
temocapril (3.9 mg/kg/d) (for 84 days) |
Koga K, et al., Mol Med. 2002 Oct;8(10):591-9. |
body mass |
male |
364 days
| 11 |
|
|
766.7 |
g |
13.9 |
46.1 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99414 |
2298 |
FHH/EurMcwi |
body weight |
control condition |
Westbrook L, et al., J Am Soc Nephrol. 2014 Nov;25(11):2499-510. doi: 10.1681/ASN.2013070786. Epub 2014 Apr 10. |
body mass |
male |
168 days
| 6 |
|
|
429.0 |
g |
9.5 |
23.27 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99455 |
2318 |
SS/NEisSlc |
body weight |
controlled sodium chloride content diet (8 %) (for 21 days) then 0.9% sodium chloride solution (for 21 days) |
Yoshihara F, et al., Regul Pept. 2005 May 15;128(1):7-13. |
body mass |
male |
77 days
| 14 |
|
|
348.0 |
g |
4.01 |
15.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102454 |
2689 |
SS/JrIpcv |
body weight |
controlled sodium content diet (0.3 %) |
Hojn¿ S, et al., Physiol Res. 2005;54(2):201-6. |
body mass |
male |
0 days
| 0 |
|
|
271.0 |
g |
10.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102390 |
2688 |
WKY |
body weight |
left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) |
Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. |
body mass |
male |
266 days-280 days |
16 |
|
|
599.0 |
g |
35.0 |
140.0 |
body weighing method |
0.0 |
lad occlusion |
210 |
days |
|
|
|
|
100274 |
2460 |
SD |
body weight |
control condition |
Finch JL, et al., Am J Physiol Renal Physiol. 2011 Sep 28. |
body mass |
female |
0 days
| 8 |
|
|
305.4 |
g |
5.3 |
14.99 |
body weighing method |
0.0 |
- |
0 |
days |
|
|
|
|
100631 |
2499 |
GK/Jcl |
body weight |
Omacor (400 mg/kg/d) (for 56 days) |
Radosinska J, et al., Physiol Res. 2015;64(6):795-806. Epub 2015 Oct 8. |
body mass |
male |
84 days
| 8 |
|
|
342.0 |
g |
4.95 |
14.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103058 |
2785 |
SS |
body weight |
controlled sodium content diet (0.3 %) (for 42 days) |
Fujii N, et al., Am J Physiol Heart Circ Physiol. 2004 Aug;287(2):H760-6. doi: 10.1152/ajpheart.00734.2003. Epub 2004 Mar 18. |
body mass |
male |
42 days
| 5 |
|
|
195.0 |
g |
3.58 |
8.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103296 |
2803 |
SR |
body weight |
controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 84 days) |
Fujii N, et al., Am J Physiol Heart Circ Physiol. 2004 Aug;287(2):H760-6. doi: 10.1152/ajpheart.00734.2003. Epub 2004 Mar 18. |
body mass |
male |
126 days
| 6 |
|
|
445.0 |
g |
11.84 |
29.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103301 |
2803 |
LH/Mav |
body weight |
controlled perindopril content drinking water (1.5 mg/kg/d) (for 63 days) then controlled sodium chloride content drinking water (2 %) (for 8 days) |
Naelten G, et al., J Cardiovasc Pharmacol. 2011 Feb;57(2):240-5. doi: 10.1097/FJC.0b013e318204bb7b. |
body mass |
male |
119 days
| 8 |
|
|
380.0 |
g |
10.0 |
28.28 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103406 |
2824 |
LH/Mav |
body weight |
controlled hydralazine content drinking water (75 mg/kg/d) (for 63 days) and controlled hydrochlorothiazide content drinking water (15 mg/kg/d) (for 63 days) and controlled reserpine content drinking water (0.75 mg/kg/d) (for 63 days) then controlled sodium chloride content drinking water (2 %) (for 8 days) |
Naelten G, et al., J Cardiovasc Pharmacol. 2011 Feb;57(2):240-5. doi: 10.1097/FJC.0b013e318204bb7b. |
body mass |
male |
119 days
| 7 |
|
|
383.0 |
g |
7.0 |
18.52 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103408 |
2824 |
LH/Mav |
body weight |
controlled perindopril content drinking water (3 mg/kg/d) (for 63 days) |
Bertram D, et al., Am J Physiol Regul Integr Comp Physiol. 2002 Nov;283(5):R1041-5. doi: 10.1152/ajpregu.00620.2001. |
body mass |
male |
147 days-154 days |
6 |
|
|
436.0 |
g |
8.0 |
19.6 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103431 |
2825 |
GK |
body weight |
control condition |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
body mass |
male |
140 days
| 6 |
|
|
359.0 |
g |
6.0 |
14.7 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103489 |
2827 |
GK |
body weight |
salidroside (40 mg/kg) (for 28 days) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
body mass |
male |
168 days
| 6 |
|
|
367.0 |
g |
7.0 |
17.15 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103493 |
2827 |
WF/Mol |
body weight gain |
vehicle control condition then artificial aortocaval fistula (for 7 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 6 |
|
|
8.0 |
g |
2.0 |
4.9 |
body weighing method |
0.0 |
acf |
7 |
days |
|
change from surgery weight |
|
|
101342 |
2585 |
SS |
body weight |
standard diet |
Wu F, et al., Int J Hypertens. 2016;2016:9146870. doi: 10.1155/2016/9146870. Epub 2016 Dec 19. |
body mass |
male |
49 days
| 8 |
|
|
208.0 |
g |
2.72 |
7.7 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102270 |
2683 |
SS |
body weight |
controlled sodium chloride content diet (8 %) (for 42 days) |
Wu F, et al., Int J Hypertens. 2016;2016:9146870. doi: 10.1155/2016/9146870. Epub 2016 Dec 19. |
body mass |
male |
91 days
| 8 |
|
|
309.0 |
g |
6.36 |
18.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102272 |
2683 |
SS-Nppbem2Mcwi-/- |
body weight |
vehicle control condition |
Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. |
body mass |
male |
168 days
| 7 |
|
|
425.0 |
g |
22.0 |
58.21 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99758 |
2319 |
GK |
body weight |
controlled air oxygen content (21 %) (for 28 days) |
Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. |
body mass |
male |
16 days
| 5 |
|
|
379.0 |
g |
2.0 |
4.47 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103001 |
2784 |
GK |
body weight |
controlled air oxygen content (5 %) (for 28 days) |
Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. |
body mass |
male |
16 days
| 7 |
|
|
333.0 |
g |
6.0 |
15.87 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103002 |
2784 |
Crlj:WI |
body weight |
controlled air oxygen content (21 %) (for 28 days) |
Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. |
body mass |
male |
16 days
| 6 |
|
|
322.0 |
g |
6.0 |
14.7 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102999 |
2784 |
SD |
change in body weight |
unilateral nephrectomy (for 28 days) then spironolactone (5.56 mg/kg/d) (for 28 days) |
Greene EL, et al., J Clin Invest. 1996 Aug 15;98(4):1063-8. |
body mass |
male |
0 days
| 8 |
|
|
48.0 |
g |
10.96 |
31.0 |
body weighing method |
0.0 |
unx |
28 |
days |
|
change from surgery weight |
|
|
101610 |
2602 |
GK/Jcl |
body weight |
controlled hesperidin content diet (1 %) |
Akiyama S, et al., Biosci Biotechnol Biochem. 2009 Dec;73(12):2779-82. doi: 10.1271/bbb.90576. Epub 2009 Dec 7. |
body mass |
male |
24 days
| 6 |
|
|
52.98 |
g |
1.45 |
3.55 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103906 |
2884 |
GK/Jcl |
body weight |
controlled hesperidin content diet (1 %) |
Akiyama S, et al., Biosci Biotechnol Biochem. 2009 Dec;73(12):2779-82. doi: 10.1271/bbb.90576. Epub 2009 Dec 7. |
body mass |
male |
24 days
| 6 |
|
|
172.3 |
g |
5.83 |
14.28 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103910 |
2884 |
SR/JrHsd |
body weight |
controlled sodium content diet (0.1 %) (for 112 days) then sham surgical control condition (between 56 and 63 days) |
Esqueda ME, et al., Hypertension. 2007 Oct;50(4):768-72. Epub 2007 Aug 13. |
body mass |
female |
112 days
| 6 |
|
|
253.5 |
g |
4.9 |
12.0 |
body weighing method |
0.0 |
sham ovx |
63 |
days |
|
|
|
|
102343 |
2686 |
LH/Mav |
body weight |
streptozotocin (75 mg/kg) |
Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3. |
body mass |
male |
49 days-56 days |
37 |
|
|
233.0 |
g |
4.0 |
24.33 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102643 |
2703 |
SD |
body weight |
left nephrectomy (for 70 days) then puromycin (100 mg/kg) then anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) then puromycin (40 mg/kg) |
Ma LJ, et al., Kidney Int. 2004 Jan;65(1):106-15. |
body mass |
male |
0 days
| 7 |
|
|
267.0 |
g |
7.0 |
18.52 |
body weighing method |
0.0 |
unx |
70 |
days |
|
|
|
|
98935 |
2179 |
SD |
body weight |
left nephrectomy (for 70 days) then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (5 mg/kg) then puromycin (40 mg/kg) |
Ma LJ, et al., Kidney Int. 2004 Jan;65(1):106-15. |
body mass |
male |
0 days
| 9 |
|
|
281.0 |
g |
15.0 |
45.0 |
body weighing method |
0.0 |
unx |
70 |
days |
|
|
|
|
98936 |
2179 |
SS-Renem1Mcwi+/+ |
body weight |
controlled sodium content diet (0.4 %) (for 49 days) |
Moreno C, et al., Hypertension. 2011 Mar;57(3):614-9. doi: 10.1161/HYPERTENSIONAHA.110.163840. Epub 2011 Jan 17. |
body mass |
male |
70 days
| 5 |
|
|
301.0 |
g |
18.06 |
40.38 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
98191 |
2038 |
SS/NEisSlc |
body weight |
controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days) |
Ishikawa M, et al., Int Heart J. 2013;54(2):98-106. |
body mass |
male |
126 days
| 8 |
|
|
361.0 |
g |
9.0 |
25.46 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102311 |
2684 |
LH/Mav |
body weight |
control condition |
Egan EJ, et al., Acta Pharmacol Sin. 2008 Nov;29(11):1296-300. doi: 10.1111/j.1745-7254.2008.00862.x. |
body mass |
male |
112 days
| 4 |
|
|
374.0 |
g |
6.0 |
12.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102791 |
2723 |
GK/MolTac |
body weight |
control condition then controlled saxagliptin content diet (10 mg/kg/d) (for 12 days) |
Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. |
body mass |
male |
147 days
| 0 |
|
|
389.0 |
g |
7.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103985 |
2885 |
Crl:WI(WU) |
body weight |
abdominal aorta constriction then losartan (3 mg/kg/d) (for 14 days) |
Goetz RM and Holtz J, Clin Sci (Lond). 1999 Aug;97(2):165-74. |
body mass |
male |
91 days
| 14 |
|
|
274.0 |
g |
6.0 |
22.45 |
body weighing method |
0.0 |
aorta coarctation |
35 |
days |
|
|
|
|
100010 |
2398 |
SR/NEisSlc |
body weight |
controlled sodium chloride content diet (8 %) (for 14 days) |
Yoshihara F, et al., Regul Pept. 2005 May 15;128(1):7-13. |
body mass |
male |
70 days
| 8 |
|
|
309.0 |
g |
3.89 |
11.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102407 |
2689 |
SS/JrHsd |
body weight |
gelled diet (200 g/kg/d) (for 8 days) then carbenoxolone (100 mg/kg/d) (for 6 days) |
Fenton RA, et al., Am J Physiol Renal Physiol. 2003 Jul;285(1):F143-51. Epub 2003 Apr 8. |
body mass |
male |
0 days
| 6 |
|
|
139.0 |
g |
2.8 |
6.86 |
body weighing method |
0.0 |
osmotic pump implant |
6 |
days |
|
|
|
|
102545 |
2691 |
MWF/ZtmRrrc |
body weight |
vehicle control condition |
Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9. |
body mass |
male |
246 days
| 8 |
|
|
433.0 |
g |
9.19 |
26.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
100905 |
2541 |
MWF/ZtmRrrc |
body weight |
vehicle control condition |
Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9. |
body mass |
male |
126 days
| 7 |
|
|
385.0 |
g |
11.34 |
30.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
100903 |
2541 |
WKY |
body weight |
controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) |
Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. |
body mass |
male |
0 days
| 10 |
|
|
241.0 |
g |
5.0 |
15.81 |
body weighing method |
0.0 |
PA IV 50mg/kg |
15 |
days |
|
|
|
|
100393 |
2479 |
WKY |
body weight |
controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) |
Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. |
body mass |
male |
0 days
| 8 |
|
|
305.0 |
g |
6.0 |
16.97 |
body weighing method |
0.0 |
PA IV 50mg/kg |
0 |
|
|
|
|
|
100432 |
2479 |
WKY |
body weight |
0.9% sodium chloride solution (3 ml) |
Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. |
body mass |
male |
0 days
| 9 |
|
|
412.0 |
g |
6.0 |
18.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
100433 |
2479 |
WKY |
body weight |
puromycin aminonucleoside (50 mg/kg) |
Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. |
body mass |
male |
0 days
| 8 |
|
|
418.0 |
g |
15.0 |
42.43 |
body weighing method |
0.0 |
PA IV 50mg/kg |
490 |
days |
|
|
|
|
100434 |
2479 |
WF/Mol |
body weight |
controlled ramipril content drinking water (3 mg/kg/d) (for 5 days) then sham surgical control condition (for 4 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 5 |
|
|
193.0 |
g |
3.0 |
6.71 |
body weighing method |
0.0 |
sham acf |
4 |
days |
|
|
|
|
101301 |
2585 |
WF/Mol |
body weight |
controlled ramipril content drinking water (3 mg/kg/d) (for 8 days) then sham surgical control condition (for 7 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 5 |
|
|
186.0 |
g |
1.0 |
2.24 |
body weighing method |
0.0 |
sham acf |
7 |
days |
|
|
|
|
101305 |
2585 |
WF/Mol |
body weight |
controlled losartan content drinking water (10 mg/kg/d) (for 5 days) then sham surgical control condition (for 4 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 6 |
|
|
184.0 |
g |
2.0 |
4.9 |
body weighing method |
0.0 |
sham acf |
4 |
days |
|
|
|
|
101315 |
2585 |
WF/Mol |
body weight |
controlled losartan content drinking water (10 mg/kg/d) (for 8 days) then artificial aortocaval fistula (for 7 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 7 |
|
|
203.0 |
g |
3.0 |
7.94 |
body weighing method |
0.0 |
acf |
7 |
days |
|
|
|
|
101318 |
2585 |
WF/Mol |
body weight gain |
controlled losartan content drinking water (10 mg/kg/d) (for 3 days) then artificial aortocaval fistula (for 2 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 8 |
|
|
-12.0 |
g |
2.0 |
5.66 |
body weighing method |
0.0 |
acf |
2 |
days |
|
change from surgery weight |
|
|
101332 |
2585 |
WF/Mol |
body weight gain |
controlled losartan content drinking water (10 mg/kg/d) (for 3 days) then sham surgical control condition (for 2 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 6 |
|
|
-5.0 |
g |
2.0 |
4.9 |
body weighing method |
0.0 |
sham acf |
2 |
days |
|
change from surgery weight |
|
|
101333 |
2585 |
SS/Hsd |
body weight gain |
artificial cerebrospinal fluid with 0.15 M sodium (4.4-4.6 ul/hr) (for 14 days) |
Huang BS, et al., Am J Physiol Heart Circ Physiol. 2005 Feb;288(2):H517-24. doi: 10.1152/ajpheart.00651.2004. Epub 2004 Sep 30. |
body mass |
male |
52 days-61 days |
0 |
|
|
58.0 |
g |
4.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
change from surgery weight (2wks) |
|
|
103216 |
2801 |
SS/Jr |
body weight |
controlled sodium chloride content diet (8 %) (for 35 days) |
Vokurkov? M, et al., Hypertens Res. 2003 May;26(5):397-404. |
body mass |
male |
63 days
| 10 |
|
|
201.0 |
g |
20.0 |
63.25 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103237 |
2802 |
SS/JrHsdMcwi |
body weight |
control condition |
McPherson KC, et al., Am J Physiol Renal Physiol. 2016 Oct 1;311(4):F793-F804. doi: 10.1152/ajprenal.00590.2015. Epub 2016 Jul 27. |
body mass |
male |
42 days
| 27 |
|
|
176.0 |
g |
6.0 |
31.18 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
100067 |
2418 |
WKY |
body weight |
unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
body mass |
male |
0 days
| 8 |
|
|
233.0 |
g |
5.0 |
14.14 |
body weighing method |
0.0 |
unx |
28 |
days |
|
|
|
|
99938 |
2378 |
Crl:WI(WU) |
body weight |
thoracic aorta constriction |
Goetz RM and Holtz J, Clin Sci (Lond). 1999 Aug;97(2):165-74. |
body mass |
male |
91 days
| 8 |
|
|
282.0 |
g |
11.0 |
31.11 |
body weighing method |
0.0 |
aorta coarctation |
35 |
days |
|
|
|
|
100007 |
2398 |
SD-Nfe2l2em1Mcwi-/- |
body weight |
controlled sodium chloride content diet (0.4 %) (between 70 and 84 days) then controlled sodium chloride content diet (4 %) (for 3 days) then 0.9% sodium chloride solution (for 3 days) |
Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4. |
body mass |
male |
62 days-76 days |
4 |
|
|
299.0 |
g |
22.2 |
44.4 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
100734 |
2520 |
MW |
body weight |
right nephrectomy (for 112 days) then reserpine (5 mg/l) (for 56 days) and hydralazine (80 mg/l) (for 56 days) and controlled hydralazine content drinking water (25 mg/l) (for 56 days) |
Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55. |
body mass |
male |
0 days
| 10 |
|
|
244.3 |
g |
17.2 |
54.39 |
body weighing method |
0.0 |
~5/6 to 7/8 nephrectomy |
112 |
days |
|
|
|
|
100828 |
2523 |
SS/JrHsdMcwi |
body weight |
control condition |
Stodola TJ, et al., Physiol Genomics. 2011 Jul 14;43(13):808-17. doi: 10.1152/physiolgenomics.00171.2010. Epub 2011 Apr 26. |
body mass |
male |
49 days-63 days |
5 |
|
|
249.8 |
g |
14.4 |
32.2 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99011 |
2198 |
SS/JrHsdMcwi |
body weight |
control condition |
Stodola TJ, et al., Physiol Genomics. 2011 Jul 14;43(13):808-17. doi: 10.1152/physiolgenomics.00171.2010. Epub 2011 Apr 26. |
body mass |
male |
49 days-63 days |
4 |
|
|
259.4 |
g |
5.9 |
11.8 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99013 |
2198 |
MWF/ZtmRrrc |
body weight |
enalapril (50 mg/l) (for 60 days) |
Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9. |
body mass |
male |
126 days
| 8 |
|
|
373.0 |
g |
4.6 |
13.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
100904 |
2541 |
MHS |
body weight |
control condition |
Pugliese G, et al., Kidney Int. 2005 Apr;67(4):1440-52. doi: 10.1111/j.1523-1755.2005.00221.x. |
body mass |
male |
252 days
| 14 |
|
|
558.0 |
g |
7.48 |
28.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
104070 |
2907 |
MNS |
body weight |
streptozotocin (55 mg/kg) then insulin (4 IU/kg) (for 168 days) |
Pugliese G, et al., Kidney Int. 2005 Apr;67(4):1440-52. doi: 10.1111/j.1523-1755.2005.00221.x. |
body mass |
male |
252 days
| 12 |
|
|
345.0 |
g |
15.01 |
52.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
104069 |
2907 |
MHS |
body weight |
streptozotocin (55 mg/kg) then insulin (4 IU/kg) (for 168 days) |
Pugliese G, et al., Kidney Int. 2005 Apr;67(4):1440-52. doi: 10.1111/j.1523-1755.2005.00221.x. |
body mass |
male |
252 days
| 14 |
|
|
337.0 |
g |
12.56 |
47.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
104071 |
2907 |
Crl:WI |
body weight |
streptozotocin (55 mg/kg) then insulin (4 IU/kg) (for 168 days) |
Pugliese G, et al., Kidney Int. 2005 Apr;67(4):1440-52. doi: 10.1111/j.1523-1755.2005.00221.x. |
body mass |
male |
252 days
| 14 |
|
|
354.0 |
g |
10.69 |
40.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
104073 |
2907 |
MHS |
body weight |
standard diet |
Menini S, et al., J Hypertens. 2004 Nov;22(11):2185-92. |
body mass |
male |
63 days
| 10 |
|
|
235.0 |
g |
1.87 |
5.9 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
104194 |
2927 |
MHS |
body weight |
standard diet |
Menini S, et al., J Hypertens. 2004 Nov;22(11):2185-92. |
body mass |
male |
63 days
| 10 |
|
|
544.4 |
g |
11.45 |
36.2 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
104197 |
2927 |
SS-Sod3m1Mcwi |
body weight |
monocrotaline (40 mg/kg) |
Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. |
body mass |
male |
56 days
| 15 |
|
|
205.0 |
g |
4.6 |
17.82 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
106553 |
3032 |
Crl:WI |
body weight |
control condition |
Stepp DW, et al., Physiol Rep. 2013 Nov;1(6):e00146. doi: 10.1002/phy2.146. Epub 2013 Nov 13. |
body mass |
male |
70 days-140 days |
8 |
|
|
511.0 |
g |
45.0 |
127.28 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
105506 |
3017 |
Hsd:SD |
body weight |
control condition (for 84 days) |
Harrill JA, et al., Toxicol Appl Pharmacol. 2013 Oct 15;272(2):503-18. doi: 10.1016/j.taap.2013.06.024. Epub 2013 Jul 13. |
body mass |
male |
84 days
| 5 |
|
|
386.2 |
g |
20.4 |
45.62 |
body weighing method |
|
|
0 |
|
|
|
|
|
106438 |
3025 |
SD-Ahrem2Sage |
body weight |
control condition (for 84 days) |
Harrill JA, et al., Toxicol Appl Pharmacol. 2013 Oct 15;272(2):503-18. doi: 10.1016/j.taap.2013.06.024. Epub 2013 Jul 13. |
body mass |
female |
84 days
| 5 |
|
|
252.7 |
g |
18.8 |
42.04 |
body weighing method |
|
|
0 |
|
|
|
|
|
106441 |
3025 |
SBN/Ygl |
body weight |
sham surgical control condition (for 56 days) and water (for 56 days) and standard rat chow (for 56 days) |
Rothermund L, et al., Eur J Pharmacol. 2003 May 16;468(3):209-16. doi: 10.1016/s0014-2999(03)01714-x. |
body mass |
male |
16 days
| 8 |
|
|
328.0 |
g |
5.4 |
15.27 |
body weighing method |
0.0 |
|
0 |
|
|
n=8-15 |
|
|
106640 |
3035 |
SBH/Ygl |
body weight |
sham surgical control condition (for 56 days) and water (for 56 days) and standard rat chow (for 56 days) |
Rothermund L, et al., Eur J Pharmacol. 2003 May 16;468(3):209-16. doi: 10.1016/s0014-2999(03)01714-x. |
body mass |
male |
16 days
| 8 |
|
|
359.0 |
g |
3.1 |
8.77 |
body weighing method |
0.0 |
|
0 |
|
|
n=8-15 |
|
|
106643 |
3035 |
SBN/Ygl |
body weight |
deoxycorticosterone acetate (75 mg) (for 56 days) and controlled sodium content drinking water (1 %) (for 56 days) and darusentan (50 mg/kg/d) (for 56 days) |
Rothermund L, et al., Eur J Pharmacol. 2003 May 16;468(3):209-16. doi: 10.1016/s0014-2999(03)01714-x. |
body mass |
male |
16 days
| 8 |
|
|
377.0 |
g |
7.4 |
20.93 |
body weighing method |
0.0 |
|
0 |
|
|
n=8-15 |
|
|
106645 |
3035 |
Crl:WI |
body weight |
finerenone (10 mg/kg/d) (for 28 days) |
Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275. |
body mass |
male |
112 days
| 10 |
|
|
392.5 |
g |
12.7 |
40.16 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109388 |
3140 |
WAG/Rij |
body weight |
azoxymethane (15 mg/kg) |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
male |
91 days-0 days |
4 |
|
|
327.0 |
g |
10.0 |
20.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
107010 |
3074 |
F344/NHsd |
body weight |
azoxymethane (15 mg/kg) |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
female |
98 days-0 days |
8 |
|
|
224.0 |
g |
3.11 |
8.8 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
107004 |
3074 |
GK |
body weight |
running (3.91 km/d) (for 42 days) |
Kupai K, et al., Diabetol Metab Syndr. 2015 Oct 6;7:85. doi: 10.1186/s13098-015-0080-x. eCollection 2015. |
body mass |
male |
0 days
| 20 |
|
|
314.0 |
g |
2.7 |
12.07 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109896 |
3160 |
GK/CskCrlj |
body weight |
control condition |
Mine T, etal., Biol Pharm Bull. 2002 Nov;25(11):1412-6. doi: 10.1248/bpb.25.1412. |
body mass |
male |
224 days-238 days |
10 |
|
|
412.9 |
g |
10.8 |
34.15 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
106889 |
3070 |
SHRSP/A3NCrl |
body weight |
control condition |
Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. |
body mass |
male |
134 days-141 days |
8 |
|
|
332.0 |
g |
3.0 |
8.49 |
body weighing method |
0.0 |
|
0 |
|
normal diet |
normal diet |
|
|
106957 |
3073 |
F344/NHsd |
body weight |
control condition |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
female |
63 days
| 2 |
|
|
152.0 |
g |
0.0 |
5.7 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
106960 |
3074 |
F344/NHsd |
body weight |
0.9% sodium chloride solution (1 ml) |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
female |
91 days-0 days |
2 |
|
|
232.0 |
g |
4.53 |
6.4 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
107013 |
3074 |
COP/OlaHsd |
maximum body weight loss to initial body weight ratio |
arterial catheter implantation (for 1 days) |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
body mass |
male |
89 days-95 days |
10 |
|
|
3.9 |
% |
1.0 |
3.16 |
body weighing method |
0.0 |
arterial catheter implantation |
1 |
days |
|
|
|
|
107173 |
3077 |
BN/Crl |
body weight |
control condition |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
body mass |
male |
88 days-94 days |
10 |
|
|
259.0 |
g |
6.0 |
18.97 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
107346 |
3077 |
FHH/EurMcwiCrl |
body weight |
control condition |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
body mass |
male |
88 days-94 days |
10 |
|
|
361.0 |
g |
7.0 |
22.14 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
107349 |
3077 |
SS/HsdMcwiCrl |
body weight |
control condition |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
body mass |
male |
88 days-94 days |
8 |
|
|
341.0 |
g |
16.0 |
45.25 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
107348 |
3077 |
ACI/EurMcwi |
body weight |
control condition |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
body mass |
male |
88 days-94 days |
9 |
|
|
230.0 |
g |
4.0 |
12.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
107352 |
3077 |
PVG/OlaHsd |
body weight |
control condition |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
body mass |
male |
88 days-94 days |
10 |
|
|
261.0 |
g |
4.0 |
12.65 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
107358 |
3077 |
SHRSP/A3N |
body weight |
control condition |
Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. |
body mass |
male |
120 days-140 days |
24 |
|
|
316.0 |
g |
9.0 |
44.09 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
107572 |
3093 |
Hsd:WI |
fetal body weight |
control condition |
Rothermund L, etal., J Hypertens. 2006 Sep 24(9). |
body mass |
not specified |
-6 days
| 0 |
|
|
0.31 |
g |
0.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108070 |
3115 |
BN/HsdMcwiCrl |
volume of blood removed to total prehemorrhagic blood volume ratio |
arterial catheter implantation (for 1 days) then controlled hemorrhage (for 0.4 hours) |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
blood amount |
male |
89 days-95 days |
11 |
5.83 mL/100 g of body weight |
|
56.8 |
% |
0.4 |
1.33 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109124 |
3077 |
SHR-Chr 8MWF/Rkb |
body weight |
unilateral nephrectomy (for 126 days) |
Schulz A, etal., Physiol Genomics. 2012 Jan 18;44(1):110-6. Epub 2011 Nov 22. |
body mass |
male |
168 days
| 15 |
|
|
336.5 |
g |
6.7 |
25.95 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109552 |
3148 |
SHR-Chr 8MWF/Rkb |
body weight |
sham surgical control condition (for 126 days) |
Schulz A, etal., Physiol Genomics. 2012 Jan 18;44(1):110-6. Epub 2011 Nov 22. |
body mass |
male |
168 days
| 9 |
|
|
345.0 |
g |
7.8 |
23.4 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109551 |
3148 |
GK/Jpe |
body weight |
controlled cocoa butter content diet (7.5 null) (for 90 days) and controlled cholesterol content diet (1.25 null) (for 90 days) |
Sena CM, etal., Int J Mol Sci. 2018 Sep 11;19(9). pii: ijms19092706. doi: 10.3390/ijms19092706. |
body mass |
male |
540 days
| 7 |
|
|
410.9 |
g |
5.1 |
13.49 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110861 |
3193 |
SR/Hsd |
volume of blood removed to total prehemorrhagic blood volume ratio |
arterial catheter implantation (for 1 days) then controlled hemorrhage (for 0.4 hours) |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
blood amount |
male |
89 days-95 days |
10 |
5.83 mL/100 g of body weight |
|
56.0 |
% |
0.4 |
1.26 |
body weighing method |
0.0 |
|
0 |
|
|
volume of blood removed to total prehemorrhagic blood volume ratio (CMO:0003663) |
|
|
109129 |
3077 |
LH/MavRrrcAek |
body weight to body length (nose to rump) ratio |
standard rat chow (for 84 days) |
Wang J, et al., Circ Cardiovasc Genet. 2015 Apr;8(2):316-26. doi: 10.1161/CIRCGENETICS.114.000520. Epub 2015 Jan 8. |
body mass |
male |
84 days
| 0 |
|
|
15.9 |
g/cm |
0.21 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
107398 |
3014 |
MWF/Fub |
body weight |
controlled sodium content diet (8 %) (for 56 days) |
Kreutz R, etal., J Hypertens. 2000 Jun;18(6):777-82. doi: 10.1097/00004872-200018060-00017. |
body mass |
male |
104 days
| 8 |
|
|
310.0 |
g |
3.9 |
11.03 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109003 |
3134 |
MWF/Ztm |
body weight |
control condition |
Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882. |
body mass |
male |
45 days
| 5 |
|
|
170.0 |
g |
2.58 |
5.76 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109296 |
3137 |
LEW/Ztm |
body weight |
control condition |
Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882. |
body mass |
male |
10 days
| 5 |
|
|
20.1 |
g |
0.38 |
0.85 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109300 |
3137 |
LEW/Ztm |
body weight |
control condition |
Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882. |
body mass |
male |
150 days
| 5 |
|
|
365.9 |
g |
17.22 |
38.5 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109305 |
3137 |
MWF/Ztm |
body weight |
control condition |
Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882. |
body mass |
male |
150 days
| 5 |
|
|
420.5 |
g |
6.44 |
14.4 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109299 |
3137 |
LOU/MWsl |
change in body weight to initial body weight ratio |
doxorubicin (1 mg/kg) (for 42 days) |
van Hoesel QG, etal., J Natl Cancer Inst. 1984 May;72(5):1141-50. |
body mass |
male |
144 days
| 5 |
|
|
-15.0 |
% |
0.0 |
0.0 |
body weighing method |
0.0 |
|
42 |
days |
|
|
|
|
109753 |
3155 |
MWF/Fub |
body weight |
control condition |
Kreutz R, etal., J Hypertens. 2007 Nov;25(11):2308-16. doi: 10.1097/HJH.0b013e3282ef8611. |
body mass |
male |
112 days
| 8 |
|
|
372.8 |
g |
12.13 |
34.3 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109846 |
3156 |
NBL/CrCrl |
maximum body weight loss to initial body weight ratio |
arterial catheter implantation (for 1 days) |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
body mass |
male |
89 days-95 days |
10 |
|
|
2.7 |
% |
0.1 |
0.32 |
body weighing method |
0.0 |
arterial catheter implantation |
1 |
days |
|
|
|
|
107190 |
3077 |
GK/Wnsm |
body weight |
control condition |
El-Omar MM, et al., Basic Res Cardiol. 2004 Mar;99(2):133-41. doi: 10.1007/s00395-004-0440-4. Epub 2003 Oct 7. |
body mass |
male |
150 days-240 days |
6 |
|
|
379.6 |
g |
16.0 |
39.19 |
body weighing method |
0.0 |
|
0 |
|
|
at least 6 animals |
|
|
110440 |
3174 |
GK/MolTac |
body weight |
control condition |
Kold-Petersen H, etal., J Vasc Res. 2012;49(3):267-78. doi: 10.1159/000335487. Epub 2012 Apr 11. |
body mass |
male |
154 days
| 0 |
|
|
419.0 |
g |
7.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108027 |
3109 |
WM/Nem |
fetal body weight |
trypan blue (30 mg/kg) |
Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. |
body mass |
male |
-1 days
| 44 |
|
|
2.63 |
g |
0.05 |
0.34 |
body weighing method |
0.0 |
|
12 |
days |
|
|
|
|
111217 |
3199 |
GK |
body weight |
control condition |
Weng S, etal., Obes Surg. 2017 Mar;27(3):657-664. doi: 10.1007/s11695-016-2320-z. |
body mass |
male |
77 days
| 10 |
|
|
315.12 |
g |
4.13 |
13.06 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109066 |
3111 |
MWF/FubRkb |
fetal body weight |
control condition |
Rothermund L, etal., J Hypertens. 2006 Sep 24(9). |
body mass |
not specified |
-2 days
| 0 |
|
|
2.03 |
g |
0.05 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108069 |
3115 |
Hsd:WI |
neonatal body weight |
control condition |
Rothermund L, etal., J Hypertens. 2006 Sep 24(9). |
body mass |
not specified |
7 days
| 0 |
|
|
14.3 |
g |
0.2 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108078 |
3115 |
WAG/Rij |
body weight |
control condition |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
female |
98 days-0 days |
2 |
|
|
211.0 |
g |
4.53 |
6.4 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
106980 |
3074 |
BDIX/Orl |
body weight |
0.9% sodium chloride solution (0.4 ml) |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
male |
63 days
| 2 |
|
|
233.0 |
g |
26.52 |
37.5 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
106982 |
3074 |
F344/NHsd |
body weight |
0.9% sodium chloride solution (0.4 ml) |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
female |
56 days
| 2 |
|
|
135.0 |
g |
0.0 |
0.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
106983 |
3074 |
WAG/Rij |
body weight |
azoxymethane (15 mg/kg) |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
female |
63 days
| 8 |
|
|
146.0 |
g |
2.44 |
6.9 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
106989 |
3074 |
BDIX/Orl |
body weight |
azoxymethane (15 mg/kg) |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
female |
63 days
| 4 |
|
|
180.0 |
g |
2.35 |
4.7 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
106990 |
3074 |
WAG/Rij |
body weight |
azoxymethane (15 mg/kg) |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
male |
56 days
| 4 |
|
|
203.0 |
g |
4.9 |
9.8 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
106995 |
3074 |
NBL/CrCrl |
volume of blood removed to total prehemorrhagic blood volume ratio |
arterial catheter implantation (for 1 days) then controlled hemorrhage (for 0.4 hours) |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
blood amount |
male |
89 days-95 days |
10 |
5.83 mL/100 g of body weight |
|
56.7 |
% |
0.6 |
1.9 |
body weighing method |
|
|
0 |
|
|
volume of blood removed to total prehemorrhagic blood volume ratio (CMO:0003663) |
|
|
109138 |
3077 |
MWF/Hsd |
volume of blood removed to total prehemorrhagic blood volume ratio |
arterial catheter implantation (for 1 days) then controlled hemorrhage (for 0.4 hours) |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
blood amount |
male |
89 days-95 days |
10 |
5.83 mL/100 g of body weight |
|
57.5 |
% |
0.4 |
1.26 |
body weighing method |
0.0 |
|
0 |
|
|
volume of blood removed to total prehemorrhagic blood volume ratio (CMO:0003663) |
|
|
109136 |
3077 |
BDIX/CrCrl |
volume of blood removed to total prehemorrhagic blood volume ratio |
arterial catheter implantation (for 1 days) then controlled hemorrhage (for 0.4 hours) |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
blood amount |
male |
89 days-95 days |
10 |
5.83 mL/100 g of body weight |
|
56.9 |
% |
0.3 |
0.95 |
body weighing method |
|
|
0 |
|
|
volume of blood removed to total prehemorrhagic blood volume ratio (CMO:0003663) |
|
|
109137 |
3077 |
WAG/Nov |
body weight |
control condition |
Ragaeva DS, et al., Physiol Behav. 2017 Jun 1;175:22-30. doi: 10.1016/j.physbeh.2017.03.026. Epub 2017 Mar 21. |
body mass |
male |
25 days
| 15 |
|
|
40.6 |
g |
5.3 |
20.53 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110676 |
3182 |
BDIX/Nem |
fetal body weight |
trypan blue (120 mg/kg) |
Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. |
body mass |
female |
-1 days
| 42 |
|
|
2.58 |
g |
0.05 |
0.34 |
body weighing method |
0.0 |
|
12 |
days |
|
|
|
|
111232 |
3199 |
BDIX/Nem |
fetal body weight |
trypan blue (60 mg/kg) |
Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. |
body mass |
female |
-1 days
| 58 |
|
|
2.66 |
g |
0.03 |
0.24 |
body weighing method |
0.0 |
|
12 |
days |
|
|
|
|
111231 |
3199 |
WAG/RijCrl |
body weight |
CC531 cells (25 X 10E3) (for 28 days) |
Echevarria-Uraga JJ, et al., Int J Nanomedicine. 2012;7:2399-410. doi: 10.2147/IJN.S31302. Epub 2012 May 9. |
body mass |
male |
148 days
| 23 |
|
|
288.0 |
g |
7.24 |
34.7 |
body weighing method |
0.0 |
CC531 injection |
28 |
days |
|
|
|
|
107971 |
3104 |
BDIX/Nem |
fetal body weight |
control condition |
Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. |
body mass |
female |
-1 days
| 40 |
|
|
2.74 |
g |
0.02 |
0.15 |
body weighing method |
0.0 |
|
12 |
days |
|
|
|
|
111230 |
3199 |
GK/Far |
body weight |
control condition |
Nobrega MA, et al., Diabetes 2004 Mar;53(3):735-42. |
body mass |
male |
180 days
| 6 |
|
|
351.0 |
g |
13.0 |
31.84 |
body weighing method |
0.0 |
|
0 |
|
|
n=6-27 |
|
|
110591 |
3177 |
WKY |
body weight |
unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days) |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
body mass |
male |
0 days
| 16 |
|
|
261.0 |
g |
7.0 |
28.0 |
body weighing method |
0.0 |
unx |
150 |
days |
|
|
|
|
107448 |
2378 |
GK/MolTac |
body weight |
control condition |
Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. |
body mass |
female |
56 days
| 9 |
|
|
188.0 |
g |
3.0 |
9.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110243 |
3168 |
HanTac:WH |
body weight |
anti-rh-VEGF165 monoclonal antibody (1 mg) (for 14 days) |
Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. |
body mass |
female |
70 days
| 8 |
|
|
208.0 |
g |
4.0 |
11.31 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110246 |
3168 |
GK/MolTac |
body weight |
control IgG monoclonal antibody (1 mg) (for 14 days) |
Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. |
body mass |
female |
70 days
| 9 |
|
|
207.0 |
g |
5.0 |
15.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110247 |
3168 |
WAG |
body weight |
CC531 cells (5 X 10E6) (for 21 days) then phosphoramidon (250 mg) (for 21 days) |
Pross M, et al., Surg Endosc. 2001 Aug;15(8):882-5. doi: 10.1007/s004640090029. Epub 2001 May 2. |
body mass |
male |
0 days
| 16 |
|
|
281.87 |
g |
1.98 |
7.91 |
body weighing method |
0.0 |
IP injection |
21 |
days |
cells and vehicle injected |
|
|
|
107873 |
3098 |
WAG |
body weight |
CC531 cells (5 X 10E6) (for 21 days) then vehicle control condition (1 ml) (for 21 days) |
Pross M, et al., Surg Endosc. 2001 Aug;15(8):882-5. doi: 10.1007/s004640090029. Epub 2001 May 2. |
body mass |
male |
0 days
| 16 |
|
|
272.4 |
g |
3.35 |
13.4 |
body weighing method |
0.0 |
IP injection |
21 |
days |
cells and vehicle injected |
|
|
|
107872 |
3098 |
BDIX/OrlCrl |
body weight |
control condition |
Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. |
body mass |
male |
0 days
| 5 |
|
|
196.0 |
g |
4.47 |
10.0 |
body weighing method |
0.0 |
|
0 |
|
|
baseline group B |
|
|
111022 |
3195 |
WM/Nem |
fetal body weight |
trypan blue (20 mg/kg) |
Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. |
body mass |
female |
-1 days
| 40 |
|
|
2.76 |
g |
0.02 |
0.1 |
body weighing method |
0.0 |
|
12 |
days |
|
|
|
|
111225 |
3199 |
WM/Nem |
fetal body weight |
trypan blue (120 mg/kg) |
Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. |
body mass |
female |
-1 days
| 26 |
|
|
2.32 |
g |
0.09 |
0.47 |
body weighing method |
0.0 |
|
12 |
days |
|
|
|
|
111229 |
3199 |
SHRSP/A3N |
body weight |
controlled sodium content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) and controlled carvedilol content diet (2400 ppm) (for 126 days) |
Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. |
body mass |
male |
203 days-224 days |
10 |
|
|
367.0 |
g |
10.0 |
31.62 |
body weighing method |
0.0 |
|
0 |
|
|
high salt high fat diet +carvedilol |
|
|
107103 |
3075 |
BDIX/CrCrl |
maximum body weight loss to initial body weight ratio |
arterial catheter implantation (for 1 days) |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
body mass |
male |
89 days-95 days |
10 |
|
|
3.1 |
% |
0.6 |
1.9 |
body weighing method |
0.0 |
arterial catheter implantation |
1 |
days |
|
|
|
|
107189 |
3077 |
SHR-Chr 6MWF/Rkb |
body weight |
control condition |
Schulz A, etal., Physiol Genomics. 2010 Jun. |
body mass |
male |
84 days
| 0 |
|
|
280.5 |
g |
15.3 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109036 |
3116 |
SHR/FubRkb |
body weight |
controlled NG-nitroarginine methyl ester content drinking water (5 mg/kg/d) (for 42 days) |
Schulz A, etal., Physiol Genomics. 2010 Jun. |
body mass |
male |
84 days
| 0 |
|
|
263.5 |
g |
9.8 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109035 |
3116 |
SHR-Chr 6MWF/Rkb |
body weight |
controlled NG-nitroarginine methyl ester content drinking water (5 mg/kg/d) (for 42 days) |
Schulz A, etal., Physiol Genomics. 2010 Jun. |
body mass |
male |
84 days
| 0 |
|
|
277.5 |
g |
17.9 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109038 |
3116 |
MWF/FubRkb |
body weight |
controlled NG-nitroarginine methyl ester content drinking water (5 mg/kg/d) (for 42 days) |
Schulz A, etal., Physiol Genomics. 2010 Jun. |
body mass |
male |
84 days
| 0 |
|
|
270.7 |
g |
4.9 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109040 |
3116 |
BN/SsNHsd |
body weight |
control condition |
Keele GR, etal., Obesity (Silver Spring). 2018 Jan;26(1):213-222. doi: 10.1002/oby.22075. Epub 2017 Nov 28. |
body mass |
male |
119 days
| 10 |
|
|
283.5 |
g |
4.47 |
14.12 |
body weighing method |
|
|
0 |
|
|
|
|
|
138388 |
3200 |
ACI/EurMcwi |
body weight |
control condition |
Keele GR, etal., Obesity (Silver Spring). 2018 Jan;26(1):213-222. doi: 10.1002/oby.22075. Epub 2017 Nov 28. |
body mass |
male |
119 days
| 18 |
|
|
289.28 |
g |
7.64 |
32.41 |
body weighing method |
|
|
0 |
|
|
|
|
|
138383 |
3200 |
BUF/NHsd |
body weight |
control condition |
Keele GR, etal., Obesity (Silver Spring). 2018 Jan;26(1):213-222. doi: 10.1002/oby.22075. Epub 2017 Nov 28. |
body mass |
male |
119 days
| 8 |
|
|
365.25 |
g |
24.86 |
70.32 |
body weighing method |
|
|
0 |
|
|
|
|
|
138393 |
3200 |
M520/N |
nose to tail body mass index |
control condition |
Keele GR, etal., Obesity (Silver Spring). 2018 Jan;26(1):213-222. doi: 10.1002/oby.22075. Epub 2017 Nov 28. |
body mass |
male |
119 days
| 11 |
|
|
1.88 |
(g/cm2) x 10 |
0.05 |
0.18 |
body weighing method |
|
|
0 |
|
|
|
|
|
138405 |
3200 |
SD-Apoeem1Sage |
body weight |
control condition |
Ekuni D, et al., Lipids Health Dis. 2014 Sep 5;13:144. doi: 10.1186/1476-511X-13-144. |
body mass |
male |
56 days
| 7 |
|
|
421.4 |
g |
11.0 |
29.1 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
138265 |
2968 |
SS/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 25 and 28 days) |
Kumarasamy S, et al., Hypertens Res. 2011 Dec;34(12):1263-70. doi: 10.1038/hr.2011.116. Epub 2011 Aug 4. |
body mass |
not specified |
0 days
| 0 |
|
|
334.0 |
g |
5.6 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67531 |
749 |
ACI.FHH-(D1Rat475-D1Rat90)(D3Rat84-D3Rat59)/Eur |
body weight |
right nephrectomy |
Van Dijk SJ, et al., Kidney Int. 2006 |
body mass |
male |
168 days-175 days |
12 |
|
|
304.0 |
g |
5.0 |
17.32 |
body weighing method |
|
|
0 |
|
|
|
|
|
11953 |
62 |
F344.OLETF-(D1Rat166-D1Rat90)/Tj |
body weight |
fasting (for 16 hours) |
Kose H, et al., Mamm Genome 2002 Oct;13(10):558-62. |
body mass |
male |
210 days
| 15 |
|
|
382.8 |
g |
4.8 |
18.59 |
body weighing method |
|
|
0 |
|
|
|
|
|
12027 |
230 |
SS/Jr |
body weight |
controlled sodium content diet |
Garrett MR, et al., Physiol Genomics 2000 Jun 29;3(1):33-8. |
body mass |
male |
53 days
| 10 |
|
|
222.0 |
g |
5.1 |
16.13 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
66105 |
691 |
SS.LEW-(D18Rat61-D18Rat45)/Ayd |
body weight |
controlled sodium content diet (2 %) (between 35 and 98 days) |
Duong C, et al., Mamm Genome 2006; 17(12): 1147-1161 |
body mass |
male |
98 days
| 6 |
|
|
379.0 |
g |
8.0 |
19.6 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12073 |
226 |
F344.OLETF-(D10Wox7-D10Wox6)/Tj |
body weight |
fasting (for 16 hours) |
Kose H, et al., Mamm Genome 2002 Oct;13(10):558-62. |
body mass |
male |
210 days
| 7 |
|
|
345.3 |
g |
2.8 |
7.41 |
body weighing method |
|
|
0 |
|
|
|
|
|
12083 |
230 |
F344.OLETF-(D16Wox4-D16Rat13)/Tj |
body weight |
fasting (for 16 hours) |
Kose H, et al., Mamm Genome 2002 Oct;13(10):558-62. |
body mass |
male |
210 days
| 10 |
|
|
378.4 |
g |
6.5 |
20.55 |
body weighing method |
|
|
0 |
|
|
|
|
|
12081 |
230 |
F344/NHsd |
body weight |
control condition |
Sebkhi A, et al., Hypertension 1999 Apr;33(4):949-53. |
body mass |
not specified |
84 days
| 23 |
|
|
262.8 |
g |
4.48 |
21.5 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
12133 |
233 |
SS/Jr |
body weight |
controlled sodium content diet (2 %) (for 24 days) |
Saad Y, et al., Mamm Genome. 2008 Jan 4 |
body mass |
male |
64 days-68 days |
20 |
|
|
308.0 |
g |
1.28 |
5.72 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12142 |
232 |
SS.MNS-(D10Mco30-D10Got91)/1Mco |
body weight |
controlled sodium content diet (2 %) (for 24 days) |
Saad Y, et al., Mamm Genome. 2008 Jan 4 |
body mass |
male |
64 days-68 days |
20 |
|
|
306.0 |
g |
2.31 |
10.33 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12150 |
232 |
SHR.SS-(D13Rat1-D13Mgh6)/Mco |
body weight |
controlled sodium content diet (0.3 %) |
Packard M, et al., Am J Physiol Renal Physiol. 2009 Apr;296(4):F839-46. Epub 2009 Jan 28. |
body mass |
male |
84 days
| 12 |
|
|
298.0 |
g |
3.6 |
12.47 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12337 |
246 |
SS.SR-(D7Mco19-D7Mco7)/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 28 days) then controlled sodium content diet (4 %) (between 46 and 48 days) |
Cicila GT, et al., Hypertension. 2009 Apr;53(4):725-32. Epub 2009 Mar 2. |
body mass |
male |
114 days-118 days |
3 |
|
|
360.3 |
g |
15.3 |
26.5 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65099 |
283 |
F344.GK-(D1Arb42a-D1Rat90)/Swe |
body weight |
fasting (for 6 hours) |
Granhall C, et al., Genetics. 2006 Nov;174(3):1565-72. Epub 2006 Sep 1. |
body mass |
male |
95 days
| 24 |
|
|
286.0 |
g |
3.0 |
14.7 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
13088 |
330 |
SS/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 28 days) |
Saad Y, et al., Physiol Genomics 2001 Jan 19;4(3):201-14. |
body mass |
male |
68 days-70 days |
20 |
|
|
305.0 |
g |
4.02 |
17.98 |
body weighing method |
|
|
0 |
|
|
|
|
|
12492 |
266 |
SS.LEW-(D1Uia8-D1Rat18)/Mco |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 28 days) |
Saad Y, et al., Physiol Genomics 2001 Jan 19;4(3):201-14. |
body mass |
male |
68 days-70 days |
20 |
|
|
308.0 |
g |
1.72 |
7.69 |
body weighing method |
|
|
0 |
|
|
|
|
|
12505 |
266 |
BN.GK-(D8Got302-D8Got130)/Ox |
body weight |
control condition |
Wallis RH, et al., Diabetologia 2004 Jun;47(6):1096-106. Epub 2004 May 26 |
body mass |
male |
84 days
| 17 |
|
|
244.0 |
g |
5.0 |
20.62 |
body weighing method |
|
|
0 |
|
|
|
|
|
11291 |
66 |
BN.GK-(D8Rat29-D8Got130)/Ox |
body weight |
control condition |
Wallis RH, et al., Diabetologia 2004 Jun;47(6):1096-106. Epub 2004 May 26 |
body mass |
female |
84 days
| 15 |
|
|
164.0 |
g |
4.0 |
15.49 |
body weighing method |
|
|
0 |
|
|
|
|
|
11296 |
66 |
F344/DuCrl |
body weight |
control condition |
Galli J, et al., NatGenet 1996 Jan;12(1):31-7. |
body mass |
not specified |
80 days
| 10 |
|
|
168.0 |
g |
16.0 |
50.6 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
11401 |
82 |
SS.LEW-(D1Mco36-D1Mco77)/Mco |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 24 days) |
Toland EJ, et al., Mamm Genome. 2008 Mar;19(3):209-18. Epub 2008 Mar 7. |
body mass |
male |
64 days-66 days |
20 |
|
|
334.0 |
g |
2.4 |
10.73 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12875 |
313 |
SHR/Mol |
body weight |
control condition |
Kloting I, et al., Biochem Biophys Res Commun 2001 Jun 29;284(5):1126-33. |
body mass |
female |
98 days
| 12 |
|
|
201.0 |
g |
2.31 |
8.0 |
body weighing method |
|
|
0 |
|
|
|
|
|
12941 |
323 |
SS.SHR-(D9Wox16-D9Mco77)/Mco |
body weight |
controlled sodium content diet (2 %) (for 28 days) |
Toland EJ, et al., J Hypertens. 2008 Nov;26(11):2134-41. |
body mass |
male |
68 days-70 days |
20 |
|
|
301.0 |
g |
5.65 |
25.27 |
body weighing method |
|
|
0 |
|
|
|
|
|
12951 |
305 |
SS.SHR-(D9Wox16-D9Rat64)/Mco |
body weight |
controlled sodium content diet (2 %) (for 28 days) |
Toland EJ, et al., J Hypertens. 2008 Nov;26(11):2134-41. |
body mass |
male |
68 days-70 days |
20 |
|
|
311.0 |
g |
3.93 |
17.58 |
body weighing method |
|
|
0 |
|
|
|
|
|
12943 |
305 |
SS.SHR-(D9Wox16-D9Mco85)/Mco |
body weight |
controlled sodium content diet (2 %) (for 28 days) |
Toland EJ, et al., J Hypertens. 2008 Nov;26(11):2134-41. |
body mass |
male |
68 days-70 days |
14 |
|
|
295.0 |
g |
3.95 |
14.78 |
body weighing method |
|
|
0 |
|
|
|
|
|
12954 |
305 |
SS.SHR-(D9Rat7-D9Mco93)/Mco |
body weight |
controlled sodium content diet (2 %) (for 28 days) |
Toland EJ, et al., J Hypertens. 2008 Nov;26(11):2134-41. |
body mass |
male |
68 days-70 days |
20 |
|
|
314.0 |
g |
2.76 |
12.34 |
body weighing method |
|
|
0 |
|
|
|
|
|
12957 |
305 |
SHRSP/Izm |
body weight |
control condition (0 null) |
Kato N, et al., Hypertension 2003 DXCO;42(6):1191-7. |
body mass |
male |
91 days
| 5 |
|
|
245.4 |
g |
5.9 |
13.19 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
64828 |
115 |
SS.SR-(D7Rat16-D7Rat176)/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 24 and 27 days) |
Cicila GT, et al., Genomics 2001 Feb 15;72(1):51-60. |
body mass |
male |
68 days-70 days |
19 |
|
|
306.4 |
g |
1.7 |
7.41 |
body weighing method |
|
|
0 |
|
|
|
|
|
11830 |
147 |
HTG |
body weight |
control condition |
Ueno T, et al., Physiol Genomics 2004 Mar 12;17(1):38-47. |
body mass |
male |
150 days-180 days |
10 |
|
|
309.3 |
g |
15.9 |
50.28 |
body weighing method |
|
|
0 |
|
|
|
|
|
13151 |
120 |
E3/Ztm |
body weight gain |
spinal cord homogenate (10 mg) |
Bergsteinsdottir K, et al., J Immunol 2000 Feb 1;164(3):1564-8 |
body mass |
male |
56 days-103 days |
3 |
|
|
39.0 |
g |
5.2 |
9.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
69957 |
1258 |
DA/Bkl |
body weight loss |
type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) |
Griffiths MM, et al., Arthritis Rheum 2000 Jun;43(6):1278-89 |
body mass |
both |
66 days-126 days |
105 |
|
|
19.0 |
% |
0.49 |
5.0 |
body weighing method |
0.0 |
immunized |
10 |
days |
variable |
(weight loss) |
|
|
69960 |
850 |
ACI.FHH-(D3Wox2-D3Rat59)/Eur |
body weight |
NG-nitroarginine methyl ester (50-150 mg/l) |
Van Dijk SJ, et al., Kidney Int. 2006 |
body mass |
male |
168 days-175 days |
12 |
|
|
321.0 |
g |
4.0 |
13.86 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67701 |
62 |
WKY.SHR-(D1Wox19-D1Mit2)/Njs |
body weight |
left nephrectomy |
Clemitson JR, et al., Hypertension 2002 Sep;40(3):292-7 |
body mass |
male |
175 days
| 19 |
|
|
341.3 |
g |
6.81 |
29.7 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67745 |
110 |
Crl:SD |
body weight |
controlled fructose content drinking water (5 %) and controlled bisphenol A content drinking water (0.25 mg/l) |
Ronn M, et al., Toxicology. 2013 Jan 7;303:125-32. doi: 10.1016/j.tox.2012.09.013. Epub 2012 Nov 8. |
body mass |
female |
35 days
| 12 |
|
|
88.7 |
g |
2.97 |
10.3 |
body weighing method |
0.0 |
|
0 |
|
|
week one |
|
|
75750 |
1538 |
DA/Ztm |
maximum body weight loss to initial body weight ratio |
squalene (200 ul) |
Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. |
body mass |
both |
120 days-200 days |
9 |
|
|
12.8 |
% |
0.9 |
2.7 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
69807 |
1162 |
BluHsd:LE |
body weight |
controlled in utero environment (for 9 days) and bisphenol A (2.5 ug/kg) (for 30 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days) |
Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. |
body mass |
male |
98 days
| 8 |
|
|
485.7 |
g |
16.9 |
47.8 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
76154 |
1543 |
BluHsd:LE |
body weight gain |
controlled in utero environment (for 9 days) and bisphenol A (2.5 ug/kg) (for 30 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days) |
Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. |
body mass |
male |
71 days-98 days |
8 |
|
|
146.1 |
g |
9.1 |
25.74 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
76162 |
1543 |
Crl:SD |
body weight gain |
controlled ethanol content drinking water (1 %) (for 70 days) |
Ronn M, et al., Toxicology. 2013 Jan 7;303:125-32. doi: 10.1016/j.tox.2012.09.013. Epub 2012 Nov 8. |
body mass |
female |
35 days-105 days |
12 |
|
|
80.1 |
g |
2.6 |
9.0 |
body weighing method |
0.0 |
|
0 |
|
|
week one |
|
|
75757 |
1538 |
SR/Hsd |
cubic root of body weight to nasoanal length ratio |
controlled sodium content diet (0.3 %) then fasting (for 16 hours) |
Herrera VL, et al., Circ Res 2004 Mar 5; 94(4):446-52 |
body mass |
female |
180 days
| 14 |
|
|
306.0 |
g/mm x 10000 |
2.0 |
7.48 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67894 |
204 |
FHH/Eur |
body weight |
controlled hydrogen ion content drinking water (2.4-2.8 pH) |
Van Dijk SJ, et al., Nephron Exp Nephrol 2005 Jun 20;101(2):e59-e66. |
body mass |
male |
98 days
| 15 |
|
|
308.0 |
g |
4.0 |
15.49 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
68034 |
751 |
Crl:CD(SD) |
body weight |
standard diet |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
71 days
| 19 |
|
|
373.0 |
g |
4.59 |
20.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85310 |
1604 |
GK/Ox |
body weight |
fasting (between 16 and 18 hours) |
Finlay C, et al., Mamm Genome. 2010 Oct;21(9-10):499-508. Epub 2010 Sep 29. |
body mass |
female |
60 days
| 6 |
|
|
176.0 |
g |
5.0 |
12.25 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
68771 |
1012 |
Crl:CD(SD) |
body weight |
standard diet and restricted feeding (4 h) then acetaminophen (300 mg/kg) (for 56 days) |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
126 days
| 8 |
|
|
404.0 |
g |
12.37 |
35.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85540 |
1604 |
HanTac:WH |
body weight |
bisphenol A (0.025 mg/kg/d) (between 16 and 17 days) |
Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. |
body mass |
male |
16 days-17 days |
20 |
|
|
29.9 |
g |
0.96 |
4.3 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
96613 |
1559 |
BN/Cub |
body weight |
controlled sucrose content diet (for 7 days) then dexamethasone (0.03 mg/ml) (for 3 days) |
Seda O, et al., Physiol Genomics. 2005 Apr 14;21(2):243-52. Epub 2005 Feb 22. |
body mass |
male |
310 days
| 6 |
|
|
257.6 |
g |
10.29 |
25.2 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
70212 |
1318 |
ACI.FHH-(D1Rat384-D1Rat452)(D17Rat61-D1Arb5)(D17Rat51)/Eur |
body weight |
unilateral nephrectomy then NG-nitroarginine methyl ester (10-21 ml/kg/d) (for 126 days) |
van Dijk SJ, et al., Nephron Exp Nephrol. 2006;104(3):e96-e102. Epub 2006 Jul 12. |
body mass |
not specified |
168 days-175 days |
9 |
|
|
277.0 |
g |
6.0 |
18.0 |
body weighing method |
0.0 |
unilateral nephrectomy |
126 |
days |
|
|
|
|
67910 |
832 |
ACI/Eur |
body weight |
unilateral nephrectomy then controlled NG-nitroarginine methyl ester content in acidified drinking water (11-15 mg/kg/d) (for 126 days) |
Van Dijk SJ, et al., Nephron Exp Nephrol 2005 Jun 20;101(2):e59-e66. |
body mass |
male |
173 days-180 days |
11 |
|
|
292.0 |
g |
9.0 |
29.85 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67681 |
751 |
Iusm:LAD1 |
body weight |
control condition |
Alam I, etal., Alcohol Clin Exp Res. 2005 Oct;29(10):1769-76. doi: 10.1097/01.alc.0000183005.28502.4f. |
body mass |
male |
120 days
| 16 |
|
geometric mean |
442.5 |
g |
4.56 |
18.24 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
138515 |
3202 |
SD |
body weight |
control condition |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
male |
70 days-84 days |
6 |
|
|
257.3 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84764 |
1602 |
SS.BN-(D13Rat25-RN34_13048990782)/Mcwi |
body weight |
common peroneal nerve direct electrical stimulation (3 V) (for 8 hours) then controlled losartan content drinking water (50 mg/kg/d) (for 7 days) |
Stodola TJ, et al., Physiol Genomics. 2011 Jul 14;43(13):808-17. doi: 10.1152/physiolgenomics.00171.2010. Epub 2011 Apr 26. |
body mass |
male |
56 days-70 days |
10 |
|
|
275.8 |
g |
9.6 |
30.36 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99010 |
2198 |
SS/JrHsdMcwi |
body weight |
common peroneal nerve direct electrical stimulation (3 V) (for 8 hours) then angiotensin II (3 ng/kg/min) (for 7 days) then controlled losartan content drinking water (50 mg/kg/d) (for 7 days) |
Stodola TJ, et al., Physiol Genomics. 2011 Jul 14;43(13):808-17. doi: 10.1152/physiolgenomics.00171.2010. Epub 2011 Apr 26. |
body mass |
male |
56 days-70 days |
3 |
|
|
282.8 |
g |
2.9 |
5.02 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99016 |
2198 |
PXO2/Cub |
body weight |
controlled sucrose content diet (70 % of calories) (between 0 and 168 hours) and controlled protein content diet (19.6 % of calories) (between 0 and 168 hours) and controlled fat content diet (10.4 % of calories) (between 0 and 168 hours) then fasting (between 0 and 16 hours) |
Hodulova M, et al., PLoS One. 2014 Oct 8;9(10):e109983. doi: 10.1371/journal.pone.0109983. eCollection 2014. |
body mass |
male |
127 days
| 11 |
|
|
270.2 |
g |
4.7 |
15.59 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97164 |
1858 |
PXO3-1/Cub |
body weight |
controlled sucrose content diet (70 % of calories) (between 0 and 168 hours) and controlled protein content diet (19.6 % of calories) (between 0 and 168 hours) and controlled fat content diet (10.4 % of calories) (between 0 and 168 hours) then fasting (between 0 and 16 hours) |
Hodulova M, et al., PLoS One. 2014 Oct 8;9(10):e109983. doi: 10.1371/journal.pone.0109983. eCollection 2014. |
body mass |
male |
127 days
| 10 |
|
|
306.3 |
g |
5.1 |
16.13 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97170 |
1858 |
PXO7-1/Cub |
body weight |
controlled sucrose content diet (70 % of calories) (between 0 and 168 hours) and controlled protein content diet (19.6 % of calories) (between 0 and 168 hours) and controlled fat content diet (10.4 % of calories) (between 0 and 168 hours) then fasting (between 0 and 16 hours) |
Hodulova M, et al., PLoS One. 2014 Oct 8;9(10):e109983. doi: 10.1371/journal.pone.0109983. eCollection 2014. |
body mass |
male |
127 days
| 8 |
|
|
250.9 |
g |
3.8 |
10.75 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97161 |
1858 |
CrljJcl:SD |
body weight |
gestation (for 14 days) |
Xu X, et al., Neurotoxicol Teratol. 2011 Jul-Aug;33(4):458-63. doi: 10.1016/j.ntt.2011.06.002. Epub 2011 Jun 17. |
body mass |
female |
0 days
| 6 |
|
|
282.33 |
g |
20.46 |
50.12 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
75901 |
1539 |
CrljJcl:SD |
body weight |
gestation (for 21 days) then controlled bisphenol A content drinking water (0.01 mg/l) (for 31 days) then lactation (for 21 days) |
Xu X, et al., Neurotoxicol Teratol. 2011 Jul-Aug;33(4):458-63. doi: 10.1016/j.ntt.2011.06.002. Epub 2011 Jun 17. |
body mass |
female |
0 days
| 8 |
|
|
258.37 |
g |
14.66 |
41.46 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
75910 |
1539 |
MW |
body weight |
right nephrectomy (for 56 days) then lisinopril (10 mg/kg/d) |
Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55. |
body mass |
male |
0 days
| 10 |
|
|
282.7 |
g |
5.1 |
16.13 |
body weighing method |
0.0 |
~5/6 to 7/8 nephrectomy |
56 |
days |
|
|
|
|
100803 |
2523 |
SR/JrHsd |
body weight |
controlled sodium chloride content diet (4 %) (for 14 days) then sham surgical control condition then peanut oil (0.2 ml) (for 14 days) |
Zheng W, et al., Am J Physiol Heart Circ Physiol. 2008 Apr;294(4):H1508-13. doi: 10.1152/ajpheart.01322.2007. Epub 2008 Feb 1. |
body mass |
female |
0 days
| 0 |
|
|
232.0 |
g |
4.1 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102184 |
2681 |
F344.ZUC-(Leprfa),OLETF-(D5Rat166-D5Rat90)/Tj |
body weight |
control condition |
Kotoh J, et al., J Vet Med Sci. 2016 Aug 11. |
body mass |
male |
175 days
| 5 |
|
|
595.36 |
g |
17.66 |
39.49 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
98034 |
1978 |
WKY |
body weight |
sham surgical control condition |
Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. |
body mass |
male |
42 days-56 days |
12 |
|
|
223.0 |
g |
1.4 |
4.85 |
body weighing method |
0.0 |
lad occlusion |
0 |
days |
|
|
|
|
100267 |
2460 |
iNP/Iusm |
body weight |
control condition |
Alam I, et al., J Bone Miner Res. 2010 Jan 8. |
body mass |
male |
180 days
| 8 |
|
|
639.0 |
g |
10.25 |
29.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
12754 |
308 |
SHRSR/Ta |
body weight |
control condition |
Ohashi H, et al., Jpn Circ J. 1986 Feb;50(2):140-6. |
body mass |
male |
245 days
| 6 |
|
|
334.2 |
g |
19.15 |
46.9 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99848 |
2338 |
SD |
change in body weight |
unilateral nephrectomy (between 12 and 14 days) |
Greene EL, et al., J Clin Invest. 1996 Aug 15;98(4):1063-8. |
body mass |
male |
0 days
| 11 |
|
|
66.0 |
g |
7.84 |
26.0 |
body weighing method |
0.0 |
unx |
13 |
days |
|
change from surgery weight |
|
|
101540 |
2602 |
LN/MavRrrcAek |
body weight area under curve (AUC) |
standard rat chow (for 98 days) then controlled sodium chloride content diet (4 %) (for 21 days) |
Wang J, et al., Circ Cardiovasc Genet. 2015 Apr;8(2):316-26. doi: 10.1161/CIRCGENETICS.114.000520. Epub 2015 Jan 8. |
body mass |
male |
21 days-126 days |
0 |
body weight X week = growth AUC |
|
2.8740096E7 |
g x min |
358848.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
growth auc |
|
|
102618 |
3014 |
Hsd:WI |
body weight |
bisphenol A (250 mg/kg/d) (for 91 days) |
Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796. |
body mass |
male |
119 days-126 days |
6 |
|
|
336.83 |
g |
12.66 |
31.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
76044 |
1545 |
SD |
body weight |
acetaminophen (500 mg/kg) (for 8 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
male |
50 days-64 days |
6 |
|
|
209.3 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84771 |
1602 |
SD |
body weight |
acetaminophen (1000 mg/kg) (for 22 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
female |
64 days-78 days |
6 |
|
|
157.9 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84812 |
1602 |
Crl:WI |
body weight |
control condition |
Devanathan S, et al., PLoS One. 2013 Oct 21;8(10):e78477. doi: 10.1371/journal.pone.0078477. eCollection 2013. |
body mass |
male |
168 days
| 4 |
|
|
491.67 |
g |
4.63 |
9.25 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103087 |
2786 |
Crl:WI |
body weight |
control condition |
Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. |
body mass |
male |
147 days
| 6 |
|
|
525.0 |
g |
15.0 |
36.74 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103978 |
2885 |
Crl:CD(SD) |
body weight |
standard diet |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
168 days
| 19 |
|
|
588.0 |
g |
14.45 |
63.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85320 |
1604 |
LH/Mav |
body weight |
control condition |
Egan EJ, et al., Acta Pharmacol Sin. 2008 Nov;29(11):1296-300. doi: 10.1111/j.1745-7254.2008.00862.x. |
body mass |
male |
112 days
| 8 |
|
|
391.0 |
g |
6.0 |
16.97 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102787 |
2723 |
SS/NEisSlc |
body weight |
controlled sodium chloride content diet (8 %) (for 7 days) |
Yoshihara F, et al., Regul Pept. 2005 May 15;128(1):7-13. |
body mass |
male |
63 days
| 8 |
|
|
292.0 |
g |
3.18 |
9.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102406 |
2689 |
WF/Mol |
body weight |
vehicle control condition then sham surgical control condition (for 4 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 5 |
|
|
192.0 |
g |
3.0 |
6.71 |
body weighing method |
0.0 |
|
4 |
days |
|
|
|
|
101317 |
2585 |
HanTac:WH |
body weight |
bisphenol A (5 mg/kg/d) (for 1 days) |
Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. |
body mass |
male |
1 days
| 17 |
|
|
6.3 |
g |
0.12 |
0.5 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
96615 |
1559 |
BN/NHsdMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
21 days
| 11 |
|
|
45.27 |
g |
1.4 |
4.65 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139046 |
3292 |
BN/NHsdMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
7 days
| 11 |
|
|
13.43 |
g |
0.36 |
1.18 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139044 |
3292 |
BN/NHsdMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 49 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
70 days
| 11 |
|
|
220.0 |
g |
2.17 |
7.21 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139053 |
3292 |
BN/NHsdMcwi |
body mass index (BMI) |
controlled bisphenol F content drinking water (1.125 mg/l) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
91 days
| 11 |
|
|
0.52 |
g/cm2 |
0.01 |
0.03 |
body weighing method |
|
|
0 |
|
"weight scale, tape measure" |
Body Mass Index (BMI) |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139106 |
3292 |
BUF/MnaMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
21 days
| 10 |
|
|
40.2 |
g |
1.06 |
3.36 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139238 |
3292 |
BUF/MnaMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 21 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
42 days
| 10 |
|
|
152.5 |
g |
1.85 |
5.84 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139241 |
3292 |
BUF/MnaMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 49 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
70 days
| 10 |
|
|
291.4 |
g |
2.23 |
7.06 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139245 |
3292 |
WKY/NCrl |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
14 days
| 15 |
|
|
23.38 |
g |
0.62 |
2.42 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
140011 |
3292 |
WKY/NCrl |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 28 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
49 days
| 15 |
|
|
161.4 |
g |
2.55 |
9.86 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
140016 |
3292 |
BUF/MnaMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 56 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
77 days
| 10 |
|
|
310.4 |
g |
3.26 |
10.31 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139246 |
3292 |
WKY/NCrl |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 42 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
63 days
| 14 |
|
|
221.79 |
g |
3.11 |
11.62 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
140018 |
3292 |
WKY/NCrl |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 56 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
77 days
| 15 |
|
|
266.47 |
g |
3.63 |
14.07 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
140020 |
3292 |
WKY/NCrl |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
91 days
| 15 |
|
|
300.67 |
g |
3.27 |
12.68 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
140022 |
3292 |
BUF/MnaMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 56 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
77 days
| 11 |
|
|
310.73 |
g |
3.68 |
12.22 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139312 |
3292 |
WKY/NCrl |
body mass index (BMI) |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
91 days
| 15 |
|
|
0.59 |
g/cm2 |
0.0 |
0.02 |
body weighing method |
|
|
0 |
|
"weight scale, tape measure" |
Body Mass Index (BMI) |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
140075 |
3292 |
WKY/NCrl |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 7 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
28 days
| 15 |
|
|
63.67 |
g |
2.46 |
9.54 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
140079 |
3292 |
WKY/NCrl |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 42 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
63 days
| 14 |
|
|
223.57 |
g |
3.4 |
12.71 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
140084 |
3292 |
WKY/NCrl |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
91 days
| 15 |
|
|
297.87 |
g |
3.72 |
14.43 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
140088 |
3292 |
ACI/EurMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 63 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
84 days
| 12 |
|
|
212.83 |
g |
2.13 |
7.37 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138753 |
3292 |
ACI/EurMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
91 days
| 12 |
|
|
217.67 |
g |
2.12 |
7.35 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138754 |
3292 |
F344/StmMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 35 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
56 days
| 12 |
|
|
202.5 |
g |
3.9 |
13.51 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139501 |
3292 |
ACI/EurMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
14 days
| 13 |
|
|
20.98 |
g |
0.29 |
1.05 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138809 |
3292 |
ACI/EurMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 21 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
42 days
| 13 |
|
|
118.08 |
g |
1.6 |
5.77 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138813 |
3292 |
BN/NHsdMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
91 days
| 10 |
|
|
245.7 |
g |
4.37 |
13.81 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138994 |
3292 |
BN/NHsdMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 7 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
28 days
| 10 |
|
|
63.0 |
g |
1.81 |
5.73 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138874 |
3292 |
BN/NHsdMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 56 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
77 days
| 10 |
|
|
143.5 |
g |
4.12 |
13.03 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138938 |
3292 |
F344/StmMcwi |
body mass index (BMI) |
controlled bisphenol F content drinking water (1.125 mg/l) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
91 days
| 9 |
|
|
0.43 |
g/cm2 |
0.01 |
0.02 |
body weighing method |
|
|
0 |
|
"weight scale, tape measure" |
Body Mass Index (BMI) |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139493 |
3292 |
BN/NHsdMcwi |
body mass index (BMI) |
controlled bisphenol F content drinking water (1.125 mg/l) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
91 days
| 10 |
|
|
0.41 |
g/cm2 |
0.01 |
0.02 |
body weighing method |
|
|
0 |
|
"weight scale, tape measure" |
Body Mass Index (BMI) |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138981 |
3292 |
BN/NHsdMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 35 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
56 days
| 10 |
|
|
181.2 |
g |
3.57 |
11.3 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138989 |
3292 |
ACI/EurMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 28 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
49 days
| 11 |
|
|
107.27 |
g |
1.56 |
5.18 |
body weighing method |
|
|
0 |
|
|
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138685 |
3292 |
ACI/EurMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 49 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
70 days
| 11 |
|
|
135.45 |
g |
1.38 |
4.57 |
body weighing method |
|
|
0 |
|
|
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138688 |
3292 |
ACI/EurMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 56 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
77 days
| 11 |
|
|
137.36 |
g |
1.7 |
5.63 |
body weighing method |
|
|
0 |
|
|
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138689 |
3292 |
ACI/EurMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 42 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
63 days
| 11 |
|
|
129.45 |
g |
1.34 |
4.46 |
body weighing method |
|
|
0 |
|
|
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138687 |
3292 |
BN/NHsdMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 35 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
56 days
| 11 |
|
|
181.55 |
g |
2.47 |
8.2 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139051 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 49 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
70 days
| 11 |
|
|
140.45 |
g |
1.95 |
6.46 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139632 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 28 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
49 days
| 11 |
|
|
115.27 |
g |
1.98 |
6.56 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139629 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
91 days
| 11 |
|
|
154.36 |
g |
2.26 |
7.5 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139635 |
3292 |
F344/StmMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
14 days
| 12 |
|
|
21.92 |
g |
0.48 |
1.65 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139495 |
3292 |
F344/StmMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 42 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
63 days
| 12 |
|
|
230.0 |
g |
3.63 |
12.59 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139502 |
3292 |
BUF/MnaMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
7 days
| 10 |
|
|
12.2 |
g |
0.52 |
1.65 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139173 |
3292 |
BUF/MnaMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 35 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
56 days
| 10 |
|
|
164.2 |
g |
2.47 |
7.8 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139180 |
3292 |
BUF/MnaMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 42 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
63 days
| 10 |
|
|
176.5 |
g |
2.47 |
7.81 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139181 |
3292 |
F344/StmMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 56 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
77 days
| 12 |
|
|
265.5 |
g |
3.33 |
11.53 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139570 |
3292 |
M520/NRrrcMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
21 days
| 9 |
|
|
42.44 |
g |
1.51 |
4.53 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139691 |
3292 |
WKY/NCrl |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 42 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
63 days
| 10 |
|
|
159.5 |
g |
2.14 |
6.75 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139889 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 7 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
28 days
| 12 |
|
|
74.75 |
g |
2.78 |
9.64 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139755 |
3292 |
M520/NRrrcMcwi |
body weight |
control condition (0 null) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
21 days
| 12 |
|
|
44.75 |
g |
2.06 |
7.14 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139820 |
3292 |
WKY/NCrl |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 63 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
84 days
| 10 |
|
|
192.6 |
g |
2.83 |
8.93 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139892 |
3292 |
WKY/NCrl |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 35 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
56 days
| 15 |
|
|
193.73 |
g |
2.84 |
11.0 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
140017 |
3292 |
WKY/NCrl |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 7 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
28 days
| 15 |
|
|
63.93 |
g |
2.46 |
9.53 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
140013 |
3292 |
WKY/NCrl |
body weight |
control condition (0 null) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
21 days
| 15 |
|
|
39.2 |
g |
1.46 |
5.66 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
140078 |
3292 |
WKY/NCrl |
body mass index (BMI) |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
91 days
| 10 |
|
|
0.49 |
g/cm2 |
0.01 |
0.02 |
body weighing method |
|
|
0 |
|
"weight scale, tape measure" |
Body Mass Index (BMI) |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139946 |
3292 |
WKY/NCrl |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
21 days
| 10 |
|
|
39.8 |
g |
1.43 |
4.52 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139949 |
3292 |
WKY/NCrl |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 14 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
35 days
| 10 |
|
|
85.3 |
g |
2.38 |
7.53 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139951 |
3292 |
WKY/NCrl |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 49 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
70 days
| 10 |
|
|
171.6 |
g |
2.32 |
7.35 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139956 |
3292 |
WKY/NCrl |
body mass index (BMI) |
controlled bisphenol F content drinking water (1.125 mg/l) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
91 days
| 15 |
|
|
0.58 |
g/cm2 |
0.01 |
0.02 |
body weighing method |
|
|
0 |
|
"weight scale, tape measure" |
Body Mass Index (BMI) |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
140138 |
3292 |
BN/NHsdMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
14 days
| 10 |
|
|
25.7 |
g |
0.54 |
1.72 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138872 |
3292 |
F344/StmMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 7 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
28 days
| 9 |
|
|
59.89 |
g |
1.37 |
4.11 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139434 |
3292 |
F344/StmMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 14 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
35 days
| 9 |
|
|
83.0 |
g |
1.42 |
4.27 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139435 |
3292 |
F344/StmMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 21 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
42 days
| 9 |
|
|
102.56 |
g |
1.09 |
3.28 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139436 |
3292 |
ACI/EurMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
7 days
| 15 |
|
|
11.02 |
g |
0.37 |
1.42 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138613 |
3292 |
ACI/EurMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 7 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
28 days
| 11 |
|
|
52.0 |
g |
1.48 |
4.92 |
body weighing method |
|
|
0 |
|
|
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138682 |
3292 |
ACI/EurMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 63 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
84 days
| 11 |
|
|
141.73 |
g |
1.68 |
5.59 |
body weighing method |
|
|
0 |
|
|
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138690 |
3292 |
F344/StmMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 63 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
84 days
| 9 |
|
|
159.67 |
g |
2.58 |
7.75 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139442 |
3292 |
ACI/EurMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
21 days
| 15 |
|
|
31.53 |
g |
0.77 |
2.97 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138615 |
3292 |
ACI/EurMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 28 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
49 days
| 15 |
|
|
109.87 |
g |
1.25 |
4.82 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138619 |
3292 |
ACI/EurMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 42 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
63 days
| 15 |
|
|
131.0 |
g |
1.15 |
4.46 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138621 |
3292 |
ACI/EurMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
91 days
| 15 |
|
|
145.8 |
g |
1.19 |
4.62 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138625 |
3292 |
ACI/EurMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 21 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
42 days
| 12 |
|
|
118.58 |
g |
1.29 |
4.48 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138747 |
3292 |
SS.SR-(D3Arb14-D3Mco36)/Mco |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 28 days) then controlled sodium content diet (4 %) (between 46 and 48 days) |
Cicila GT, et al., Hypertension. 2009 Apr;53(4):725-32. Epub 2009 Mar 2. |
body mass |
male |
114 days-118 days |
6 |
|
|
367.5 |
g |
4.7 |
11.51 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65097 |
283 |
SS/Jr |
body weight |
controlled sodium content diet (2 %) (for 24 days) |
Rapp JP, et al., Genomics 1998 Jul 15;51(2):191-6 |
body mass |
male |
62 days
| 20 |
|
|
324.0 |
g |
2.5 |
11.18 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65831 |
633 |
SS.SR-Inha/Jr |
body weight |
controlled sodium content diet (2 %) (for 24 days) |
Rapp JP, et al., Genomics 1998 Jul 15;51(2):191-6 |
body mass |
male |
62 days
| 20 |
|
|
316.0 |
g |
2.2 |
9.84 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65833 |
633 |
SS/Jr |
body weight |
controlled sodium content diet (2 %) (between 24 and 27 days) |
Garrett MR, et al., Genome Res 1998 Jul;8(7):711-23 |
body mass |
not specified |
64 days-71 days |
20 |
|
|
290.0 |
g |
1.9 |
8.5 |
body weighing method |
0 |
|
0 |
|
|
|
|
4 rats per cage, 2 SR/Jr 2 LEW/NCrl |
64718 |
222 |
SS/Jr |
body weight |
controlled sodium content diet (2 %) (between 24 and 27 days) |
Garrett MR, et al., Genome Res 1998 Jul;8(7):711-23 |
body mass |
not specified |
64 days-71 days |
40 |
|
|
304.0 |
g |
1.6 |
10.12 |
body weighing method |
0 |
|
0 |
|
|
|
|
4 rats per cage, 2 SR/Jr 2 LEW/NCrl |
64716 |
222 |
BN.GK-(D8Rat29-D8Got130)/Ox |
body weight |
control condition |
Wallis RH, et al., Diabetologia 2004 Jun;47(6):1096-106. Epub 2004 May 26 |
body mass |
male |
84 days
| 11 |
|
|
234.0 |
g |
5.0 |
16.58 |
body weighing method |
|
|
0 |
|
|
|
|
|
11290 |
66 |
BN.GK-(D2Rat40-D2Got149)/Ox |
body weight |
control condition |
Wallace KJ, et al., Physiol Genomics 2004 Sep 16;19(1):1-10. Epub 2004 Jul 20. |
body mass |
male |
90 days
| 15 |
|
|
248.0 |
g |
4.0 |
15.49 |
body weighing method |
|
|
0 |
|
|
|
|
|
11302 |
69 |
BN/Crl |
body weight |
control condition |
Wallace KJ, et al., Physiol Genomics 2004 Sep 16;19(1):1-10. Epub 2004 Jul 20. |
body mass |
female |
90 days
| 36 |
|
|
159.0 |
g |
2.0 |
12.0 |
body weighing method |
|
|
0 |
|
|
|
|
|
11303 |
69 |
BN.GK-(D2Wox30-D2Wox68)/Ox |
body weight |
control condition |
Wallace KJ, et al., Physiol Genomics 2004 Sep 16;19(1):1-10. Epub 2004 Jul 20. |
body mass |
female |
90 days
| 17 |
|
|
174.0 |
g |
4.0 |
16.49 |
body weighing method |
|
|
0 |
|
|
|
|
|
11305 |
69 |
BN.GH-(D6Mit12-D6Rat15)/Mcwi |
body weight |
angiotensin II (5-50 ng/kg/min) (between 0.2 and 1 hours) then norepinephrine (0.1-1 ug/kg/min) (between 0.2 and 1 hours) then phenylephrine (4 ug/kg) (between 0 and 0 hours) |
Bilusic M, et al., Croat Med J. 2008 Oct;49(5):586-99. |
body mass |
male |
132 days-146 days |
16 |
|
|
299.9 |
g |
6.0 |
24.0 |
body weighing method |
|
|
0 |
|
|
|
|
|
11541 |
101 |
SHR/Izm |
body weight |
control condition |
Tsujita Y, et al., Am J Physiol Heart Circ Physiol 2000 Nov;279(5):H2062-7 |
body mass |
male |
168 days
| 6 |
|
|
348.0 |
g |
3.67 |
9.0 |
body weighing method |
|
|
0 |
|
|
|
|
|
11579 |
103 |
SS.SR-(D3Mco19-D3Mco5)/Jr |
body weight |
controlled sodium content diet (0.2 %) (for 7 days) then controlled sodium content diet (2 %) (for 28 days) |
Cicila GT, et al., Mamm Genome 1999 Feb;10(2):112-6. |
body mass |
male |
65 days
| 19 |
|
|
307.3 |
g |
2.4 |
10.46 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
11780 |
145 |
SS/Jr |
body weight |
controlled sodium content diet (0.2 %) (for 7 days) then controlled sodium content diet (2 %) (for 28 days) |
Cicila GT, et al., Mamm Genome 1999 Feb;10(2):112-6. |
body mass |
male |
65 days
| 20 |
|
|
306.8 |
g |
4.6 |
20.57 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
11779 |
145 |
SS.SR-(Cyp11b1)/Jr |
body weight |
controlled sodium content diet (1 %) (for 30 days) then controlled sodium content diet (0.2 %) (for 40 days) |
Cicila GT, et al., Mamm Genome 1997 Dec;8(12):896-902. |
body mass |
male |
100 days
| 16 |
|
|
336.7 |
g |
6.7 |
26.8 |
body weighing method |
|
|
0 |
|
|
|
|
|
11786 |
146 |
SS/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 24 and 27 days) |
Cicila GT, et al., Genomics 2001 Feb 15;72(1):51-60. |
body mass |
male |
68 days-70 days |
20 |
|
|
297.7 |
g |
2.5 |
11.18 |
body weighing method |
|
|
0 |
|
|
|
|
|
11823 |
147 |
OLETF/Got |
body weight |
control condition |
Ogino Genom 2000 Nov 15;70(1):19-25. |
body mass |
male |
245 days-252 days |
14 |
|
|
650.6 |
g |
8.61 |
32.2 |
body weighing method |
|
|
0 |
|
|
|
|
|
11406 |
83 |
ACI.FHH-(D1Rat298-D1Rat90)/Eur |
body weight |
right nephrectomy |
Van Dijk SJ, et al., Kidney Int. 2006 |
body mass |
male |
168 days-175 days |
12 |
|
|
330.0 |
g |
6.0 |
20.78 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
11951 |
62 |
SS/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 24 days) |
Saad Y, et al., Hypertension. 2007 |
body mass |
male |
64 days-66 days |
0 |
|
|
331.0 |
g |
2.08 |
|
body weighing method |
|
|
0 |
|
|
|
|
|
11975 |
205 |
SS/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 24 days) |
Saad Y, et al., Hypertension. 2007 |
body mass |
male |
64 days-66 days |
0 |
|
|
302.0 |
g |
5.58 |
|
body weighing method |
|
|
0 |
|
|
|
|
|
11974 |
205 |
SS.LEW-(D2Rat18-D2Chm277)/Ayd |
body weight |
controlled sodium content diet (2 %) (between 35 and 98 days) |
Duong C, et al., Mamm Genome 2006; 17(12): 1147-1161 |
body mass |
male |
98 days
| 6 |
|
|
311.0 |
g |
20.0 |
48.99 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12014 |
226 |
SS.LEW-(D2Rat199-D2Mco17)/Ayd |
body weight |
controlled sodium content diet (2 %) (between 35 and 98 days) |
Duong C, et al., Mamm Genome 2006; 17(12): 1147-1161 |
body mass |
male |
98 days
| 8 |
|
|
321.0 |
g |
5.0 |
14.14 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12017 |
226 |
SS.LEW-(D3Rat52-D3Rat130)/Ayd |
body weight |
controlled sodium content diet (2 %) (between 35 and 98 days) |
Duong C, et al., Mamm Genome 2006; 17(12): 1147-1161 |
body mass |
male |
98 days
| 7 |
|
|
390.0 |
g |
6.0 |
15.87 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12037 |
226 |
SS.LEW-(D16Rat12-D16Chm23)/Ayd |
body weight |
controlled sodium content diet (2 %) (between 35 and 98 days) |
Duong C, et al., Mamm Genome 2006; 17(12): 1147-1161 |
body mass |
male |
98 days
| 10 |
|
|
374.0 |
g |
12.0 |
37.95 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12066 |
226 |
SS.LEW-(D17Chm9-D17Rat97)/Ayd |
body weight |
controlled sodium content diet (2 %) (between 35 and 98 days) |
Duong C, et al., Mamm Genome 2006; 17(12): 1147-1161 |
body mass |
male |
98 days
| 10 |
|
|
367.0 |
g |
15.0 |
47.43 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12071 |
226 |
SS/Jr |
body weight |
controlled sodium content diet (2 %) (between 35 and 98 days) |
Duong C, et al., Mamm Genome 2006; 17(12): 1147-1161 |
body mass |
male |
98 days
| 16 |
|
|
348.0 |
g |
9.0 |
36.0 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12079 |
226 |
SS/Jr |
body weight |
controlled sodium content diet (2 %) (for 24 days) |
Saad Y, et al., Mamm Genome. 2008 Jan 4 |
body mass |
male |
64 days-68 days |
20 |
|
|
340.0 |
g |
5.26 |
23.52 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12141 |
232 |
SS.MNS-(D10Mco62-D10Mco30)/Mco |
body weight |
controlled sodium content diet (2 %) (for 24 days) |
Saad Y, et al., Mamm Genome. 2008 Jan 4 |
body mass |
male |
64 days-68 days |
20 |
|
|
345.0 |
g |
7.09 |
31.71 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12146 |
232 |
SR/Jr |
body weight |
controlled sodium content diet (0.2 %) (for 112 days) |
Garrett MR, et al., Genome Res 1998 Jul;8(7):711-23 |
body mass |
male |
147 days
| 10 |
|
|
379.0 |
g |
5.7 |
18.02 |
body weighing method |
0 |
|
0 |
|
|
|
|
4 rats per cage, 2 SR/Jr 2 LEW/NCrl |
12182 |
222 |
LEW/NCrl |
body weight |
controlled sodium content diet (0.2 %) (for 168 days) |
Garrett MR, et al., Genome Res 1998 Jul;8(7):711-23 |
body mass |
male |
203 days
| 8 |
|
|
506.0 |
g |
12.4 |
35.07 |
body weighing method |
0 |
|
0 |
|
|
|
|
4 rats per cage, 2 SR/Jr 2 LEW/NCrl |
12192 |
222 |
ACI/Eur |
body weight |
right nephrectomy |
Van Dijk SJ, et al., Kidney Int. 2006 |
body mass |
male |
168 days-175 days |
12 |
|
|
315.0 |
g |
3.0 |
10.39 |
body weighing method |
|
|
0 |
|
|
|
|
|
11930 |
62 |
SHR/N |
body weight |
control condition |
Ye P and West MJ, Clin Exp Pharmacol Physiol 2003 Dec;30(12):930-6. |
body mass |
female |
84 days
| 16 |
|
|
331.0 |
g |
24.0 |
96.0 |
body weighing method |
|
|
0 |
|
|
|
|
|
13054 |
327 |
WKY/N |
body weight |
control condition |
Ye P and West MJ, Clin Exp Pharmacol Physiol 2003 Dec;30(12):930-6. |
body mass |
male |
84 days
| 15 |
|
|
399.0 |
g |
16.0 |
61.97 |
body weighing method |
|
|
0 |
|
|
|
|
|
13062 |
327 |
F344/NCrl |
body weight |
fasting (for 6 hours) |
Granhall C, et al., Genetics. 2006 Nov;174(3):1565-72. Epub 2006 Sep 1. |
body mass |
male |
95 days
| 24 |
|
|
289.0 |
g |
3.0 |
14.7 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
13076 |
330 |
SS/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 28 days) |
Saad Y, et al., Physiol Genomics 2001 Jan 19;4(3):201-14. |
body mass |
male |
68 days-70 days |
20 |
|
|
309.0 |
g |
3.43 |
15.34 |
body weighing method |
|
|
0 |
|
|
|
|
|
12485 |
266 |
SHR/Izm |
body weight |
controlled fat content diet (5 %) (for 70 days) and controlled potassium content diet (0.75 %) (for 70 days) |
Watanabe T, et al., Biochem Biophys Res Commun 2005 Apr 15;329(3):879-87. |
body mass |
male |
91 days-98 days |
10 |
|
|
285.7 |
g |
3.45 |
10.9 |
body weighing method |
|
|
0 |
|
|
|
|
|
12487 |
263 |
SS/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 24 days) |
Toland EJ, et al., Mamm Genome. 2008 Mar;19(3):209-18. Epub 2008 Mar 7. |
body mass |
male |
64 days-66 days |
20 |
|
|
345.0 |
g |
1.65 |
7.38 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12865 |
313 |
SS.LEW-(D1Mco36-D1Rat131)/2Mco |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 24 days) |
Toland EJ, et al., Mamm Genome. 2008 Mar;19(3):209-18. Epub 2008 Mar 7. |
body mass |
male |
64 days-66 days |
20 |
|
|
306.0 |
g |
1.91 |
8.54 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12874 |
313 |
SHRSP |
body weight |
controlled sodium content diet (0.4 %) (for 122 days) then controlled sodium content diet (1.4 %) (for 210 days) |
Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81. |
body mass |
male |
360 days
| 4 |
|
|
245.2 |
g |
6.5 |
13.0 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12532 |
268 |
SHRSP |
body weight |
controlled sodium content diet (0.4 %) (for 122 days) then controlled sodium content diet (1.4 %) (for 210 days) |
Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81. |
body mass |
female |
360 days
| 4 |
|
|
160.4 |
g |
4.05 |
8.1 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12539 |
268 |
SHR |
body weight |
controlled sodium content diet (0.4 %) (for 122 days) then controlled sodium content diet (1.4 %) (for 210 days) |
Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81. |
body mass |
female |
360 days
| 4 |
|
|
173.5 |
g |
2.3 |
4.6 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12575 |
268 |
SS/Jr |
body weight |
controlled sodium content diet (2 %) (for 28 days) |
Toland EJ, et al., J Hypertens. 2008 Nov;26(11):2134-41. |
body mass |
male |
68 days-70 days |
20 |
|
|
343.0 |
g |
5.2 |
23.26 |
body weighing method |
|
|
0 |
|
|
|
|
|
12948 |
305 |
SS.SHR-(D9Wox16-D9Mco73)/Mco |
body weight |
controlled sodium content diet (2 %) (for 28 days) |
Toland EJ, et al., J Hypertens. 2008 Nov;26(11):2134-41. |
body mass |
male |
68 days-70 days |
20 |
|
|
328.0 |
g |
7.67 |
34.3 |
body weighing method |
|
|
0 |
|
|
|
|
|
12952 |
305 |
SS.SHR-(D9Wox16-D9Rat76)/Mco |
body weight |
controlled sodium content diet (2 %) (for 28 days) |
Toland EJ, et al., J Hypertens. 2008 Nov;26(11):2134-41. |
body mass |
male |
68 days-70 days |
20 |
|
|
366.0 |
g |
3.96 |
17.71 |
body weighing method |
|
|
0 |
|
|
|
|
|
12953 |
305 |
F344/NSlc |
body weight |
specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) |
Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. |
body mass |
male |
211 days
| 7 |
|
|
393.6 |
g |
6.2 |
16.4 |
body weighing method |
|
oral glucose |
0 |
min |
|
|
|
|
12785 |
311 |
SS.LEW-(D17Chm14-D17Rat181)/Ayd |
body weight gain |
controlled sodium content diet (8 %) (between 8 and 10 days) |
Huang BS, et al., Hypertension. 2007 Apr 9;. |
body mass |
male |
43 days-52 days |
8 |
|
|
56.0 |
g |
3.0 |
8.49 |
body weighing method |
|
|
0 |
|
|
|
|
|
13317 |
344 |
ACI.FHH-(D1Rat324-D1Rat156)/Eur |
body weight |
unilateral nephrectomy then controlled hydrogen ion content drinking water (2.4-2.8 pH) |
Van Dijk SJ, et al., Nephron Exp Nephrol 2005 Jun 20;101(2):e59-e66. |
body mass |
male |
173 days-180 days |
8 |
|
|
284.0 |
g |
5.0 |
14.14 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67680 |
751 |
ACI/Eur |
body weight |
unilateral nephrectomy then controlled hydrogen ion content drinking water (2.4-2.8 pH) |
Van Dijk SJ, et al., Nephron Exp Nephrol 2005 Jun 20;101(2):e59-e66. |
body mass |
male |
173 days-180 days |
8 |
|
|
308.0 |
g |
5.0 |
14.14 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67678 |
751 |
SS.LEW-(D18Rat30-D18Chm29)/Ayd |
body weight |
controlled sodium content diet (2 %) (between 35 and 98 days) |
Duong C, et al., Mamm Genome 2006; 17(12): 1147-1161 |
body mass |
male |
98 days
| 8 |
|
|
378.0 |
g |
9.0 |
25.46 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
64803 |
226 |
SHR |
body weight |
control condition (for 98 days) |
Aneas I, et al., Physiol Genomics. 2009 Mar 3;37(1):52-7. Epub 2009 Jan 6. |
body mass |
male |
87 days
| 23 |
|
|
271.0 |
g |
4.0 |
19.18 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65428 |
306 |
SHR.BN-(D2Rat114-D2Rat123)/Jk |
body weight |
control condition (for 98 days) |
Aneas I, et al., Physiol Genomics. 2009 Mar 3;37(1):52-7. Epub 2009 Jan 6. |
body mass |
male |
87 days
| 22 |
|
|
270.0 |
g |
4.0 |
18.76 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65430 |
306 |
SHR.BN-(D4Rat33-D4Rat54)/Jk |
body weight |
control condition (for 98 days) |
Aneas I, et al., Physiol Genomics. 2009 Mar 3;37(1):52-7. Epub 2009 Jan 6. |
body mass |
male |
87 days
| 22 |
|
|
267.0 |
g |
3.0 |
14.07 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65434 |
306 |
WKY/Izm |
body weight |
control condition (0 null) |
Kato N, et al., Hypertension 2003 DXCO;42(6):1191-7. |
body mass |
male |
91 days
| 5 |
|
|
318.0 |
g |
5.9 |
13.19 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
64830 |
115 |
SS/Jr |
body weight |
control condition |
Garrett MR, et al., J Am Soc Nephrol 2003 May;14(5):1175-87 |
body mass |
male |
56 days-57 days |
6 |
|
|
293.0 |
g |
9.8 |
24.0 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65440 |
104 |
SHR/NHsd |
body weight |
control condition |
Garrett MR, et al., J Am Soc Nephrol 2003 May;14(5):1175-87 |
body mass |
male |
84 days-85 days |
6 |
|
|
285.0 |
g |
6.0 |
14.7 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65443 |
104 |
WN/N |
body weight |
control condition |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
body mass |
both |
70 days
| 220 |
|
|
256.0 |
g |
0.53 |
7.8 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
66012 |
114 |
BN.GK-(D8Got302-D8Got130)/Ox |
body weight |
control condition |
Wallis RH, et al., Diabetologia 2004 Jun;47(6):1096-106. Epub 2004 May 26 |
body mass |
female |
168 days
| 16 |
|
|
209.0 |
g |
3.0 |
12.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67314 |
66 |
LEW/Rkb |
body weight |
control condition |
Schulz A, et al., J Am Soc Nephrol 2002 Nov;13(11):2706-14. |
body mass |
not specified |
126 days
| 8 |
|
|
312.3 |
g |
4.95 |
14.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67594 |
769 |
SS/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) |
Cicila GT, et al., Hypertension. 2009 Apr;53(4):725-32. Epub 2009 Mar 2. |
body mass |
male |
40 days-42 days |
20 |
|
|
161.0 |
g |
2.1 |
9.39 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65024 |
283 |
SS.SR-(D3Arb14-D3Mco36)/Mco |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) |
Cicila GT, et al., Hypertension. 2009 Apr;53(4):725-32. Epub 2009 Mar 2. |
body mass |
male |
40 days-42 days |
15 |
|
|
145.1 |
g |
3.6 |
13.94 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65022 |
283 |
ACI.FHH-(D17Rat117-D17Arb5)(D17Rat180-D17Rat51)/Eur |
body weight |
controlled hydrogen ion content drinking water (2.4-2.8 pH) |
Van Dijk SJ, et al., Nephron Exp Nephrol 2005 Jun 20;101(2):e59-e66. |
body mass |
male |
98 days
| 15 |
|
|
248.0 |
g |
6.0 |
23.24 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
68033 |
751 |
DA/K |
body weight |
control condition |
Kovacs P, et al., Biochem Biophys Res Commun 2000 Mar 24;269(3):660-5. |
body mass |
not specified |
224 days
| 12 |
|
|
254.0 |
g |
9.53 |
33.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
69109 |
1123 |
WAG/RijKyo |
body weight |
control condition |
Redina OE, et al., Clin Exp Pharmacol Physiol. 2006 May-Jun;33(5-6):456-64. |
body mass |
not specified |
180 days
| 9 |
|
|
310.0 |
g |
5.0 |
15.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
68050 |
835 |
BN |
body weight |
control condition |
Kanemoto N, et al., Mamm Genome 1998 Jun;9(6):419-25 |
body mass |
male |
210 days
| 20 |
|
|
355.3 |
g |
5.8 |
25.94 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
68066 |
836 |
SS/JrTol |
body weight |
control condition (for 140 days) |
Garrett MR, et al., Physiol Genomics. 2007 May 15;. |
body mass |
male |
140 days
| 6 |
|
|
421.0 |
g |
11.1 |
27.19 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67963 |
834 |
DA/ZtmKini |
maximum body weight loss to initial body weight ratio |
myelin oligodendrocyte glycoprotein (20 ug) |
Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. |
body mass |
male |
103 days-131 days |
10 |
|
|
2.8 |
% |
1.26 |
4.0 |
body weighing method |
0.0 |
intradermal injection |
40 |
days |
from before p.i. |
|
|
|
68716 |
839 |
ACI.FHH-(D1Rat384-D1Rat156)/Eur |
body weight |
unilateral nephrectomy |
van Dijk SJ, et al., Nephron Exp Nephrol. 2006;104(3):e96-e102. Epub 2006 Jul 12. |
body mass |
not specified |
168 days-175 days |
12 |
|
|
305.0 |
g |
8.0 |
27.71 |
body weighing method |
0.0 |
unilateral nephrectomy |
126 |
days |
|
|
|
|
67900 |
832 |
E3/Ztm |
body weight gain |
spinal cord homogenate (10 mg) |
Bergsteinsdottir K, et al., J Immunol 2000 Feb 1;164(3):1564-8 |
body mass |
female |
56 days-103 days |
12 |
|
|
80.0 |
g |
0.87 |
3.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
69956 |
1258 |
ACI.FHH-(D1Rat475-D1Rat90)(D3Rat84-D3Rat59)/Eur |
body weight |
NG-nitroarginine methyl ester (50-150 mg/l) |
Van Dijk SJ, et al., Kidney Int. 2006 |
body mass |
male |
168 days-175 days |
12 |
|
|
296.0 |
g |
6.0 |
20.78 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67703 |
62 |
WKY/NCruk |
body weight |
left nephrectomy and left kidney transplant then right nephrectomy |
Clemitson JR, et al., Hypertension 2002 Sep;40(3):292-7 |
body mass |
male |
175 days
| 17 |
|
|
335.8 |
g |
7.62 |
31.4 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67746 |
110 |
WKY.SHRSP-(D1Wox29-D1Arb21)/Izm |
body weight |
cold ambient air exposure (4 degrees C) (for 90 days) |
Cui ZH, et al., J Hypertens 2004 Nov;22(11):2103-9. |
body mass |
not specified |
112 days
| 10 |
|
|
406.0 |
g |
5.06 |
16.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
68693 |
971 |
DA/Ztm |
maximum body weight loss to initial body weight ratio |
squalene (200 ul) |
Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. |
body mass |
both |
120 days-200 days |
15 |
|
|
12.8 |
% |
0.6 |
2.32 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
69794 |
1162 |
DA.PVG.1AV1-(D4Rat155-Spr) |
maximum body weight loss to initial body weight ratio |
type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) |
Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. |
body mass |
both |
120 days-200 days |
14 |
|
|
12.5 |
% |
0.9 |
3.37 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
69800 |
1162 |
Crl:CD(SD) |
body weight |
standard diet then acetaminophen (500 mg/kg) (for 14 days) |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
84 days
| 8 |
|
|
413.0 |
g |
6.01 |
17.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85526 |
1604 |
Crl:CD(SD) |
body weight |
standard diet then acetaminophen (500 mg/kg) (for 77 days) |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
147 days
| 8 |
|
|
549.0 |
g |
12.73 |
36.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85544 |
1604 |
Crl:CD(SD) |
body weight |
standard diet |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
105 days
| 19 |
|
|
481.0 |
g |
11.7 |
51.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85314 |
1604 |
Crl:CD(SD) |
body weight |
standard diet then acetaminophen (300 mg/kg) (for 56 days) |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
126 days
| 8 |
|
|
522.0 |
g |
8.13 |
23.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85537 |
1604 |
Crl:CD(SD) |
body weight |
standard diet and restricted feeding (4 h) then acetaminophen (300 mg/kg) (for 1 days) |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
71 days
| 8 |
|
|
287.0 |
g |
6.72 |
19.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85522 |
1604 |
Crl:CD(SD) |
body weight |
standard diet then acetaminophen (300 mg/kg) (for 98 days) |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
168 days
| 8 |
|
|
581.0 |
g |
9.19 |
26.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85549 |
1604 |
HanTac:WH |
body weight |
vehicle control condition (between 16 and 17 days) |
Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. |
body mass |
female |
16 days-17 days |
15 |
|
|
29.1 |
g |
0.67 |
2.6 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
96687 |
1559 |
W/Nin |
body weight |
controlled retinyl palmitate content diet (2.6 mg/kg) (between 36 and 42 days) then fasting (for 12 hours) |
Tiruvalluru M, et al., Nutrition. 2013 Jan;29(1):298-304. doi: 10.1016/j.nut.2012.06.006. Epub 2012 Oct 2. |
body mass |
male |
284 days
| 6 |
|
|
424.0 |
g |
19.8 |
48.5 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
96717 |
1660 |
W-LeprfaNin |
body weight |
controlled retinyl palmitate content diet (52 mg/kg) (between 36 and 42 days) then fasting (for 12 hours) |
Tiruvalluru M, et al., Nutrition. 2013 Jan;29(1):298-304. doi: 10.1016/j.nut.2012.06.006. Epub 2012 Oct 2. |
body mass |
male |
284 days
| 6 |
|
|
811.0 |
g |
33.4 |
81.81 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
96723 |
1660 |
Crl:SD |
body weight |
controlled fructose content drinking water (5 %) and controlled bisphenol A content drinking water (2.5 mg/l) |
Ronn M, et al., Toxicology. 2013 Jan 7;303:125-32. doi: 10.1016/j.tox.2012.09.013. Epub 2012 Nov 8. |
body mass |
female |
35 days
| 12 |
|
|
88.3 |
g |
3.38 |
11.7 |
body weighing method |
0.0 |
|
0 |
|
|
week one |
|
|
75751 |
1538 |
BluHsd:LE |
body weight |
controlled in utero environment (for 9 days) and bisphenol A (25 ug/kg) (for 30 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days) |
Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. |
body mass |
male |
98 days
| 8 |
|
|
486.9 |
g |
8.7 |
24.61 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
76155 |
1543 |
Crl:SD |
body weight gain |
controlled fructose content drinking water (5 %) (for 70 days) and controlled bisphenol A content drinking water (0.25 mg/l) (for 70 days) |
Ronn M, et al., Toxicology. 2013 Jan 7;303:125-32. doi: 10.1016/j.tox.2012.09.013. Epub 2012 Nov 8. |
body mass |
female |
35 days-105 days |
12 |
|
|
82.6 |
g |
2.57 |
8.9 |
body weighing method |
0.0 |
|
0 |
|
|
week one |
|
|
75760 |
1538 |
F344/NHsd |
body weight |
control condition |
Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17. |
body mass |
male |
579 days-945 days |
9 |
|
|
424.8 |
g |
14.5 |
43.5 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84701 |
1599 |
SD |
body weight |
acetaminophen (500 mg/kg) (for 28 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
male |
70 days-84 days |
6 |
|
|
256.6 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84774 |
1602 |
SD |
body weight |
acetaminophen (1000 mg/kg) (for 8 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
male |
50 days-64 days |
6 |
|
|
211.6 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84776 |
1602 |
SD |
body weight |
acetaminophen (1000 mg/kg) (for 22 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
male |
64 days-78 days |
6 |
|
|
246.8 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84778 |
1602 |
SD |
body weight |
control condition |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
male |
64 days-78 days |
6 |
|
|
246.1 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84786 |
1602 |
SD |
body weight |
control condition |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
female |
57 days-71 days |
6 |
|
|
156.6 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84796 |
1602 |
SD |
body weight |
control condition |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
female |
64 days-78 days |
6 |
|
|
167.0 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84797 |
1602 |
SD |
body weight |
acetaminophen (250 mg/kg) (for 8 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
female |
50 days-64 days |
6 |
|
|
152.8 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84800 |
1602 |
SD |
body weight |
acetaminophen (250 mg/kg) (for 15 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
female |
57 days-71 days |
6 |
|
|
161.2 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84801 |
1602 |
SD |
body weight |
acetaminophen (1000 mg/kg) (for 22 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
female |
64 days-78 days |
6 |
|
|
160.7 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84822 |
1602 |
CrljJcl:SD |
body weight |
gestation (for 21 days) then controlled bisphenol A content drinking water (0.01 mg/l) (for 24 days) then lactation (for 14 days) |
Xu X, et al., Neurotoxicol Teratol. 2011 Jul-Aug;33(4):458-63. doi: 10.1016/j.ntt.2011.06.002. Epub 2011 Jun 17. |
body mass |
female |
0 days
| 8 |
|
|
261.4 |
g |
18.62 |
52.67 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
75909 |
1539 |
CrljJcl:SD |
body weight |
gestation (for 21 days) then controlled bisphenol A content drinking water (0.1 mg/l) (for 17 days) then lactation (for 7 days) |
Xu X, et al., Neurotoxicol Teratol. 2011 Jul-Aug;33(4):458-63. doi: 10.1016/j.ntt.2011.06.002. Epub 2011 Jun 17. |
body mass |
female |
0 days
| 8 |
|
|
265.19 |
g |
15.46 |
43.73 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
75913 |
1539 |
CrljJcl:SD |
body weight |
gestation (for 21 days) then controlled bisphenol A content drinking water (1 mg/l) (for 17 days) then lactation (for 7 days) |
Xu X, et al., Neurotoxicol Teratol. 2011 Jul-Aug;33(4):458-63. doi: 10.1016/j.ntt.2011.06.002. Epub 2011 Jun 17. |
body mass |
female |
0 days
| 8 |
|
|
259.23 |
g |
24.17 |
68.36 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
75918 |
1539 |
Crl:SD |
body weight |
controlled fructose content drinking water (5 %) (for 70 days) and controlled bisphenol A content drinking water (0.025 mg/l) (for 70 days) |
Ronn M, et al., Toxicology. 2013 Jan 7;303:125-32. doi: 10.1016/j.tox.2012.09.013. Epub 2012 Nov 8. |
body mass |
female |
105 days
| 12 |
|
|
173.7 |
g |
2.86 |
9.9 |
body weighing method |
0.0 |
|
0 |
|
|
week one |
|
|
75754 |
1538 |
Hsd:WI |
body weight |
silymarin (50 mg/kg/d) (for 10 days) then cisplatin (7.5 mg/kg) |
Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90. |
body mass |
male |
0 days
| 6 |
|
|
143.6 |
g |
0.41 |
1.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
75954 |
1544 |
BluHsd:LE |
body weight |
vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) |
Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. |
body mass |
male |
98 days
| 8 |
|
|
457.7 |
g |
15.9 |
44.97 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
75962 |
1543 |
BluHsd:LE |
body weight gain |
vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) |
Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. |
body mass |
male |
71 days-98 days |
8 |
|
|
104.6 |
g |
5.9 |
16.69 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
75969 |
1543 |
Hsd:WI |
body weight |
vehicle control condition (for 91 days) |
Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796. |
body mass |
male |
119 days-126 days |
5 |
|
|
388.0 |
g |
16.82 |
37.6 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
76041 |
1545 |
Hsd:WI |
body weight |
octylphenol (125 mg/kg/d) (for 91 days) |
Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796. |
body mass |
male |
119 days-126 days |
6 |
|
|
326.67 |
g |
14.98 |
36.69 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
76047 |
1545 |
SD |
body weight |
acetaminophen (1000 mg/kg) (for 15 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
female |
57 days-71 days |
6 |
|
|
150.9 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84811 |
1602 |
HanTac:WH |
body weight |
bisphenol A (0.25 mg/kg/d) (for 1 days) |
Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. |
body mass |
male |
1 days
| 17 |
|
|
6.1 |
g |
0.12 |
0.5 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
96614 |
1559 |
SD |
body weight |
control condition |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
female |
70 days-84 days |
6 |
|
|
160.5 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84818 |
1602 |
PXO4/Cub |
body weight |
controlled sucrose content diet (70 % of calories) (between 0 and 168 hours) and controlled protein content diet (19.6 % of calories) (between 0 and 168 hours) and controlled fat content diet (10.4 % of calories) (between 0 and 168 hours) then fasting (between 0 and 16 hours) |
Hodulova M, et al., PLoS One. 2014 Oct 8;9(10):e109983. doi: 10.1371/journal.pone.0109983. eCollection 2014. |
body mass |
male |
127 days
| 9 |
|
|
300.1 |
g |
5.1 |
15.3 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97169 |
1858 |
SHR-Ndufc2em1Mcwi-/+ |
body weight |
controlled protein content diet (19.7 %) (for 56 days) and controlled potassium content diet (6.3 mg/g) (for 56 days) and controlled sodium content diet (3.7 mg/g) (for 56 days) |
Rubattu S, et al., J Am Heart Assoc. 2016 Feb 17;5(2). pii: e002701. doi: 10.1161/JAHA.115.002701. |
body mass |
not specified |
98 days
| 17 |
|
|
281.0 |
g |
4.37 |
18.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97898 |
1938 |
SHR-Ndufc2em2Mcwi+/+ |
body weight |
controlled protein content diet (19.7 %) (for 28 days) and controlled potassium content diet (6.3 mg/g) (for 28 days) and controlled sodium content diet (3.7 mg/g) (for 28 days) |
Rubattu S, et al., J Am Heart Assoc. 2016 Feb 17;5(2). pii: e002701. doi: 10.1161/JAHA.115.002701. |
body mass |
not specified |
70 days
| 12 |
|
|
239.0 |
g |
3.75 |
13.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97900 |
1938 |
SHRSP/Bbb |
body weight |
controlled protein content diet (19.7 %) (for 28 days) and controlled potassium content diet (6.3 mg/g) (for 28 days) and controlled sodium content diet (3.7 mg/g) (for 28 days) |
Rubattu S, et al., J Am Heart Assoc. 2016 Feb 17;5(2). pii: e002701. doi: 10.1161/JAHA.115.002701. |
body mass |
not specified |
70 days
| 18 |
|
|
177.0 |
g |
1.41 |
6.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97909 |
1938 |
SS/JrTol |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 24 days) |
Mell B, et al., Hypertens Res. 2015 Jan;38(1):61-7. doi: 10.1038/hr.2014.134. Epub 2014 Sep 18. |
body mass |
male |
73 days-75 days |
10 |
|
|
338.0 |
g |
4.0 |
12.65 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
96966 |
1778 |
PXO6-2/Cub |
body weight |
controlled sucrose content diet (70 % of calories) (between 0 and 168 hours) and controlled protein content diet (19.6 % of calories) (between 0 and 168 hours) and controlled fat content diet (10.4 % of calories) (between 0 and 168 hours) then fasting (between 0 and 16 hours) |
Hodulova M, et al., PLoS One. 2014 Oct 8;9(10):e109983. doi: 10.1371/journal.pone.0109983. eCollection 2014. |
body mass |
male |
127 days
| 8 |
|
|
278.6 |
g |
5.2 |
14.71 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97165 |
1858 |
SHR-Ndufc2em1Mcwi+/+ |
body weight |
controlled protein content diet (19.7 %) (for 28 days) and controlled potassium content diet (6.3 mg/g) (for 28 days) and controlled sodium content diet (3.7 mg/g) (for 28 days) |
Rubattu S, et al., J Am Heart Assoc. 2016 Feb 17;5(2). pii: e002701. doi: 10.1161/JAHA.115.002701. |
body mass |
not specified |
70 days
| 10 |
|
|
235.0 |
g |
4.74 |
15.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97877 |
1938 |
MW |
body weight |
right nephrectomy (for 56 days) then reserpine (5 mg/l) and hydralazine (80 mg/l) and controlled hydralazine content drinking water (25 mg/l) |
Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55. |
body mass |
male |
0 days
| 10 |
|
|
276.6 |
g |
7.4 |
23.4 |
body weighing method |
0.0 |
~5/6 to 7/8 nephrectomy |
56 |
days |
|
|
|
|
100800 |
2523 |
SS-Clcn6em2Mcwi |
body weight |
controlled sodium content diet (0.4 %) (between 56 and 63 days) then controlled sodium content diet (4 %) (for 12 days) |
Flister MJ, et al., Genome Res. 2013 Dec;23(12):1996-2002. doi: 10.1101/gr.160283.113. Epub 2013 Sep 4. |
body mass |
male |
60 days-69 days |
0 |
|
|
282.0 |
g |
5.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
98468 |
2059 |
SS-Nppbem2Mcwi+/+ |
body weight |
control condition (for 84 days) |
Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. |
body mass |
male |
84 days
| 6 |
|
|
398.0 |
g |
16.0 |
39.19 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99547 |
2319 |
SS-Nppbem2Mcwi+/+ |
body weight |
control condition (for 168 days) |
Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. |
body mass |
male |
168 days
| 5 |
|
|
438.0 |
g |
21.0 |
46.96 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99549 |
2319 |
SS-Nppbem2Mcwi-/- |
body weight |
control condition (for 56 days) |
Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. |
body mass |
male |
56 days
| 6 |
|
|
253.0 |
g |
30.0 |
73.48 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99546 |
2319 |
SS/JrHsd |
body weight |
controlled sodium chloride content diet (4 %) (for 14 days) then bilateral ovariectomy then peanut oil (0.2 ml) (for 14 days) |
Zheng W, et al., Am J Physiol Heart Circ Physiol. 2008 Apr;294(4):H1508-13. doi: 10.1152/ajpheart.01322.2007. Epub 2008 Feb 1. |
body mass |
female |
0 days
| 0 |
|
|
297.0 |
g |
5.1 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102192 |
2681 |
LL/Mav |
body weight |
vehicle control condition |
Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. |
body mass |
male |
112 days
| 9 |
|
|
364.0 |
g |
6.0 |
18.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102722 |
2721 |
OLETF |
body weight |
control condition (for 84 days) |
Koga K, et al., Mol Med. 2002 Oct;8(10):591-9. |
body mass |
male |
364 days
| 12 |
|
|
748.6 |
g |
33.0 |
114.32 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99411 |
2298 |
FHH-Nr4a1m1Mcwi |
body weight |
control condition |
Westbrook L, et al., J Am Soc Nephrol. 2014 Nov;25(11):2499-510. doi: 10.1681/ASN.2013070786. Epub 2014 Apr 10. |
body mass |
male |
56 days
| 6 |
|
|
190.0 |
g |
2.6 |
6.37 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99452 |
2318 |
SR/NEisSlc |
body weight |
controlled sodium chloride content diet (0.3 %) (for 42 days) then controlled sodium chloride content diet (8 %) (for 35 days) |
Horinaka S, et al., Int J Cardiol. 2003 Sep;91(1):25-35. |
body mass |
male |
77 days
| 10 |
|
|
356.0 |
g |
3.48 |
11.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102480 |
2690 |
SS/NEisSlc |
body weight |
controlled sodium chloride content diet (0.3 %) (for 42 days) then controlled sodium chloride content diet (8 %) (for 35 days) |
Horinaka S, et al., Int J Cardiol. 2003 Sep;91(1):25-35. |
body mass |
male |
77 days
| 10 |
|
|
344.0 |
g |
8.22 |
26.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102482 |
2690 |
F344.ZUC-Leprfa/Tj |
body weight |
control condition |
Kotoh J, et al., J Vet Med Sci. 2016 Aug 11. |
body mass |
male |
175 days
| 10 |
|
|
607.3 |
g |
14.1 |
44.59 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
98033 |
1978 |
WKY |
body weight |
left anterior descending coronary artery occlusion then vehicle control condition |
Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. |
body mass |
male |
42 days-56 days |
30 |
|
|
225.0 |
g |
1.8 |
9.86 |
body weighing method |
0.0 |
lad occlusion |
0 |
days |
|
|
|
|
100269 |
2460 |
WKY |
body weight |
sham surgical control condition (for 224 days) |
Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. |
body mass |
male |
266 days-280 days |
5 |
|
|
562.0 |
g |
22.0 |
49.19 |
body weighing method |
0.0 |
lad occlusion sham |
210 |
days |
|
|
|
|
100273 |
2460 |
WKY |
body weight |
left anterior descending coronary artery occlusion then furosemide |
Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. |
body mass |
male |
42 days-56 days |
20 |
|
|
225.0 |
g |
3.0 |
13.42 |
body weighing method |
0.0 |
lad occlusion |
0 |
days |
|
|
|
|
100268 |
2460 |
SD |
body weight |
controlled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then paricalcitol (0.8 mg/kg) (for 90 days) |
Finch JL, et al., Am J Physiol Renal Physiol. 2011 Sep 28. |
body mass |
female |
0 days
| 10 |
|
|
291.9 |
g |
6.4 |
20.24 |
body weighing method |
0.0 |
unx |
97 |
days |
|
|
|
|
100634 |
2499 |
SS |
body weight |
controlled sodium content diet (6 %) (between 21 and 28 days) |
Kamei K, et al., Circ J. 2007 Mar;71(3):390-6. |
body mass |
male |
63 days-70 days |
7 |
|
|
312.0 |
g |
11.72 |
31.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103347 |
2804 |
SS |
body weight |
controlled sodium content diet (6 %) (between 56 and 70 days) |
Kamei K, et al., Circ J. 2007 Mar;71(3):390-6. |
body mass |
male |
98 days-132 days |
7 |
|
|
417.0 |
g |
31.75 |
84.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103349 |
2804 |
SD-Tg(Ren2)27-/- |
body weight |
control condition (for 0 hours) |
Cerutti C, et al., Physiol Genomics. 2006 Nov 27;27(3):295-308. doi: 10.1152/physiolgenomics.00318.2005. Epub 2006 Aug 1. |
body mass |
male |
84 days
| 6 |
|
|
405.0 |
g |
31.0 |
75.93 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103474 |
2826 |
LH/Mav |
body weight |
control condition (for 0 hours) |
Cerutti C, et al., Physiol Genomics. 2006 Nov 27;27(3):295-308. doi: 10.1152/physiolgenomics.00318.2005. Epub 2006 Aug 1. |
body mass |
male |
84 days
| 5 |
|
|
360.0 |
g |
6.0 |
13.42 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103479 |
2826 |
WKY/NCrl |
body weight |
vehicle control condition (for 28 days) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
body mass |
male |
168 days
| 6 |
|
|
463.0 |
g |
7.0 |
17.15 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103490 |
2827 |
LH/Mav |
body weight |
control condition |
Egan EJ, et al., Acta Pharmacol Sin. 2008 Nov;29(11):1296-300. doi: 10.1111/j.1745-7254.2008.00862.x. |
body mass |
male |
161 days
| 4 |
|
|
431.0 |
g |
8.0 |
16.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102805 |
2723 |
SR/Hsd |
body weight |
standard diet |
Wu F, et al., Int J Hypertens. 2016;2016:9146870. doi: 10.1155/2016/9146870. Epub 2016 Dec 19. |
body mass |
male |
49 days
| 8 |
|
|
213.0 |
g |
2.4 |
6.8 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102271 |
2683 |
Crlj:WI |
body weight |
controlled air oxygen content (5 %) (for 28 days) |
Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1. |
body mass |
male |
16 days
| 7 |
|
|
300.0 |
g |
5.0 |
13.23 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103000 |
2784 |
GK |
body weight |
bilateral ovariectomy (for 24 days) |
Apaijai N, et al., Biosci Rep. 2017 Oct 17;37(5). pii: BSR20170886. doi: 10.1042/BSR20170886. Print 2017 Oct 31. |
body mass |
female |
87 days
| 6 |
|
|
314.0 |
g |
5.0 |
12.25 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103756 |
2782 |
SD |
change in body weight |
sham surgical control condition (between 12 and 14 days) |
Greene EL, et al., J Clin Invest. 1996 Aug 15;98(4):1063-8. |
body mass |
male |
0 days
| 6 |
|
|
84.0 |
g |
4.9 |
12.0 |
body weighing method |
0.0 |
sham unx |
13 |
days |
|
change from surgery weight |
|
|
101539 |
2602 |
SD |
change in body weight |
unilateral nephrectomy (between 12 and 14 days) then enalapril (50 mg/l) (between 12 and 14 days) and losartan (180 mg/l) (between 12 and 14 days) |
Greene EL, et al., J Clin Invest. 1996 Aug 15;98(4):1063-8. |
body mass |
male |
0 days
| 5 |
|
|
74.0 |
g |
7.6 |
17.0 |
body weighing method |
0.0 |
unx |
13 |
days |
|
change from surgery weight |
|
|
101541 |
2602 |
SD |
change in body weight |
unilateral nephrectomy (for 28 days) then enalapril (50 mg/l) (for 28 days) and losartan (180 mg/l) (for 28 days) and aldosterone (35 mg/kg/d) (for 28 days) |
Greene EL, et al., J Clin Invest. 1996 Aug 15;98(4):1063-8. |
body mass |
male |
0 days
| 6 |
|
|
106.0 |
g |
10.61 |
26.0 |
body weighing method |
0.0 |
unx |
28 |
days |
|
change from surgery weight |
|
|
101578 |
2602 |
SD |
change in body weight |
unilateral nephrectomy (for 28 days) |
Greene EL, et al., J Clin Invest. 1996 Aug 15;98(4):1063-8. |
body mass |
male |
0 days
| 8 |
|
|
59.0 |
g |
10.96 |
31.0 |
body weighing method |
0.0 |
unx |
28 |
days |
|
change from surgery weight |
|
|
101609 |
2602 |
LH/MavRrrcAek |
body weight area under curve (AUC) |
standard rat chow (for 98 days) then controlled sodium chloride content diet (4 %) (for 21 days) |
Wang J, et al., Circ Cardiovasc Genet. 2015 Apr;8(2):316-26. doi: 10.1161/CIRCGENETICS.114.000520. Epub 2015 Jan 8. |
body mass |
male |
21 days-126 days |
0 |
body weight X week = growth AUC |
|
4.1351184E7 |
g x min |
396144.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
growth auc |
|
|
102617 |
3014 |
SS-Renem1Mcwi+/- |
body weight |
controlled sodium content diet (0.4 %) (for 49 days) |
Moreno C, et al., Hypertension. 2011 Mar;57(3):614-9. doi: 10.1161/HYPERTENSIONAHA.110.163840. Epub 2011 Jan 17. |
body mass |
female |
70 days
| 8 |
|
|
203.13 |
g |
3.02 |
8.54 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
98293 |
2038 |
GK/Jcl |
body weight |
controlled cyclodextrin (CD)-clathrated hesperetin content diet (4.6 %) |
Akiyama S, et al., Biosci Biotechnol Biochem. 2009 Dec;73(12):2779-82. doi: 10.1271/bbb.90576. Epub 2009 Dec 7. |
body mass |
male |
24 days
| 6 |
|
|
52.81 |
g |
1.57 |
3.85 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103907 |
2884 |
WKY |
body weight |
streptozotocin (60 mg/kg) then gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 null) |
Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. |
body mass |
male |
156 days
| 10 |
|
|
295.56 |
g |
21.89 |
69.22 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99110 |
2219 |
SD |
body weight |
left nephrectomy (for 28 days) then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (5 mg/kg) then puromycin (40 mg/kg) |
Ma LJ, et al., Kidney Int. 2004 Jan;65(1):106-15. |
body mass |
male |
0 days
| 9 |
|
|
300.0 |
g |
5.0 |
15.0 |
body weighing method |
0.0 |
unx |
28 |
days |
|
|
|
|
98930 |
2179 |
LH/Mav |
body weight |
perindopril (0.04 mg/kg/d) (for 98 days) |
Egan EJ, et al., Acta Pharmacol Sin. 2008 Nov;29(11):1296-300. doi: 10.1111/j.1745-7254.2008.00862.x. |
body mass |
male |
112 days
| 8 |
|
|
394.0 |
g |
4.0 |
11.31 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102788 |
2723 |
F344/NSlc |
body weight |
control condition |
Kotoh J, et al., J Vet Med Sci. 2016 Aug 11. |
body mass |
male |
175 days
| 8 |
|
|
412.03 |
g |
8.93 |
25.26 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
98031 |
1978 |
MW |
body weight |
nephrectomy (for 28 days) then reserpine (5 mg/l) (for 21 days) and hydralazine (80 mg/l) (for 21 days) and controlled hydralazine content drinking water (25 mg/l) (for 21 days) |
Anderson S, et al., J Clin Invest. 1986 Jun;77(6):1993-2000. |
body mass |
male |
0 days
| 8 |
|
|
233.0 |
g |
4.0 |
11.31 |
body weighing method |
0.0 |
5/6 nephrectomy |
28 |
days |
|
|
|
|
100985 |
2561 |
Crl:WI |
body weight |
running on treadmill (0-10 m/min) (between 0.1 and 0.2 hours) then running on treadmill (15 m/min) (for 0.5 hours) then running on treadmill (15 m/min) (for 0.8 hours) |
Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. |
body mass |
male |
147 days
| 6 |
|
|
499.0 |
g |
15.0 |
36.74 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103979 |
2885 |
GK/MolTac |
body weight |
control condition |
Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. |
body mass |
male |
147 days
| 0 |
|
|
389.0 |
g |
7.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103983 |
2885 |
Crl:WI |
body weight |
control condition then controlled saxagliptin content diet (10 mg/kg/d) (for 12 days) |
Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. |
body mass |
male |
147 days
| 6 |
|
|
553.0 |
g |
23.0 |
56.34 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103980 |
2885 |
SR/NEisSlc |
body weight |
controlled sodium chloride content diet (8 %) (for 7 days) |
Yoshihara F, et al., Regul Pept. 2005 May 15;128(1):7-13. |
body mass |
male |
63 days
| 7 |
|
|
286.0 |
g |
6.05 |
16.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102405 |
2689 |
SS/JrHsd |
body weight |
gelled diet (200 g/kg/d) (for 8 days) then carbenoxolone (100 mg/kg/d) |
Fenton RA, et al., Am J Physiol Renal Physiol. 2003 Jul;285(1):F143-51. Epub 2003 Apr 8. |
body mass |
male |
0 days
| 6 |
|
|
128.0 |
g |
2.9 |
7.1 |
body weighing method |
0.0 |
osmotic pump implant |
0 |
days |
|
|
|
|
102544 |
2691 |
MWF/ZtmRrrc |
body weight |
enalapril (50 mg/l) (for 60 days) |
Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9. |
body mass |
male |
126 days
| 10 |
|
|
376.0 |
g |
5.69 |
18.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
100902 |
2541 |
MWF/ZtmRrrc |
body weight |
enalapril (50 mg/l) (for 182 days) |
Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9. |
body mass |
male |
246 days
| 6 |
|
|
442.0 |
g |
7.35 |
18.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
100906 |
2541 |
WKY |
body weight |
controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) |
Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. |
body mass |
male |
0 days
| 9 |
|
|
395.0 |
g |
7.0 |
21.0 |
body weighing method |
0.0 |
PA IV 50mg/kg |
490 |
days |
|
|
|
|
100435 |
2479 |
WF/Mol |
body weight |
controlled ramipril content drinking water (3 mg/kg/d) (for 10 days) then artificial aortocaval fistula (for 9 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 7 |
|
|
176.0 |
g |
3.0 |
7.94 |
body weighing method |
0.0 |
acf |
9 |
days |
|
|
|
|
101308 |
2585 |
WF/Mol |
body weight |
vehicle control condition then sham surgical control condition (for 2 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 6 |
|
|
200.0 |
g |
2.0 |
4.9 |
body weighing method |
0.0 |
|
2 |
days |
|
|
|
|
101313 |
2585 |
WF/Mol |
body weight gain |
controlled ramipril content drinking water (3 mg/kg/d) (for 5 days) then artificial aortocaval fistula (for 4 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 7 |
|
|
-4.0 |
g |
2.0 |
5.29 |
body weighing method |
0.0 |
acf |
4 |
days |
|
change from surgery weight |
|
|
101322 |
2585 |
WF/Mol |
body weight gain |
controlled ramipril content drinking water (3 mg/kg/d) (for 8 days) then sham surgical control condition (for 7 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 5 |
|
|
30.0 |
g |
2.0 |
4.47 |
body weighing method |
0.0 |
sham acf |
7 |
days |
|
change from surgery weight |
|
|
101327 |
2585 |
WF/Mol |
body weight gain |
vehicle control condition then sham surgical control condition (for 4 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 5 |
|
|
18.0 |
g |
1.0 |
2.24 |
body weighing method |
0.0 |
|
4 |
days |
|
change from surgery weight |
|
|
101325 |
2585 |
WF/Mol |
body weight gain |
vehicle control condition then artificial aortocaval fistula (for 2 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 7 |
|
|
-14.0 |
g |
2.0 |
5.29 |
body weighing method |
0.0 |
acf |
2 |
days |
|
change from surgery weight |
|
|
101334 |
2585 |
WF/Mol |
body weight gain |
controlled losartan content drinking water (10 mg/kg/d) (for 5 days) then artificial aortocaval fistula (for 4 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 8 |
|
|
-5.0 |
g |
2.0 |
5.66 |
body weighing method |
0.0 |
acf |
4 |
days |
|
change from surgery weight |
|
|
101336 |
2585 |
WF/Mol |
body weight gain |
controlled losartan content drinking water (10 mg/kg/d) (for 5 days) then sham surgical control condition (for 4 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 6 |
|
|
-1.0 |
g |
1.0 |
2.45 |
body weighing method |
0.0 |
sham acf |
4 |
days |
|
change from surgery weight |
|
|
101337 |
2585 |
SS.ZUC-Leprfa+/+/Slc |
body weight |
bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
body mass |
female |
91 days
| 12 |
|
|
220.0 |
g |
4.0 |
13.86 |
body weighing method |
0.0 |
ovariectomy |
42 |
days |
|
|
|
|
101662 |
2622 |
SS.ZUC-Leprfa-/-/Slc |
body weight |
bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
body mass |
female |
91 days
| 7 |
|
|
339.0 |
g |
13.0 |
34.39 |
body weighing method |
0.0 |
ovariectomy |
42 |
days |
|
|
|
|
101664 |
2622 |
SR/Jr |
body weight |
controlled sodium chloride content diet (0.3 %) (for 35 days) |
Vokurkov? M, et al., Hypertens Res. 2003 May;26(5):397-404. |
body mass |
male |
63 days
| 16 |
|
|
218.0 |
g |
9.0 |
36.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103234 |
2802 |
SS-Leprem2Mcwi |
body weight |
control condition |
McPherson KC, et al., Am J Physiol Renal Physiol. 2016 Oct 1;311(4):F793-F804. doi: 10.1152/ajprenal.00590.2015. Epub 2016 Jul 27. |
body mass |
male |
126 days
| 19 |
|
|
528.0 |
g |
15.0 |
65.38 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
100070 |
2418 |
WKY |
body weight |
0.9% sodium chloride solution (3 ml) |
Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. |
body mass |
male |
0 days
| 10 |
|
|
241.0 |
g |
5.0 |
15.81 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
100391 |
2479 |
Crl:WI(WU) |
body weight |
abdominal aorta constriction then quinapril (2 mg/kg/d) (for 14 days) |
Goetz RM and Holtz J, Clin Sci (Lond). 1999 Aug;97(2):165-74. |
body mass |
male |
91 days
| 11 |
|
|
284.0 |
g |
7.0 |
23.22 |
body weighing method |
0.0 |
aorta coarctation |
35 |
days |
|
|
|
|
100008 |
2398 |
SS/NEisSlc |
body weight |
controlled sodium content diet (0.3 %) (for 91 days) |
Otsuka F, et al., Am J Physiol. 1998 Jun;274(6 Pt 2):R1797-806. |
body mass |
male |
91 days
| 6 |
|
|
374.7 |
g |
7.32 |
17.93 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
100697 |
2519 |
SD-Nfe2l2em1Mcwi+/+ |
body weight |
controlled sodium chloride content diet (0.4 %) (between 70 and 84 days) then controlled sodium chloride content diet (4 %) (for 3 days) then 0.9% sodium chloride solution (for 3 days) |
Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4. |
body mass |
male |
62 days-76 days |
8 |
|
|
281.0 |
g |
17.7 |
50.06 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
100733 |
2520 |
MW |
body weight |
right nephrectomy (for 84 days) then lisinopril (10 mg/kg/d) (for 28 days) |
Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55. |
body mass |
male |
0 days
| 10 |
|
|
293.5 |
g |
5.4 |
17.08 |
body weighing method |
0.0 |
~5/6 to 7/8 nephrectomy |
84 |
days |
|
|
|
|
100824 |
2523 |
MW |
body weight |
right nephrectomy (for 84 days) then captopril (30 mg/kg/d) (for 28 days) |
Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55. |
body mass |
male |
0 days
| 10 |
|
|
290.8 |
g |
8.0 |
25.3 |
body weighing method |
0.0 |
~5/6 to 7/8 nephrectomy |
84 |
days |
|
|
|
|
100822 |
2523 |
MW |
body weight |
right nephrectomy (for 112 days) then enalapril (20 mg/kg/d) (for 56 days) |
Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55. |
body mass |
male |
0 days
| 9 |
|
|
313.8 |
g |
15.0 |
45.0 |
body weighing method |
0.0 |
~5/6 to 7/8 nephrectomy |
112 |
days |
|
|
|
|
100830 |
2523 |
MW |
body weight |
right nephrectomy (for 112 days) then angiotensin II receptor antagonist (20 mg/l) (for 56 days) |
Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55. |
body mass |
male |
0 days
| 7 |
|
|
289.0 |
g |
13.6 |
35.98 |
body weighing method |
0.0 |
~5/6 to 7/8 nephrectomy |
112 |
days |
|
|
|
|
100832 |
2523 |
SS.BN-(D13Hmgc64-D13Hmgc23)/Mcwi |
body weight |
control condition |
Stodola TJ, et al., Physiol Genomics. 2011 Jul 14;43(13):808-17. doi: 10.1152/physiolgenomics.00171.2010. Epub 2011 Apr 26. |
body mass |
male |
49 days-63 days |
12 |
|
|
268.3 |
g |
7.5 |
25.98 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
98999 |
2198 |
SS.BN-(D13Rat25-RN34_13048990782)/Mcwi |
body weight |
control condition |
Stodola TJ, et al., Physiol Genomics. 2011 Jul 14;43(13):808-17. doi: 10.1152/physiolgenomics.00171.2010. Epub 2011 Apr 26. |
body mass |
male |
49 days-63 days |
10 |
|
|
262.6 |
g |
9.2 |
29.09 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99009 |
2198 |
WI |
body weight |
controlled in utero environment (for 21 days) and standard diet (50 % of calories) (for 21 days) |
Ceravolo GS, et al., Life Sci. 2007 Jan 30;80(8):782-7. Epub 2006 Nov 10. |
body mass |
male |
68 days
| 35 |
|
|
303.6 |
g |
6.5 |
38.45 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
101054 |
2563 |
SS.ZUC-Leprfa+/+/Slc |
body weight |
control condition |
Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. |
body mass |
male |
126 days
| 6 |
|
|
443.75 |
g |
21.62 |
52.96 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
101885 |
2642 |
F344-Hsd11b2em1Jmul-/- |
body weight |
standard rat chow |
Mullins LJ, et al., Hypertension. 2015 Sep;66(3):667-73. doi: 10.1161/HYPERTENSIONAHA.115.05262. Epub 2015 Jun 15. |
body mass |
male |
98 days
| 7 |
|
|
276.7 |
g |
4.1 |
10.85 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
104989 |
3008 |
Crl:WI |
body weight |
control condition |
Pugliese G, et al., Kidney Int. 2005 Apr;67(4):1440-52. doi: 10.1111/j.1523-1755.2005.00221.x. |
body mass |
male |
84 days
| 8 |
|
|
330.0 |
g |
6.36 |
18.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
104063 |
2907 |
MNS |
body weight |
control condition |
Pugliese G, et al., Kidney Int. 2005 Apr;67(4):1440-52. doi: 10.1111/j.1523-1755.2005.00221.x. |
body mass |
male |
84 days
| 9 |
|
|
336.0 |
g |
8.33 |
25.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
104061 |
2907 |
Crl:WI |
body weight |
control condition |
Pugliese G, et al., Kidney Int. 2005 Apr;67(4):1440-52. doi: 10.1111/j.1523-1755.2005.00221.x. |
body mass |
male |
252 days
| 10 |
|
|
558.0 |
g |
24.67 |
78.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
104072 |
2907 |
MNS |
body weight |
control condition |
Capasso G, et al., Am J Physiol Renal Physiol. 2005 Jun;288(6):F1173-82. doi: 10.1152/ajprenal.00228.2004. Epub 2005 Feb 1. |
body mass |
not specified |
23 days-25 days |
11 |
|
|
71.0 |
g |
2.6 |
8.62 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
104154 |
2926 |
MHS |
body weight |
control condition |
Capasso G, et al., Am J Physiol Renal Physiol. 2005 Jun;288(6):F1173-82. doi: 10.1152/ajprenal.00228.2004. Epub 2005 Feb 1. |
body mass |
not specified |
23 days-25 days |
11 |
|
|
72.0 |
g |
2.1 |
6.96 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
104155 |
2926 |
SBH/Ygl |
body weight |
controlled sodium chloride content diet (8 %) (for 42 days) |
Landau D, et al., J Endocrinol. 2008 Apr;197(1):75-83. doi: 10.1677/JOE-08-0040. |
body mass |
male |
98 days
| 7 |
|
|
270.0 |
g |
7.0 |
18.52 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
106701 |
3038 |
MWF/FubRkb |
body weight |
vehicle control condition (for 28 days) |
Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275. |
body mass |
male |
112 days
| 10 |
|
|
362.8 |
g |
12.8 |
40.48 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109389 |
3140 |
MWF/FubRkb |
fetal body weight |
control condition |
Schulte L, etal., J Hypertens. 2012 Oct;30(10):2031-8. doi: 10.1097/HJH.0b013e328356a60a. |
body mass |
not specified |
-6 days
| 11 |
|
|
0.26 |
g |
0.01 |
0.03 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109501 |
3145 |
MWF-Chr 6SHR/Rkb |
fetal body weight |
control condition |
Schulte L, etal., J Hypertens. 2012 Oct;30(10):2031-8. doi: 10.1097/HJH.0b013e328356a60a. |
body mass |
not specified |
-6 days
| 12 |
|
|
0.27 |
g |
0.0 |
0.02 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109506 |
3145 |
SHR/FubRkb |
fetal body weight |
control condition |
Schulte L, etal., J Hypertens. 2012 Oct;30(10):2031-8. doi: 10.1097/HJH.0b013e328356a60a. |
body mass |
not specified |
-5 days
| 10 |
|
|
0.24 |
g |
0.01 |
0.02 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109507 |
3145 |
MWF/FubRkb |
fetal body weight |
control condition |
Schulte L, etal., J Hypertens. 2012 Oct;30(10):2031-8. doi: 10.1097/HJH.0b013e328356a60a. |
body mass |
not specified |
-6 days
| 11 |
|
|
0.26 |
g |
0.01 |
0.03 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109508 |
3145 |
LOU/MWsl |
change in body weight to initial body weight ratio |
rat IgM immunocytoma cells (1 x 10E4 cells) then positively charged liposome-entrapped doxorubicin (1 mg/kg) (for 10 days) |
van Hoesel QG, etal., Cancer Res. 1984 Sep;44(9):3698-705. |
body mass |
male |
105 days-115 days |
6 |
|
|
-3.2 |
% |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109577 |
3150 |
LH/MavRrrcAek |
body weight to body length (nose to rump) ratio |
standard rat chow (for 98 days) then controlled sodium chloride content diet (4 %) (for 14 days) |
Wang J, et al., Circ Cardiovasc Genet. 2015 Apr;8(2):316-26. doi: 10.1161/CIRCGENETICS.114.000520. Epub 2015 Jan 8. |
body mass |
male |
112 days
| 0 |
|
|
17.0 |
g/cm |
0.21 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
107400 |
3014 |
LH/MavRrrcAek |
maximum slope of body weight growth curve |
standard rat chow (for 98 days) then controlled sodium chloride content diet (4 %) (for 21 days) |
Wang J, et al., Circ Cardiovasc Genet. 2015 Apr;8(2):316-26. doi: 10.1161/CIRCGENETICS.114.000520. Epub 2015 Jan 8. |
body mass |
male |
21 days-126 days |
0 |
y=mx + c |
|
45.1 |
g/week |
0.74 |
|
body weighing method |
0.0 |
|
0 |
|
|
maximum slope of body weight growth curve (CMO:0003452) |
|
|
107402 |
3014 |
LOU/MWsl |
change in body weight to initial body weight ratio |
doxorubicin (2 mg/kg) (for 7 days) |
van Hoesel QG, etal., J Natl Cancer Inst. 1984 May;72(5):1141-50. |
body mass |
male |
109 days
| 5 |
|
|
-24.0 |
% |
0.0 |
0.0 |
body weighing method |
0.0 |
|
7 |
days |
|
|
|
|
109754 |
3155 |
GK |
body weight |
resting (for 42 days) |
Kupai K, et al., Diabetol Metab Syndr. 2015 Oct 6;7:85. doi: 10.1186/s13098-015-0080-x. eCollection 2015. |
body mass |
male |
0 days
| 20 |
|
|
338.0 |
g |
3.7 |
16.55 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109895 |
3160 |
GK/MolTac |
body weight |
control condition |
Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. |
body mass |
female |
60 days
| 6 |
|
|
209.0 |
g |
6.0 |
14.7 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
106893 |
3071 |
WKY/NMolTac |
body weight |
control condition |
Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. |
body mass |
female |
60 days
| 6 |
|
|
178.0 |
g |
5.0 |
12.25 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
106896 |
3071 |
WKY/NMolTac |
body weight |
control condition |
Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. |
body mass |
female |
420 days
| 9 |
|
|
268.0 |
g |
6.0 |
18.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
106898 |
3071 |
SHRSP/A3NCrl |
body weight |
controlled sodium chloride content drinking water (1 %) (for 49 days) and controlled fat content diet (24.5 %) (for 49 days) |
Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. |
body mass |
male |
134 days-141 days |
11 |
|
|
315.0 |
g |
7.0 |
23.22 |
body weighing method |
0.0 |
|
0 |
|
|
high salt/fat diet HSFD |
|
|
106958 |
3073 |
F344/NHsd |
body weight |
control condition |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
female |
98 days-0 days |
2 |
|
|
224.0 |
g |
0.0 |
9.2 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
106961 |
3074 |
SHRSP/A3NCrl |
body weight |
controlled sodium chloride content drinking water (1 %) (for 49 days) and controlled fat content diet (24.5 %) (for 49 days) then controlled GSK2181236A content diet (0.1 mg/kg/d) (for 42 days) |
Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. |
body mass |
male |
134 days-141 days |
6 |
|
|
331.0 |
g |
16.0 |
39.19 |
body weighing method |
0.0 |
|
0 |
|
|
HSFD +0.1 mg/kg/day GSK2181236A |
|
|
106959 |
3073 |
F344/NHsd |
body weight |
azoxymethane (15 mg/kg) |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
female |
91 days-0 days |
4 |
|
|
222.0 |
g |
8.9 |
17.8 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
107007 |
3074 |
WAG/Rij |
body weight |
0.9% sodium chloride solution (1 ml) |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
male |
91 days-0 days |
2 |
|
|
326.0 |
g |
18.03 |
25.5 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
107016 |
3074 |
MWF/Hsd |
maximum body weight loss to initial body weight ratio |
arterial catheter implantation (for 1 days) |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
body mass |
male |
89 days-95 days |
10 |
|
|
5.1 |
% |
0.8 |
2.53 |
body weighing method |
0.0 |
arterial catheter implantation |
1 |
days |
|
|
|
|
107188 |
3077 |
FHH/EurMcwiCrl |
maximum body weight loss to initial body weight ratio |
arterial catheter implantation (for 1 days) |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
body mass |
male |
89 days-95 days |
10 |
|
|
6.4 |
% |
0.5 |
1.58 |
body weighing method |
0.0 |
arterial catheter implantation |
1 |
days |
|
|
|
|
107187 |
3077 |
BDIX/CrCrl |
body weight |
control condition |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
body mass |
male |
88 days-94 days |
10 |
|
|
331.0 |
g |
9.0 |
28.46 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
107345 |
3077 |
NBL/CrCrl |
body weight |
control condition |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
body mass |
male |
88 days-94 days |
10 |
|
|
317.0 |
g |
10.0 |
31.62 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
107350 |
3077 |
COP/CrCrl |
body weight |
control condition |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
body mass |
male |
88 days-94 days |
10 |
|
|
250.0 |
g |
3.0 |
9.49 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
107353 |
3077 |
SHRSP/A3NCrl |
body weight |
controlled sodium chloride content drinking water (1 %) (for 91 days) and controlled fat content diet (24.5 %) (for 91 days) then controlled SB-239063 content diet (1200 ppm) (for 35 days) |
Lenhard SC, etal., J Pharmacol Exp Ther. 2003 Dec;307(3):939-46. doi: 10.1124/jpet.103.057398. Epub 2003 Oct 15. |
body mass |
male |
161 days-175 days |
8 |
|
|
310.0 |
g |
7.0 |
19.8 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
107381 |
3083 |
SHRSP/A3N |
body weight |
controlled sodium chloride content drinking water (1 %) (for 42 days) and controlled fat content diet (24.5 %) (for 42 days) and eprosartan (60 mg/kg/d) (for 42 days) |
Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. |
body mass |
male |
126 days-147 days |
0 |
|
|
298.0 |
g |
2.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
107528 |
3090 |
GK/CskCrljCrl |
body weight |
control condition |
Wakuta M, etal., Invest Ophthalmol Vis Sci. 2007 Feb;48(2):590-6. doi: 10.1167/iovs.05-1168. |
body mass |
male |
91 days-105 days |
6 |
|
|
347.0 |
g |
6.94 |
17.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
107991 |
3106 |
Crlj:WI |
body weight |
control condition |
Wakuta M, etal., Invest Ophthalmol Vis Sci. 2007 Feb;48(2):590-6. doi: 10.1167/iovs.05-1168. |
body mass |
male |
91 days-105 days |
5 |
|
|
474.0 |
g |
13.86 |
31.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
107992 |
3106 |
GK/Jpe |
body weight gain |
controlled cholesterol content diet (1.25 %) (for 90 days) and controlled cocoa butter content diet (7.5 %) (for 90 days) then lipoic acid (50 mg/kg) (for 90 days) |
Sena CM, etal., Br J Pharmacol. 2008 Mar;153(5):894-906. doi: 10.1038/sj.bjp.0707474. Epub 2007 Oct 1. |
body mass |
male |
450 days-540 days |
10 |
|
|
11.9 |
g |
3.7 |
11.7 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108003 |
3108 |
Hsd:WI |
neonatal body weight |
control condition |
Rothermund L, etal., J Hypertens. 2006 Sep 24(9). |
body mass |
not specified |
1 days
| 0 |
|
|
6.58 |
g |
0.16 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108076 |
3115 |
Hsd:WI |
neonatal body weight |
control condition |
Rothermund L, etal., J Hypertens. 2006 Sep 24(9). |
body mass |
not specified |
12 days
| 0 |
|
|
22.8 |
g |
0.4 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108080 |
3115 |
MWF/FubRkb |
neonatal body weight |
control condition |
Rothermund L, etal., J Hypertens. 2006 Sep 24(9). |
body mass |
not specified |
12 days
| 0 |
|
|
21.6 |
g |
0.6 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108081 |
3115 |
MWF/Hsd |
body weight |
control condition |
Szymanski MK, etal., Basic Res Cardiol. 2012 Mar;107(2):242. doi: 10.1007/s00395-011-0242-4. Epub 2012 Jan 19. |
body mass |
male |
84 days
| 5 |
|
|
249.0 |
g |
14.0 |
31.3 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108752 |
3130 |
GK |
body weight |
control condition |
Weng S, etal., Obes Surg. 2017 Mar;27(3):657-664. doi: 10.1007/s11695-016-2320-z. |
body mass |
male |
77 days
| 10 |
|
|
319.82 |
g |
3.96 |
12.51 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109070 |
3111 |
LEW/SsNHsd |
volume of blood removed to total prehemorrhagic blood volume ratio |
arterial catheter implantation (for 1 days) then controlled hemorrhage (for 0.4 hours) |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
blood amount |
male |
89 days-95 days |
9 |
5.83 mL/100 g of body weight |
|
57.2 |
% |
1.1 |
3.3 |
body weighing method |
0.0 |
|
0 |
|
|
volume of blood removed to total prehemorrhagic blood volume ratio (CMO:0003663) |
|
|
109127 |
3077 |
GK/CskCrlj |
body weight |
fasting (for 16 hours) |
Ohta T, et al., Br J Pharmacol. 1999 Apr;126(7):1674-80. doi: 10.1038/sj.bjp.0702481. |
body mass |
male |
56 days
| 5 |
|
|
204.4 |
g |
1.9 |
4.25 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110767 |
3185 |
SHR/FubRkb |
body weight |
unilateral nephrectomy (for 126 days) |
Schulz A, etal., Physiol Genomics. 2012 Jan 18;44(1):110-6. Epub 2011 Nov 22. |
body mass |
male |
168 days
| 15 |
|
|
330.4 |
g |
6.0 |
23.24 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109550 |
3148 |
WM/Nem |
fetal body weight |
control condition |
Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. |
body mass |
male |
-1 days
| 84 |
|
|
2.92 |
g |
0.02 |
0.2 |
body weighing method |
0.0 |
|
12 |
days |
|
|
|
|
111215 |
3199 |
Slc:ZUC-Leprfa-/- |
body weight |
control condition |
Mine T, etal., Biol Pharm Bull. 2002 Nov;25(11):1412-6. doi: 10.1248/bpb.25.1412. |
body mass |
male |
84 days-105 days |
44 |
|
|
499.6 |
g |
7.3 |
48.42 |
body weighing method |
0.0 |
|
0 |
|
|
slc:zuc-leprfa-/- |
|
|
106935 |
3070 |
MWF/Ztm |
body weight |
control condition |
Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882. |
body mass |
male |
10 days
| 5 |
|
|
16.2 |
g |
0.25 |
0.55 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109294 |
3137 |
MWF/Ztm |
body weight |
control condition |
Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882. |
body mass |
male |
20 days
| 5 |
|
|
34.7 |
g |
0.91 |
2.03 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109295 |
3137 |
MWF/Ztm |
body weight |
control condition |
Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882. |
body mass |
male |
60 days
| 5 |
|
|
229.9 |
g |
4.4 |
9.83 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109297 |
3137 |
LEW/Ztm |
body weight |
control condition |
Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882. |
body mass |
male |
20 days
| 5 |
|
|
36.0 |
g |
0.8 |
1.79 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109301 |
3137 |
LEW/Ztm |
body weight |
control condition |
Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882. |
body mass |
male |
60 days
| 5 |
|
|
249.7 |
g |
7.2 |
16.1 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109303 |
3137 |
LEW/Ztm |
body weight |
control condition |
Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882. |
body mass |
male |
100 days
| 5 |
|
|
338.1 |
g |
3.58 |
8.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109304 |
3137 |
SS/HsdMcwiCrl |
maximum body weight loss to initial body weight ratio |
arterial catheter implantation (for 1 days) |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
body mass |
male |
89 days-95 days |
8 |
|
|
3.6 |
% |
0.8 |
2.26 |
body weighing method |
0.0 |
arterial catheter implantation |
1 |
days |
|
|
|
|
107182 |
3077 |
GK/MolTac |
body weight |
control condition |
Kold-Petersen H, etal., J Vasc Res. 2012;49(3):267-78. doi: 10.1159/000335487. Epub 2012 Apr 11. |
body mass |
male |
112 days
| 0 |
|
|
351.0 |
g |
5.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108025 |
3109 |
HanTac:WH |
body weight |
control condition |
Kold-Petersen H, etal., J Vasc Res. 2012;49(3):267-78. doi: 10.1159/000335487. Epub 2012 Apr 11. |
body mass |
male |
154 days
| 0 |
|
|
452.0 |
g |
13.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108026 |
3109 |
MWF/FubRkb |
body weight |
control condition |
Ijpelaar DH, etal., Am J Physiol Renal Physiol. 2008 Apr;294(4):F758-67. Epub 2008 Jan 16. |
body mass |
female |
30 days
| 5 |
|
|
80.61 |
g |
3.72 |
8.31 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109704 |
3152 |
Hsd:WI |
fetal body weight |
control condition |
Rothermund L, etal., J Hypertens. 2006 Sep 24(9). |
body mass |
not specified |
-2 days
| 0 |
|
|
2.26 |
g |
0.03 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108072 |
3115 |
GK/MolTac |
body weight |
control condition |
Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. |
body mass |
male |
105 days
| 8 |
|
|
325.4 |
g |
9.2 |
26.02 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110729 |
3183 |
GK/MolTac |
body weight |
control condition |
Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. |
body mass |
male |
119 days
| 9 |
|
|
350.8 |
g |
9.8 |
29.4 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110737 |
3183 |
GK/MolTac |
body weight |
control condition |
Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. |
body mass |
male |
119 days
| 10 |
|
|
350.1 |
g |
7.7 |
24.35 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110736 |
3183 |
DA/OlaHsd |
volume of blood removed to total prehemorrhagic blood volume ratio |
arterial catheter implantation (for 1 days) then controlled hemorrhage (for 0.4 hours) |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
blood amount |
male |
89 days-95 days |
9 |
5.83 mL/100 g of body weight |
|
57.3 |
% |
0.4 |
1.2 |
body weighing method |
0.0 |
|
0 |
|
|
volume of blood removed to total prehemorrhagic blood volume ratio (CMO:0003663) |
|
|
109131 |
3077 |
Crl:WI |
body weight |
control condition |
Kreutz R, etal., J Hypertens. 2007 Nov;25(11):2308-16. doi: 10.1097/HJH.0b013e3282ef8611. |
body mass |
male |
112 days
| 8 |
|
|
455.7 |
g |
12.87 |
36.4 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109847 |
3156 |
WAG/Rij |
body weight |
control condition |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
female |
63 days
| 2 |
|
|
148.0 |
g |
1.98 |
2.8 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
106979 |
3074 |
BDIX/Orl |
body weight |
control condition |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
female |
119 days-0 days |
2 |
|
|
241.0 |
g |
7.99 |
11.3 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
106978 |
3074 |
WAG/Rij |
body weight |
0.9% sodium chloride solution (0.4 ml) |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
female |
56 days
| 2 |
|
|
126.0 |
g |
4.03 |
5.7 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
106985 |
3074 |
BDIX/Orl |
body weight |
0.9% sodium chloride solution (0.4 ml) |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
female |
63 days
| 2 |
|
|
173.0 |
g |
7.5 |
10.6 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
106981 |
3074 |
SHRSP/A3N |
body weight |
reproduction condition |
Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. |
body mass |
female |
120 days-140 days |
15 |
|
|
158.0 |
g |
14.0 |
54.22 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
107575 |
3093 |
WKY/NCrl |
body weight |
control condition |
Steireif C, etal., J Hypertens. 2013 Nov;31(11):2203-12; discussion 2212. doi: 10.1097/HJH.0b013e3283642384. |
body mass |
male |
84 days
| 10 |
|
|
282.4 |
g |
4.9 |
15.5 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109272 |
3141 |
ISIAH |
body weight |
control condition |
Ragaeva DS, et al., Physiol Behav. 2017 Jun 1;175:22-30. doi: 10.1016/j.physbeh.2017.03.026. Epub 2017 Mar 21. |
body mass |
male |
7 days
| 13 |
|
|
11.4 |
g |
1.0 |
3.61 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110671 |
3182 |
WAG/Nov |
body weight |
control condition |
Ragaeva DS, et al., Physiol Behav. 2017 Jun 1;175:22-30. doi: 10.1016/j.physbeh.2017.03.026. Epub 2017 Mar 21. |
body mass |
male |
84 days-98 days |
6 |
|
|
282.1 |
g |
13.71 |
33.58 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110686 |
3182 |
WM/Nem |
fetal body weight |
trypan blue (30 mg/kg) |
Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. |
body mass |
female |
-1 days
| 41 |
|
|
2.49 |
g |
0.05 |
0.29 |
body weighing method |
0.0 |
|
12 |
days |
|
|
|
|
111226 |
3199 |
GK/Par |
body weight |
controlled ethanol content drinking water used as vehicle (1 %) (for 56 days) |
Fourny N, et al., Nutrients. 2019 Jan 6;11(1). pii: nu11010105. doi: 10.3390/nu11010105. |
body mass |
female |
270 days-300 days |
9 |
|
|
267.5 |
g |
5.7 |
17.1 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109875 |
3159 |
GK/Far |
body weight |
control condition |
Nobrega MA, et al., Diabetes 2004 Mar;53(3):735-42. |
body mass |
male |
360 days
| 6 |
|
|
421.0 |
g |
20.0 |
48.99 |
body weighing method |
0.0 |
|
0 |
|
|
n=6-27 |
|
|
110594 |
3177 |
GK/Jpe |
body weight |
control condition |
Sena CM, etal., Int J Mol Sci. 2018 Sep 11;19(9). pii: ijms19092706. doi: 10.3390/ijms19092706. |
body mass |
male |
540 days
| 7 |
|
|
358.5 |
g |
8.7 |
23.02 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110847 |
3193 |
W/Jpe |
body weight |
control condition |
Sena CM, etal., Int J Mol Sci. 2018 Sep 11;19(9). pii: ijms19092706. doi: 10.3390/ijms19092706. |
body mass |
male |
540 days
| 7 |
|
|
559.7 |
g |
28.8 |
76.2 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110845 |
3193 |
HanTac:WH |
body weight |
control condition |
Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. |
body mass |
female |
56 days
| 8 |
|
|
178.0 |
g |
4.0 |
11.31 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110242 |
3168 |
GK/MolTac |
body weight |
control condition |
Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. |
body mass |
female |
56 days
| 10 |
|
|
191.0 |
g |
3.0 |
9.49 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110244 |
3168 |
HanTac:WH |
body weight |
control IgG monoclonal antibody (1 mg) (for 28 days) |
Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. |
body mass |
female |
84 days
| 8 |
|
|
219.0 |
g |
7.0 |
19.8 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110249 |
3168 |
HanTac:WH |
body weight |
anti-rh-VEGF165 monoclonal antibody (1 mg) (for 42 days) |
Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. |
body mass |
female |
98 days
| 8 |
|
|
234.0 |
g |
5.0 |
14.14 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110254 |
3168 |
GK/MolTac |
body weight |
control IgG monoclonal antibody (1 mg) (for 42 days) |
Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. |
body mass |
female |
98 days
| 9 |
|
|
237.0 |
g |
4.0 |
12.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110255 |
3168 |
MWF-Chr 8SHR/Rkb |
body weight |
control condition |
Schulz A, etal., Physiol Genomics. 2008 Sep 17;35(1):30-5. Epub 2008 Jul 22. |
body mass |
male |
168 days
| 20 |
|
|
351.1 |
g |
6.8 |
30.41 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108918 |
3133 |
MWF/FubRkb |
body weight |
control condition |
Schulz A, etal., Physiol Genomics. 2008 Sep 17;35(1):30-5. Epub 2008 Jul 22. |
body mass |
male |
168 days
| 18 |
|
|
363.9 |
g |
11.3 |
47.94 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108920 |
3133 |
MWF/FubRkb |
body weight |
control condition |
Schulz A, etal., Physiol Genomics. 2008 Sep 17;35(1):30-5. Epub 2008 Jul 22. |
body mass |
female |
168 days
| 18 |
|
|
207.2 |
g |
1.2 |
5.09 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108921 |
3133 |
MWF |
body weight |
cyclosporine A (50 mg/kg/d) (for 7 days) |
Fassi A, etal., Am J Kidney Dis. 1999 Feb;33(2):267-75. doi: 10.1016/s0272-6386(99)70299-4. |
body mass |
male |
132 days-146 days |
6 |
|
|
376.0 |
g |
8.98 |
22.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110001 |
3163 |
BDIX/OrlCrl |
body weight |
control condition |
Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. |
body mass |
male |
0 days
| 5 |
|
|
204.0 |
g |
7.6 |
17.0 |
body weighing method |
0.0 |
|
0 |
|
|
baseline group 2 |
|
|
111025 |
3195 |
SHRSP/A3N |
body weight |
controlled sodium chloride content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) |
Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. |
body mass |
male |
203 days-224 days |
10 |
|
|
329.0 |
g |
6.0 |
18.97 |
body weighing method |
0.0 |
|
0 |
|
|
high salt high fat diet |
|
|
107104 |
3075 |
ACI/EurMcwi |
nose to rump body mass index |
control condition |
Keele GR, etal., Obesity (Silver Spring). 2018 Jan;26(1):213-222. doi: 10.1002/oby.22075. Epub 2017 Nov 28. |
body mass |
male |
119 days
| 18 |
|
|
6.54 |
(g/cm2) x 10 |
0.18 |
0.77 |
body weighing method |
|
|
0 |
|
|
|
|
|
138384 |
3200 |
F344/NHsd |
nose to rump body mass index |
control condition |
Keele GR, etal., Obesity (Silver Spring). 2018 Jan;26(1):213-222. doi: 10.1002/oby.22075. Epub 2017 Nov 28. |
body mass |
male |
119 days
| 14 |
|
|
7.93 |
(g/cm2) x 10 |
0.22 |
0.83 |
body weighing method |
|
|
0 |
|
|
|
|
|
138399 |
3200 |
M520/N |
nose to rump body mass index |
control condition |
Keele GR, etal., Obesity (Silver Spring). 2018 Jan;26(1):213-222. doi: 10.1002/oby.22075. Epub 2017 Nov 28. |
body mass |
male |
119 days
| 11 |
|
|
7.43 |
(g/cm2) x 10 |
0.33 |
1.1 |
body weighing method |
|
|
0 |
|
|
|
|
|
138404 |
3200 |
M520/N |
body weight |
control condition |
Keele GR, etal., Obesity (Silver Spring). 2018 Jan;26(1):213-222. doi: 10.1002/oby.22075. Epub 2017 Nov 28. |
body mass |
male |
119 days
| 11 |
|
|
257.45 |
g |
6.91 |
22.92 |
body weighing method |
|
|
0 |
|
|
|
|
|
138403 |
3200 |
NMcwi:HS |
nose to tail body mass index |
control condition |
Keele GR, etal., Obesity (Silver Spring). 2018 Jan;26(1):213-222. doi: 10.1002/oby.22075. Epub 2017 Nov 28. |
body mass |
male |
119 days
| 741 |
|
|
2.25 |
(g/cm2) x 10 |
0.01 |
0.19 |
body weighing method |
|
|
0 |
|
|
|
|
|
138410 |
3200 |
LE-Lrrk2em1Sage-/- |
body weight |
control condition |
Ness D, et al., PLoS One. 2013 Jun 14;8(6):e66164. doi: 10.1371/journal.pone.0066164. Print 2013. |
body mass |
male |
28 days
| 0 |
|
|
86.4 |
g |
|
3.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
138271 |
2947 |
SR/Hsd |
body weight gain |
aldosterone (22.5 ng/hr) (for 14 days) and artificial cerebrospinal fluid with 0.15 M sodium (4.4-4.6 ul/hr) (for 14 days) |
Huang BS, et al., Am J Physiol Heart Circ Physiol. 2005 Feb;288(2):H517-24. doi: 10.1152/ajpheart.00651.2004. Epub 2004 Sep 30. |
body mass |
male |
52 days-61 days |
0 |
|
|
59.0 |
g |
4.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
change from surgery weight (2wks) |
|
|
138419 |
2801 |
SHR/OlaIpcv |
body weight |
control condition |
Pravenec M, et al., J Hypertens 2001 Jun;19(6):1061-4. |
body mass |
male |
100 days
| 12 |
|
|
268.4 |
g |
8.1 |
28.06 |
body weighing method |
|
|
0 |
|
|
|
|
|
11283 |
61 |
COP/OlaHsd |
body weight |
running on inclined treadmill (10 m/min) (for 0.1 hours) |
Lee SJ, et al., Physiol Genomics 2005 Jul 20;. |
body mass |
male |
105 days
| 4 |
|
|
260.5 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
13335 |
345 |
SS.SHR-(D9Mco72-D9Mco105)/Mco |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 25 and 28 days) |
Kumarasamy S, et al., Hypertens Res. 2011 Dec;34(12):1263-70. doi: 10.1038/hr.2011.116. Epub 2011 Aug 4. |
body mass |
not specified |
0 days
| 0 |
|
|
328.0 |
g |
6.89 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67534 |
749 |
SS/HsdMcwiCrl |
body weight to tibia length ratio |
controlled carbohydrate content diet (53 %) (for 63 days) and controlled fat content diet (14 %) (for 63 days) and controlled protein content diet (33 %) (for 63 days) then controlled carbohydrate content diet (69 %) (for 28 days) and controlled fat content diet (12 %) (for 28 days) and controlled protein content diet (19 %) (for 28 days) |
Spradley FT, et al., Am J Physiol Regul Integr Comp Physiol. 2012 Jan 1;302(1):R150-8. Epub 2011 Oct 26. |
body mass |
male |
112 days
| 9 |
|
|
98.04 |
g/cm |
2.35 |
7.05 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67615 |
735 |
SS.MNS-(D2Chm51-D2Rat341)/Ayd |
body weight |
controlled sodium content diet (2 %) (between 35 and 98 days) |
Duong C, et al., Mamm Genome 2006; 17(12): 1147-1161 |
body mass |
male |
98 days
| 8 |
|
|
368.0 |
g |
10.0 |
28.28 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12033 |
226 |
SHR/NHsd |
body weight |
controlled sodium content diet (4 %) (for 14 days) |
Garrett MR, et al., Physiol Genomics 2000 Jun 29;3(1):33-8. |
body mass |
male |
53 days-67 days |
10 |
|
|
215.0 |
g |
4.2 |
13.28 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
66108 |
691 |
SHR/NHsd |
body weight |
controlled sodium content diet (4 %) (for 28 days) |
Garrett MR, et al., Physiol Genomics 2000 Jun 29;3(1):33-8. |
body mass |
male |
53 days-81 days |
10 |
|
|
255.0 |
g |
4.7 |
14.86 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
66110 |
691 |
SS.MNS-(D10Mco30-D10Got91)/3Mco |
body weight |
controlled sodium content diet (2 %) (for 24 days) |
Saad Y, et al., Mamm Genome. 2008 Jan 4 |
body mass |
male |
64 days-68 days |
20 |
|
|
300.0 |
g |
3.15 |
14.09 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12152 |
232 |
SS.LEW-(D18Rat29-D18Rat55)/Ayd |
body weight |
controlled sodium content diet (0.2 %) (for 14 days) then controlled sodium content diet (2 %) (for 35 days) |
Deng AY, et al., J Hypertens. 2008 Oct;26(10):1935-1943. |
body mass |
male |
77 days
| 11 |
|
|
324.5 |
g |
3.89 |
12.9 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65006 |
542 |
SS.LEW-(D16Rat112-D16Chm60)/Ayd |
body weight |
controlled sodium content diet (0.2 %) (for 14 days) then controlled sodium content diet (2 %) (for 35 days) |
Deng AY, et al., J Hypertens. 2008 Oct;26(10):1935-1943. |
body mass |
male |
77 days
| 14 |
|
|
317.8 |
g |
3.31 |
12.4 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65009 |
542 |
SS.LEW-(D3Rat52-D3Chm57)/Ayd |
body weight |
controlled sodium content diet (0.2 %) (for 14 days) then controlled sodium content diet (2 %) (for 35 days) |
Deng AY, et al., J Hypertens. 2008 Oct;26(10):1935-1943. |
body mass |
male |
77 days
| 5 |
|
|
291.1 |
g |
3.09 |
6.9 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65011 |
542 |
F344/NSlc |
body weight |
fasting (between 16 and 18 hours) |
Kose H, et al., Exp Anim. 2008 Apr;57(2):135-8. |
body mass |
male |
210 days
| 20 |
|
|
409.9 |
g |
5.3 |
23.7 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
66179 |
716 |
SHR/NCruk |
body weight |
control condition |
Aitman TJ, et al., Nat Genet 1997 Jun;16(2):197-201 |
body mass |
not specified |
115 days
| 23 |
|
|
308.0 |
g |
1.58 |
7.6 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
11921 |
223 |
BC/CpbU |
body weight |
controlled olive oil content diet (5 %) (for 28 days) and controlled cholesterol content diet (2 %) (for 28 days) |
Bonne AC, et al., Arterioscler Thromb Vasc Biol 2002 Dec 1;22(12):2072-9. |
body mass |
male |
77 days
| 6 |
|
|
223.0 |
g |
6.94 |
17.0 |
body weighing method |
|
|
0 |
|
|
|
|
|
12602 |
271 |
LEW/OlaHsd |
body weight |
controlled olive oil content diet (5 %) (for 28 days) and controlled cholesterol content diet (2 %) (for 28 days) |
Bonne AC, et al., Arterioscler Thromb Vasc Biol 2002 Dec 1;22(12):2072-9. |
body mass |
male |
77 days
| 6 |
|
|
341.0 |
g |
14.29 |
35.0 |
body weighing method |
|
|
0 |
|
|
|
|
|
12610 |
271 |
BN.GK-(D2Rat40-D2Got149)/Ox |
body weight |
control condition |
Wallace KJ, et al., Physiol Genomics 2004 Sep 16;19(1):1-10. Epub 2004 Jul 20. |
body mass |
female |
90 days
| 8 |
|
|
158.0 |
g |
5.0 |
14.14 |
body weighing method |
|
|
0 |
|
|
|
|
|
11307 |
69 |
SHR/Mol |
body weight |
control condition |
Kloting I, et al., Biochem Biophys Res Commun 2001 Jun 29;284(5):1126-33. |
body mass |
male |
21 days
| 12 |
|
|
28.0 |
g |
1.15 |
4.0 |
body weighing method |
0.0 |
|
0 |
|
Kent Scientific Corp |
|
|
|
12927 |
323 |
SHR/Mol |
body weight |
control condition |
Kloting I, et al., Biochem Biophys Res Commun 2001 Jun 29;284(5):1126-33. |
body mass |
female |
56 days
| 12 |
|
|
144.0 |
g |
1.73 |
6.0 |
body weighing method |
|
|
0 |
|
|
|
|
|
12938 |
323 |
SD |
body weight |
control condition |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
male |
42 days-56 days |
6 |
|
|
180.4 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84760 |
1602 |
SD |
body weight |
acetaminophen (250 mg/kg) (for 1 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
male |
42 days-56 days |
6 |
|
|
182.3 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84765 |
1602 |
DA/OlaHsd |
body weight |
control condition |
Ways JA, et al., Physiol Genomics. 2006 Dec 19;. |
body mass |
not specified |
105 days
| 12 |
|
|
257.0 |
g |
3.5 |
12.12 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
68486 |
933 |
HanTac:WH |
body weight |
vehicle control condition (between 16 and 17 days) |
Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. |
body mass |
male |
16 days-17 days |
18 |
|
|
28.6 |
g |
1.08 |
4.6 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
96632 |
1559 |
HanTac:WH |
body weight |
bisphenol A (0.025 mg/kg/d) (between 16 and 17 days) |
Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. |
body mass |
female |
16 days-17 days |
20 |
|
|
31.2 |
g |
0.89 |
4.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
96688 |
1559 |
PD/Cub |
body weight |
controlled sucrose content diet (for 7 days) |
Seda O, et al., Physiol Genomics. 2005 Apr 14;21(2):243-52. Epub 2005 Feb 22. |
body mass |
male |
307 days
| 6 |
|
|
398.0 |
g |
0.86 |
2.1 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
70207 |
1318 |
ISIAH |
body weight |
control condition |
Redina OE, et al., Clin Exp Pharmacol Physiol. 2006 May-Jun;33(5-6):456-64. |
body mass |
not specified |
180 days
| 11 |
|
|
302.0 |
g |
4.5 |
14.92 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
68062 |
835 |
ACI.FHH-(D1Rat384-D1Rat452)(D17Rat61-D1Arb5)(D17Rat51)/Eur |
body weight |
NG-nitroarginine methyl ester (9-16 mg/kg/d) (for 126 days) |
van Dijk SJ, et al., Nephron Exp Nephrol. 2006;104(3):e96-e102. Epub 2006 Jul 12. |
body mass |
not specified |
168 days-175 days |
12 |
|
|
296.0 |
g |
5.0 |
17.32 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67938 |
832 |
MWF/FubRkb |
body weight |
control condition |
Schulz A, et al., J Am Soc Nephrol 2002 Nov;13(11):2706-14. |
body mass |
not specified |
126 days
| 8 |
|
|
333.1 |
g |
6.93 |
19.6 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67593 |
769 |
Iusm:NP |
body weight |
control condition |
Alam I, etal., Alcohol Clin Exp Res. 2005 Oct;29(10):1769-76. doi: 10.1097/01.alc.0000183005.28502.4f. |
body mass |
male |
90 days
| 16 |
|
geometric mean |
507.87 |
g |
6.38 |
25.52 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
138483 |
3202 |
SD |
body weight |
control condition |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
male |
57 days-71 days |
6 |
|
|
228.0 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84784 |
1602 |
SD |
body weight |
acetaminophen (1000 mg/kg) (for 8 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
female |
50 days-64 days |
6 |
|
|
147.0 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84810 |
1602 |
SS.BN-(D13Rat25-RN34_13048990782)/Mcwi |
body weight |
common peroneal nerve direct electrical stimulation (3 V) (for 8 hours) |
Stodola TJ, et al., Physiol Genomics. 2011 Jul 14;43(13):808-17. doi: 10.1152/physiolgenomics.00171.2010. Epub 2011 Apr 26. |
body mass |
male |
56 days-70 days |
14 |
|
|
281.8 |
g |
6.7 |
25.07 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99004 |
2198 |
SS-Chr 13BN/Mcwi |
body weight |
common peroneal nerve direct electrical stimulation (3 V) (for 8 hours) |
Stodola TJ, et al., Physiol Genomics. 2011 Jul 14;43(13):808-17. doi: 10.1152/physiolgenomics.00171.2010. Epub 2011 Apr 26. |
body mass |
male |
56 days-70 days |
15 |
|
|
316.4 |
g |
6.8 |
26.34 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99006 |
2198 |
BN-Chr 13SS/Mcwi |
body weight |
common peroneal nerve direct electrical stimulation (3 V) (for 8 hours) |
Stodola TJ, et al., Physiol Genomics. 2011 Jul 14;43(13):808-17. doi: 10.1152/physiolgenomics.00171.2010. Epub 2011 Apr 26. |
body mass |
male |
56 days-70 days |
12 |
|
|
227.3 |
g |
6.9 |
23.9 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99008 |
2198 |
SS/JrHsdMcwi |
body weight |
common peroneal nerve direct electrical stimulation (3 V) (for 8 hours) then angiotensin II (3 ng/kg/min) (for 7 days) |
Stodola TJ, et al., Physiol Genomics. 2011 Jul 14;43(13):808-17. doi: 10.1152/physiolgenomics.00171.2010. Epub 2011 Apr 26. |
body mass |
male |
56 days-70 days |
4 |
|
|
270.8 |
g |
7.8 |
15.6 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99014 |
2198 |
WI |
body weight |
controlled in utero environment (for 21 days) and standard diet (100 % of calories) (for 21 days) |
Ceravolo GS, et al., Life Sci. 2007 Jan 30;80(8):782-7. Epub 2006 Nov 10. |
body mass |
male |
1 days
| 21 |
|
|
8.4 |
g |
0.8 |
3.67 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
101051 |
2563 |
MHS |
body weight |
standard diet |
Menini S, et al., J Hypertens. 2004 Nov;22(11):2185-92. |
body mass |
male |
63 days
| 10 |
|
|
245.4 |
g |
3.98 |
12.6 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
104193 |
2927 |
PXO1/Cub |
body weight |
controlled sucrose content diet (70 % of calories) (between 0 and 168 hours) and controlled protein content diet (19.6 % of calories) (between 0 and 168 hours) and controlled fat content diet (10.4 % of calories) (between 0 and 168 hours) then fasting (between 0 and 16 hours) |
Hodulova M, et al., PLoS One. 2014 Oct 8;9(10):e109983. doi: 10.1371/journal.pone.0109983. eCollection 2014. |
body mass |
male |
127 days
| 11 |
|
|
257.2 |
g |
5.2 |
17.25 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97163 |
1858 |
SS/JrHsd |
body weight |
controlled sodium chloride content diet (0.4 %) (for 14 days) then sham surgical control condition then peanut oil (0.2 ml) (for 14 days) |
Zheng W, et al., Am J Physiol Heart Circ Physiol. 2008 Apr;294(4):H1508-13. doi: 10.1152/ajpheart.01322.2007. Epub 2008 Feb 1. |
body mass |
female |
0 days
| 0 |
|
|
252.0 |
g |
3.8 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102189 |
2681 |
OLETF |
body weight |
olmesartan medoxomil (3.8 mg/kg/d) (for 84 days) |
Koga K, et al., Mol Med. 2002 Oct;8(10):591-9. |
body mass |
male |
364 days
| 12 |
|
|
792.3 |
g |
10.5 |
36.37 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99413 |
2298 |
WKY |
body weight |
left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) |
Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. |
body mass |
male |
238 days-252 days |
30 |
|
|
617.0 |
g |
52.0 |
284.82 |
body weighing method |
0.0 |
lad occlusion |
196 |
days |
|
|
|
|
100272 |
2460 |
SS |
body weight |
controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 84 days) |
Fujii N, et al., Am J Physiol Heart Circ Physiol. 2004 Aug;287(2):H760-6. doi: 10.1152/ajpheart.00734.2003. Epub 2004 Mar 18. |
body mass |
male |
126 days
| 6 |
|
|
323.0 |
g |
5.72 |
14.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103300 |
2803 |
SD |
body weight |
in utero condition (for 7 days) and dibutyl phthalate (850 mg/kg/d) (for 7 days) |
Jiang JT, et al., Toxicology. 2015 Dec 2;338:77-85. doi: 10.1016/j.tox.2015.10.006. Epub 2015 Oct 26. |
body mass |
male |
1 days
| 43 |
|
|
4.9 |
g |
0.06 |
0.39 |
body weighing method |
1.0 |
|
0 |
|
|
|
|
|
98735 |
2158 |
LH/Mav |
body weight |
controlled hydralazine content drinking water (75 mg/kg/d) (for 63 days) and controlled hydrochlorothiazide content drinking water (15 mg/kg/d) (for 63 days) then controlled sodium chloride content drinking water (2 %) (for 8 days) |
Naelten G, et al., J Cardiovasc Pharmacol. 2011 Feb;57(2):240-5. doi: 10.1097/FJC.0b013e318204bb7b. |
body mass |
male |
119 days
| 6 |
|
|
362.0 |
g |
8.0 |
19.6 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103407 |
2824 |
Iusm:P |
body weight |
control condition |
Alam I, etal., Alcohol Clin Exp Res. 2005 Oct;29(10):1769-76. doi: 10.1097/01.alc.0000183005.28502.4f. |
body mass |
male |
120 days
| 16 |
|
geometric mean |
518.12 |
g |
7.38 |
29.52 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
138514 |
3202 |
BluHsd:LE |
body weight |
controlled in utero environment (for 9 days) and bisphenol A (25 ug/kg) (for 30 days) then maternal milk (for 21 days) |
Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. |
body mass |
male |
98 days
| 8 |
|
|
426.1 |
g |
15.4 |
43.56 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
75964 |
1543 |
SD |
body weight |
sham surgical control condition (between 120 and 12 hours) |
Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. |
body mass |
male |
0 days
| 6 |
|
|
284.0 |
g |
4.0 |
9.8 |
body weighing method |
1.0 |
sham ACF |
5 |
days |
|
|
|
|
98776 |
2160 |
SR/JrHsd |
body weight |
controlled sodium content diet (0.1 %) (for 112 days) then bilateral ovariectomy (between 56 and 63 days) |
Esqueda ME, et al., Hypertension. 2007 Oct;50(4):768-72. Epub 2007 Aug 13. |
body mass |
female |
112 days
| 6 |
|
|
309.7 |
g |
13.4 |
32.82 |
body weighing method |
0.0 |
ovx |
63 |
days |
|
|
|
|
102344 |
2686 |
Jcl:WI |
body weight |
control condition |
Akiyama S, et al., Biosci Biotechnol Biochem. 2009 Dec;73(12):2779-82. doi: 10.1271/bbb.90576. Epub 2009 Dec 7. |
body mass |
male |
24 days
| 6 |
|
|
53.56 |
g |
0.98 |
2.4 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103904 |
2884 |
LH/Mav |
body weight |
vehicle control condition |
Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3. |
body mass |
male |
49 days-56 days |
8 |
|
|
232.0 |
g |
6.0 |
16.97 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102642 |
2703 |
SD |
body weight |
left nephrectomy then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (5 mg/kg) then puromycin (40 mg/kg) |
Ma LJ, et al., Kidney Int. 2004 Jan;65(1):106-15. |
body mass |
male |
0 days
| 9 |
|
|
258.0 |
g |
3.0 |
9.0 |
body weighing method |
0.0 |
unx |
0 |
|
|
|
|
|
98927 |
2179 |
MW |
body weight |
nephrectomy (for 28 days) then enalapril (50 mg/l) (for 21 days) |
Anderson S, et al., J Clin Invest. 1986 Jun;77(6):1993-2000. |
body mass |
male |
0 days
| 8 |
|
|
248.0 |
g |
4.0 |
11.31 |
body weighing method |
0.0 |
5/6 nephrectomy |
28 |
days |
|
|
|
|
100984 |
2561 |
GK/MolTac |
body weight |
running on treadmill (0-10 m/min) (between 0.1 and 0.2 hours) then running on treadmill (15 m/min) (for 0.5 hours) then running on treadmill (15 m/min) (for 0.8 hours) |
Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. |
body mass |
male |
147 days
| 6 |
|
|
373.0 |
g |
5.0 |
12.25 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103982 |
2885 |
WF/Mol |
body weight gain |
controlled ramipril content drinking water (3 mg/kg/d) (for 10 days) then artificial aortocaval fistula (for 9 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 7 |
|
|
21.0 |
g |
3.0 |
7.94 |
body weighing method |
0.0 |
acf |
9 |
days |
|
change from surgery weight |
|
|
101330 |
2585 |
WF/Mol |
body weight gain |
vehicle control condition then sham surgical control condition (for 2 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 6 |
|
|
-6.0 |
g |
1.0 |
2.45 |
body weighing method |
0.0 |
sham acf |
2 |
days |
|
change from surgery weight |
|
|
101335 |
2585 |
SS/JrHsdMcwi |
body weight |
control condition |
McPherson KC, et al., Am J Physiol Renal Physiol. 2016 Oct 1;311(4):F793-F804. doi: 10.1152/ajprenal.00590.2015. Epub 2016 Jul 27. |
body mass |
male |
126 days
| 27 |
|
|
373.0 |
g |
4.0 |
20.78 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
100069 |
2418 |
F344/StmMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
7 days
| 12 |
|
|
10.29 |
g |
0.45 |
1.54 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139560 |
3292 |
F344/StmMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 21 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
42 days
| 12 |
|
|
129.83 |
g |
3.36 |
11.65 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139565 |
3292 |
F344/StmMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 7 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
28 days
| 11 |
|
|
64.18 |
g |
2.67 |
8.86 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139563 |
3292 |
F344/StmMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 63 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
84 days
| 12 |
|
|
278.83 |
g |
3.07 |
10.63 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139571 |
3292 |
BN/NHsdMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 42 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
63 days
| 11 |
|
|
201.45 |
g |
2.59 |
8.61 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139052 |
3292 |
BN/NHsdMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 56 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
77 days
| 11 |
|
|
219.55 |
g |
5.45 |
18.07 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139054 |
3292 |
BN/NHsdMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
91 days
| 11 |
|
|
245.91 |
g |
2.22 |
7.35 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139056 |
3292 |
M520/NRrrcMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
7 days
| 12 |
|
|
12.48 |
g |
0.53 |
1.82 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139752 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 14 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
35 days
| 12 |
|
|
104.08 |
g |
3.25 |
11.24 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139756 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 49 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
70 days
| 12 |
|
|
219.33 |
g |
5.36 |
18.58 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139761 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 56 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
77 days
| 12 |
|
|
227.33 |
g |
5.72 |
19.82 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139762 |
3292 |
M520/NRrrcMcwi |
body weight |
control condition (0 null) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
14 days
| 12 |
|
|
25.07 |
g |
1.0 |
3.47 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139819 |
3292 |
M520/NRrrcMcwi |
body weight |
control condition (0 null) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
7 days
| 12 |
|
|
11.97 |
g |
0.55 |
1.92 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139818 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 49 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
70 days
| 12 |
|
|
221.0 |
g |
3.97 |
13.74 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139827 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 63 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
84 days
| 12 |
|
|
235.25 |
g |
4.93 |
17.08 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139829 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
91 days
| 12 |
|
|
236.92 |
g |
4.47 |
15.47 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139830 |
3292 |
BUF/MnaMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 28 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
49 days
| 7 |
|
|
194.86 |
g |
1.97 |
5.21 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139242 |
3292 |
WKY/NCrl |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 14 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
35 days
| 15 |
|
|
93.0 |
g |
2.6 |
10.09 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
140014 |
3292 |
BUF/MnaMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
7 days
| 11 |
|
|
11.72 |
g |
0.46 |
1.51 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139302 |
3292 |
BUF/MnaMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 14 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
35 days
| 11 |
|
|
106.45 |
g |
2.2 |
7.29 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139306 |
3292 |
BUF/MnaMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
21 days
| 11 |
|
|
39.91 |
g |
0.89 |
2.95 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139304 |
3292 |
BUF/MnaMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 21 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
42 days
| 11 |
|
|
150.91 |
g |
2.34 |
7.76 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139307 |
3292 |
WKY/NCrl |
body weight |
control condition (0 null) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
14 days
| 15 |
|
|
23.32 |
g |
0.56 |
2.19 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
140077 |
3292 |
WKY/NCrl |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 14 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
35 days
| 15 |
|
|
92.87 |
g |
2.95 |
11.43 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
140080 |
3292 |
WKY/NCrl |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 63 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
84 days
| 15 |
|
|
283.13 |
g |
3.76 |
14.57 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
140087 |
3292 |
ACI/EurMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 28 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
49 days
| 12 |
|
|
146.83 |
g |
1.41 |
4.9 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138748 |
3292 |
F344/StmMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
21 days
| 12 |
|
|
37.92 |
g |
1.08 |
3.73 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139496 |
3292 |
F344/StmMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 21 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
42 days
| 12 |
|
|
129.0 |
g |
3.23 |
11.18 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139499 |
3292 |
F344/StmMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 49 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
70 days
| 12 |
|
|
252.25 |
g |
3.54 |
12.26 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139503 |
3292 |
ACI/EurMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 56 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
77 days
| 13 |
|
|
202.92 |
g |
2.63 |
9.47 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138818 |
3292 |
ACI/EurMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
91 days
| 13 |
|
|
216.08 |
g |
2.68 |
9.67 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138820 |
3292 |
BN/NHsdMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
7 days
| 10 |
|
|
13.42 |
g |
0.2 |
0.65 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138982 |
3292 |
BN/NHsdMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 14 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
35 days
| 10 |
|
|
95.2 |
g |
2.19 |
6.92 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138986 |
3292 |
BN/NHsdMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 21 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
42 days
| 10 |
|
|
124.6 |
g |
2.71 |
8.57 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138987 |
3292 |
BN/NHsdMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 42 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
63 days
| 10 |
|
|
198.3 |
g |
3.27 |
10.33 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138990 |
3292 |
BN/NHsdMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 35 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
56 days
| 10 |
|
|
124.9 |
g |
1.59 |
5.04 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138878 |
3292 |
BN/NHsdMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
21 days
| 10 |
|
|
42.2 |
g |
1.47 |
4.64 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138930 |
3292 |
BN/NHsdMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 21 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
42 days
| 10 |
|
|
98.9 |
g |
2.02 |
6.38 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138933 |
3292 |
BN/NHsdMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 28 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
49 days
| 10 |
|
|
112.9 |
g |
1.93 |
6.12 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138934 |
3292 |
M520/NRrrcMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
7 days
| 11 |
|
|
12.65 |
g |
0.42 |
1.39 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139623 |
3292 |
ACI/EurMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
14 days
| 11 |
|
|
18.93 |
g |
0.62 |
2.05 |
body weighing method |
|
|
0 |
|
|
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138680 |
3292 |
ACI/EurMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
91 days
| 11 |
|
|
143.45 |
g |
1.46 |
4.84 |
body weighing method |
|
|
0 |
|
|
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138691 |
3292 |
BUF/MnaMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
21 days
| 10 |
|
|
40.1 |
g |
0.95 |
3.0 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139109 |
3292 |
BUF/MnaMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 21 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
42 days
| 10 |
|
|
127.3 |
g |
1.54 |
4.88 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139112 |
3292 |
BUF/MnaMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
91 days
| 10 |
|
|
339.6 |
g |
3.66 |
11.57 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139248 |
3292 |
BUF/MnaMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 42 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
63 days
| 9 |
|
|
266.89 |
g |
2.81 |
8.42 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139244 |
3292 |
M520/NRrrcMcwi |
body mass index (BMI) |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
91 days
| 11 |
|
|
0.42 |
g/cm2 |
0.0 |
0.01 |
body weighing method |
|
|
0 |
|
"weight scale, tape measure" |
Body Mass Index (BMI) |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139688 |
3292 |
BUF/MnaMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 7 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
28 days
| 11 |
|
|
71.0 |
g |
1.54 |
5.1 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139305 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 21 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
42 days
| 9 |
|
|
105.11 |
g |
1.65 |
4.96 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139694 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 35 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
56 days
| 9 |
|
|
129.78 |
g |
2.15 |
6.44 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139696 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 63 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
84 days
| 9 |
|
|
150.78 |
g |
2.44 |
7.33 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139700 |
3292 |
F344/StmMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 56 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
77 days
| 9 |
|
|
153.33 |
g |
2.06 |
6.18 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139441 |
3292 |
BUF/MnaMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 14 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
35 days
| 10 |
|
|
98.0 |
g |
1.81 |
5.72 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139177 |
3292 |
BUF/MnaMcwi |
body mass index (BMI) |
controlled bisphenol F content drinking water (1.125 mg/l) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
91 days
| 10 |
|
|
0.49 |
g/cm2 |
0.01 |
0.02 |
body weighing method |
|
|
0 |
|
"weight scale, tape measure" |
Body Mass Index (BMI) |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139235 |
3292 |
F344/StmMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 28 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
49 days
| 9 |
|
|
123.33 |
g |
2.37 |
7.12 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139371 |
3292 |
F344/StmMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 56 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
77 days
| 9 |
|
|
157.22 |
g |
3.36 |
10.07 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139375 |
3292 |
F344/StmMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 42 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
63 days
| 9 |
|
|
145.22 |
g |
2.23 |
6.7 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139373 |
3292 |
WKY/NCrl |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
21 days
| 10 |
|
|
40.3 |
g |
1.55 |
4.9 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139883 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 28 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
49 days
| 12 |
|
|
162.83 |
g |
3.27 |
11.32 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139824 |
3292 |
WKY/NCrl |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 42 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
63 days
| 10 |
|
|
160.7 |
g |
2.32 |
7.33 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139955 |
3292 |
WKY/NCrl |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
91 days
| 10 |
|
|
200.6 |
g |
2.68 |
8.47 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139959 |
3292 |
M520/NRrrcMcwi |
body mass index (BMI) |
controlled bisphenol F content drinking water (1.125 mg/l) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
91 days
| 9 |
|
|
0.42 |
g/cm2 |
0.0 |
0.01 |
body weighing method |
|
|
0 |
|
"weight scale, tape measure" |
Body Mass Index (BMI) |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139751 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 63 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
84 days
| 11 |
|
|
150.55 |
g |
2.53 |
8.38 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139634 |
3292 |
BUF/MnaMcwi |
body mass index (BMI) |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
91 days
| 10 |
|
|
0.62 |
g/cm2 |
0.0 |
0.01 |
body weighing method |
|
|
0 |
|
"weight scale, tape measure" |
Body Mass Index (BMI) |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139301 |
3292 |
F344/StmMcwi |
body weight |
control condition (0 null) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
7 days
| 9 |
|
|
8.82 |
g |
0.22 |
0.65 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139431 |
3292 |
F344/StmMcwi |
body weight |
control condition (0 null) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
21 days
| 9 |
|
|
36.44 |
g |
0.93 |
2.79 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139433 |
3292 |
ACI/EurMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 35 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
56 days
| 15 |
|
|
121.67 |
g |
1.2 |
4.64 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138620 |
3292 |
ACI/EurMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 63 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
84 days
| 15 |
|
|
143.07 |
g |
1.4 |
5.43 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138624 |
3292 |
ACI/EurMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 21 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
42 days
| 15 |
|
|
96.93 |
g |
1.35 |
5.24 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138618 |
3292 |
ACI/EurMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 49 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
70 days
| 15 |
|
|
137.2 |
g |
1.35 |
5.21 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138622 |
3292 |
ACI/EurMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 56 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
77 days
| 15 |
|
|
138.87 |
g |
1.19 |
4.63 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138623 |
3292 |
ACI/EurMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
14 days
| 12 |
|
|
20.76 |
g |
0.27 |
0.94 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138743 |
3292 |
ACI/EurMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 49 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
70 days
| 12 |
|
|
199.83 |
g |
1.85 |
6.39 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138751 |
3292 |
MWF-Chr 6SHR/Rkb |
body weight |
control condition |
Schulz A, et al., J Am Soc Nephrol. 2007 Jan;18(1):113-21 |
body mass |
not specified |
168 days
| 19 |
|
|
375.0 |
g |
8.9 |
38.79 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
65359 |
117 |
BB.SHR-(D6Rat184-D6Rat3)/K |
body weight |
control condition |
Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. |
body mass |
female |
84 days
| 15 |
|
|
214.0 |
g |
3.36 |
13.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
66145 |
324 |
SHR/NHsd |
body weight |
controlled sodium content diet |
Garrett MR, et al., Physiol Genomics 2000 Jun 29;3(1):33-8. |
body mass |
male |
53 days
| 10 |
|
|
145.0 |
g |
3.9 |
12.33 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
66106 |
691 |
BN.GK-(D8Rat29-D8Got130)/Ox |
body weight |
control condition |
Wallis RH, et al., Diabetologia 2004 Jun;47(6):1096-106. Epub 2004 May 26 |
body mass |
female |
168 days
| 8 |
|
|
192.0 |
g |
4.0 |
11.31 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67313 |
66 |
LEW/NCrl |
body weight |
controlled sodium content diet (0.2 %) (for 5 days) then controlled sodium content diet (8 %) (for 56 days) |
Garrett MR, et al., Genome Res 1998 Jul;8(7):711-23 |
body mass |
male |
91 days
| 8 |
|
|
352.0 |
g |
4.6 |
13.01 |
body weighing method |
0 |
|
0 |
|
|
|
|
4 rats per cage, 2 SR/Jr 2 LEW/NCrl |
64710 |
222 |
SS/JrSeac |
body weight |
control condition |
Fukushima K, et al., Nucl Med Biol. 2010 Nov;37(8):1005-12. Epub 2010 Sep 1. |
body mass |
not specified |
42 days
| 20 |
|
|
195.0 |
g |
3.35 |
15.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67247 |
733 |
SS/JrHsdMcwi |
body weight |
controlled sodium content diet (0.4 %) |
Moreno C, et al., Physiol Genomics 2003 Nov 11;15(3):243-57. |
body mass |
female |
84 days
| 28 |
|
|
230.0 |
g |
3.0 |
15.87 |
body weighing method |
0.0 |
|
0 |
|
after catheterization and jacket attachment |
|
|
|
67294 |
151 |
BN/Crl |
body weight |
control condition |
Wallis RH, et al., Diabetologia 2004 Jun;47(6):1096-106. Epub 2004 May 26 |
body mass |
male |
168 days
| 15 |
|
|
313.0 |
g |
4.0 |
15.49 |
body weighing method |
|
|
0 |
|
|
|
|
|
11292 |
66 |
BN.GK-(D2Rat40-D2Wox35)/Ox |
body weight |
control condition |
Wallace KJ, et al., Physiol Genomics 2004 Sep 16;19(1):1-10. Epub 2004 Jul 20. |
body mass |
female |
90 days
| 6 |
|
|
178.0 |
g |
8.0 |
19.6 |
body weighing method |
|
|
0 |
|
|
|
|
|
11306 |
69 |
F344/DuCrlCrlj |
body weight |
control condition (for 95 days) |
Galli J, et al., Diabetes 1999 Dec;48(12):2463-70. |
body mass |
male |
95 days
| 15 |
|
|
279.0 |
g |
4.0 |
15.49 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
11444 |
85 |
F344.GK-(D1Arb42a-D1Rat90)/Swe |
body weight |
control condition (for 185 days) |
Galli J, et al., Diabetes 1999 Dec;48(12):2463-70. |
body mass |
male |
185 days
| 10 |
|
|
35.0 |
g |
6.0 |
18.97 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
11485 |
85 |
BN.GH-(D2Rat22-D2Mgh11)/Mcwi |
body weight |
angiotensin II (5-50 ng/kg/min) (between 0.2 and 1 hours) then norepinephrine (0.1-1 ug/kg/min) (between 0.2 and 1 hours) then phenylephrine (4 ug/kg) (between 0 and 0 hours) |
Bilusic M, et al., Croat Med J. 2008 Oct;49(5):586-99. |
body mass |
male |
132 days-146 days |
19 |
|
|
330.6 |
g |
5.96 |
26.0 |
body weighing method |
|
|
0 |
|
|
|
|
|
11534 |
101 |
WKY/NCruk |
body weight |
control condition |
Zhao L et al., 2001, Circulation, 103(3), 442-7 |
body mass |
male |
105 days
| 12 |
|
median |
250.0 |
g |
|
|
body weighing method |
|
|
0 |
|
|
|
|
|
11570 |
102 |
WKY.SHR-(D1Wox19-D1Mit2)/Njs |
body weight |
control condition |
Clemitson JR, et al., Hypertension 2002 Sep;40(3):292-7 |
body mass |
male |
175 days
| 20 |
|
|
343.1 |
g |
6.02 |
26.9 |
body weighing method |
|
|
0 |
|
|
|
|
|
11642 |
110 |
SHR/N |
body weight |
control condition |
Innes BA, et al., Hypertension 1998 Mar;31(3):741-6 |
body mass |
male |
140 days
| 34 |
|
|
355.0 |
g |
3.43 |
20.0 |
body weighing method |
|
|
0 |
|
|
|
|
|
11663 |
113 |
SS/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 24 and 27 days) |
Cicila GT, et al., Genomics 2001 Feb 15;72(1):51-60. |
body mass |
male |
68 days-70 days |
20 |
|
|
297.1 |
g |
2.3 |
10.29 |
body weighing method |
|
|
0 |
|
|
|
|
|
11811 |
147 |
F344/DuCrlCrlj |
body weight |
fasting (for 16 hours) |
Moralejo DH, et al., Proc Assoc Am Physicians 1998 Nov-Dec;110(6):545-58 |
body mass |
male |
210 days
| 10 |
|
|
374.1 |
g |
8.0 |
25.3 |
body weighing method |
|
|
0 |
|
|
|
|
|
11968 |
228 |
SS/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 24 days) |
Saad Y, et al., Hypertension. 2007 |
body mass |
male |
64 days-66 days |
0 |
|
|
337.0 |
g |
2.36 |
|
body weighing method |
|
|
0 |
|
|
|
|
|
11973 |
205 |
SS.LEW-(D10Mco84-D10Mco134)/Mco |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 24 days) |
Saad Y, et al., Hypertension. 2007 |
body mass |
male |
64 days-66 days |
0 |
|
|
306.0 |
g |
2.34 |
|
body weighing method |
|
|
0 |
|
|
|
|
|
11978 |
205 |
F344.OLETF-(D14Rat8-D14Rat26)/2Tj |
body weight |
fasting (for 16 hours) |
Kose H, et al., Mamm Genome 2002 Oct;13(10):558-62. |
body mass |
male |
210 days
| 15 |
|
|
384.0 |
g |
3.4 |
13.17 |
body weighing method |
|
|
0 |
|
|
|
|
|
11991 |
230 |
SS.LEW-(D10Chm128-D10Chm121)/Ayd |
body weight |
controlled sodium content diet (2 %) (between 35 and 98 days) |
Duong C, et al., Mamm Genome 2006; 17(12): 1147-1161 |
body mass |
male |
98 days
| 9 |
|
|
379.0 |
g |
11.0 |
33.0 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12060 |
226 |
LEW |
body weight |
controlled sodium content diet (2 %) (between 35 and 98 days) |
Duong C, et al., Mamm Genome 2006; 17(12): 1147-1161 |
body mass |
male |
98 days
| 6 |
|
|
372.0 |
g |
9.0 |
22.05 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12080 |
226 |
SS/Jr |
body weight |
controlled sodium content diet (2 %) (for 24 days) |
Saad Y, et al., Mamm Genome. 2008 Jan 4 |
body mass |
male |
64 days-68 days |
20 |
|
|
312.0 |
g |
3.22 |
14.4 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12143 |
232 |
SS.MNS-(D10Mco30-D10Got101)/Mco |
body weight |
controlled sodium content diet (2 %) (for 24 days) |
Saad Y, et al., Mamm Genome. 2008 Jan 4 |
body mass |
male |
64 days-68 days |
20 |
|
|
297.0 |
g |
1.47 |
6.57 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12149 |
232 |
SR/Jr |
body weight |
controlled sodium content diet (0.2 %) (for 28 days) |
Garrett MR, et al., Genome Res 1998 Jul;8(7):711-23 |
body mass |
male |
63 days
| 10 |
|
|
238.0 |
g |
4.7 |
14.86 |
body weighing method |
0 |
|
0 |
|
|
|
|
4 rats per cage, 2 SR/Jr 2 LEW/NCrl |
12180 |
222 |
WKY/NCruk |
body weight |
control condition |
Sebkhi A, et al., Hypertension 1999 Apr;33(4):949-53. |
body mass |
not specified |
84 days
| 22 |
|
|
273.4 |
g |
4.43 |
20.8 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
12183 |
233 |
LEW/NCrl |
body weight |
controlled sodium content diet (0.2 %) (for 112 days) |
Garrett MR, et al., Genome Res 1998 Jul;8(7):711-23 |
body mass |
male |
147 days
| 8 |
|
|
455.0 |
g |
9.1 |
25.74 |
body weighing method |
0 |
|
0 |
|
|
|
|
4 rats per cage, 2 SR/Jr 2 LEW/NCrl |
12191 |
222 |
LEW/NCrl |
body weight |
controlled sodium content diet (0.2 %) (for 28 days) |
Garrett MR, et al., Genome Res 1998 Jul;8(7):711-23 |
body mass |
male |
63 days
| 8 |
|
|
284.0 |
g |
6.2 |
17.54 |
body weighing method |
0 |
|
0 |
|
|
|
|
4 rats per cage, 2 SR/Jr 2 LEW/NCrl |
12198 |
222 |
F344/NRrrc |
body weight |
control condition |
Tanomura H, et al., J Vet Med Sci 2002 Jan;64(1):45-50. |
body mass |
male |
245 days
| 7 |
|
|
375.6 |
g |
7.56 |
20.0 |
body weighing method |
|
|
0 |
|
|
|
|
|
12202 |
234 |
SS/Jr |
body weight |
controlled sodium content diet (0.4 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 24 and 28 days) |
Lee SJ, et al., Genetics 2006 Dec;174(4):2203-13. |
body mass |
male |
70 days-72 days |
20 |
|
|
288.1 |
g |
2.8 |
12.52 |
body weighing method |
|
|
0 |
|
|
|
|
|
12287 |
237 |
SS/Jr |
body weight |
controlled sodium content diet (0.4 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 24 and 28 days) |
Lee SJ, et al., Genetics 2006 Dec;174(4):2203-13. |
body mass |
male |
70 days-72 days |
20 |
|
|
301.8 |
g |
2.4 |
10.73 |
body weighing method |
|
|
0 |
|
|
|
|
|
12296 |
237 |
SS.SR-(D3Mco39-D3Got130)/Jr |
body weight |
controlled sodium content diet (0.4 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 24 and 28 days) |
Lee SJ, et al., Genetics 2006 Dec;174(4):2203-13. |
body mass |
male |
70 days-72 days |
39 |
|
|
319.1 |
g |
1.8 |
11.24 |
body weighing method |
|
|
0 |
|
|
|
|
|
12302 |
237 |
SS.SHR-(D13Rat63-D13Mit1)/Mco |
body weight |
controlled sodium content diet (0.3 %) |
Packard M, et al., Am J Physiol Renal Physiol. 2009 Apr;296(4):F839-46. Epub 2009 Jan 28. |
body mass |
male |
84 days
| 12 |
|
|
397.0 |
g |
3.4 |
11.78 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12333 |
246 |
ACI.FHH-(D1Rat298-D1Rat90)/Eur |
body weight |
control condition |
Van Dijk SJ, et al., Kidney Int. 2006 |
body mass |
male |
168 days-175 days |
12 |
|
|
333.0 |
g |
7.0 |
24.25 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
11924 |
62 |
WKY/N |
body weight |
control condition |
Ye P and West MJ, Clin Exp Pharmacol Physiol 2003 Dec;30(12):930-6. |
body mass |
female |
84 days
| 22 |
|
|
353.0 |
g |
19.0 |
89.12 |
body weighing method |
|
|
0 |
|
|
|
|
|
13070 |
327 |
F344.GK-(D1Rat175-D1Rat90)/Swe |
body weight |
fasting (for 6 hours) |
Granhall C, et al., Genetics. 2006 Nov;174(3):1565-72. Epub 2006 Sep 1. |
body mass |
male |
95 days
| 24 |
|
|
307.0 |
g |
2.0 |
9.8 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
13094 |
330 |
F344.GK-(D1Got250-D1Rat90)/Swe |
body weight |
fasting (for 6 hours) |
Granhall C, et al., Genetics. 2006 Nov;174(3):1565-72. Epub 2006 Sep 1. |
body mass |
male |
95 days
| 24 |
|
|
303.0 |
g |
3.0 |
14.7 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
13098 |
330 |
SS/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 28 days) |
Saad Y, et al., Physiol Genomics 2001 Jan 19;4(3):201-14. |
body mass |
male |
68 days-70 days |
20 |
|
|
304.0 |
g |
2.95 |
13.19 |
body weighing method |
|
|
0 |
|
|
|
|
|
12488 |
266 |
SS/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 28 days) |
Saad Y, et al., Physiol Genomics 2001 Jan 19;4(3):201-14. |
body mass |
male |
68 days-70 days |
20 |
|
|
302.0 |
g |
3.24 |
14.49 |
body weighing method |
|
|
0 |
|
|
|
|
|
12490 |
266 |
SS.LEW-(D1Mco87-D1Rat71)/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 28 days) |
Saad Y, et al., Physiol Genomics 2001 Jan 19;4(3):201-14. |
body mass |
male |
68 days-70 days |
20 |
|
|
329.0 |
g |
2.27 |
10.15 |
body weighing method |
|
|
0 |
|
|
|
|
|
12494 |
266 |
WKY/Izm |
body weight |
controlled fat content diet (5 %) (for 70 days) and controlled potassium content diet (0.75 %) (for 70 days) then controlled fat content diet (26 %) (for 14 days) and controlled potassium content diet (0.44 %) (for 14 days) |
Watanabe T, et al., Biochem Biophys Res Commun 2005 Apr 15;329(3):879-87. |
body mass |
male |
119 days
| 10 |
|
|
325.0 |
g |
5.34 |
16.9 |
body weighing method |
|
|
0 |
|
|
|
|
|
12491 |
263 |
BC/CpbU |
body weight |
controlled olive oil content diet (5 %) (for 30 days) and controlled cholesterol content diet (2 %) (for 30 days) |
de Wolf ID, et al., Exp Biol Med (Maywood) 2002 Jul;227(7):529-34. |
body mass |
female |
77 days
| 4 |
|
|
177.0 |
g |
2.5 |
5.0 |
body weighing method |
|
|
0 |
|
|
|
|
|
12512 |
267 |
LEW/OlaHsd |
body weight |
control condition |
Bonne AC, et al., Arterioscler Thromb Vasc Biol 2002 Dec 1;22(12):2072-9. |
body mass |
female |
49 days
| 6 |
|
|
160.0 |
g |
3.27 |
8.0 |
body weighing method |
|
|
0 |
|
|
|
|
|
12611 |
271 |
SS.LEW-(D1Mco36-D1Rat106)/Mco |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 24 days) |
Toland EJ, et al., Mamm Genome. 2008 Mar;19(3):209-18. Epub 2008 Mar 7. |
body mass |
male |
64 days-66 days |
30 |
|
|
335.0 |
g |
2.61 |
14.3 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12876 |
313 |
SS.LEW-(D1Mco99-D1Rat49)/Mco |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 24 days) |
Toland EJ, et al., Mamm Genome. 2008 Mar;19(3):209-18. Epub 2008 Mar 7. |
body mass |
male |
64 days-66 days |
20 |
|
|
302.0 |
g |
1.89 |
8.45 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12879 |
313 |
WBN/KobSlc |
body weight |
controlled protein content diet |
Tsuji A, et al., Genomics 2001 Jun 15;74(3):365-9. |
body mass |
male |
120 days
| 5 |
|
|
332.7 |
g |
6.1 |
13.64 |
body weighing method |
|
|
0 |
|
|
|
|
|
12906 |
321 |
SHR/Mol |
body weight |
control condition |
Kloting I, et al., Biochem Biophys Res Commun 2001 Jun 29;284(5):1126-33. |
body mass |
female |
84 days
| 12 |
|
|
188.0 |
g |
1.73 |
6.0 |
body weighing method |
|
|
0 |
|
|
|
|
|
12940 |
323 |
SS/Jr |
body weight |
controlled sodium content diet (2 %) (for 28 days) |
Toland EJ, et al., J Hypertens. 2008 Nov;26(11):2134-41. |
body mass |
male |
68 days-70 days |
20 |
|
|
316.0 |
g |
2.83 |
12.66 |
body weighing method |
|
|
0 |
|
|
|
|
|
12950 |
305 |
MWF/Fub |
body weight |
control condition |
Schulz A, et al., J Am Soc Nephrol 2003 Dec;14(12):3081-9. |
body mass |
male |
126 days
| 8 |
|
|
333.1 |
g |
6.93 |
19.6 |
body weighing method |
|
|
0 |
|
|
|
|
|
13002 |
325 |
SHR/Fub |
body weight |
control condition |
Schulz A, et al., J Am Soc Nephrol 2003 Dec;14(12):3081-9. |
body mass |
male |
126 days
| 8 |
|
|
391.3 |
g |
8.38 |
23.7 |
body weighing method |
|
|
0 |
|
|
|
|
|
13007 |
325 |
WOKW |
body weight |
control condition |
Kloting I, et al., Biochem Biophys Res Commun 2001 Jun 1;284(1):150-6. |
body mass |
female |
210 days
| 12 |
|
|
255.0 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
12398 |
251 |
SS.LEW-(D10Chm10-D10Rat11)/Ayd |
body weight gain |
controlled sodium content diet (8 %) (between 8 and 10 days) |
Huang BS, et al., Hypertension. 2007 Apr 9;. |
body mass |
male |
43 days-52 days |
10 |
|
|
53.0 |
g |
3.0 |
9.49 |
body weighing method |
|
|
0 |
|
|
|
|
|
13316 |
344 |
SS/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 25 and 28 days) |
Kumarasamy S, et al., Hypertens Res. 2011 Dec;34(12):1263-70. doi: 10.1038/hr.2011.116. Epub 2011 Aug 4. |
body mass |
not specified |
0 days
| 0 |
|
|
312.0 |
g |
2.8 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67529 |
749 |
SS.SHR-(D9Rat7-D9Rat52)/Mco |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 25 and 28 days) |
Kumarasamy S, et al., Hypertens Res. 2011 Dec;34(12):1263-70. doi: 10.1038/hr.2011.116. Epub 2011 Aug 4. |
body mass |
not specified |
0 days
| 0 |
|
|
365.0 |
g |
3.84 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67542 |
749 |
ACI/Eur |
body weight |
controlled NG-nitroarginine methyl ester content in acidified drinking water (8-13 mg/kg/d) (for 126 days) |
Van Dijk SJ, et al., Nephron Exp Nephrol 2005 Jun 20;101(2):e59-e66. |
body mass |
male |
173 days-180 days |
8 |
|
|
312.0 |
g |
2.0 |
5.66 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67675 |
751 |
SS.LEW-(D10Got112-Igfbp4)/Ayd |
body weight |
controlled sodium content diet (0.2 %) (for 14 days) then controlled sodium content diet (2 %) (for 35 days) |
Deng AY, et al., J Hypertens. 2008 Oct;26(10):1935-1943. |
body mass |
male |
77 days
| 5 |
|
|
318.8 |
g |
9.03 |
20.2 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65010 |
542 |
SS/Jr |
body weight |
controlled sodium content diet (0.2 %) (for 14 days) then controlled sodium content diet (2 %) (for 35 days) |
Deng AY, et al., J Hypertens. 2008 Oct;26(10):1935-1943. |
body mass |
male |
77 days
| 40 |
|
|
305.6 |
g |
4.38 |
27.7 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65005 |
542 |
SHR.BN-(D2Rat226-D2Rat294)/Jk |
body weight |
control condition (for 98 days) |
Aneas I, et al., Physiol Genomics. 2009 Mar 3;37(1):52-7. Epub 2009 Jan 6. |
body mass |
male |
87 days
| 22 |
|
|
292.0 |
g |
4.0 |
18.76 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65432 |
306 |
SHR.BN-(D16Rat87-D16Mgh1)/Jk |
body weight |
control condition (for 98 days) |
Aneas I, et al., Physiol Genomics. 2009 Mar 3;37(1):52-7. Epub 2009 Jan 6. |
body mass |
male |
87 days
| 22 |
|
|
260.0 |
g |
7.0 |
32.83 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65436 |
306 |
HTG |
body weight |
losartan (10 mg/kg) (for 0.2 hours) then pentolinium (5 mg/kg) (for 0.1 hours) then NG-nitroarginine methyl ester (30 mg/kg) (for 0.3 hours) |
Ueno T, et al., Physiol Res 2003;52(6):689-700. |
body mass |
not specified |
0 days
| 10 |
|
serial mean |
309.3 |
g |
|
|
body weighing method |
0 |
|
0 |
|
|
|
|
|
65438 |
568 |
SS/Jr |
body weight |
control condition |
Garrett MR, et al., J Am Soc Nephrol 2003 May;14(5):1175-87 |
body mass |
male |
182 days-183 days |
6 |
|
|
485.0 |
g |
11.9 |
29.15 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65446 |
104 |
N:HS |
body weight |
control condition |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
body mass |
both |
70 days
| 220 |
|
|
234.2 |
g |
3.85 |
57.1 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
66005 |
114 |
ACI/N |
body weight |
control condition |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
body mass |
both |
70 days
| 220 |
|
|
202.4 |
g |
0.68 |
10.1 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
66007 |
114 |
BUF/N |
body weight |
control condition |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
body mass |
both |
70 days
| 220 |
|
|
269.3 |
g |
0.47 |
6.9 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
66011 |
114 |
F344/NRrrc |
body weight |
control condition |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
body mass |
both |
70 days
| 220 |
|
|
233.2 |
g |
0.55 |
8.2 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
66013 |
114 |
SS/JrRkb |
body weight |
controlled sodium content diet (4 %) (for 56 days) |
Wendt N, et al., J Hypertens. 2007 Jan;25(1):95-102. |
body mass |
male |
98 days
| 14 |
|
|
342.0 |
g |
6.0 |
22.45 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
66083 |
669 |
WOKW/K |
body weight |
control condition |
Kovacs P, et al., Biochem Biophys Res Commun 2000 Mar 24;269(3):660-5. |
body mass |
not specified |
224 days
| 12 |
|
|
513.0 |
g |
5.77 |
20.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
69108 |
1123 |
BN/Cub |
body weight |
control condition |
Seda O, et al., Physiol Genomics. 2005 Apr 14;21(2):243-52. Epub 2005 Feb 22. |
body mass |
male |
300 days
| 6 |
|
|
274.1 |
g |
8.37 |
20.5 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
70206 |
1318 |
SHR/NHsdMco |
body weight |
control condition (for 140 days) |
Garrett MR, et al., Physiol Genomics. 2007 May 15;. |
body mass |
male |
140 days
| 6 |
|
|
339.0 |
g |
9.3 |
22.78 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67973 |
834 |
DA.ACI-(D10Rat2-D10Rat29)/Kini |
maximum body weight loss to initial body weight ratio |
myelin oligodendrocyte glycoprotein (20 ug) |
Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. |
body mass |
male |
103 days-131 days |
10 |
|
|
1.2 |
% |
1.14 |
3.6 |
body weighing method |
0.0 |
intradermal injection |
40 |
days |
from before p.i. |
|
|
|
68720 |
839 |
DA.ACI-(D10Rat2-D10Rat29)/Kini |
maximum body weight loss to initial body weight ratio |
myelin oligodendrocyte glycoprotein (20 ug) |
Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. |
body mass |
male |
103 days-131 days |
8 |
|
|
0.0 |
% |
0.0 |
0.0 |
body weighing method |
0.0 |
intradermal injection |
40 |
days |
from before p.i. |
|
|
|
68725 |
839 |
ACI.FHH-(D1Mit18-D1Mit8)(D14Mit11-D14Hmgc14b)(D14Rat65-D14Rat90)/Eur |
body weight |
specific pathogen-free condition |
van Dijk SJ, et al., Nephron Exp Nephrol. 2006;104(3):e96-e102. Epub 2006 Jul 12. |
body mass |
not specified |
168 days-175 days |
12 |
|
|
305.0 |
g |
2.0 |
6.93 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67905 |
832 |
ACI/Eur |
body weight |
unilateral nephrectomy then NG-nitroarginine methyl ester (10-21 ml/kg/d) (for 126 days) |
van Dijk SJ, et al., Nephron Exp Nephrol. 2006;104(3):e96-e102. Epub 2006 Jul 12. |
body mass |
not specified |
168 days-175 days |
12 |
|
|
314.0 |
g |
5.0 |
17.32 |
body weighing method |
0.0 |
unilateral nephrectomy |
126 |
days |
|
|
|
|
67907 |
832 |
DA/K |
body mass index (BMI) |
control condition |
Kloting I, et al., Biochem Biophys Res Commun 2001 Jun 1;284(1):150-6. |
body mass |
female |
224 days
| 12 |
|
|
0.51 |
g/cm2 |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67914 |
251 |
FHH/Eur |
body weight |
unilateral nephrectomy |
Shiozawa M, et al., J Am Soc Nephrol 2000 Nov;11(11):2068-78. |
body mass |
male |
91 days-98 days |
26 |
|
|
310.0 |
g |
2.94 |
15.0 |
body weighing method |
0.0 |
unilateral nephrectomy |
39 |
days |
performed at 5 to 6 weeks of age |
|
|
|
69140 |
1128 |
BN/SsN |
body weight loss |
type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) |
Griffiths MM, et al., Arthritis Rheum 2000 Jun;43(6):1278-89 |
body mass |
both |
66 days-126 days |
13 |
|
|
0.0 |
% |
0.0 |
0.0 |
body weighing method |
0.0 |
immunized |
10 |
days |
variable |
(weight loss) |
|
|
69958 |
850 |
ACI.FHH-(D3Wox2-D3Rat59)/Eur |
body weight |
right nephrectomy then NG-nitroarginine methyl ester (50-150 mg/l) |
Van Dijk SJ, et al., Kidney Int. 2006 |
body mass |
male |
168 days-175 days |
11 |
|
|
301.0 |
g |
6.0 |
19.9 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67705 |
62 |
ACI.FHH-(D1Rat298-D1Rat90)/Eur |
body weight |
right nephrectomy then NG-nitroarginine methyl ester (50-150 mg/l) |
Van Dijk SJ, et al., Kidney Int. 2006 |
body mass |
male |
168 days-175 days |
12 |
|
|
319.0 |
g |
6.0 |
20.78 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67706 |
62 |
WKY/NCruk |
body weight |
left nephrectomy |
Clemitson JR, et al., Hypertension 2002 Sep;40(3):292-7 |
body mass |
male |
175 days
| 20 |
|
|
347.3 |
g |
7.94 |
35.5 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67744 |
110 |
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini |
body weight |
control condition |
Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. |
body mass |
female |
56 days-77 days |
0 |
|
|
153.5 |
g |
|
16.7 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
68121 |
837 |
DA.ACI-(D10Rat2-D10Rat29)/Kini |
maximum body weight loss to initial body weight ratio |
myelin oligodendrocyte glycoprotein (20 ug) |
Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. |
body mass |
male |
103 days-131 days |
7 |
|
|
0.0 |
% |
0.0 |
0.0 |
body weighing method |
0.0 |
intradermal injection |
40 |
days |
from before p.i. |
|
|
|
68728 |
839 |
DA.PVG.1AV1-(D4Rat155-D4Rat84) |
maximum body weight loss to initial body weight ratio |
Freund's complete adjuvant (100 ul) |
Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. |
body mass |
both |
120 days-200 days |
14 |
|
|
5.9 |
% |
3.7 |
13.84 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
69797 |
1162 |
DA.PVG.1AV1-(D4Rat155-Spr) |
maximum body weight loss to initial body weight ratio |
pristane (150 ul) |
Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. |
body mass |
both |
120 days-200 days |
24 |
|
|
10.6 |
% |
1.1 |
5.39 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
69806 |
1162 |
DA/Ztm |
maximum body weight loss to initial body weight ratio |
type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) |
Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. |
body mass |
both |
120 days-200 days |
10 |
|
|
22.8 |
% |
1.1 |
3.48 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
69809 |
1162 |
SS/JrHsdMcwi |
body weight |
controlled sodium content diet (4 %) (for 21 days) |
Mattson DL, et al., Am J Physiol Regul Integr Comp Physiol. 2013 Jan 30. |
body mass |
not specified |
84 days
| 0 |
|
|
395.0 |
g |
10.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
69205 |
1057 |
Crl:CD(SD) |
body weight |
standard diet and restricted feeding (4 h) |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
168 days
| 19 |
|
|
444.0 |
g |
6.65 |
29.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85321 |
1604 |
Crl:CD(SD) |
body weight |
standard diet and restricted feeding (4 h) |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
126 days
| 19 |
|
|
401.0 |
g |
4.82 |
21.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85317 |
1604 |
Crl:CD(SD) |
body weight |
standard diet then acetaminophen (500 mg/kg) (for 56 days) |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
126 days
| 8 |
|
|
516.0 |
g |
12.73 |
36.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85538 |
1604 |
Crl:SD |
body weight |
controlled fructose content drinking water (5 %) (for 70 days) and controlled ethanol content drinking water (1 %) (for 70 days) |
Ronn M, et al., Toxicology. 2013 Jan 7;303:125-32. doi: 10.1016/j.tox.2012.09.013. Epub 2012 Nov 8. |
body mass |
female |
105 days
| 12 |
|
|
171.7 |
g |
2.08 |
7.2 |
body weighing method |
0.0 |
|
0 |
|
|
week one |
|
|
75753 |
1538 |
BluHsd:LE |
body weight gain |
vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days) |
Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. |
body mass |
male |
71 days-98 days |
8 |
|
|
145.3 |
g |
9.3 |
26.3 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
76161 |
1543 |
HanTac:WH |
body weight gain |
bisphenol A (5 mg/kg/d) (for 14 days) |
Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. |
body mass |
female |
0 days
| 18 |
|
|
81.1 |
g |
4.9 |
20.8 |
body weighing method |
0.0 |
|
0 |
|
|
G7-G21 |
|
|
76273 |
1559 |
SD |
body weight |
acetaminophen (250 mg/kg) (for 8 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
male |
50 days-64 days |
6 |
|
|
211.0 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84766 |
1602 |
SD |
body weight |
acetaminophen (250 mg/kg) (for 28 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
male |
70 days-84 days |
6 |
|
|
258.5 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84769 |
1602 |
SD |
body weight |
control condition |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
male |
70 days-84 days |
6 |
|
|
255.5 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84788 |
1602 |
SD |
body weight |
acetaminophen (500 mg/kg) (for 1 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
female |
42 days-56 days |
6 |
|
|
134.7 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84804 |
1602 |
SD |
body weight |
control condition |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
female |
42 days-56 days |
6 |
|
|
137.3 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84814 |
1602 |
CrljJcl:SD |
body weight |
gestation (for 20 days) |
Xu X, et al., Neurotoxicol Teratol. 2011 Jul-Aug;33(4):458-63. doi: 10.1016/j.ntt.2011.06.002. Epub 2011 Jun 17. |
body mass |
female |
0 days
| 6 |
|
|
355.48 |
g |
29.85 |
73.12 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
75902 |
1539 |
CrljJcl:SD |
body weight |
gestation (for 20 days) then controlled bisphenol A content drinking water (0.01 mg/l) (for 9 days) |
Xu X, et al., Neurotoxicol Teratol. 2011 Jul-Aug;33(4):458-63. doi: 10.1016/j.ntt.2011.06.002. Epub 2011 Jun 17. |
body mass |
female |
0 days
| 8 |
|
|
361.54 |
g |
33.76 |
95.49 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
75907 |
1539 |
CrljJcl:SD |
body weight |
gestation (for 14 days) then controlled bisphenol A content drinking water (0.1 mg/l) (for 3 days) |
Xu X, et al., Neurotoxicol Teratol. 2011 Jul-Aug;33(4):458-63. doi: 10.1016/j.ntt.2011.06.002. Epub 2011 Jun 17. |
body mass |
female |
0 days
| 8 |
|
|
287.17 |
g |
20.44 |
57.81 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
75911 |
1539 |
CrljJcl:SD |
body weight |
gestation (for 21 days) then controlled bisphenol A content drinking water (1 mg/l) (for 31 days) then lactation (for 21 days) |
Xu X, et al., Neurotoxicol Teratol. 2011 Jul-Aug;33(4):458-63. doi: 10.1016/j.ntt.2011.06.002. Epub 2011 Jun 17. |
body mass |
female |
0 days
| 8 |
|
|
260.55 |
g |
27.27 |
77.13 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
75920 |
1539 |
W-LeprfaNin |
body weight |
controlled retinyl palmitate content diet (26 mg/kg) (between 36 and 42 days) then fasting (for 12 hours) |
Tiruvalluru M, et al., Nutrition. 2013 Jan;29(1):298-304. doi: 10.1016/j.nut.2012.06.006. Epub 2012 Oct 2. |
body mass |
male |
284 days
| 6 |
|
|
883.0 |
g |
38.9 |
95.29 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
96722 |
1660 |
BluHsd:LE |
body weight gain |
controlled in utero environment (for 9 days) and bisphenol A (2.5 ug/kg) (for 30 days) then maternal milk (for 21 days) |
Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. |
body mass |
male |
71 days-98 days |
8 |
|
|
103.7 |
g |
4.2 |
11.88 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
75970 |
1543 |
SD |
body weight |
control condition |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
male |
50 days-64 days |
6 |
|
|
207.4 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84761 |
1602 |
SD |
body weight |
acetaminophen (500 mg/kg) (for 22 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
male |
64 days-78 days |
6 |
|
|
241.1 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84773 |
1602 |
HanTac:WH |
body weight |
bisphenol A (50 mg/kg/d) (for 1 days) |
Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. |
body mass |
male |
1 days
| 17 |
|
|
5.9 |
g |
0.22 |
0.9 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
96616 |
1559 |
HanTac:WH |
body weight |
bisphenol A (0.025 mg/kg/d) (for 1 days) |
Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. |
body mass |
male |
1 days
| 17 |
|
|
6.3 |
g |
0.12 |
0.5 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
96633 |
1559 |
F344/NHsd |
body weight |
fasting (for 16 hours) |
Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17. |
body mass |
male |
714 days-882 days |
5 |
|
|
415.7 |
g |
28.9 |
64.62 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84706 |
1599 |
PXO9/Cub |
body weight |
controlled sucrose content diet (70 % of calories) (between 0 and 168 hours) and controlled protein content diet (19.6 % of calories) (between 0 and 168 hours) and controlled fat content diet (10.4 % of calories) (between 0 and 168 hours) then fasting (between 0 and 16 hours) |
Hodulova M, et al., PLoS One. 2014 Oct 8;9(10):e109983. doi: 10.1371/journal.pone.0109983. eCollection 2014. |
body mass |
male |
127 days
| 9 |
|
|
245.0 |
g |
6.2 |
18.6 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97160 |
1858 |
PXO5-1/Cub |
body weight |
controlled sucrose content diet (70 % of calories) (between 0 and 168 hours) and controlled protein content diet (19.6 % of calories) (between 0 and 168 hours) and controlled fat content diet (10.4 % of calories) (between 0 and 168 hours) then fasting (between 0 and 16 hours) |
Hodulova M, et al., PLoS One. 2014 Oct 8;9(10):e109983. doi: 10.1371/journal.pone.0109983. eCollection 2014. |
body mass |
male |
127 days
| 11 |
|
|
235.1 |
g |
4.8 |
15.92 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97158 |
1858 |
PXO8-1/Cub |
body weight |
controlled sucrose content diet (70 % of calories) (between 0 and 168 hours) and controlled protein content diet (19.6 % of calories) (between 0 and 168 hours) and controlled fat content diet (10.4 % of calories) (between 0 and 168 hours) then fasting (between 0 and 16 hours) |
Hodulova M, et al., PLoS One. 2014 Oct 8;9(10):e109983. doi: 10.1371/journal.pone.0109983. eCollection 2014. |
body mass |
male |
127 days
| 10 |
|
|
279.1 |
g |
4.2 |
13.28 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97166 |
1858 |
SHR-Ndufc2em2Mcwi+/+ |
body weight |
controlled protein content diet (19.7 %) (for 56 days) and controlled potassium content diet (6.3 mg/g) (for 56 days) and controlled sodium content diet (3.7 mg/g) (for 56 days) |
Rubattu S, et al., J Am Heart Assoc. 2016 Feb 17;5(2). pii: e002701. doi: 10.1161/JAHA.115.002701. |
body mass |
not specified |
98 days
| 12 |
|
|
299.0 |
g |
4.62 |
16.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97901 |
1938 |
SHR/Bbb |
body weight |
controlled protein content diet (19.7 %) (for 56 days) and controlled potassium content diet (6.3 mg/g) (for 56 days) and controlled sodium content diet (3.7 mg/g) (for 56 days) |
Rubattu S, et al., J Am Heart Assoc. 2016 Feb 17;5(2). pii: e002701. doi: 10.1161/JAHA.115.002701. |
body mass |
not specified |
98 days
| 18 |
|
|
260.0 |
g |
3.77 |
16.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97907 |
1938 |
SHR/Bbb |
body weight |
controlled protein content diet (19.7 %) (for 84 days) and controlled potassium content diet (6.3 mg/g) (for 84 days) and controlled sodium content diet (3.7 mg/g) (for 84 days) |
Rubattu S, et al., J Am Heart Assoc. 2016 Feb 17;5(2). pii: e002701. doi: 10.1161/JAHA.115.002701. |
body mass |
not specified |
126 days
| 18 |
|
|
289.0 |
g |
1.89 |
8.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97908 |
1938 |
SHR-Ndufc2em1Mcwi+/+ |
body weight |
controlled protein content diet (19.7 %) (for 56 days) and controlled potassium content diet (6.3 mg/g) (for 56 days) and controlled sodium content diet (3.7 mg/g) (for 56 days) |
Rubattu S, et al., J Am Heart Assoc. 2016 Feb 17;5(2). pii: e002701. doi: 10.1161/JAHA.115.002701. |
body mass |
not specified |
98 days
| 10 |
|
|
287.0 |
g |
3.79 |
12.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97878 |
1938 |
PXO6-3/Cub |
body weight |
controlled sucrose content diet (70 % of calories) (between 0 and 168 hours) and controlled protein content diet (19.6 % of calories) (between 0 and 168 hours) and controlled fat content diet (10.4 % of calories) (between 0 and 168 hours) then fasting (between 0 and 16 hours) |
Hodulova M, et al., PLoS One. 2014 Oct 8;9(10):e109983. doi: 10.1371/journal.pone.0109983. eCollection 2014. |
body mass |
male |
127 days
| 10 |
|
|
235.6 |
g |
6.8 |
21.5 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97159 |
1858 |
PXO6-1/Cub |
body weight |
controlled sucrose content diet (70 % of calories) (between 0 and 168 hours) and controlled protein content diet (19.6 % of calories) (between 0 and 168 hours) and controlled fat content diet (10.4 % of calories) (between 0 and 168 hours) then fasting (between 0 and 16 hours) |
Hodulova M, et al., PLoS One. 2014 Oct 8;9(10):e109983. doi: 10.1371/journal.pone.0109983. eCollection 2014. |
body mass |
male |
127 days
| 10 |
|
|
251.2 |
g |
5.5 |
17.39 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97162 |
1858 |
F344.ZUC-(Leprfa),OLETF-(D14Rat23-D14Rat12)/Tj |
body weight |
control condition |
Sasaki D, et al., Mamm Genome. 2015 Dec;26(11-12):619-29. doi: 10.1007/s00335-015-9597-4. Epub 2015 Aug 22. |
body mass |
male |
168 days-175 days |
5 |
|
|
461.5 |
g |
13.65 |
30.52 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97721 |
1918 |
MW |
body weight |
right nephrectomy (for 56 days) |
Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55. |
body mass |
male |
0 days
| 6 |
|
|
258.7 |
g |
11.0 |
26.94 |
body weighing method |
0.0 |
~5/6 to 7/8 nephrectomy |
56 |
days |
|
|
|
|
100799 |
2523 |
MW |
body weight |
right nephrectomy (for 84 days) then reserpine (5 mg/l) (for 28 days) and hydralazine (80 mg/l) (for 28 days) and controlled hydralazine content drinking water (25 mg/l) (for 28 days) |
Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55. |
body mass |
male |
0 days
| 10 |
|
|
276.6 |
g |
7.4 |
23.4 |
body weighing method |
0.0 |
~5/6 to 7/8 nephrectomy |
84 |
days |
|
|
|
|
100807 |
2523 |
SS/Jr |
body weight |
controlled sodium chloride content diet (0.3 %) (for 21 days) then controlled sodium chloride content diet (8 %) (for 42 days) |
Sobajima M, et al., Am J Physiol Heart Circ Physiol. 2011 Jun;300(6):H2214-20. doi: 10.1152/ajpheart.00615.2010. Epub 2011 Mar 18. |
body mass |
not specified |
84 days
| 5 |
|
|
332.0 |
g |
22.36 |
50.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103141 |
2787 |
SS-Nppbem2Mcwi-/- |
body weight |
controlled sodium content diet (0.4 %) (between 56 and 63 days) then controlled sodium content diet (4 %) (for 12 days) |
Flister MJ, et al., Genome Res. 2013 Dec;23(12):1996-2002. doi: 10.1101/gr.160283.113. Epub 2013 Sep 4. |
body mass |
male |
60 days-69 days |
0 |
|
|
330.0 |
g |
4.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
98466 |
2059 |
SS-Mthfrem1Mcwi-/+ |
body weight |
controlled sodium content diet (0.4 %) (between 56 and 63 days) then controlled sodium content diet (4 %) (for 12 days) |
Flister MJ, et al., Genome Res. 2013 Dec;23(12):1996-2002. doi: 10.1101/gr.160283.113. Epub 2013 Sep 4. |
body mass |
male |
60 days-69 days |
0 |
|
|
333.0 |
g |
10.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
98469 |
2059 |
SS/Hsd |
body weight |
controlled sodium content diet (0.4 %) (between 56 and 63 days) then controlled sodium content diet (4 %) (for 12 days) |
Flister MJ, et al., Genome Res. 2013 Dec;23(12):1996-2002. doi: 10.1101/gr.160283.113. Epub 2013 Sep 4. |
body mass |
male |
60 days-69 days |
0 |
|
|
321.0 |
g |
5.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
98471 |
2059 |
SS-Agtrapem4Mcwi-/- |
body weight |
controlled sodium content diet (0.4 %) (between 56 and 63 days) then controlled sodium content diet (4 %) (for 12 days) |
Flister MJ, et al., Genome Res. 2013 Dec;23(12):1996-2002. doi: 10.1101/gr.160283.113. Epub 2013 Sep 4. |
body mass |
male |
60 days-69 days |
0 |
|
|
327.0 |
g |
4.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
98470 |
2059 |
SS-Nppbem2Mcwi+/+ |
body weight |
control condition (for 28 days) |
Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. |
body mass |
male |
28 days
| 5 |
|
|
96.0 |
g |
7.0 |
15.65 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99543 |
2319 |
SR/JrHsd |
body weight |
controlled sodium chloride content diet (0.4 %) (for 14 days) then bilateral ovariectomy then 17 beta-estradiol (10 ug/d) (for 14 days) |
Zheng W, et al., Am J Physiol Heart Circ Physiol. 2008 Apr;294(4):H1508-13. doi: 10.1152/ajpheart.01322.2007. Epub 2008 Feb 1. |
body mass |
female |
0 days
| 0 |
|
|
200.0 |
g |
2.5 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102187 |
2681 |
SS/JrHsd |
body weight |
controlled sodium chloride content diet (0.4 %) (for 14 days) then bilateral ovariectomy then peanut oil (0.2 ml) (for 14 days) |
Zheng W, et al., Am J Physiol Heart Circ Physiol. 2008 Apr;294(4):H1508-13. doi: 10.1152/ajpheart.01322.2007. Epub 2008 Feb 1. |
body mass |
female |
0 days
| 0 |
|
|
294.0 |
g |
4.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102191 |
2681 |
LH/Mav |
body weight |
vehicle control condition |
Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. |
body mass |
male |
112 days
| 11 |
|
|
384.0 |
g |
9.0 |
29.85 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102724 |
2721 |
WKY |
body weight |
left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days) |
Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. |
body mass |
male |
238 days-252 days |
20 |
|
|
583.0 |
g |
56.0 |
250.44 |
body weighing method |
0.0 |
lad occlusion |
196 |
days |
|
|
|
|
100271 |
2460 |
SD |
body weight |
controlled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then vehicle control condition (100 ul) (for 90 days) |
Finch JL, et al., Am J Physiol Renal Physiol. 2011 Sep 28. |
body mass |
female |
0 days
| 13 |
|
|
283.6 |
g |
3.8 |
13.7 |
body weighing method |
0.0 |
unx |
97 |
days |
|
|
|
|
100632 |
2499 |
Jcl:WI |
body weight |
standard diet |
Radosinska J, et al., Physiol Res. 2015;64(6):795-806. Epub 2015 Oct 8. |
body mass |
male |
84 days
| 8 |
|
|
432.0 |
g |
10.25 |
29.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103055 |
2785 |
Jcl:WI |
body weight |
Omacor (400 mg/kg/d) (for 56 days) |
Radosinska J, et al., Physiol Res. 2015;64(6):795-806. Epub 2015 Oct 8. |
body mass |
male |
84 days
| 8 |
|
|
429.0 |
g |
6.01 |
17.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103056 |
2785 |
GK/Jcl |
body weight |
standard diet |
Radosinska J, et al., Physiol Res. 2015;64(6):795-806. Epub 2015 Oct 8. |
body mass |
male |
84 days
| 8 |
|
|
353.0 |
g |
7.07 |
20.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103057 |
2785 |
WKY |
body weight |
in utero condition (30 % of calories) (for 22 days) |
Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. |
body mass |
not specified |
1 days
| 36 |
|
|
4.91 |
g |
0.15 |
0.9 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99074 |
2218 |
SR |
body weight |
controlled sodium content diet (6 %) (between 21 and 28 days) |
Kamei K, et al., Circ J. 2007 Mar;71(3):390-6. |
body mass |
male |
63 days-70 days |
7 |
|
|
303.0 |
g |
10.96 |
29.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103344 |
2804 |
LH/Mav |
body weight |
controlled perindopril content drinking water (0.4 mg/kg/d) (for 63 days) then controlled sodium chloride content drinking water (2 %) (for 8 days) |
Naelten G, et al., J Cardiovasc Pharmacol. 2011 Feb;57(2):240-5. doi: 10.1097/FJC.0b013e318204bb7b. |
body mass |
male |
119 days
| 8 |
|
|
393.0 |
g |
7.0 |
19.8 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103405 |
2824 |
LH/Mav |
body weight |
controlled perindopril content drinking water (0.4 mg/kg/d) (for 63 days) |
Bertram D, et al., Am J Physiol Regul Integr Comp Physiol. 2002 Nov;283(5):R1041-5. doi: 10.1152/ajpregu.00620.2001. |
body mass |
male |
147 days-154 days |
6 |
|
|
428.0 |
g |
6.0 |
14.7 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103430 |
2825 |
SHR |
body weight |
control condition (for 0 hours) |
Cerutti C, et al., Physiol Genomics. 2006 Nov 27;27(3):295-308. doi: 10.1152/physiolgenomics.00318.2005. Epub 2006 Aug 1. |
body mass |
male |
84 days
| 5 |
|
|
276.0 |
g |
10.0 |
22.36 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103477 |
2826 |
WKY/NCrl |
body weight |
control condition |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
body mass |
male |
140 days
| 6 |
|
|
437.0 |
g |
3.0 |
7.35 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103487 |
2827 |
SD |
body weight |
streptozotocin (60 mg/kg) then insulin |
Perico N, et al., J Am Soc Nephrol. 1994 Oct;5(4):1139-46. |
body mass |
male |
0 days
| 8 |
|
|
526.0 |
g |
10.25 |
29.0 |
body weighing method |
0.0 |
stz |
154 |
days |
|
|
|
|
99871 |
2358 |
LH/Mav |
body weight |
perindopril (0.1 mg/kg/d) (for 98 days) |
Egan EJ, et al., Acta Pharmacol Sin. 2008 Nov;29(11):1296-300. doi: 10.1111/j.1745-7254.2008.00862.x. |
body mass |
male |
161 days
| 8 |
|
|
452.0 |
g |
5.0 |
14.14 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102803 |
2723 |
LH/Mav |
body weight |
perindopril (0.04 mg/kg/d) (for 98 days) |
Egan EJ, et al., Acta Pharmacol Sin. 2008 Nov;29(11):1296-300. doi: 10.1111/j.1745-7254.2008.00862.x. |
body mass |
male |
161 days
| 8 |
|
|
442.0 |
g |
6.0 |
16.97 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102802 |
2723 |
LH/Mav |
body weight |
perindopril (0.01 mg/kg/d) (for 98 days) |
Egan EJ, et al., Acta Pharmacol Sin. 2008 Nov;29(11):1296-300. doi: 10.1111/j.1745-7254.2008.00862.x. |
body mass |
male |
161 days
| 6 |
|
|
460.0 |
g |
14.0 |
34.29 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102806 |
2723 |
WF/Mol |
body weight |
controlled ramipril content drinking water (3 mg/kg/d) (for 5 days) then artificial aortocaval fistula (for 4 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 7 |
|
|
197.0 |
g |
3.0 |
7.94 |
body weighing method |
0.0 |
acf |
4 |
days |
|
|
|
|
101294 |
2585 |
SS-Nppbem2Mcwi-/- |
body weight |
control condition |
Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. |
body mass |
male |
84 days
| 7 |
|
|
378.0 |
g |
20.0 |
52.92 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99756 |
2319 |
SS-Nppbem2Mcwi-/- |
body weight |
vehicle control condition |
Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. |
body mass |
male |
252 days
| 7 |
|
|
452.0 |
g |
21.0 |
55.56 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99760 |
2319 |
SD |
body weight |
unilateral nephrectomy (between 12 and 14 days) then enalapril (50 mg/l) (between 12 and 14 days) and losartan (180 mg/l) (between 12 and 14 days) and aldosterone (30-40 mg/kg/d) (between 12 and 14 days) |
Greene EL, et al., J Clin Invest. 1996 Aug 15;98(4):1063-8. |
body mass |
male |
0 days
| 5 |
|
|
302.0 |
g |
6.26 |
14.0 |
body weighing method |
0.0 |
unx |
13 |
days |
|
|
|
|
101538 |
2602 |
SD |
change in body weight |
unilateral nephrectomy (between 12 and 14 days) then enalapril (50 mg/l) (between 12 and 14 days) and losartan (180 mg/l) (between 12 and 14 days) and aldosterone (30-40 mg/kg/d) (between 12 and 14 days) |
Greene EL, et al., J Clin Invest. 1996 Aug 15;98(4):1063-8. |
body mass |
male |
0 days
| 5 |
|
|
66.0 |
g |
4.92 |
11.0 |
body weighing method |
0.0 |
unx |
13 |
days |
|
change from surgery weight |
|
|
101542 |
2602 |
SD |
body weight |
sham surgical control condition (for 28 days) |
Greene EL, et al., J Clin Invest. 1996 Aug 15;98(4):1063-8. |
body mass |
male |
0 days
| 6 |
|
|
347.0 |
g |
7.35 |
18.0 |
body weighing method |
0.0 |
sham unx |
28 |
days |
|
|
|
|
101571 |
2602 |
SD |
body weight |
unilateral nephrectomy (for 28 days) then enalapril (50 mg/l) (for 28 days) and losartan (180 mg/l) (for 28 days) |
Greene EL, et al., J Clin Invest. 1996 Aug 15;98(4):1063-8. |
body mass |
male |
0 days
| 7 |
|
|
307.0 |
g |
36.66 |
25.0 |
body weighing method |
0.0 |
unx |
28 |
days |
|
|
|
|
101573 |
2602 |
SD |
body weight |
unilateral nephrectomy (for 28 days) then enalapril (50 mg/l) (for 28 days) and losartan (180 mg/l) (for 28 days) and aldosterone (35 mg/kg/d) (for 28 days) |
Greene EL, et al., J Clin Invest. 1996 Aug 15;98(4):1063-8. |
body mass |
male |
0 days
| 6 |
|
|
312.0 |
g |
9.8 |
24.0 |
body weighing method |
0.0 |
unx |
28 |
days |
|
|
|
|
101574 |
2602 |
SS/JrHsd |
body weight |
controlled sodium content diet (0.1 %) (for 112 days) then sham surgical control condition (between 56 and 63 days) |
Esqueda ME, et al., Hypertension. 2007 Oct;50(4):768-72. Epub 2007 Aug 13. |
body mass |
female |
112 days
| 6 |
|
|
281.5 |
g |
4.1 |
10.04 |
body weighing method |
0.0 |
sham ovx |
63 |
days |
|
|
|
|
102340 |
2686 |
SS/JrHsd |
body weight |
controlled sodium content diet (0.1 %) (for 112 days) then bilateral ovariectomy (between 56 and 63 days) |
Esqueda ME, et al., Hypertension. 2007 Oct;50(4):768-72. Epub 2007 Aug 13. |
body mass |
female |
112 days
| 6 |
|
|
350.5 |
g |
11.3 |
27.68 |
body weighing method |
0.0 |
ovx |
63 |
days |
|
|
|
|
102341 |
2686 |
GK/Jcl |
body weight |
control condition |
Akiyama S, et al., Biosci Biotechnol Biochem. 2009 Dec;73(12):2779-82. doi: 10.1271/bbb.90576. Epub 2009 Dec 7. |
body mass |
male |
24 days
| 6 |
|
|
53.67 |
g |
1.48 |
3.63 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103905 |
2884 |
GK/Jcl |
body weight |
controlled cyclodextrin (CD)-clathrated hesperetin content diet (4.6 %) |
Akiyama S, et al., Biosci Biotechnol Biochem. 2009 Dec;73(12):2779-82. doi: 10.1271/bbb.90576. Epub 2009 Dec 7. |
body mass |
male |
24 days
| 6 |
|
|
166.41 |
g |
2.36 |
5.78 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103911 |
2884 |
WKY |
body weight |
vehicle control condition (1 null) |
Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. |
body mass |
male |
156 days
| 10 |
|
|
450.39 |
g |
9.36 |
29.6 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99107 |
2219 |
WKY |
body weight |
streptozotocin (60 mg/kg) then benazepril (10 mg/kg/d) then gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 null) |
Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. |
body mass |
male |
156 days
| 10 |
|
|
286.6 |
g |
21.95 |
69.41 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99112 |
2219 |
SD |
body weight |
left nephrectomy then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (0.5 mg/kg) then puromycin (40 mg/kg) |
Ma LJ, et al., Kidney Int. 2004 Jan;65(1):106-15. |
body mass |
male |
0 days
| 7 |
|
|
256.0 |
g |
3.0 |
7.94 |
body weighing method |
0.0 |
unx |
0 |
|
|
|
|
|
98928 |
2179 |
SD |
body weight |
left nephrectomy (for 70 days) then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (0.5 mg/kg) then puromycin (40 mg/kg) |
Ma LJ, et al., Kidney Int. 2004 Jan;65(1):106-15. |
body mass |
male |
0 days
| 7 |
|
|
346.0 |
g |
17.0 |
44.98 |
body weighing method |
0.0 |
unx |
70 |
days |
|
|
|
|
98937 |
2179 |
SD |
mean arterial blood pressure |
left nephrectomy (for 70 days) then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (5 mg/kg) then puromycin (80 mg/kg) |
Ma LJ, et al., Kidney Int. 2004 Jan;65(1):106-15. |
arterial blood pressure trait |
male |
0 days
| 9 |
|
|
129.0 |
mmHg |
4.0 |
12.0 |
body weighing method |
0.0 |
unx |
70 |
days |
|
|
|
|
98948 |
2179 |
SD |
body weight |
control condition |
Jung FF, etal., J Am Soc Nephrol. 1995 Feb;5(8):1573-80. |
body mass |
male |
420 days-450 days |
9 |
|
|
572.0 |
g |
14.4 |
43.2 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
101215 |
2582 |
SS/NEisSlc |
body weight |
controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then tolvaptan (0.05 %) (for 49 days) |
Ishikawa M, et al., Int Heart J. 2013;54(2):98-106. |
body mass |
male |
126 days
| 8 |
|
|
386.0 |
g |
6.0 |
16.97 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102312 |
2684 |
GK/MolTac |
body weight |
running on treadmill (0-10 m/min) (between 0.1 and 0.2 hours) then controlled saxagliptin content diet (10 mg/kg/d) (for 12 days) then running on treadmill (15 m/min) (for 0.5 hours) then running on treadmill (15 m/min) (for 0.8 hours) |
Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. |
body mass |
male |
147 days
| 0 |
|
|
366.0 |
g |
6.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103986 |
2885 |
Crl:WI(WU) |
body weight |
abdominal aorta constriction then losartan (3 mg/kg/d) (for 14 days) and icatibant (0.4 mg/kg/d) (for 14 days) |
Goetz RM and Holtz J, Clin Sci (Lond). 1999 Aug;97(2):165-74. |
body mass |
male |
91 days
| 10 |
|
|
322.0 |
g |
7.0 |
22.14 |
body weighing method |
0.0 |
aorta coarctation |
35 |
days |
|
|
|
|
100011 |
2398 |
SR/JrHsd |
body weight |
gelled diet (200 g/kg/d) (for 8 days) then distilled water |
Fenton RA, et al., Am J Physiol Renal Physiol. 2003 Jul;285(1):F143-51. Epub 2003 Apr 8. |
body mass |
male |
0 days
| 6 |
|
|
118.0 |
g |
0.58 |
1.42 |
body weighing method |
0.0 |
osmotic pump implant |
0 |
days |
|
|
|
|
102540 |
2691 |
SR/JrHsd |
body weight |
gelled diet (200 g/kg/d) (for 8 days) then distilled water (for 6 days) |
Fenton RA, et al., Am J Physiol Renal Physiol. 2003 Jul;285(1):F143-51. Epub 2003 Apr 8. |
body mass |
male |
0 days
| 6 |
|
|
130.0 |
g |
0.63 |
1.54 |
body weighing method |
0.0 |
osmotic pump implant |
6 |
days |
|
|
|
|
102541 |
2691 |
MWF/ZtmRrrc |
body weight |
vehicle control condition |
Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9. |
body mass |
male |
126 days
| 8 |
|
|
378.0 |
g |
10.61 |
30.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
100901 |
2541 |
WKY |
body weight |
0.9% sodium chloride solution (3 ml) |
Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. |
body mass |
male |
0 days
| 9 |
|
|
244.0 |
g |
8.0 |
24.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
100427 |
2479 |
WKY |
body weight |
puromycin aminonucleoside (50 mg/kg) |
Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. |
body mass |
male |
0 days
| 7 |
|
|
245.0 |
g |
9.0 |
23.81 |
body weighing method |
0.0 |
PA IV 50mg/kg |
15 |
days |
|
|
|
|
100428 |
2479 |
WKY |
body weight |
puromycin aminonucleoside (50 mg/kg) |
Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. |
body mass |
male |
0 days
| 9 |
|
|
297.0 |
g |
4.0 |
12.0 |
body weighing method |
0.0 |
PA IV 50mg/kg |
0 |
|
|
|
|
|
100431 |
2479 |
SD |
body weight |
left anterior descending coronary artery occlusion (for 28 days) |
Lax CJ, et al., Clin Exp Pharmacol Physiol. 2004 Aug;31(8):512-7. |
body mass |
male |
77 days
| 6 |
|
|
403.2 |
g |
7.4 |
18.13 |
body weighing method |
0.0 |
lad occlusion |
28 |
days |
|
|
|
|
101075 |
2564 |
WF/Mol |
body weight |
vehicle control condition then artificial aortocaval fistula (for 4 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 7 |
|
|
186.0 |
g |
2.0 |
5.29 |
body weighing method |
0.0 |
acf |
4 |
days |
|
|
|
|
101302 |
2585 |
WF/Mol |
body weight |
controlled losartan content drinking water (10 mg/kg/d) (for 3 days) then sham surgical control condition (for 2 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 6 |
|
|
190.0 |
g |
5.0 |
12.25 |
body weighing method |
0.0 |
sham acf |
2 |
days |
|
|
|
|
101311 |
2585 |
WF/Mol |
body weight |
controlled losartan content drinking water (10 mg/kg/d) (for 3 days) then artificial aortocaval fistula (for 2 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 8 |
|
|
189.0 |
g |
2.0 |
5.66 |
body weighing method |
0.0 |
acf |
2 |
days |
|
|
|
|
101310 |
2585 |
WF/Mol |
body weight |
controlled losartan content drinking water (10 mg/kg/d) (for 5 days) then artificial aortocaval fistula (for 4 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 8 |
|
|
187.0 |
g |
1.0 |
2.83 |
body weighing method |
0.0 |
acf |
4 |
days |
|
|
|
|
101314 |
2585 |
WF/Mol |
body weight |
vehicle control condition then artificial aortocaval fistula (for 4 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 8 |
|
|
194.0 |
g |
3.0 |
8.49 |
body weighing method |
0.0 |
acf |
4 |
days |
|
|
|
|
101316 |
2585 |
WF/Mol |
body weight gain |
vehicle control condition then artificial aortocaval fistula (for 4 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 7 |
|
|
-10.0 |
g |
3.0 |
7.94 |
body weighing method |
0.0 |
acf |
4 |
days |
|
change from surgery weight |
|
|
101324 |
2585 |
WF/Mol |
body weight gain |
controlled losartan content drinking water (10 mg/kg/d) (for 8 days) then artificial aortocaval fistula (for 7 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 7 |
|
|
3.0 |
g |
6.0 |
15.87 |
body weighing method |
0.0 |
acf |
7 |
days |
|
change from surgery weight |
|
|
101340 |
2585 |
SS.ZUC-Leprfa+/+/Slc |
body weight |
bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
body mass |
female |
91 days
| 9 |
|
|
294.0 |
g |
6.0 |
18.0 |
body weighing method |
0.0 |
ovariectomy |
42 |
days |
|
|
|
|
101661 |
2622 |
SS/Hsd |
body weight gain |
aldosterone (22.5 ng/hr) (for 14 days) and artificial cerebrospinal fluid with 0.15 M sodium (4.4-4.6 ul/hr) (for 14 days) |
Huang BS, et al., Am J Physiol Heart Circ Physiol. 2005 Feb;288(2):H517-24. doi: 10.1152/ajpheart.00651.2004. Epub 2004 Sep 30. |
body mass |
male |
52 days-61 days |
0 |
|
|
61.0 |
g |
6.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
change from surgery weight (2wks) |
|
|
103217 |
2801 |
WKY |
body weight |
unilateral nephrectomy (for 28 days) then vehicle control condition |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
body mass |
male |
0 days
| 7 |
|
|
268.0 |
g |
13.0 |
34.39 |
body weighing method |
0.0 |
unx |
28 |
days |
|
|
|
|
99935 |
2378 |
WKY |
body weight |
unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) and bosentan (100 mg/kg/d) (for 14 days) |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
body mass |
male |
0 days
| 6 |
|
|
229.0 |
g |
6.0 |
14.7 |
body weighing method |
0.0 |
unx |
28 |
days |
|
|
|
|
99939 |
2378 |
SS/NEisSlc |
body weight |
controlled sodium content diet (8 %) (for 42 days) then candesartan (1 mg/kg/d) (for 42 days) |
Otsuka F, et al., Am J Physiol. 1998 Jun;274(6 Pt 2):R1797-806. |
body mass |
male |
91 days
| 6 |
|
|
343.8 |
g |
10.05 |
24.62 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
100700 |
2519 |
MW |
body weight |
right nephrectomy (for 112 days) then captopril (30 mg/kg/d) (for 56 days) |
Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55. |
body mass |
male |
0 days
| 10 |
|
|
320.6 |
g |
15.0 |
47.43 |
body weighing method |
0.0 |
~5/6 to 7/8 nephrectomy |
112 |
days |
|
|
|
|
100829 |
2523 |
WI |
body weight |
swimming with water weights (for 1 hours) |
Ma Z, et al., Eur J Appl Physiol. 2013 Oct;113(10):2473-86. doi: 10.1007/s00421-013-2685-9. Epub 2013 Jun 28. |
body mass |
female |
0 days
| 16 |
|
|
267.2 |
g |
3.35 |
13.4 |
body weighing method |
1.0 |
swim |
1 |
days |
following 8 wk protocol |
|
|
|
98747 |
2159 |
SS-Chr 13BN/Mcwi |
body weight |
control condition |
Stodola TJ, et al., Physiol Genomics. 2011 Jul 14;43(13):808-17. doi: 10.1152/physiolgenomics.00171.2010. Epub 2011 Apr 26. |
body mass |
male |
49 days-63 days |
15 |
|
|
294.8 |
g |
8.3 |
32.15 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99005 |
2198 |
BN-Chr 13SS/Mcwi |
body weight |
control condition |
Stodola TJ, et al., Physiol Genomics. 2011 Jul 14;43(13):808-17. doi: 10.1152/physiolgenomics.00171.2010. Epub 2011 Apr 26. |
body mass |
male |
49 days-63 days |
12 |
|
|
215.3 |
g |
6.9 |
23.9 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99007 |
2198 |
WI |
body weight |
controlled in utero environment (for 21 days) and standard diet (50 % of calories) (for 21 days) |
Ceravolo GS, et al., Life Sci. 2007 Jan 30;80(8):782-7. Epub 2006 Nov 10. |
body mass |
male |
1 days
| 35 |
|
|
4.7 |
g |
0.07 |
0.41 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
101052 |
2563 |
SD |
body weight |
sham surgical control condition (for 6 hours) |
Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. |
body mass |
male |
0 days
| 6 |
|
|
291.0 |
g |
10.0 |
24.49 |
body weighing method |
1.0 |
sham ACF |
360 |
min |
|
|
|
|
98756 |
2160 |
SS.ZUC-Leprfa-/-/Slc |
body weight |
control condition |
Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. |
body mass |
male |
126 days
| 7 |
|
|
536.92 |
g |
6.98 |
18.47 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
101886 |
2642 |
F344-Hsd11b2em1Jmul+/+ |
body weight |
standard rat chow |
Mullins LJ, et al., Hypertension. 2015 Sep;66(3):667-73. doi: 10.1161/HYPERTENSIONAHA.115.05262. Epub 2015 Jun 15. |
body mass |
female |
98 days
| 4 |
|
|
190.5 |
g |
2.5 |
5.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
104992 |
3008 |
F344-Hsd11b2em1Jmul+/+ |
body weight |
standard rat chow |
Mullins LJ, et al., Hypertension. 2015 Sep;66(3):667-73. doi: 10.1161/HYPERTENSIONAHA.115.05262. Epub 2015 Jun 15. |
body mass |
male |
98 days
| 9 |
|
|
319.8 |
g |
6.1 |
18.3 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
104990 |
3008 |
MNS |
body weight |
control condition |
Pugliese G, et al., Kidney Int. 2005 Apr;67(4):1440-52. doi: 10.1111/j.1523-1755.2005.00221.x. |
body mass |
male |
168 days
| 8 |
|
|
470.0 |
g |
10.25 |
29.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
104064 |
2907 |
MHS |
body weight |
streptozotocin (55 mg/kg) then insulin (4 IU/kg) (for 84 days) |
Pugliese G, et al., Kidney Int. 2005 Apr;67(4):1440-52. doi: 10.1111/j.1523-1755.2005.00221.x. |
body mass |
male |
168 days
| 9 |
|
|
364.0 |
g |
13.67 |
41.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
104067 |
2907 |
SS-Kcnj1em1Kasu+/- |
body weight |
control condition (for 13 days) |
Zhou X, et al., Hypertension. 2013 Aug;62(2):288-94. doi: 10.1161/HYPERTENSIONAHA.111.01051. Epub 2013 Jun 10. |
body mass |
male |
13 days
| 6 |
|
|
26.6 |
g |
1.4 |
3.43 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
104416 |
2948 |
SS-Sod3m1Mcwi |
body weight |
vehicle control condition |
Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. |
body mass |
male |
56 days
| 10 |
|
|
259.0 |
g |
2.8 |
8.85 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
106551 |
3032 |
SS-Plekha7em4Mcwi-/- |
body weight |
controlled sodium content diet (0.4 %) (for 42 days) |
Endres BT, et al., Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):12817-22. doi: 10.1073/pnas.1410745111. Epub 2014 Aug 18. |
body mass |
male |
63 days
| 10 |
|
|
264.0 |
g |
9.0 |
28.46 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
105737 |
3022 |
SS-Plekha7em4Mcwi-/- |
body weight |
controlled sodium content diet (8 %) (for 28 days) |
Endres BT, et al., Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):12817-22. doi: 10.1073/pnas.1410745111. Epub 2014 Aug 18. |
body mass |
male |
91 days
| 10 |
|
|
279.0 |
g |
4.0 |
12.65 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
105743 |
3022 |
SD-Ahrem2Sage |
body weight |
control condition (for 84 days) |
Harrill JA, et al., Toxicol Appl Pharmacol. 2013 Oct 15;272(2):503-18. doi: 10.1016/j.taap.2013.06.024. Epub 2013 Jul 13. |
body mass |
male |
84 days
| 5 |
|
|
380.5 |
g |
12.6 |
28.17 |
body weighing method |
|
|
0 |
|
|
|
|
|
106439 |
3025 |
MWF/Ztm |
body weight |
standard diet |
Remuzzi A, etal., Kidney Int. 1988 Oct;34(4):481-6. doi: 10.1038/ki.1988.206. |
body mass |
male |
105 days-147 days |
8 |
|
|
317.0 |
g |
18.74 |
53.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109197 |
3138 |
LOU/M |
body weight |
control condition |
van Hoesel QG, etal., J Natl Cancer Inst. 1986 Feb;76(2):299-307. |
body mass |
male |
84 days
| 43 |
|
|
259.0 |
g |
3.2 |
21.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109289 |
3144 |
LOU/M |
body weight |
control condition |
van Hoesel QG, etal., J Natl Cancer Inst. 1986 Feb;76(2):299-307. |
body mass |
female |
84 days
| 43 |
|
|
162.0 |
g |
1.83 |
12.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109290 |
3144 |
MWF/FubRkb |
body weight |
finerenone (10 mg/kg/d) (for 28 days) |
Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275. |
body mass |
male |
112 days
| 10 |
|
|
350.3 |
g |
9.0 |
28.46 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109390 |
3140 |
BDIX/Orl |
body weight |
azoxymethane (15 mg/kg) |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
female |
119 days-0 days |
8 |
|
|
232.0 |
g |
3.15 |
8.9 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
107002 |
3074 |
BDIX/Orl |
body weight |
0.9% sodium chloride solution (1 ml) |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
female |
98 days-0 days |
2 |
|
|
231.0 |
g |
7.5 |
10.6 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
107011 |
3074 |
MWF-Chr 6SHR/Rkb |
fetal body weight |
control condition |
Schulte L, etal., J Hypertens. 2012 Oct;30(10):2031-8. doi: 10.1097/HJH.0b013e328356a60a. |
body mass |
not specified |
-6 days
| 12 |
|
|
0.27 |
g |
0.01 |
0.02 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109505 |
3145 |
LOU/MWsl |
change in body weight to initial body weight ratio |
rat IgM immunocytoma cells (1 x 10E4 cells) then negatively charged liposome-entrapped doxorubicin (1 mg/kg) (for 10 days) |
van Hoesel QG, etal., Cancer Res. 1984 Sep;44(9):3698-705. |
body mass |
male |
105 days-115 days |
6 |
|
|
-4.1 |
% |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109576 |
3150 |
LOU/MWsl |
change in body weight to initial body weight ratio |
rat IgM immunocytoma cells (1 x 10E4 cells) then negatively charged liposome-entrapped doxorubicin (2 mg/kg) (for 14 days) |
van Hoesel QG, etal., Cancer Res. 1984 Sep;44(9):3698-705. |
body mass |
male |
105 days-119 days |
6 |
|
|
-10.0 |
% |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109580 |
3150 |
MWF/Hsd |
body weight |
control condition |
Ulu N, etal., Am J Nephrol. 2009;30(3):209-17. doi: 10.1159/000218062. Epub 2009 May 5. |
body mass |
male |
182 days
| 12 |
|
|
375.0 |
g |
7.0 |
24.25 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109756 |
3153 |
BDIX/Orl |
body weight |
azoxymethane (15 mg/kg) |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
female |
98 days-0 days |
4 |
|
|
210.0 |
g |
3.05 |
6.1 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
107005 |
3074 |
MWF/Hsd |
body weight |
control condition |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
body mass |
male |
88 days-94 days |
10 |
|
|
276.0 |
g |
5.0 |
15.81 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
107357 |
3077 |
WKY/N |
body weight |
control condition (for 42 days) |
Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. |
body mass |
male |
126 days-147 days |
0 |
|
|
309.0 |
g |
8.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
107525 |
3090 |
SHRSP/A3N |
body weight |
reproduction condition |
Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. |
body mass |
male |
120 days-140 days |
10 |
|
|
254.0 |
g |
11.0 |
34.79 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
107573 |
3093 |
W/Jpe |
body weight gain |
control condition |
Sena CM, etal., Br J Pharmacol. 2008 Mar;153(5):894-906. doi: 10.1038/sj.bjp.0707474. Epub 2007 Oct 1. |
body mass |
male |
450 days-540 days |
20 |
|
|
2.4 |
g |
0.8 |
3.58 |
body weighing method |
0.0 |
|
0 |
|
|
wistar |
|
|
107999 |
3108 |
GK/Jpe |
body weight gain |
controlled cholesterol content diet (1.25 %) (for 90 days) and controlled cocoa butter content diet (7.5 %) (for 90 days) then soybean oil (2 ml/kg) (for 90 days) |
Sena CM, etal., Br J Pharmacol. 2008 Mar;153(5):894-906. doi: 10.1038/sj.bjp.0707474. Epub 2007 Oct 1. |
body mass |
male |
450 days-540 days |
10 |
|
|
50.1 |
g |
6.4 |
20.24 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108002 |
3108 |
MWF/FubRkb |
neonatal body weight |
control condition |
Rothermund L, etal., J Hypertens. 2006 Sep 24(9). |
body mass |
not specified |
1 days
| 0 |
|
|
6.12 |
g |
0.8 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108077 |
3115 |
MWF/FubRkb |
body weight |
control condition |
Rothermund L, etal., J Hypertens. 2006 Sep 24(9). |
body mass |
not specified |
100 days
| 0 |
|
|
334.0 |
g |
6.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108083 |
3115 |
GK |
body weight |
control condition |
Weng S, etal., Obes Surg. 2017 Mar;27(3):657-664. doi: 10.1007/s11695-016-2320-z. |
body mass |
male |
77 days
| 10 |
|
|
301.31 |
g |
6.99 |
22.1 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109071 |
3111 |
PVG/OlaHsd |
volume of blood removed to total prehemorrhagic blood volume ratio |
arterial catheter implantation (for 1 days) then controlled hemorrhage (for 0.4 hours) |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
blood amount |
male |
89 days-95 days |
10 |
5.83 mL/100 g of body weight |
|
58.3 |
% |
0.5 |
1.58 |
body weighing method |
0.0 |
|
0 |
|
|
volume of blood removed to total prehemorrhagic blood volume ratio (CMO:0003663) |
|
|
109128 |
3077 |
WKY |
body weight |
unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 136 days) |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
body mass |
male |
0 days
| 17 |
|
|
274.0 |
g |
6.0 |
24.74 |
body weighing method |
0.0 |
unx |
150 |
days |
|
|
|
|
107447 |
2378 |
Crlj:WI |
body weight |
fasting (for 16 hours) |
Ohta T, et al., Br J Pharmacol. 1999 Apr;126(7):1674-80. doi: 10.1038/sj.bjp.0702481. |
body mass |
male |
56 days
| 5 |
|
|
238.0 |
g |
2.5 |
5.59 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110766 |
3185 |
SHR/FubRkb |
body weight |
sham surgical control condition (for 126 days) |
Schulz A, etal., Physiol Genomics. 2012 Jan 18;44(1):110-6. Epub 2011 Nov 22. |
body mass |
male |
168 days
| 9 |
|
|
329.2 |
g |
8.2 |
24.6 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109549 |
3148 |
SD |
body weight |
control condition |
Eisenberger U, etal., Ren Physiol Biochem. 1995 Mar-Apr;18(2):89-96. doi: 10.1159/000173904. |
body mass |
female |
96 days-121 days |
7 |
|
|
201.0 |
g |
4.91 |
13.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110176 |
3166 |
MWF |
body weight |
doxorubicin (5 mg/kg) (between 6 and 7 days) |
Eisenberger U, etal., Ren Physiol Biochem. 1995 Mar-Apr;18(2):89-96. doi: 10.1159/000173904. |
body mass |
female |
96 days-121 days |
11 |
|
|
182.0 |
g |
4.82 |
16.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110179 |
3166 |
SD |
body weight |
doxorubicin (5 mg/kg) (between 6 and 7 days) |
Eisenberger U, etal., Ren Physiol Biochem. 1995 Mar-Apr;18(2):89-96. doi: 10.1159/000173904. |
body mass |
female |
96 days-121 days |
7 |
|
|
192.0 |
g |
2.65 |
7.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110178 |
3166 |
MWF/Ztm |
body weight |
standard diet |
Remuzzi A, etal., Am J Kidney Dis. 1999 Oct;34(4):626-32. doi: 10.1016/S0272-6386(99)70385-9. |
body mass |
male |
210 days
| 10 |
|
|
423.0 |
g |
5.38 |
17.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109975 |
3162 |
MWF/Ztm |
body weight |
controlled lisinopril content drinking water (50 mg/l) (for 70 days) |
Remuzzi A, etal., Am J Kidney Dis. 1999 Oct;34(4):626-32. doi: 10.1016/S0272-6386(99)70385-9. |
body mass |
male |
210 days
| 7 |
|
|
417.0 |
g |
12.85 |
34.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109976 |
3162 |
MWF/Ztm |
body weight |
control condition |
Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882. |
body mass |
male |
100 days
| 5 |
|
|
311.7 |
g |
18.02 |
40.3 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109298 |
3137 |
BN/Crl |
maximum body weight loss to initial body weight ratio |
arterial catheter implantation (for 1 days) |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
body mass |
male |
89 days-95 days |
10 |
|
|
3.6 |
% |
0.7 |
2.21 |
body weighing method |
0.0 |
arterial catheter implantation |
1 |
days |
|
|
|
|
107185 |
3077 |
Crl:SD |
maximum body weight loss to initial body weight ratio |
arterial catheter implantation (for 1 days) |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
body mass |
male |
89 days-95 days |
11 |
|
|
3.3 |
% |
0.6 |
1.99 |
body weighing method |
0.0 |
arterial catheter implantation |
1 |
days |
|
|
|
|
107186 |
3077 |
Crl:WI |
body weight |
control condition |
El-Omar MM, et al., Basic Res Cardiol. 2004 Mar;99(2):133-41. doi: 10.1007/s00395-004-0440-4. Epub 2003 Oct 7. |
body mass |
male |
150 days-240 days |
6 |
|
|
559.5 |
g |
18.5 |
45.32 |
body weighing method |
0.0 |
|
0 |
|
|
at least 6 animals |
|
|
110439 |
3174 |
W/Kyo |
body weight |
control condition |
Kondo H, etal., Muscle Nerve. 2015 Mar;51(3):391-9. doi: 10.1002/mus.24316. Epub 2015 Jan 6. |
body mass |
male |
63 days
| 6 |
|
|
219.0 |
g |
2.0 |
4.9 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108038 |
3110 |
GK |
body weight |
running on treadmill (15 m/min) (for 1 hours) |
Kondo H, etal., Muscle Nerve. 2015 Mar;51(3):391-9. doi: 10.1002/mus.24316. Epub 2015 Jan 6. |
body mass |
male |
63 days
| 6 |
|
|
223.0 |
g |
5.0 |
12.25 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108041 |
3110 |
W/Kyo |
body weight |
running on treadmill (15 m/min) (for 1 hours) |
Kondo H, etal., Muscle Nerve. 2015 Mar;51(3):391-9. doi: 10.1002/mus.24316. Epub 2015 Jan 6. |
body mass |
male |
63 days
| 6 |
|
|
194.0 |
g |
3.0 |
7.35 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108039 |
3110 |
GK |
body weight |
control condition |
Kondo H, etal., Muscle Nerve. 2015 Mar;51(3):391-9. doi: 10.1002/mus.24316. Epub 2015 Jan 6. |
body mass |
male |
63 days
| 6 |
|
|
240.0 |
g |
6.0 |
14.7 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108040 |
3110 |
WM/Nem |
fetal body weight |
trypan blue (20 mg/kg) |
Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. |
body mass |
male |
-1 days
| 36 |
|
|
2.83 |
g |
0.02 |
0.14 |
body weighing method |
0.0 |
|
12 |
days |
|
|
|
|
111216 |
3199 |
SR/Hsd |
maximum body weight loss to initial body weight ratio |
arterial catheter implantation (for 1 days) |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
body mass |
male |
89 days-95 days |
10 |
|
|
2.2 |
% |
0.7 |
2.21 |
body weighing method |
0.0 |
arterial catheter implantation |
1 |
days |
|
|
|
|
107181 |
3077 |
LEW/SsNHsd |
maximum body weight loss to initial body weight ratio |
arterial catheter implantation (for 1 days) |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
body mass |
male |
89 days-95 days |
9 |
|
|
5.0 |
% |
0.7 |
2.1 |
body weighing method |
0.0 |
arterial catheter implantation |
1 |
days |
|
|
|
|
107178 |
3077 |
MWF/FubRkb |
body weight |
control condition |
Ijpelaar DH, etal., Am J Physiol Renal Physiol. 2008 Apr;294(4):F758-67. Epub 2008 Jan 16. |
body mass |
male |
30 days
| 5 |
|
|
98.42 |
g |
0.88 |
1.96 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109703 |
3152 |
MWF/FubRkb |
body weight |
control condition |
Ijpelaar DH, etal., Am J Physiol Renal Physiol. 2008 Apr;294(4):F758-67. Epub 2008 Jan 16. |
body mass |
male |
44 days
| 5 |
|
|
203.06 |
g |
10.29 |
23.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109705 |
3152 |
MWF/FubRkb |
body weight |
control condition |
Ijpelaar DH, etal., Am J Physiol Renal Physiol. 2008 Apr;294(4):F758-67. Epub 2008 Jan 16. |
body mass |
female |
44 days
| 5 |
|
|
145.2 |
g |
2.44 |
5.45 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109706 |
3152 |
MWF/FubRkb |
body weight |
control condition |
Ijpelaar DH, etal., Am J Physiol Renal Physiol. 2008 Apr;294(4):F758-67. Epub 2008 Jan 16. |
body mass |
female |
58 days
| 5 |
|
|
164.3 |
g |
5.56 |
12.44 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109708 |
3152 |
MWF/FubRkb |
fetal body weight |
control condition |
Rothermund L, etal., J Hypertens. 2006 Sep 24(9). |
body mass |
not specified |
-6 days
| 0 |
|
|
0.24 |
g |
0.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108067 |
3115 |
MWF/Hsd |
body weight |
sham surgical control condition |
Szymanski MK, etal., Basic Res Cardiol. 2012 Mar;107(2):242. doi: 10.1007/s00395-011-0242-4. Epub 2012 Jan 19. |
body mass |
male |
175 days
| 9 |
|
|
340.0 |
g |
9.0 |
27.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108788 |
3130 |
GK/MolTac |
body weight |
control condition |
Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. |
body mass |
male |
112 days
| 8 |
|
|
337.1 |
g |
9.3 |
26.3 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110732 |
3183 |
GK/MolTac |
body weight |
control condition |
Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. |
body mass |
male |
112 days
| 10 |
|
|
352.4 |
g |
6.5 |
20.55 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110733 |
3183 |
BDIX/Orl |
body weight |
control condition |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
female |
84 days
| 2 |
|
|
207.0 |
g |
0.0 |
15.6 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
106977 |
3074 |
F344/NHsd |
body weight |
azoxymethane (15 mg/kg) |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
female |
63 days
| 8 |
|
|
161.0 |
g |
2.37 |
6.7 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
106988 |
3074 |
F344/NHsd |
body weight |
azoxymethane (15 mg/kg) |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
male |
56 days
| 4 |
|
|
197.0 |
g |
5.15 |
10.3 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
106993 |
3074 |
SHR/FubRkb |
body weight |
control condition |
Steireif C, etal., J Hypertens. 2013 Nov;31(11):2203-12; discussion 2212. doi: 10.1097/HJH.0b013e3283642384. |
body mass |
male |
84 days
| 10 |
|
|
287.2 |
g |
9.3 |
29.41 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109273 |
3141 |
WM/Nem |
fetal body weight |
trypan blue (60 mg/kg) |
Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. |
body mass |
female |
-1 days
| 36 |
|
|
2.45 |
g |
0.03 |
0.15 |
body weighing method |
0.0 |
|
12 |
days |
|
|
|
|
111228 |
3199 |
WM/Nem |
fetal body weight |
control condition |
Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. |
body mass |
female |
-1 days
| 57 |
|
|
2.76 |
g |
0.03 |
0.21 |
body weighing method |
0.0 |
|
12 |
days |
|
|
|
|
111224 |
3199 |
WAG/Rij |
body weight |
azoxymethane (15 mg/kg) |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
female |
98 days-0 days |
8 |
|
|
198.0 |
g |
2.76 |
7.8 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
107003 |
3074 |
BDIX/Orl |
body weight |
azoxymethane (15 mg/kg) |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
male |
98 days-0 days |
4 |
|
|
361.0 |
g |
8.8 |
17.6 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
107006 |
3074 |
T2DN/Mcwi |
body weight |
control condition |
Nobrega MA, et al., Diabetes 2004 Mar;53(3):735-42. |
body mass |
male |
180 days
| 6 |
|
|
375.0 |
g |
15.0 |
36.74 |
body weighing method |
0.0 |
|
0 |
|
|
n=6-27 |
|
|
110592 |
3177 |
T2DN/Mcwi |
body weight |
control condition |
Nobrega MA, et al., Diabetes 2004 Mar;53(3):735-42. |
body mass |
male |
360 days
| 6 |
|
|
424.0 |
g |
17.0 |
41.64 |
body weighing method |
0.0 |
|
0 |
|
|
n=6-27 |
|
|
110595 |
3177 |
BN/NHsdMcwi |
body weight |
control condition |
Nobrega MA, et al., Diabetes 2004 Mar;53(3):735-42. |
body mass |
male |
360 days
| 6 |
|
|
432.0 |
g |
18.0 |
44.09 |
body weighing method |
0.0 |
|
0 |
|
|
n=6-27 |
|
|
110593 |
3177 |
HanTac:WH |
body weight |
control IgG monoclonal antibody (1 mg) (for 14 days) |
Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. |
body mass |
female |
70 days
| 8 |
|
|
203.0 |
g |
7.0 |
19.8 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110245 |
3168 |
GK/MolTac |
body weight |
anti-rh-VEGF165 monoclonal antibody (1 mg) (for 28 days) |
Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. |
body mass |
female |
84 days
| 10 |
|
|
235.0 |
g |
5.0 |
15.81 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110252 |
3168 |
HanTac:WH |
body weight |
control IgG monoclonal antibody (1 mg) (for 42 days) |
Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. |
body mass |
female |
98 days
| 8 |
|
|
227.0 |
g |
7.0 |
19.8 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110253 |
3168 |
WAG |
body weight |
control condition |
Pross M, et al., Surg Endosc. 2001 Aug;15(8):882-5. doi: 10.1007/s004640090029. Epub 2001 May 2. |
body mass |
male |
0 days
| 16 |
|
|
263.0 |
g |
2.2 |
8.8 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
107870 |
3098 |
WAG |
body weight |
control condition |
Pross M, et al., Surg Endosc. 2001 Aug;15(8):882-5. doi: 10.1007/s004640090029. Epub 2001 May 2. |
body mass |
male |
0 days
| 16 |
|
|
271.9 |
g |
1.78 |
7.1 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
107871 |
3098 |
MWF-Chr 8SHR/Rkb |
body weight |
control condition |
Schulz A, etal., Physiol Genomics. 2008 Sep 17;35(1):30-5. Epub 2008 Jul 22. |
body mass |
female |
168 days
| 20 |
|
|
204.4 |
g |
2.4 |
10.73 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108919 |
3133 |
MWF/FubRkb |
fetal body weight |
control condition |
Rothermund L, etal., J Hypertens. 2006 Sep 24(9). |
body mass |
not specified |
-4 days
| 0 |
|
|
0.62 |
g |
0.01 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108068 |
3115 |
SD-Myh7bem1Blar-/- |
body weight |
control condition |
Chen P, etal., Sci China Life Sci. 2020 Sep;63(9):1347-1362. doi: 10.1007/s11427-019-1627-y. Epub 2020 Mar 17. |
body mass |
not specified |
84 days
| 0 |
|
|
244.6 |
g |
28.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110826 |
3192 |
SD-Myh7bem1Blar+/- |
body weight |
control condition |
Chen P, etal., Sci China Life Sci. 2020 Sep;63(9):1347-1362. doi: 10.1007/s11427-019-1627-y. Epub 2020 Mar 17. |
body mass |
not specified |
84 days
| 0 |
|
|
292.65 |
g |
16.8 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110825 |
3192 |
WKY/NCrl |
body weight |
standard condition (for 126 days) |
Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. |
body mass |
male |
203 days-224 days |
10 |
|
|
409.0 |
g |
7.0 |
22.14 |
body weighing method |
0.0 |
|
0 |
|
|
standard rat chow |
|
|
107108 |
3075 |
LEW/Mol |
body weight |
standard diet |
Kreutz R, etal., J Hypertens. 2000 Jun;18(6):777-82. doi: 10.1097/00004872-200018060-00017. |
body mass |
male |
104 days
| 8 |
|
|
280.0 |
g |
8.5 |
24.04 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108997 |
3134 |
LEW/Mol |
body weight |
controlled sodium chloride content diet (8 %) (for 56 days) |
Kreutz R, etal., J Hypertens. 2000 Jun;18(6):777-82. doi: 10.1097/00004872-200018060-00017. |
body mass |
male |
104 days
| 8 |
|
|
287.0 |
g |
3.6 |
10.18 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108999 |
3134 |
BDIX/OrlCrl |
body weight |
control condition |
Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. |
body mass |
male |
0 days
| 5 |
|
|
201.0 |
g |
7.6 |
17.0 |
body weighing method |
0.0 |
|
0 |
|
|
baseline group 1 |
|
|
111024 |
3195 |
BDIX/OrlCrl |
body weight |
control condition |
Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. |
body mass |
male |
0 days
| 5 |
|
|
195.0 |
g |
5.81 |
13.0 |
body weighing method |
0.0 |
|
0 |
|
|
baseline group 3 |
|
|
111026 |
3195 |
WM/Nem |
fetal body weight |
trypan blue (60 mg/kg) |
Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. |
body mass |
male |
-1 days
| 38 |
|
|
2.59 |
g |
0.04 |
0.26 |
body weighing method |
0.0 |
|
12 |
days |
|
|
|
|
111219 |
3199 |
BDIX/Nem |
fetal body weight |
trypan blue (120 mg/kg) |
Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. |
body mass |
male |
-1 days
| 31 |
|
|
2.69 |
g |
0.06 |
0.33 |
body weighing method |
0.0 |
|
12 |
days |
|
|
|
|
111223 |
3199 |
MWF |
body weight |
cyclosporine A (50 mg/kg/d) (for 7 days) and lacidipine (1 mg/kg/d) (for 7 days) |
Fassi A, etal., Am J Kidney Dis. 1999 Feb;33(2):267-75. doi: 10.1016/s0272-6386(99)70299-4. |
body mass |
male |
132 days-146 days |
7 |
|
|
381.0 |
g |
5.67 |
15.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110002 |
3163 |
BN/SsNHsd |
nose to tail body mass index |
control condition |
Keele GR, etal., Obesity (Silver Spring). 2018 Jan;26(1):213-222. doi: 10.1002/oby.22075. Epub 2017 Nov 28. |
body mass |
male |
119 days
| 10 |
|
|
2.18 |
(g/cm2) x 10 |
0.04 |
0.14 |
body weighing method |
|
|
0 |
|
|
|
|
|
138390 |
3200 |
BUF/NHsd |
nose to rump body mass index |
control condition |
Keele GR, etal., Obesity (Silver Spring). 2018 Jan;26(1):213-222. doi: 10.1002/oby.22075. Epub 2017 Nov 28. |
body mass |
male |
119 days
| 8 |
|
|
9.05 |
(g/cm2) x 10 |
0.55 |
1.56 |
body weighing method |
|
|
0 |
|
|
|
|
|
138394 |
3200 |
BUF/NHsd |
nose to tail body mass index |
control condition |
Keele GR, etal., Obesity (Silver Spring). 2018 Jan;26(1):213-222. doi: 10.1002/oby.22075. Epub 2017 Nov 28. |
body mass |
male |
119 days
| 8 |
|
|
3.15 |
(g/cm2) x 10 |
0.33 |
0.93 |
body weighing method |
|
|
0 |
|
|
|
|
|
138395 |
3200 |
NMcwi:HS |
nose to rump body mass index |
control condition |
Keele GR, etal., Obesity (Silver Spring). 2018 Jan;26(1):213-222. doi: 10.1002/oby.22075. Epub 2017 Nov 28. |
body mass |
male |
119 days
| 740 |
|
|
8.04 |
(g/cm2) x 10 |
0.03 |
0.93 |
body weighing method |
|
|
0 |
|
|
|
|
|
138409 |
3200 |
Crl:LE |
body weight |
control condition |
Ness D, et al., PLoS One. 2013 Jun 14;8(6):e66164. doi: 10.1371/journal.pone.0066164. Print 2013. |
body mass |
male |
28 days
| 0 |
|
|
74.2 |
g |
|
2.4 |
body weighing method |
|
|
0 |
|
|
|
|
|
138267 |
2947 |
SD-Apoeem1Sage |
body weight |
removal of maxillary molar crown (for 56 days) |
Ekuni D, et al., Lipids Health Dis. 2014 Sep 5;13:144. doi: 10.1186/1476-511X-13-144. |
body mass |
male |
56 days
| 7 |
|
|
410.0 |
g |
10.92 |
28.9 |
body weighing method |
|
|
0 |
|
|
|
|
|
138266 |
2968 |
SS.SHR-(D9Rat7-D9Mco91)/Mco |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 25 and 28 days) |
Kumarasamy S, et al., Hypertens Res. 2011 Dec;34(12):1263-70. doi: 10.1038/hr.2011.116. Epub 2011 Aug 4. |
body mass |
not specified |
0 days
| 0 |
|
|
367.0 |
g |
3.77 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67541 |
749 |
F344.OLETF-(D1Mit20-D1Mgh26)/2Tj |
body weight |
fasting (for 16 hours) |
Kose H, et al., Mamm Genome 2002 Oct;13(10):558-62. |
body mass |
male |
210 days
| 15 |
|
|
368.4 |
g |
3.8 |
14.72 |
body weighing method |
|
|
0 |
|
|
|
|
|
12019 |
230 |
SS.MNS-(D2Chm25-Fgg)/Ayd |
body weight |
controlled sodium content diet (2 %) (between 35 and 98 days) |
Duong C, et al., Mamm Genome 2006; 17(12): 1147-1161 |
body mass |
male |
98 days
| 9 |
|
|
396.0 |
g |
5.0 |
15.0 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12035 |
226 |
SS.LEW-(D3Mco21-D3Rat17)/Ayd |
body weight |
controlled sodium content diet (2 %) (between 35 and 98 days) |
Duong C, et al., Mamm Genome 2006; 17(12): 1147-1161 |
body mass |
male |
98 days
| 4 |
|
|
401.0 |
g |
9.0 |
18.0 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12041 |
226 |
SS.LEW-(D8Chm14-D8Rat16)/Ayd |
body weight |
controlled sodium content diet (2 %) (between 35 and 98 days) |
Duong C, et al., Mamm Genome 2006; 17(12): 1147-1161 |
body mass |
male |
98 days
| 7 |
|
|
399.0 |
g |
5.0 |
13.23 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12049 |
226 |
SS.LEW-(D10Rat24-Igfbp4)/Ayd |
body weight |
controlled sodium content diet (2 %) (between 35 and 98 days) |
Duong C, et al., Mamm Genome 2006; 17(12): 1147-1161 |
body mass |
male |
98 days
| 5 |
|
|
374.0 |
g |
14.0 |
31.3 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12059 |
226 |
SS.LEW-(D18Chm56-D18Rat55)/Ayd |
body weight |
controlled sodium content diet (2 %) (between 35 and 98 days) |
Duong C, et al., Mamm Genome 2006; 17(12): 1147-1161 |
body mass |
male |
98 days
| 5 |
|
|
351.0 |
g |
14.0 |
31.3 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12078 |
226 |
SS/Jr |
body weight |
controlled sodium content diet (2 %) (for 24 days) |
Saad Y, et al., Mamm Genome. 2008 Jan 4 |
body mass |
male |
64 days-68 days |
20 |
|
|
306.0 |
g |
3.09 |
13.82 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12144 |
232 |
SHR.BN-(D5Wox12-D5Wox20)/Ipcv |
body weight |
control condition |
Pravenec M, et al., Physiol Res 2003;52(3):285-9. |
body mass |
male |
80 days-100 days |
8 |
|
|
325.5 |
g |
8.8 |
24.89 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
65506 |
612 |
SR/Jr |
body weight |
controlled sodium content diet (0.2 %) (for 168 days) |
Garrett MR, et al., Genome Res 1998 Jul;8(7):711-23 |
body mass |
male |
203 days
| 10 |
|
|
422.0 |
g |
5.4 |
17.08 |
body weighing method |
0 |
|
0 |
|
|
|
|
4 rats per cage, 2 SR/Jr 2 LEW/NCrl |
64709 |
222 |
SS/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 28 days) then controlled sodium content diet (4 %) (between 46 and 48 days) |
Cicila GT, et al., Hypertension. 2009 Apr;53(4):725-32. Epub 2009 Mar 2. |
body mass |
male |
114 days-118 days |
4 |
|
|
357.0 |
g |
26.0 |
52.0 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65096 |
283 |
SS.LEW-(D1Uia8-D1Mco38)/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 28 days) |
Saad Y, et al., Physiol Genomics 2001 Jan 19;4(3):201-14. |
body mass |
male |
68 days-70 days |
20 |
|
|
296.0 |
g |
2.14 |
9.57 |
body weighing method |
|
|
0 |
|
|
|
|
|
12503 |
266 |
BB/OK |
body weight |
control condition |
Kovacs P, et al., Mamm Genome 1998 Apr;9(4):294-6. |
body mass |
female |
98 days
| 21 |
|
|
214.0 |
g |
5.24 |
24.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
12916 |
322 |
F344/DuCrlCrlj |
body weight |
control condition (for 185 days) |
Galli J, et al., Diabetes 1999 Dec;48(12):2463-70. |
body mass |
male |
185 days
| 9 |
|
|
365.0 |
g |
9.0 |
27.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
11486 |
85 |
F344/NHsd |
body weight |
control condition |
Zhao L et al., 2001, Circulation, 103(3), 442-7 |
body mass |
male |
105 days
| 12 |
|
median |
290.0 |
g |
|
|
body weighing method |
|
|
0 |
|
|
|
|
|
11562 |
102 |
SD |
body weight |
acetaminophen (500 mg/kg) (for 1 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
male |
42 days-56 days |
6 |
|
|
181.7 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84770 |
1602 |
Crl:SD |
body weight |
controlled fructose content drinking water (5 %) (for 70 days) and controlled bisphenol A content drinking water (0.25 mg/l) (for 70 days) |
Ronn M, et al., Toxicology. 2013 Jan 7;303:125-32. doi: 10.1016/j.tox.2012.09.013. Epub 2012 Nov 8. |
body mass |
female |
105 days
| 12 |
|
|
172.9 |
g |
3.41 |
11.8 |
body weighing method |
0.0 |
|
0 |
|
|
week one |
|
|
75755 |
1538 |
SS-Rag1em2Mcwi |
body weight |
controlled sodium content diet (4 %) (for 21 days) |
Mattson DL, et al., Am J Physiol Regul Integr Comp Physiol. 2013 Jan 30. |
body mass |
not specified |
84 days
| 4 |
|
|
354.0 |
g |
5.0 |
10.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
69288 |
1057 |
BN/NHsdMcwi |
body weight |
controlled sodium content diet (0.4 %) (for 35 days) then controlled sodium content diet (0.1 %) (for 35 days) and controlled sodium content diet (8 %) (between 22 and 24 days) |
Moreno C, et al., Physiol Genomics 2003 Nov 11;15(3):243-57. |
body mass |
female |
89 days-92 days |
24 |
|
|
168.0 |
g |
2.3 |
11.27 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
69439 |
151 |
BluHsd:LE |
body weight |
vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days) |
Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. |
body mass |
male |
98 days
| 8 |
|
|
491.1 |
g |
20.4 |
57.7 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
76148 |
1543 |
BluHsd:LE |
body weight |
vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) |
Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. |
body mass |
male |
70 days
| 8 |
|
|
353.1 |
g |
10.8 |
30.55 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
75955 |
1543 |
Crl:CD(SD) |
body weight |
standard diet and restricted feeding (4 h) |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
147 days
| 19 |
|
|
430.0 |
g |
5.96 |
26.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85319 |
1604 |
Crl:CD(SD) |
body weight |
standard diet |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
126 days
| 19 |
|
|
526.0 |
g |
13.31 |
58.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85316 |
1604 |
HanTac:WH |
body weight gain |
bisphenol A (0.25 mg/kg/d) (for 14 days) |
Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. |
body mass |
female |
0 days
| 17 |
|
|
82.9 |
g |
5.46 |
22.5 |
body weighing method |
0.0 |
|
0 |
|
|
G7-G21 |
|
|
76272 |
1559 |
Crl:CD(SD) |
body weight |
standard diet and restricted feeding (4 h) then acetaminophen (300 mg/kg) (for 14 days) |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
84 days
| 8 |
|
|
333.0 |
g |
8.13 |
23.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85528 |
1604 |
W/Nin |
body weight |
controlled retinyl palmitate content diet (52 mg/kg) (between 36 and 42 days) then fasting (for 12 hours) |
Tiruvalluru M, et al., Nutrition. 2013 Jan;29(1):298-304. doi: 10.1016/j.nut.2012.06.006. Epub 2012 Oct 2. |
body mass |
male |
284 days
| 6 |
|
|
441.0 |
g |
19.2 |
47.03 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
96719 |
1660 |
ACI/Eur |
body weight |
NG-nitroarginine methyl ester (9-16 mg/kg/d) (for 126 days) |
van Dijk SJ, et al., Nephron Exp Nephrol. 2006;104(3):e96-e102. Epub 2006 Jul 12. |
body mass |
not specified |
168 days-175 days |
12 |
|
|
314.0 |
g |
6.0 |
20.78 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67935 |
832 |
ACI.FHH-(D1Rat384-D1Rat452)(D17Rat61-D1Arb5)(D17Rat51)/Eur |
body weight |
specific pathogen-free condition |
van Dijk SJ, et al., Nephron Exp Nephrol. 2006;104(3):e96-e102. Epub 2006 Jul 12. |
body mass |
not specified |
168 days-175 days |
12 |
|
|
307.0 |
g |
5.0 |
17.32 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67906 |
832 |
WOKW |
body mass index (BMI) |
control condition |
Kloting I, et al., Biochem Biophys Res Commun 2001 Jun 1;284(1):150-6. |
body mass |
female |
224 days
| 12 |
|
|
0.62 |
g/cm2 |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67913 |
251 |
ACI/Eur |
body weight |
unilateral nephrectomy |
Shiozawa M, et al., J Am Soc Nephrol 2000 Nov;11(11):2068-78. |
body mass |
male |
91 days-98 days |
21 |
|
|
242.0 |
g |
3.06 |
14.0 |
body weighing method |
0.0 |
unilateral nephrectomy |
39 |
days |
performed at 5 to 6 weeks of age |
|
|
|
69139 |
1128 |
BB.SHR-(Acsm3-Igf2)/K |
body weight |
control condition |
Kovacs P, et al., Mamm Genome 1998 Apr;9(4):294-6. |
body mass |
female |
98 days
| 6 |
|
|
211.0 |
g |
7.35 |
18.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
66201 |
322 |
SS/Jr |
body weight |
control condition |
Garrett MR, et al., J Am Soc Nephrol 2003 May;14(5):1175-87 |
body mass |
male |
84 days-85 days |
6 |
|
|
384.0 |
g |
8.9 |
21.8 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65442 |
104 |
WKY/N |
body weight |
control condition |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
body mass |
both |
70 days
| 220 |
|
|
215.0 |
g |
1.36 |
20.1 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
66008 |
114 |
SS.SR-(D3Arb14-D3Mco36)(D7Mco19-D7Mco7)/Mco |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) |
Cicila GT, et al., Hypertension. 2009 Apr;53(4):725-32. Epub 2009 Mar 2. |
body mass |
male |
40 days-42 days |
20 |
|
|
150.2 |
g |
3.4 |
15.21 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65021 |
283 |
Crl:SD |
body weight gain |
controlled fructose content drinking water (5 %) (for 70 days) and controlled ethanol content drinking water (1 %) (for 70 days) |
Ronn M, et al., Toxicology. 2013 Jan 7;303:125-32. doi: 10.1016/j.tox.2012.09.013. Epub 2012 Nov 8. |
body mass |
female |
35 days-105 days |
12 |
|
|
86.2 |
g |
4.16 |
14.4 |
body weighing method |
0.0 |
|
0 |
|
|
week one |
|
|
75758 |
1538 |
WI |
body weight |
controlled in utero environment (for 21 days) and standard diet (100 % of calories) (for 21 days) |
Ceravolo GS, et al., Life Sci. 2007 Jan 30;80(8):782-7. Epub 2006 Nov 10. |
body mass |
male |
68 days
| 21 |
|
|
284.6 |
g |
11.24 |
51.51 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
101053 |
2563 |
PXO8-2/Cub |
body weight |
controlled sucrose content diet (70 % of calories) (between 0 and 168 hours) and controlled protein content diet (19.6 % of calories) (between 0 and 168 hours) and controlled fat content diet (10.4 % of calories) (between 0 and 168 hours) then fasting (between 0 and 16 hours) |
Hodulova M, et al., PLoS One. 2014 Oct 8;9(10):e109983. doi: 10.1371/journal.pone.0109983. eCollection 2014. |
body mass |
male |
127 days
| 13 |
|
|
291.4 |
g |
4.8 |
17.31 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97167 |
1858 |
F344.ZUC-Leprfa/Tj |
body weight |
control condition |
Sasaki D, et al., Mamm Genome. 2015 Dec;26(11-12):619-29. doi: 10.1007/s00335-015-9597-4. Epub 2015 Aug 22. |
body mass |
male |
168 days-175 days |
16 |
|
|
590.04 |
g |
7.75 |
31.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97720 |
1918 |
F344/NSlc |
body weight |
control condition |
Sasaki D, et al., Mamm Genome. 2015 Dec;26(11-12):619-29. doi: 10.1007/s00335-015-9597-4. Epub 2015 Aug 22. |
body mass |
male |
168 days-175 days |
20 |
|
|
380.2 |
g |
12.73 |
56.93 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97718 |
1918 |
CrljJcl:SD |
body weight |
gestation (for 21 days) then lactation (for 21 days) |
Xu X, et al., Neurotoxicol Teratol. 2011 Jul-Aug;33(4):458-63. doi: 10.1016/j.ntt.2011.06.002. Epub 2011 Jun 17. |
body mass |
female |
0 days
| 6 |
|
|
266.62 |
g |
16.51 |
40.44 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
75905 |
1539 |
MW |
body weight |
right nephrectomy (for 56 days) then captopril (30 mg/kg/d) |
Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55. |
body mass |
male |
0 days
| 10 |
|
|
287.2 |
g |
5.4 |
17.08 |
body weighing method |
0.0 |
~5/6 to 7/8 nephrectomy |
56 |
days |
|
|
|
|
100801 |
2523 |
WKY |
body weight |
puromycin aminonucleoside (50 mg/kg) |
Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. |
body mass |
male |
0 days
| 12 |
|
|
323.0 |
g |
5.0 |
17.32 |
body weighing method |
0.0 |
PA IV 50mg/kg |
0 |
|
|
|
|
|
100395 |
2479 |
COP/OlaHsd |
body weight |
control condition |
Ways JA, et al., Genomics 2002 Jul;80(1):13-20. |
body mass |
male |
77 days-84 days |
0 |
|
|
228.0 |
g |
7.0 |
|
body weighing method |
|
|
0 |
|
timing method |
|
|
|
84622 |
932 |
FHH-Nr4a1m1Mcwi |
body weight |
control condition |
Westbrook L, et al., J Am Soc Nephrol. 2014 Nov;25(11):2499-510. doi: 10.1681/ASN.2013070786. Epub 2014 Apr 10. |
body mass |
male |
112 days
| 6 |
|
|
328.0 |
g |
5.2 |
12.74 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99454 |
2318 |
FHH/EurMcwi |
body weight |
control condition |
Westbrook L, et al., J Am Soc Nephrol. 2014 Nov;25(11):2499-510. doi: 10.1681/ASN.2013070786. Epub 2014 Apr 10. |
body mass |
male |
56 days
| 6 |
|
|
207.0 |
g |
3.1 |
7.59 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99451 |
2318 |
SS/NEisSlc |
body weight |
controlled sodium chloride content diet (8 %) (for 21 days) then adrenomedulin (400 ng/hr) (for 21 days) |
Yoshihara F, et al., Regul Pept. 2005 May 15;128(1):7-13. |
body mass |
male |
77 days
| 14 |
|
|
350.0 |
g |
3.74 |
14.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102455 |
2689 |
WKY |
body weight |
sham surgical control condition (for 196 days) |
Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. |
body mass |
male |
238 days-252 days |
12 |
|
|
566.0 |
g |
17.0 |
58.89 |
body weighing method |
0.0 |
lad occlusion sham |
196 |
days |
|
|
|
|
100270 |
2460 |
GK |
body weight |
vehicle control condition (for 28 days) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
body mass |
male |
168 days
| 6 |
|
|
380.0 |
g |
7.0 |
17.15 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103492 |
2827 |
SHR/FubRkb |
body weight |
control condition |
Schulz A, etal., Physiol Genomics. 2008 Sep 17;35(1):30-5. Epub 2008 Jul 22. |
body mass |
male |
168 days
| 10 |
|
|
377.5 |
g |
4.4 |
13.91 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108916 |
3133 |
Iusm:LAD2 |
body weight |
control condition |
Alam I, etal., Alcohol Clin Exp Res. 2005 Oct;29(10):1769-76. doi: 10.1097/01.alc.0000183005.28502.4f. |
body mass |
male |
90 days
| 16 |
|
geometric mean |
239.93 |
g |
5.11 |
20.44 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
138487 |
3202 |
Crl:SD |
body weight |
controlled ethanol content drinking water (1 %) (for 70 days) |
Ronn M, et al., Toxicology. 2013 Jan 7;303:125-32. doi: 10.1016/j.tox.2012.09.013. Epub 2012 Nov 8. |
body mass |
female |
105 days
| 11 |
|
|
172.3 |
g |
1.63 |
5.4 |
body weighing method |
0.0 |
|
0 |
|
|
week one |
|
|
75752 |
1538 |
GK |
body weight |
sham surgical control condition (for 24 days) |
Apaijai N, et al., Biosci Rep. 2017 Oct 17;37(5). pii: BSR20170886. doi: 10.1042/BSR20170886. Print 2017 Oct 31. |
body mass |
female |
87 days
| 6 |
|
|
229.0 |
g |
5.0 |
12.25 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103755 |
2782 |
SD |
change in body weight |
unilateral nephrectomy (for 28 days) then enalapril (50 mg/l) (for 28 days) and losartan (180 mg/l) (for 28 days) |
Greene EL, et al., J Clin Invest. 1996 Aug 15;98(4):1063-8. |
body mass |
male |
0 days
| 7 |
|
|
97.0 |
g |
7.56 |
20.0 |
body weighing method |
0.0 |
unx |
28 |
days |
|
change from surgery weight |
|
|
101577 |
2602 |
SD |
body weight |
unilateral nephrectomy (for 28 days) |
Greene EL, et al., J Clin Invest. 1996 Aug 15;98(4):1063-8. |
body mass |
male |
0 days
| 8 |
|
|
315.0 |
g |
9.55 |
27.0 |
body weighing method |
0.0 |
unx |
28 |
days |
|
|
|
|
101607 |
2602 |
Hsd:WI |
body weight |
octylphenol (250 mg/kg/d) (for 91 days) |
Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796. |
body mass |
male |
119 days-126 days |
6 |
|
|
325.33 |
g |
12.4 |
30.37 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
76050 |
1545 |
Crl:CD(SD) |
body weight |
standard diet and restricted feeding (4 h) |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
71 days
| 19 |
|
|
288.0 |
g |
3.67 |
16.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85311 |
1604 |
SD |
body weight |
control condition |
Perico N, et al., J Am Soc Nephrol. 1994 Oct;5(4):1139-46. |
body mass |
male |
0 days
| 8 |
|
|
675.0 |
g |
12.37 |
35.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99892 |
2358 |
LH/Mav |
body weight |
perindopril (0.4 mg/kg/d) (for 98 days) |
Egan EJ, et al., Acta Pharmacol Sin. 2008 Nov;29(11):1296-300. doi: 10.1111/j.1745-7254.2008.00862.x. |
body mass |
male |
112 days
| 8 |
|
|
405.0 |
g |
7.0 |
19.8 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102790 |
2723 |
LH/Mav |
body weight |
perindopril (0.01 mg/kg/d) (for 98 days) |
Egan EJ, et al., Acta Pharmacol Sin. 2008 Nov;29(11):1296-300. doi: 10.1111/j.1745-7254.2008.00862.x. |
body mass |
male |
112 days
| 6 |
|
|
391.0 |
g |
8.0 |
19.6 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102792 |
2723 |
Crl:WI(WU) |
body weight |
abdominal aorta constriction then quinapril (2 mg/kg/d) (for 14 days) and icatibant (0.4 mg/kg/d) (for 14 days) |
Goetz RM and Holtz J, Clin Sci (Lond). 1999 Aug;97(2):165-74. |
body mass |
male |
91 days
| 11 |
|
|
276.0 |
g |
6.0 |
19.9 |
body weighing method |
0.0 |
aorta coarctation |
35 |
days |
|
|
|
|
100009 |
2398 |
WF/Mol |
body weight gain |
vehicle control condition then sham surgical control condition (for 4 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 5 |
|
|
6.0 |
g |
1.0 |
2.24 |
body weighing method |
0.0 |
sham acf |
4 |
days |
|
change from surgery weight |
|
|
101339 |
2585 |
F344/StmMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
14 days
| 12 |
|
|
21.91 |
g |
0.52 |
1.79 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139561 |
3292 |
F344/StmMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 14 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
35 days
| 12 |
|
|
94.58 |
g |
2.87 |
9.94 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139564 |
3292 |
BN/NHsdMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 7 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
28 days
| 11 |
|
|
68.55 |
g |
1.88 |
6.23 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139047 |
3292 |
M520/NRrrcMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
14 days
| 12 |
|
|
25.96 |
g |
0.99 |
3.44 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139753 |
3292 |
M520/NRrrcMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
21 days
| 12 |
|
|
47.25 |
g |
1.9 |
6.59 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139754 |
3292 |
BUF/MnaMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 7 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
28 days
| 10 |
|
|
72.1 |
g |
1.16 |
3.67 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139239 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 7 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
28 days
| 12 |
|
|
72.42 |
g |
2.55 |
8.85 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139821 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 21 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
42 days
| 12 |
|
|
133.17 |
g |
2.79 |
9.66 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139823 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 35 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
56 days
| 12 |
|
|
191.33 |
g |
3.88 |
13.44 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139825 |
3292 |
WKY/NCrl |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
7 days
| 15 |
|
|
10.48 |
g |
0.42 |
1.61 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
140010 |
3292 |
BUF/MnaMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 63 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
84 days
| 10 |
|
|
328.7 |
g |
3.68 |
11.65 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139247 |
3292 |
BUF/MnaMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
14 days
| 11 |
|
|
24.88 |
g |
0.37 |
1.22 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139303 |
3292 |
BUF/MnaMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 49 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
70 days
| 11 |
|
|
295.0 |
g |
3.17 |
10.53 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139311 |
3292 |
WKY/NCrl |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 21 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
42 days
| 15 |
|
|
124.87 |
g |
2.65 |
10.25 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
140081 |
3292 |
M520/NRrrcMcwi |
body mass index (BMI) |
controlled bisphenol F content drinking water (1.125 mg/l) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
91 days
| 12 |
|
|
0.5 |
g/cm2 |
0.0 |
0.01 |
body weighing method |
|
|
0 |
|
"weight scale, tape measure" |
Body Mass Index (BMI) |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139880 |
3292 |
F344/StmMcwi |
body mass index (BMI) |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
91 days
| 11 |
|
|
0.55 |
g/cm2 |
0.01 |
0.02 |
body weighing method |
|
|
0 |
|
"weight scale, tape measure" |
Body Mass Index (BMI) |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139559 |
3292 |
ACI/EurMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
21 days
| 12 |
|
|
32.58 |
g |
0.51 |
1.78 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138744 |
3292 |
ACI/EurMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 7 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
28 days
| 12 |
|
|
58.5 |
g |
0.71 |
2.47 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138745 |
3292 |
ACI/EurMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 14 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
35 days
| 13 |
|
|
86.46 |
g |
1.39 |
5.01 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138812 |
3292 |
ACI/EurMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 42 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
63 days
| 13 |
|
|
186.08 |
g |
2.16 |
7.78 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138816 |
3292 |
ACI/EurMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 49 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
70 days
| 13 |
|
|
197.85 |
g |
2.27 |
8.19 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138817 |
3292 |
BN/NHsdMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
21 days
| 10 |
|
|
45.3 |
g |
1.28 |
4.06 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138984 |
3292 |
BN/NHsdMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 49 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
70 days
| 10 |
|
|
142.3 |
g |
2.25 |
7.12 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138937 |
3292 |
BN/NHsdMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 63 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
84 days
| 10 |
|
|
151.6 |
g |
2.57 |
8.11 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138939 |
3292 |
M520/NRrrcMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
14 days
| 11 |
|
|
25.1 |
g |
0.96 |
3.17 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139624 |
3292 |
M520/NRrrcMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
21 days
| 11 |
|
|
43.55 |
g |
1.85 |
6.14 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139625 |
3292 |
BN/NHsdMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 7 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
28 days
| 10 |
|
|
68.8 |
g |
1.56 |
4.94 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138985 |
3292 |
ACI/EurMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
7 days
| 11 |
|
|
10.78 |
g |
0.44 |
1.44 |
body weighing method |
|
|
0 |
|
|
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138679 |
3292 |
ACI/EurMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
21 days
| 11 |
|
|
30.45 |
g |
0.99 |
3.27 |
body weighing method |
|
|
0 |
|
|
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138681 |
3292 |
BUF/MnaMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 35 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
56 days
| 10 |
|
|
166.2 |
g |
1.97 |
6.23 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139114 |
3292 |
BUF/MnaMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 7 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
28 days
| 10 |
|
|
67.7 |
g |
0.91 |
2.87 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139110 |
3292 |
BUF/MnaMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
14 days
| 10 |
|
|
24.64 |
g |
0.49 |
1.54 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139108 |
3292 |
BUF/MnaMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 28 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
49 days
| 10 |
|
|
148.9 |
g |
1.43 |
4.51 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139113 |
3292 |
BUF/MnaMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 56 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
77 days
| 10 |
|
|
193.6 |
g |
2.99 |
9.47 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139117 |
3292 |
BUF/MnaMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
7 days
| 10 |
|
|
11.81 |
g |
0.6 |
1.89 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139236 |
3292 |
BUF/MnaMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 63 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
84 days
| 11 |
|
|
327.73 |
g |
3.53 |
11.7 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139313 |
3292 |
F344/StmMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 63 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
84 days
| 9 |
|
|
164.56 |
g |
2.73 |
8.19 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139376 |
3292 |
M520/NRrrcMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
7 days
| 9 |
|
|
12.27 |
g |
0.38 |
1.13 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139689 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 14 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
35 days
| 9 |
|
|
86.67 |
g |
1.61 |
4.82 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139693 |
3292 |
F344/StmMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 28 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
49 days
| 9 |
|
|
119.33 |
g |
0.97 |
2.92 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139437 |
3292 |
F344/StmMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
91 days
| 12 |
|
|
288.25 |
g |
3.78 |
13.1 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139506 |
3292 |
BUF/MnaMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 7 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
28 days
| 10 |
|
|
68.3 |
g |
1.14 |
3.59 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139176 |
3292 |
BUF/MnaMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 28 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
49 days
| 10 |
|
|
147.6 |
g |
1.93 |
6.11 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139179 |
3292 |
F344/StmMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 28 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
49 days
| 12 |
|
|
165.83 |
g |
4.31 |
14.94 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139566 |
3292 |
BUF/MnaMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 56 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
77 days
| 10 |
|
|
190.9 |
g |
3.04 |
9.62 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139183 |
3292 |
BUF/MnaMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
91 days
| 10 |
|
|
200.0 |
g |
3.25 |
10.28 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139185 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 56 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
77 days
| 9 |
|
|
148.22 |
g |
2.64 |
7.92 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139699 |
3292 |
F344/StmMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
14 days
| 9 |
|
|
19.87 |
g |
0.62 |
1.85 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139366 |
3292 |
F344/StmMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
21 days
| 9 |
|
|
36.89 |
g |
0.99 |
2.98 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139367 |
3292 |
WKY/NCrl |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
14 days
| 10 |
|
|
23.19 |
g |
0.71 |
2.26 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139882 |
3292 |
WKY/NCrl |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 14 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
35 days
| 10 |
|
|
86.2 |
g |
2.12 |
6.71 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139885 |
3292 |
WKY/NCrl |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 28 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
49 days
| 10 |
|
|
131.0 |
g |
2.13 |
6.73 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139887 |
3292 |
M520/NRrrcMcwi |
body mass index (BMI) |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
91 days
| 12 |
|
|
0.51 |
g/cm2 |
0.01 |
0.02 |
body weighing method |
0.0 |
|
0 |
|
"weight scale, tape measure" |
Body Mass Index (BMI) |
|
|
139817 |
3292 |
WKY/NCrl |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 35 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
56 days
| 10 |
|
|
147.5 |
g |
2.22 |
7.03 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139954 |
3292 |
WKY/NCrl |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 28 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
49 days
| 15 |
|
|
160.4 |
g |
3.39 |
13.14 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
140082 |
3292 |
WKY/NCrl |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 21 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
42 days
| 10 |
|
|
109.4 |
g |
1.77 |
5.58 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139952 |
3292 |
BN/NHsdMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
7 days
| 10 |
|
|
13.45 |
g |
0.31 |
0.99 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138871 |
3292 |
ACI/EurMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 7 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
28 days
| 15 |
|
|
53.33 |
g |
1.12 |
4.32 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138616 |
3292 |
ACI/EurMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 35 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
56 days
| 11 |
|
|
120.27 |
g |
1.65 |
5.46 |
body weighing method |
|
|
0 |
|
|
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138686 |
3292 |
BN/NHsdMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
91 days
| 10 |
|
|
153.8 |
g |
2.27 |
7.18 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138883 |
3292 |
ACI/EurMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
14 days
| 15 |
|
|
19.64 |
g |
0.43 |
1.66 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138614 |
3292 |
SHR/FubRkb |
body weight |
control condition |
Schulz A, et al., J Am Soc Nephrol. 2007 Jan;18(1):113-21 |
body mass |
not specified |
168 days
| 10 |
|
|
377.5 |
g |
4.4 |
13.91 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
65358 |
117 |
MWF/FubRkb |
body weight |
control condition |
Schulz A, et al., J Am Soc Nephrol. 2007 Jan;18(1):113-21 |
body mass |
not specified |
168 days
| 18 |
|
|
363.9 |
g |
11.3 |
47.94 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
65360 |
117 |
SS/Jr |
body weight |
controlled sodium content diet (4 %) (for 14 days) |
Garrett MR, et al., Physiol Genomics 2000 Jun 29;3(1):33-8. |
body mass |
male |
53 days-67 days |
10 |
|
|
297.0 |
g |
5.0 |
15.81 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
66107 |
691 |
SHR/OlaIpcv |
body weight |
control condition |
Pravenec M, et al., Physiol Res 2003;52(3):285-9. |
body mass |
male |
80 days-100 days |
10 |
|
|
291.9 |
g |
11.4 |
36.05 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
65505 |
612 |
SS/Jr |
body weight |
controlled sodium content diet (2 %) (between 24 and 27 days) |
Garrett MR, et al., Genome Res 1998 Jul;8(7):711-23 |
body mass |
not specified |
64 days-71 days |
46 |
|
|
302.0 |
g |
1.8 |
12.21 |
body weighing method |
0 |
|
0 |
|
|
|
|
4 rats per cage, 2 SR/Jr 2 LEW/NCrl |
64713 |
222 |
SS/JrSeac |
body weight |
controlled sodium content diet (8 %) (for 35 days) |
Fukushima K, et al., Nucl Med Biol. 2010 Nov;37(8):1005-12. Epub 2010 Sep 1. |
body mass |
not specified |
126 days
| 5 |
|
|
273.0 |
g |
6.26 |
14.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67256 |
733 |
BN/NHsdMcwi |
body weight |
controlled sodium content diet (0.4 %) |
Moreno C, et al., Physiol Genomics 2003 Nov 11;15(3):243-57. |
body mass |
female |
84 days
| 33 |
|
|
175.0 |
g |
3.0 |
17.23 |
body weighing method |
0.0 |
|
0 |
|
after catheterization and jacket attachment |
|
|
|
67293 |
151 |
BN/Crl |
body weight |
control condition |
Wallis RH, et al., Diabetologia 2004 Jun;47(6):1096-106. Epub 2004 May 26 |
body mass |
male |
84 days
| 26 |
|
|
237.0 |
g |
5.0 |
25.5 |
body weighing method |
|
|
0 |
|
|
|
|
|
11289 |
66 |
BN/Crl |
body weight |
control condition |
Wallis RH, et al., Diabetologia 2004 Jun;47(6):1096-106. Epub 2004 May 26 |
body mass |
female |
84 days
| 33 |
|
|
160.0 |
g |
2.0 |
11.49 |
body weighing method |
|
|
0 |
|
|
|
|
|
11295 |
66 |
F344.GK-(D1Arb42a-D1Rat90)/Swe |
body weight |
control condition (for 65 days) |
Galli J, et al., Diabetes 1999 Dec;48(12):2463-70. |
body mass |
male |
65 days
| 11 |
|
|
197.0 |
g |
5.0 |
16.58 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
11464 |
85 |
F344.GK-(D1Mgh10-D1Rat119)/Swe |
body weight |
control condition (for 185 days) |
Galli J, et al., Diabetes 1999 Dec;48(12):2463-70. |
body mass |
male |
185 days
| 10 |
|
|
386.0 |
g |
4.0 |
12.65 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
11487 |
85 |
BN/Elh |
body weight |
angiotensin II (5-50 ng/kg/min) (between 0.2 and 1 hours) then norepinephrine (0.1-1 ug/kg/min) (between 0.2 and 1 hours) then phenylephrine (4 ug/kg) (between 0 and 0 hours) |
Bilusic M, et al., Croat Med J. 2008 Oct;49(5):586-99. |
body mass |
male |
132 days-146 days |
21 |
|
|
310.3 |
g |
7.64 |
35.0 |
body weighing method |
|
|
0 |
|
|
|
|
|
11555 |
101 |
WKY/NCruk |
body weight |
controlled air oxygen content (10 %) (for 21 days) |
Zhao L et al., 2001, Circulation, 103(3), 442-7 |
body mass |
male |
105 days
| 28 |
|
median |
270.0 |
g |
|
|
body weighing method |
|
|
0 |
|
|
|
|
|
11574 |
102 |
SS/Jr |
body weight |
controlled sodium content diet (1 %) (for 30 days) then controlled sodium content diet (0.2 %) (for 40 days) |
Cicila GT, et al., Mamm Genome 1997 Dec;8(12):896-902. |
body mass |
male |
100 days
| 21 |
|
|
350.0 |
g |
7.3 |
33.45 |
body weighing method |
|
|
0 |
|
|
|
|
|
11785 |
146 |
SS/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 24 and 27 days) |
Cicila GT, et al., Genomics 2001 Feb 15;72(1):51-60. |
body mass |
male |
68 days-70 days |
20 |
|
|
289.4 |
g |
2.0 |
8.94 |
body weighing method |
|
|
0 |
|
|
|
|
|
11805 |
147 |
OLETF/Got |
body weight |
fasting (for 16 hours) |
Moralejo DH, et al., Proc Assoc Am Physicians 1998 Nov-Dec;110(6):545-58 |
body mass |
male |
210 days
| 10 |
|
|
650.0 |
g |
7.7 |
24.35 |
body weighing method |
|
|
0 |
|
|
|
|
|
11961 |
228 |
F344/NSlc |
body weight |
fasting (for 16 hours) |
Kose H, et al., Mamm Genome 2002 Oct;13(10):558-62. |
body mass |
male |
210 days
| 22 |
|
|
386.4 |
g |
6.5 |
30.49 |
body weighing method |
|
|
0 |
|
|
|
|
|
11983 |
230 |
SS.MNS-(D2Wox27-Adh1)/Ayd |
body weight |
controlled sodium content diet (2 %) (between 35 and 98 days) |
Duong C, et al., Mamm Genome 2006; 17(12): 1147-1161 |
body mass |
male |
98 days
| 5 |
|
|
352.0 |
g |
15.0 |
33.54 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12032 |
226 |
SS.LEW-(D16Got3-D16Rat112)/Ayd |
body weight |
controlled sodium content diet (2 %) (between 35 and 98 days) |
Duong C, et al., Mamm Genome 2006; 17(12): 1147-1161 |
body mass |
male |
98 days
| 9 |
|
|
389.0 |
g |
7.0 |
21.0 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12068 |
226 |
SS/Jr |
body weight |
controlled sodium content diet (2 %) (for 24 days) |
Saad Y, et al., Mamm Genome. 2008 Jan 4 |
body mass |
male |
64 days-68 days |
20 |
|
|
307.0 |
g |
2.02 |
9.03 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12145 |
232 |
LEW/NCrl |
body weight |
controlled sodium content diet (0.2 %) (for 56 days) |
Garrett MR, et al., Genome Res 1998 Jul;8(7):711-23 |
body mass |
male |
91 days
| 8 |
|
|
375.0 |
g |
7.1 |
20.08 |
body weighing method |
0 |
|
0 |
|
|
|
|
4 rats per cage, 2 SR/Jr 2 LEW/NCrl |
12190 |
222 |
SR/Jr |
body weight |
controlled sodium content diet (0.2 %) (for 5 days) then controlled sodium content diet (8 %) (for 112 days) |
Garrett MR, et al., Genome Res 1998 Jul;8(7):711-23 |
body mass |
male |
147 days
| 10 |
|
|
365.0 |
g |
6.4 |
20.24 |
body weighing method |
0 |
|
0 |
|
|
|
|
4 rats per cage, 2 SR/Jr 2 LEW/NCrl |
12187 |
222 |
LEW/NCrl |
body weight |
controlled sodium content diet (0.2 %) (for 5 days) then controlled sodium content diet (8 %) (for 28 days) |
Garrett MR, et al., Genome Res 1998 Jul;8(7):711-23 |
body mass |
male |
63 days
| 8 |
|
|
286.0 |
g |
4.4 |
12.45 |
body weighing method |
0 |
|
0 |
|
|
|
|
4 rats per cage, 2 SR/Jr 2 LEW/NCrl |
12194 |
222 |
OLETF |
body weight |
control condition |
Tanomura H, et al., J Vet Med Sci 2002 Jan;64(1):45-50. |
body mass |
male |
245 days
| 7 |
|
|
650.2 |
g |
11.79 |
31.2 |
body weighing method |
|
|
0 |
|
|
|
|
|
12201 |
234 |
LEW/NCrl |
body weight |
controlled sodium content diet (0.2 %) (for 5 days) then controlled sodium content diet (8 %) (for 168 days) |
Garrett MR, et al., Genome Res 1998 Jul;8(7):711-23 |
body mass |
male |
203 days
| 8 |
|
|
452.0 |
g |
5.2 |
14.71 |
body weighing method |
0 |
|
0 |
|
|
|
|
4 rats per cage, 2 SR/Jr 2 LEW/NCrl |
12200 |
222 |
SS/Jr |
body weight |
controlled sodium content diet (0.4 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 24 and 28 days) |
Lee SJ, et al., Genetics 2006 Dec;174(4):2203-13. |
body mass |
male |
70 days-72 days |
40 |
|
|
298.6 |
g |
2.0 |
12.65 |
body weighing method |
|
|
0 |
|
|
|
|
|
12285 |
237 |
SS/Jr |
body weight |
controlled sodium content diet (0.4 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 24 and 28 days) |
Lee SJ, et al., Genetics 2006 Dec;174(4):2203-13. |
body mass |
male |
70 days-72 days |
40 |
|
|
318.6 |
g |
2.6 |
16.44 |
body weighing method |
|
|
0 |
|
|
|
|
|
12282 |
237 |
SHR.SS-(D8Uia1-D8Rat90)/Mco |
body weight |
controlled sodium content diet (0.3 %) |
Packard M, et al., Am J Physiol Renal Physiol. 2009 Apr;296(4):F839-46. Epub 2009 Jan 28. |
body mass |
male |
84 days
| 12 |
|
|
306.0 |
g |
3.6 |
12.47 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12336 |
246 |
ACI.FHH-(D3Wox2-D3Rat59)/Eur |
body weight |
control condition |
Van Dijk SJ, et al., Kidney Int. 2006 |
body mass |
male |
168 days-175 days |
12 |
|
|
314.0 |
g |
3.0 |
10.39 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
11926 |
62 |
iP/Iusm |
body weight |
control condition |
Alam I, et al., J Bone Miner Res. 2010 Jan 8. |
body mass |
male |
180 days
| 8 |
|
|
543.0 |
g |
10.25 |
29.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
12755 |
308 |
SHR/FubRkb |
body weight |
control condition |
Schulz A, et al., Clin Sci (Lond). 2007 Oct 22;. |
body mass |
female |
168 days
| 10 |
|
|
208.0 |
g |
5.5 |
17.39 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
12758 |
309 |
F344.OLETF-(D7Rat18-D7Mit2)(D14Rat23-D14Rat12)/Tj |
body weight |
specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) |
Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. |
body mass |
male |
211 days
| 11 |
|
|
423.2 |
g |
7.3 |
24.21 |
body weighing method |
0.0 |
oral glucose |
0 |
min |
|
|
|
|
12803 |
311 |
OLETF/Got |
body weight |
control condition |
Muramatsu Y, et al., Biochem Biophys Res Commun 2005 Jun 17;331(4):1270-6. |
body mass |
male |
245 days
| 12 |
|
|
605.2 |
g |
7.36 |
25.5 |
body weighing method |
|
|
0 |
|
|
|
|
|
12437 |
262 |
SHR/Izm |
body weight |
controlled fat content diet (5 %) (for 70 days) and controlled potassium content diet (0.75 %) (for 70 days) then controlled fat content diet (26 %) (for 14 days) and controlled potassium content diet (0.44 %) (for 14 days) |
Watanabe T, et al., Biochem Biophys Res Commun 2005 Apr 15;329(3):879-87. |
body mass |
male |
119 days
| 10 |
|
|
288.0 |
g |
1.42 |
4.5 |
body weighing method |
|
|
0 |
|
|
|
|
|
12449 |
263 |
SS/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 28 days) |
Saad Y, et al., Physiol Genomics 2001 Jan 19;4(3):201-14. |
body mass |
male |
68 days-70 days |
20 |
|
|
318.0 |
g |
3.57 |
15.97 |
body weighing method |
|
|
0 |
|
|
|
|
|
12484 |
266 |
SS/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 28 days) |
Saad Y, et al., Physiol Genomics 2001 Jan 19;4(3):201-14. |
body mass |
male |
68 days-70 days |
20 |
|
|
294.0 |
g |
4.02 |
17.98 |
body weighing method |
|
|
0 |
|
|
|
|
|
12483 |
266 |
SS.LEW-(D1Mco38-D1Rat49)/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 28 days) |
Saad Y, et al., Physiol Genomics 2001 Jan 19;4(3):201-14. |
body mass |
male |
68 days-70 days |
20 |
|
|
295.0 |
g |
4.32 |
19.32 |
body weighing method |
|
|
0 |
|
|
|
|
|
12498 |
266 |
BC/CpbU |
body weight |
controlled olive oil content diet (5 %) (for 30 days) and controlled cholesterol content diet (2 %) (for 30 days) |
de Wolf ID, et al., Exp Biol Med (Maywood) 2002 Jul;227(7):529-34. |
body mass |
male |
77 days
| 4 |
|
|
220.0 |
g |
10.5 |
21.0 |
body weighing method |
|
|
0 |
|
|
|
|
|
12509 |
267 |
SS/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 28 days) |
Saad Y, et al., Physiol Genomics 2001 Jan 19;4(3):201-14. |
body mass |
male |
68 days-70 days |
20 |
|
|
304.0 |
g |
2.6 |
11.63 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
12510 |
266 |
BC/CpbU |
body weight |
control condition |
Bonne AC, et al., Arterioscler Thromb Vasc Biol 2002 Dec 1;22(12):2072-9. |
body mass |
female |
49 days
| 6 |
|
|
106.0 |
g |
2.04 |
5.0 |
body weighing method |
|
|
0 |
|
|
|
|
|
12604 |
271 |
BC/CpbU |
body weight |
controlled olive oil content diet (5 %) (for 28 days) and controlled cholesterol content diet (2 %) (for 28 days) |
Bonne AC, et al., Arterioscler Thromb Vasc Biol 2002 Dec 1;22(12):2072-9. |
body mass |
female |
77 days
| 6 |
|
|
177.0 |
g |
1.63 |
4.0 |
body weighing method |
|
|
0 |
|
|
|
|
|
12606 |
271 |
DA/K |
body weight |
control condition |
Kloting I, et al., Biochem Biophys Res Commun 2001 Jun 1;284(1):150-6. |
body mass |
female |
210 days
| 12 |
|
|
199.0 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
12429 |
251 |
LEW/OlaHsd |
body weight |
controlled olive oil content diet (5 %) (for 30 days) and controlled cholesterol content diet (2 %) (for 30 days) |
de Wolf ID, et al., Exp Biol Med (Maywood) 2002 Jul;227(7):529-34. |
body mass |
male |
77 days
| 4 |
|
|
352.0 |
g |
17.0 |
34.0 |
body weighing method |
|
|
0 |
|
|
|
|
|
12514 |
267 |
WKY/Izm |
body weight |
controlled fat content diet (5 %) (for 70 days) and controlled potassium content diet (0.75 %) (for 70 days) |
Watanabe T, et al., Biochem Biophys Res Commun 2005 Apr 15;329(3):879-87. |
body mass |
male |
91 days-98 days |
10 |
|
|
318.0 |
g |
3.76 |
11.9 |
body weighing method |
|
|
0 |
|
|
|
|
|
12430 |
263 |
WKY |
body weight |
controlled sodium content diet (0.4 %) (for 122 days) then controlled sodium content diet (1.4 %) (for 210 days) |
Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81. |
body mass |
male |
360 days
| 4 |
|
|
318.0 |
g |
6.65 |
13.3 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12588 |
268 |
BB/OK |
body weight |
control condition |
Kovacs P, et al., Mamm Genome 1998 Apr;9(4):294-6. |
body mass |
male |
98 days
| 16 |
|
|
342.0 |
g |
7.75 |
31.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
12914 |
322 |
SHR/Mol |
body weight |
control condition |
Kloting I, et al., Biochem Biophys Res Commun 2001 Jun 29;284(5):1126-33. |
body mass |
male |
70 days
| 12 |
|
|
265.0 |
g |
2.89 |
10.0 |
body weighing method |
|
|
0 |
|
|
|
|
|
12929 |
323 |
SHR/Mol |
body weight |
control condition |
Kloting I, et al., Biochem Biophys Res Commun 2001 Jun 29;284(5):1126-33. |
body mass |
male |
56 days
| 12 |
|
|
221.0 |
g |
2.6 |
9.0 |
body weighing method |
|
|
0 |
|
|
|
|
|
12928 |
323 |
SS.SHR-(D9Mco72-D9Mco93)/Mco |
body weight |
controlled sodium content diet (2 %) (for 28 days) |
Toland EJ, et al., J Hypertens. 2008 Nov;26(11):2134-41. |
body mass |
male |
68 days-70 days |
20 |
|
|
329.0 |
g |
5.81 |
25.98 |
body weighing method |
|
|
0 |
|
|
|
|
|
12956 |
305 |
BB.SHR-(D6Rat184-D6Rat3)/K |
body weight |
control condition |
Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. |
body mass |
female |
84 days
| 24 |
|
|
200.0 |
g |
3.06 |
15.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
12976 |
324 |
F344/NRrrc |
body weight |
fasting (for 18 hours) |
Ogino T, et al., Mamm Genome 2003 Dec;14(12):839-44. |
body mass |
male |
246 days
| 21 |
|
|
641.0 |
g |
7.25 |
33.21 |
body weighing method |
|
|
0 |
|
|
|
|
|
12378 |
248 |
HTG |
body weight |
control condition |
Ueno T, et al., Physiol Genomics 2004 Mar 12;17(1):38-47. |
body mass |
female |
150 days-180 days |
10 |
|
|
238.2 |
g |
6.5 |
20.55 |
body weighing method |
|
|
0 |
|
|
|
|
|
13152 |
120 |
LEW |
body weight |
control condition |
Ueno T, et al., Physiol Genomics 2004 Mar 12;17(1):38-47. |
body mass |
male |
150 days-180 days |
10 |
|
|
300.2 |
g |
8.0 |
25.3 |
body weighing method |
|
|
0 |
|
|
|
|
|
13153 |
120 |
F344/Jcl |
body weight |
control condition |
Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. |
body mass |
male |
900 days
| 8 |
|
null |
350.7 |
g |
|
|
body weighing method |
|
|
0 |
|
method not specified, assumed to be digital scale |
|
|
|
13302 |
341 |
ACI.FHH-(D17Rat117-D17Arb5)(D17Rat180-D17Rat51)/Eur |
body weight |
controlled hydrogen ion content drinking water (2.4-2.8 pH) |
Van Dijk SJ, et al., Nephron Exp Nephrol 2005 Jun 20;101(2):e59-e66. |
body mass |
male |
173 days-180 days |
7 |
|
|
283.0 |
g |
8.0 |
21.17 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67500 |
751 |
SS/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 25 and 28 days) |
Kumarasamy S, et al., Hypertens Res. 2011 Dec;34(12):1263-70. doi: 10.1038/hr.2011.116. Epub 2011 Aug 4. |
body mass |
not specified |
0 days
| 0 |
|
|
307.0 |
g |
4.93 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67527 |
749 |
SS.SHR-(D9Mco72-D9Uia4)/Mco |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 25 and 28 days) |
Kumarasamy S, et al., Hypertens Res. 2011 Dec;34(12):1263-70. doi: 10.1038/hr.2011.116. Epub 2011 Aug 4. |
body mass |
not specified |
0 days
| 0 |
|
|
324.0 |
g |
2.3 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67532 |
749 |
SS/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 25 and 28 days) |
Kumarasamy S, et al., Hypertens Res. 2011 Dec;34(12):1263-70. doi: 10.1038/hr.2011.116. Epub 2011 Aug 4. |
body mass |
not specified |
0 days
| 0 |
|
|
296.0 |
g |
14.72 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67533 |
749 |
SS/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 25 and 28 days) |
Kumarasamy S, et al., Hypertens Res. 2011 Dec;34(12):1263-70. doi: 10.1038/hr.2011.116. Epub 2011 Aug 4. |
body mass |
not specified |
0 days
| 0 |
|
|
367.0 |
g |
6.23 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67540 |
749 |
SS.SHR-(D9Rat7-D9Rat84)/Mco |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 25 and 28 days) |
Kumarasamy S, et al., Hypertens Res. 2011 Dec;34(12):1263-70. doi: 10.1038/hr.2011.116. Epub 2011 Aug 4. |
body mass |
not specified |
0 days
| 0 |
|
|
339.0 |
g |
3.37 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67538 |
749 |
SS/HsdMcwiCrl |
body weight to tibia length ratio |
controlled carbohydrate content diet (69 %) (for 63 days) and controlled fat content diet (12 %) (for 63 days) and controlled protein content diet (19 %) (for 63 days) then controlled carbohydrate content diet (53 %) (for 28 days) and controlled fat content diet (14 %) (for 28 days) and controlled protein content diet (33 %) (for 28 days) |
Spradley FT, et al., Am J Physiol Regul Integr Comp Physiol. 2012 Jan 1;302(1):R150-8. Epub 2011 Oct 26. |
body mass |
male |
112 days
| 8 |
|
|
97.84 |
g/cm |
0.03 |
0.08 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67617 |
735 |
ACI.FHH-(D17Rat117-D17Arb5)(D17Rat180-D17Rat51)/Eur |
body weight |
unilateral nephrectomy then controlled hydrogen ion content drinking water (2.4-2.8 pH) |
Van Dijk SJ, et al., Nephron Exp Nephrol 2005 Jun 20;101(2):e59-e66. |
body mass |
male |
173 days-180 days |
10 |
|
|
301.0 |
g |
4.0 |
12.65 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67679 |
751 |
LEW |
body weight |
controlled sodium content diet (0.2 %) (for 14 days) then controlled sodium content diet (2 %) (for 35 days) |
Deng AY, et al., J Hypertens. 2008 Oct;26(10):1935-1943. |
body mass |
male |
77 days
| 14 |
|
|
299.2 |
g |
6.76 |
25.3 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65004 |
542 |
SHR.BN-(D2Rat226-D2Rat294)/Jk |
body weight |
controlled sodium content diet (1 %) (for 14 days) |
Aneas I, et al., Physiol Genomics. 2009 Mar 3;37(1):52-7. Epub 2009 Jan 6. |
body mass |
male |
87 days
| 22 |
|
|
281.0 |
g |
4.0 |
18.76 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65433 |
306 |
SHR.BN-(D4Rat33-D4Rat54)/Jk |
body weight |
controlled sodium content diet (1 %) (for 14 days) |
Aneas I, et al., Physiol Genomics. 2009 Mar 3;37(1):52-7. Epub 2009 Jan 6. |
body mass |
male |
87 days
| 23 |
|
|
275.0 |
g |
4.0 |
19.18 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65435 |
306 |
SHRSP/Izm |
body weight |
control condition (0 null) |
Kato N, et al., Hypertension 2003 DXCO;42(6):1191-7. |
body mass |
female |
91 days
| 5 |
|
|
160.6 |
g |
3.6 |
8.05 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
64831 |
115 |
SS/Jr |
body weight |
control condition |
Garrett MR, et al., J Am Soc Nephrol 2003 May;14(5):1175-87 |
body mass |
male |
140 days-141 days |
6 |
|
|
451.0 |
g |
18.5 |
45.32 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65444 |
104 |
SHR/NHsd |
body weight |
control condition |
Garrett MR, et al., J Am Soc Nephrol 2003 May;14(5):1175-87 |
body mass |
male |
182 days-183 days |
6 |
|
|
392.0 |
g |
7.0 |
17.15 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65447 |
104 |
BN/SsN |
body weight |
control condition |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
body mass |
both |
70 days
| 220 |
|
|
246.1 |
g |
0.55 |
8.1 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
66006 |
114 |
M520/N |
body weight |
control condition |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
body mass |
both |
70 days
| 220 |
|
|
201.0 |
g |
0.6 |
8.9 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
66009 |
114 |
MR/N |
body weight |
control condition |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
body mass |
both |
70 days
| 220 |
|
|
224.0 |
g |
0.26 |
3.9 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
66010 |
114 |
WKY/NCrl |
body weight |
anti-glomerular basement membrane antibody (500 ul) |
Kose H, et al., Exp Anim. 2009 Apr;58(2):193-8. |
body mass |
female |
64 days
| 10 |
|
|
164.6 |
g |
|
|
body weighing method |
0.0 |
antibody injection |
8 |
days |
|
|
|
|
67690 |
307 |
ACI/Eur |
body weight |
NG-nitroarginine methyl ester (50-150 mg/l) |
Van Dijk SJ, et al., Kidney Int. 2006 |
body mass |
male |
168 days-175 days |
12 |
|
|
319.0 |
g |
5.0 |
17.32 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67700 |
62 |
ACI.FHH-(D1Mit18-D1Mit8)(D14Mit11-D14Hmgc14b)(D14Rat65-D14Rat90)/Eur |
body weight |
NG-nitroarginine methyl ester (9-16 mg/kg/d) (for 126 days) |
van Dijk SJ, et al., Nephron Exp Nephrol. 2006;104(3):e96-e102. Epub 2006 Jul 12. |
body mass |
not specified |
168 days-175 days |
12 |
|
|
285.0 |
g |
8.0 |
27.71 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67937 |
832 |
SS.SHR-(D2Rat61-D2Mco18)/Mco |
body weight |
control condition (for 140 days) |
Garrett MR, et al., Physiol Genomics. 2007 May 15;. |
body mass |
male |
140 days
| 6 |
|
|
435.0 |
g |
10.0 |
24.49 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67974 |
834 |
ACI.FHH-(D1Rat384-D1Rat452)(D17Rat61-D1Arb5)(D17Rat51)/Eur |
body weight |
unilateral nephrectomy |
van Dijk SJ, et al., Nephron Exp Nephrol. 2006;104(3):e96-e102. Epub 2006 Jul 12. |
body mass |
not specified |
168 days-175 days |
12 |
|
|
304.0 |
g |
4.0 |
13.86 |
body weighing method |
0.0 |
unilateral nephrectomy |
126 |
days |
|
|
|
|
67902 |
832 |
DA/ZtmKini |
body weight |
control condition |
Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. |
body mass |
female |
56 days-77 days |
0 |
|
|
162.9 |
g |
|
9.5 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
68120 |
837 |
COP/OlaHsd |
body weight |
control condition |
Ways JA, et al., Physiol Genomics. 2006 Dec 19;. |
body mass |
not specified |
105 days
| 15 |
|
|
271.0 |
g |
5.5 |
21.3 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
68485 |
933 |
COP.DA-(D16Rat12-D16Rat90)/Mco |
body weight |
control condition |
Ways JA, et al., Physiol Genomics. 2006 Dec 19;. |
body mass |
not specified |
105 days
| 8 |
|
|
275.6 |
g |
4.6 |
13.01 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
68487 |
933 |
DA.PVG.1AV1-(D4Rat155-D4Rat84) |
maximum body weight loss to initial body weight ratio |
pristane (150 ul) |
Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. |
body mass |
both |
120 days-200 days |
16 |
|
|
8.8 |
% |
2.2 |
8.8 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
69805 |
1162 |
DA/Ztm |
maximum body weight loss to initial body weight ratio |
pristane (150 ul) |
Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. |
body mass |
both |
120 days-200 days |
10 |
|
|
14.3 |
% |
2.5 |
7.91 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
69811 |
1162 |
SS/JrHsdMcwi |
body weight |
controlled sodium content diet (4 %) (for 21 days) |
Mattson DL, et al., Am J Physiol Regul Integr Comp Physiol. 2013 Jan 30. |
body mass |
not specified |
84 days
| 4 |
|
|
343.0 |
g |
16.0 |
32.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
69287 |
1057 |
SS/JrHsdMcwi |
body weight |
controlled sodium content diet (0.4 %) (for 35 days) then controlled sodium content diet (0.1 %) (for 35 days) and controlled sodium content diet (8 %) (between 22 and 24 days) |
Moreno C, et al., Physiol Genomics 2003 Nov 11;15(3):243-57. |
body mass |
female |
89 days-92 days |
16 |
|
|
211.0 |
g |
6.0 |
24.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
69440 |
151 |
BB.SHR-(Gnal-D18Mit9)/K |
body weight |
control condition |
Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. |
body mass |
male |
84 days
| 15 |
|
|
324.0 |
g |
6.45 |
25.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
70097 |
324 |
Crl:CD(SD) |
body weight |
standard diet and restricted feeding (4 h) then acetaminophen (300 mg/kg) (for 98 days) |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
168 days
| 8 |
|
|
447.0 |
g |
16.62 |
47.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85552 |
1604 |
Crl:CD(SD) |
body weight |
standard diet then acetaminophen (300 mg/kg) (for 1 days) |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
71 days
| 8 |
|
|
371.0 |
g |
5.66 |
16.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85519 |
1604 |
Crl:CD(SD) |
body weight |
standard diet and restricted feeding (4 h) then acetaminophen (500 mg/kg) (for 56 days) |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
126 days
| 8 |
|
|
400.0 |
g |
7.78 |
22.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85541 |
1604 |
Crl:CD(SD) |
body weight |
standard diet and restricted feeding (4 h) then acetaminophen (500 mg/kg) (for 14 days) |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
84 days
| 8 |
|
|
321.0 |
g |
7.78 |
22.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85529 |
1604 |
Crl:CD(SD) |
body weight |
standard diet and restricted feeding (4 h) then acetaminophen (500 mg/kg) (for 35 days) |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
105 days
| 8 |
|
|
365.0 |
g |
6.36 |
18.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85535 |
1604 |
Crl:CD(SD) |
body weight |
standard diet then acetaminophen (500 mg/kg) (for 98 days) |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
168 days
| 8 |
|
|
564.0 |
g |
15.2 |
43.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85550 |
1604 |
HanTac:WH |
body weight |
vehicle control condition (for 1 days) |
Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. |
body mass |
male |
1 days
| 17 |
|
|
6.2 |
g |
0.12 |
0.5 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
96612 |
1559 |
HanTac:WH |
body weight |
bisphenol A (0.25 mg/kg/d) (between 16 and 17 days) |
Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. |
body mass |
female |
16 days-17 days |
16 |
|
|
29.4 |
g |
1.18 |
4.7 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
96689 |
1559 |
HanTac:WH |
body weight |
bisphenol A (5 mg/kg/d) (between 16 and 17 days) |
Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. |
body mass |
female |
16 days-17 days |
18 |
|
|
30.9 |
g |
0.71 |
3.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
96690 |
1559 |
W/Nin |
body weight |
controlled retinyl palmitate content diet (26 mg/kg) (between 36 and 42 days) then fasting (for 12 hours) |
Tiruvalluru M, et al., Nutrition. 2013 Jan;29(1):298-304. doi: 10.1016/j.nut.2012.06.006. Epub 2012 Oct 2. |
body mass |
male |
284 days
| 6 |
|
|
455.0 |
g |
7.1 |
17.39 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
96718 |
1660 |
F344/NHsd |
body weight |
fasting (for 16 hours) |
Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17. |
body mass |
male |
132 days-264 days |
9 |
|
|
375.7 |
g |
8.1 |
24.3 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84703 |
1599 |
SD |
body weight |
control condition |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
male |
64 days-78 days |
6 |
|
|
242.6 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84763 |
1602 |
SD |
body weight |
acetaminophen (1000 mg/kg) (for 1 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
male |
42 days-56 days |
6 |
|
|
182.4 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84775 |
1602 |
SD |
body weight |
acetaminophen (1000 mg/kg) (for 28 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
male |
70 days-84 days |
6 |
|
|
262.4 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84779 |
1602 |
SD |
body weight |
acetaminophen (1000 mg/kg) (for 15 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
male |
57 days-71 days |
6 |
|
|
229.6 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84777 |
1602 |
SD |
body weight |
acetaminophen (1000 mg/kg) (for 1 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
male |
42 days-56 days |
6 |
|
|
190.7 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84789 |
1602 |
SD |
body weight |
acetaminophen (1000 mg/kg) (for 15 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
male |
57 days-71 days |
6 |
|
|
231.9 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84791 |
1602 |
SD |
body weight |
control condition |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
female |
50 days-64 days |
6 |
|
|
148.3 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84795 |
1602 |
SD |
body weight |
acetaminophen (250 mg/kg) (for 22 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
female |
64 days-78 days |
6 |
|
|
170.0 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84802 |
1602 |
SD |
body weight |
acetaminophen (250 mg/kg) (for 28 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
female |
70 days-84 days |
6 |
|
|
175.3 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84803 |
1602 |
SD |
body weight |
acetaminophen (500 mg/kg) (for 15 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
female |
57 days-71 days |
6 |
|
|
151.9 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84806 |
1602 |
SD |
body weight |
acetaminophen (1000 mg/kg) (for 8 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
female |
50 days-64 days |
6 |
|
|
146.1 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84820 |
1602 |
SD |
body weight |
acetaminophen (500 mg/kg) (for 28 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
female |
70 days-84 days |
6 |
|
|
162.5 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84808 |
1602 |
SD |
body weight |
acetaminophen (1000 mg/kg) (for 28 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
female |
70 days-84 days |
6 |
|
|
164.5 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84823 |
1602 |
CrljJcl:SD |
body weight |
gestation (for 14 days) then controlled bisphenol A content drinking water (1 mg/l) (for 3 days) |
Xu X, et al., Neurotoxicol Teratol. 2011 Jul-Aug;33(4):458-63. doi: 10.1016/j.ntt.2011.06.002. Epub 2011 Jun 17. |
body mass |
female |
0 days
| 8 |
|
|
274.58 |
g |
34.95 |
98.85 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
75916 |
1539 |
Crl:SD |
body weight |
controlled ethanol content drinking water (1 %) |
Ronn M, et al., Toxicology. 2013 Jan 7;303:125-32. doi: 10.1016/j.tox.2012.09.013. Epub 2012 Nov 8. |
body mass |
female |
35 days
| 12 |
|
|
92.6 |
g |
3.03 |
10.5 |
body weighing method |
0.0 |
|
0 |
|
|
week one |
|
|
75747 |
1538 |
Hsd:WI |
body weight |
vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) |
Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90. |
body mass |
male |
0 days
| 6 |
|
|
137.6 |
g |
0.45 |
1.1 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
75952 |
1544 |
BluHsd:LE |
body weight |
controlled in utero environment (for 9 days) and bisphenol A (2.5 ug/kg) (for 30 days) then maternal milk (for 21 days) |
Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. |
body mass |
male |
70 days
| 8 |
|
|
338.8 |
g |
9.9 |
28.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
75960 |
1543 |
BluHsd:LE |
body weight |
controlled in utero environment (for 9 days) and bisphenol A (25 ug/kg) (for 30 days) then maternal milk (for 21 days) |
Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. |
body mass |
male |
70 days
| 8 |
|
|
326.6 |
g |
11.6 |
32.81 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
75961 |
1543 |
SD |
body weight |
control condition |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
female |
50 days-64 days |
6 |
|
|
143.7 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84815 |
1602 |
Hsd:WI |
change in body weight to body weight ratio |
vehicle control condition (for 91 days) |
Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796. |
body mass |
male |
119 days-126 days |
5 |
|
|
255.0 |
% |
13.42 |
30.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
76065 |
1545 |
Hsd:WI |
change in body weight to body weight ratio |
octylphenol (250 mg/kg/d) (for 91 days) |
Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796. |
body mass |
male |
119 days-126 days |
6 |
|
|
212.8 |
% |
16.9 |
41.4 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
76069 |
1545 |
Crl:CD(SD) |
body weight |
standard diet and restricted feeding (4 h) |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
84 days
| 19 |
|
|
328.0 |
g |
4.82 |
21.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85313 |
1604 |
SD |
body weight |
acetaminophen (1000 mg/kg) (for 1 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
female |
42 days-56 days |
6 |
|
|
139.0 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84819 |
1602 |
SD |
body weight |
acetaminophen (500 mg/kg) (for 22 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
female |
64 days-78 days |
6 |
|
|
157.7 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84807 |
1602 |
SD |
body weight |
acetaminophen (500 mg/kg) (for 15 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
male |
57 days-71 days |
6 |
|
|
229.6 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84772 |
1602 |
SD |
body weight |
control condition |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
female |
57 days-71 days |
6 |
|
|
151.6 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84816 |
1602 |
F344/NHsd |
body weight |
fasting (for 16 hours) |
Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17. |
body mass |
male |
579 days-945 days |
9 |
|
|
419.9 |
g |
12.2 |
36.6 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84705 |
1599 |
Crl:CD(SD) |
body weight |
standard diet and restricted feeding (4 h) then acetaminophen (300 mg/kg) (for 77 days) |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
147 days
| 8 |
|
|
432.0 |
g |
17.32 |
49.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85546 |
1604 |
PXO3-2/Cub |
body weight |
controlled sucrose content diet (70 % of calories) (between 0 and 168 hours) and controlled protein content diet (19.6 % of calories) (between 0 and 168 hours) and controlled fat content diet (10.4 % of calories) (between 0 and 168 hours) then fasting (between 0 and 16 hours) |
Hodulova M, et al., PLoS One. 2014 Oct 8;9(10):e109983. doi: 10.1371/journal.pone.0109983. eCollection 2014. |
body mass |
male |
127 days
| 9 |
|
|
307.6 |
g |
5.8 |
17.4 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97171 |
1858 |
SHR-Ndufc2em1Mcwi-/+ |
body weight |
controlled protein content diet (19.7 %) (for 28 days) and controlled potassium content diet (6.3 mg/g) (for 28 days) and controlled sodium content diet (3.7 mg/g) (for 28 days) |
Rubattu S, et al., J Am Heart Assoc. 2016 Feb 17;5(2). pii: e002701. doi: 10.1161/JAHA.115.002701. |
body mass |
not specified |
70 days
| 17 |
|
|
235.0 |
g |
3.4 |
14.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97899 |
1938 |
SHR-Ndufc2em2Mcwi-/+ |
body weight |
controlled protein content diet (19.7 %) (for 56 days) and controlled potassium content diet (6.3 mg/g) (for 56 days) and controlled sodium content diet (3.7 mg/g) (for 56 days) |
Rubattu S, et al., J Am Heart Assoc. 2016 Feb 17;5(2). pii: e002701. doi: 10.1161/JAHA.115.002701. |
body mass |
not specified |
98 days
| 24 |
|
|
293.0 |
g |
6.12 |
30.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97904 |
1938 |
BXH2/Cub |
body weight |
controlled sucrose content diet (70 % of calories) (between 0 and 168 hours) and controlled protein content diet (19.6 % of calories) (between 0 and 168 hours) and controlled fat content diet (10.4 % of calories) (between 0 and 168 hours) then fasting (between 0 and 16 hours) |
Hodulova M, et al., PLoS One. 2014 Oct 8;9(10):e109983. doi: 10.1371/journal.pone.0109983. eCollection 2014. |
body mass |
male |
127 days
| 18 |
|
|
194.0 |
g |
3.0 |
12.73 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
97100 |
1858 |
SR/Jr |
body weight |
controlled sodium chloride content diet (0.3 %) (for 21 days) then controlled sodium chloride content diet (8 %) (for 42 days) |
Sobajima M, et al., Am J Physiol Heart Circ Physiol. 2011 Jun;300(6):H2214-20. doi: 10.1152/ajpheart.00615.2010. Epub 2011 Mar 18. |
body mass |
not specified |
84 days
| 5 |
|
|
349.0 |
g |
10.29 |
23.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103142 |
2787 |
SS-Nppbem2Mcwi-/- |
body weight |
control condition (for 28 days) |
Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. |
body mass |
male |
28 days
| 7 |
|
|
79.0 |
g |
21.0 |
55.56 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99544 |
2319 |
SS-Nppbem2Mcwi-/- |
body weight |
control condition (for 84 days) |
Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. |
body mass |
male |
84 days
| 10 |
|
|
378.0 |
g |
20.0 |
63.25 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99548 |
2319 |
SS-Nppbem2Mcwi-/- |
body weight |
control condition (for 252 days) |
Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. |
body mass |
male |
252 days
| 5 |
|
|
452.0 |
g |
21.0 |
46.96 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99552 |
2319 |
SR/JrHsd |
body weight |
control condition |
Zheng W, et al., Am J Physiol Heart Circ Physiol. 2008 Apr;294(4):H1508-13. doi: 10.1152/ajpheart.01322.2007. Epub 2008 Feb 1. |
body mass |
female |
0 days
| 0 |
|
|
212.0 |
g |
4.4 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102181 |
2681 |
SS/JrHsd |
body weight |
control condition |
Zheng W, et al., Am J Physiol Heart Circ Physiol. 2008 Apr;294(4):H1508-13. doi: 10.1152/ajpheart.01322.2007. Epub 2008 Feb 1. |
body mass |
female |
0 days
| 0 |
|
|
235.0 |
g |
3.6 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102182 |
2681 |
SR/JrHsd |
body weight |
controlled sodium chloride content diet (0.4 %) (for 14 days) then sham surgical control condition then peanut oil (0.2 ml) (for 14 days) |
Zheng W, et al., Am J Physiol Heart Circ Physiol. 2008 Apr;294(4):H1508-13. doi: 10.1152/ajpheart.01322.2007. Epub 2008 Feb 1. |
body mass |
female |
0 days
| 0 |
|
|
226.0 |
g |
4.7 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102183 |
2681 |
SR/JrHsd |
body weight |
controlled sodium chloride content diet (4 %) (for 14 days) then bilateral ovariectomy then peanut oil (0.2 ml) (for 14 days) |
Zheng W, et al., Am J Physiol Heart Circ Physiol. 2008 Apr;294(4):H1508-13. doi: 10.1152/ajpheart.01322.2007. Epub 2008 Feb 1. |
body mass |
female |
0 days
| 0 |
|
|
269.0 |
g |
7.3 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102186 |
2681 |
SR/JrHsd |
body weight |
controlled sodium chloride content diet (4 %) (for 14 days) then bilateral ovariectomy then 17 beta-estradiol (10 ug/d) (for 14 days) |
Zheng W, et al., Am J Physiol Heart Circ Physiol. 2008 Apr;294(4):H1508-13. doi: 10.1152/ajpheart.01322.2007. Epub 2008 Feb 1. |
body mass |
female |
0 days
| 0 |
|
|
213.0 |
g |
2.2 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102188 |
2681 |
LL/Mav |
body weight |
streptozotocin (100 mg/kg) |
Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. |
body mass |
male |
56 days
| 18 |
|
|
215.0 |
g |
3.0 |
12.73 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102699 |
2721 |
LH/Mav |
body weight |
streptozotocin (75 mg/kg) |
Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. |
body mass |
male |
56 days
| 14 |
|
|
248.0 |
g |
4.0 |
14.97 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102701 |
2721 |
LH/Mav |
body weight |
streptozotocin (75 mg/kg) |
Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38. |
body mass |
male |
112 days
| 14 |
|
|
388.0 |
g |
5.0 |
18.71 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102725 |
2721 |
LETO |
body weight |
control condition (for 84 days) |
Koga K, et al., Mol Med. 2002 Oct;8(10):591-9. |
body mass |
male |
364 days
| 11 |
|
|
546.8 |
g |
6.5 |
21.56 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99415 |
2298 |
OLETF |
body weight |
olmesartan medoxomil (0.35 mg/kg/d) (for 84 days) |
Koga K, et al., Mol Med. 2002 Oct;8(10):591-9. |
body mass |
male |
364 days
| 11 |
|
|
865.6 |
g |
15.3 |
50.74 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99412 |
2298 |
FHH/EurMcwi |
body weight |
control condition |
Westbrook L, et al., J Am Soc Nephrol. 2014 Nov;25(11):2499-510. doi: 10.1681/ASN.2013070786. Epub 2014 Apr 10. |
body mass |
male |
112 days
| 6 |
|
|
352.0 |
g |
5.8 |
14.21 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99453 |
2318 |
SS/NEisSlc |
body weight |
controlled sodium chloride content diet (0.3 %) (for 42 days) then controlled sodium chloride content diet (8 %) (for 84 days) |
Horinaka S, et al., Int J Cardiol. 2003 Sep;91(1):25-35. |
body mass |
male |
126 days
| 10 |
|
|
298.0 |
g |
4.43 |
14.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102483 |
2690 |
SR/JrIpcv |
body weight |
controlled sodium content diet (0.3 %) |
Hojn¿ S, et al., Physiol Res. 2005;54(2):201-6. |
body mass |
male |
0 days
| 0 |
|
|
218.0 |
g |
9.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102389 |
2688 |
Crl:WI(Han) |
body weight |
bilateral ovariectomy (for 24 days) |
Apaijai N, et al., Biosci Rep. 2017 Oct 17;37(5). pii: BSR20170886. doi: 10.1042/BSR20170886. Print 2017 Oct 31. |
body mass |
female |
87 days
| 6 |
|
|
351.0 |
g |
5.0 |
12.25 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102931 |
2782 |
SD |
body weight |
controlled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then paricalcitol (0.8 mg/kg) (for 90 days) and enalapril (25 mg/l) (for 90 days) |
Finch JL, et al., Am J Physiol Renal Physiol. 2011 Sep 28. |
body mass |
female |
0 days
| 12 |
|
|
290.6 |
g |
6.8 |
23.56 |
body weighing method |
0.0 |
unx |
97 |
days |
|
|
|
|
100635 |
2499 |
SR |
body weight |
controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 42 days) |
Fujii N, et al., Am J Physiol Heart Circ Physiol. 2004 Aug;287(2):H760-6. doi: 10.1152/ajpheart.00734.2003. Epub 2004 Mar 18. |
body mass |
male |
84 days
| 6 |
|
|
352.0 |
g |
8.16 |
20.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103299 |
2803 |
SR |
body weight |
controlled sodium content diet (6 %) (between 35 and 49 days) |
Kamei K, et al., Circ J. 2007 Mar;71(3):390-6. |
body mass |
male |
77 days-91 days |
7 |
|
|
360.0 |
g |
9.83 |
26.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103345 |
2804 |
SS |
body weight |
controlled sodium content diet (6 %) (between 35 and 49 days) |
Kamei K, et al., Circ J. 2007 Mar;71(3):390-6. |
body mass |
male |
77 days-91 days |
7 |
|
|
336.0 |
g |
9.07 |
24.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103348 |
2804 |
LH/Mav |
body weight |
control condition (between 147 and 154 days) |
Bertram D, et al., Am J Physiol Regul Integr Comp Physiol. 2002 Nov;283(5):R1041-5. doi: 10.1152/ajpregu.00620.2001. |
body mass |
male |
147 days-154 days |
6 |
|
|
433.0 |
g |
7.0 |
17.15 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103428 |
2825 |
LH/Mav |
body weight |
controlled losartan content drinking water (10 mg/kg/d) (for 63 days) |
Bertram D, et al., Am J Physiol Regul Integr Comp Physiol. 2002 Nov;283(5):R1041-5. doi: 10.1152/ajpregu.00620.2001. |
body mass |
male |
84 days
| 13 |
|
|
340.0 |
g |
5.0 |
18.03 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103425 |
2825 |
LH/Mav |
body weight |
controlled losartan content drinking water (10 mg/kg/d) (for 63 days) |
Bertram D, et al., Am J Physiol Regul Integr Comp Physiol. 2002 Nov;283(5):R1041-5. doi: 10.1152/ajpregu.00620.2001. |
body mass |
male |
147 days-154 days |
5 |
|
|
432.0 |
g |
11.0 |
24.6 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103429 |
2825 |
WKY |
body weight |
control condition (for 0 hours) |
Cerutti C, et al., Physiol Genomics. 2006 Nov 27;27(3):295-308. doi: 10.1152/physiolgenomics.00318.2005. Epub 2006 Aug 1. |
body mass |
male |
84 days
| 5 |
|
|
260.0 |
g |
7.0 |
15.65 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103476 |
2826 |
GK |
body weight |
control condition |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
body mass |
male |
140 days
| 6 |
|
|
366.0 |
g |
8.0 |
19.6 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103488 |
2827 |
WKY/NCrl |
body weight |
salidroside (40 mg/kg) (for 28 days) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
body mass |
male |
168 days
| 6 |
|
|
462.0 |
g |
6.0 |
14.7 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103491 |
2827 |
WF/Mol |
body weight gain |
controlled losartan content drinking water (10 mg/kg/d) (for 8 days) then sham surgical control condition (for 7 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 6 |
|
|
8.0 |
g |
2.0 |
4.9 |
body weighing method |
0.0 |
sham acf |
7 |
days |
|
change from surgery weight |
|
|
101341 |
2585 |
SR/Hsd |
body weight |
controlled sodium chloride content diet (8 %) (for 42 days) |
Wu F, et al., Int J Hypertens. 2016;2016:9146870. doi: 10.1155/2016/9146870. Epub 2016 Dec 19. |
body mass |
male |
91 days
| 8 |
|
|
308.0 |
g |
10.61 |
30.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102273 |
2683 |
Crl:WI(WU) |
body weight |
abdominal aorta constriction then icatibant (0.4 mg/kg/d) (for 14 days) |
Goetz RM and Holtz J, Clin Sci (Lond). 1999 Aug;97(2):165-74. |
body mass |
male |
91 days
| 11 |
|
|
317.0 |
g |
7.0 |
23.22 |
body weighing method |
0.0 |
aorta coarctation |
35 |
days |
|
|
|
|
100012 |
2398 |
WKY |
body weight |
control condition |
Ohashi H, et al., Jpn Circ J. 1986 Feb;50(2):140-6. |
body mass |
male |
245 days
| 7 |
|
|
373.6 |
g |
11.11 |
29.4 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99849 |
2338 |
SD |
body weight |
unilateral nephrectomy (between 12 and 14 days) then enalapril (50 mg/l) (between 12 and 14 days) and losartan (180 mg/l) (between 12 and 14 days) |
Greene EL, et al., J Clin Invest. 1996 Aug 15;98(4):1063-8. |
body mass |
male |
0 days
| 5 |
|
|
285.0 |
g |
6.71 |
15.0 |
body weighing method |
0.0 |
unx |
13 |
days |
|
|
|
|
101537 |
2602 |
SD |
change in body weight |
sham surgical control condition (for 28 days) |
Greene EL, et al., J Clin Invest. 1996 Aug 15;98(4):1063-8. |
body mass |
male |
0 days
| 6 |
|
|
99.0 |
g |
6.53 |
16.0 |
body weighing method |
0.0 |
sham unx |
28 |
days |
|
change from surgery weight |
|
|
101575 |
2602 |
SD |
body weight |
artificial aortocaval fistula (for 2 days) |
Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. |
body mass |
male |
0 days
| 6 |
|
|
291.0 |
g |
6.0 |
14.7 |
body weighing method |
1.0 |
ACF |
2 |
days |
|
|
|
|
98773 |
2160 |
SS/JrHsd |
body weight |
controlled sodium content diet (0.1 %) (for 112 days) then bilateral ovariectomy (between 56 and 63 days) and 17 beta-estradiol (5 mg) (between 56 and 63 days) |
Esqueda ME, et al., Hypertension. 2007 Oct;50(4):768-72. Epub 2007 Aug 13. |
body mass |
female |
112 days
| 6 |
|
|
241.6 |
g |
5.0 |
12.25 |
body weighing method |
0.0 |
ovx |
63 |
days |
|
|
|
|
102342 |
2686 |
SR/JrHsd |
body weight |
controlled sodium content diet (0.1 %) (for 112 days) then bilateral ovariectomy (between 56 and 63 days) and 17 beta-estradiol (5 mg) (between 56 and 63 days) |
Esqueda ME, et al., Hypertension. 2007 Oct;50(4):768-72. Epub 2007 Aug 13. |
body mass |
female |
112 days
| 6 |
|
|
209.5 |
g |
5.3 |
12.98 |
body weighing method |
0.0 |
ovx |
63 |
days |
|
|
|
|
102345 |
2686 |
SS-Renem1Mcwi+/- |
body weight |
controlled sodium content diet (0.4 %) (for 49 days) |
Moreno C, et al., Hypertension. 2011 Mar;57(3):614-9. doi: 10.1161/HYPERTENSIONAHA.110.163840. Epub 2011 Jan 17. |
body mass |
male |
70 days
| 9 |
|
|
321.0 |
g |
11.14 |
33.42 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
98291 |
2038 |
SS-Renem1Mcwi-/- |
body weight |
controlled sodium content diet (0.4 %) (for 49 days) |
Moreno C, et al., Hypertension. 2011 Mar;57(3):614-9. doi: 10.1161/HYPERTENSIONAHA.110.163840. Epub 2011 Jan 17. |
body mass |
female |
70 days
| 4 |
|
|
148.75 |
g |
4.94 |
9.88 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
98294 |
2038 |
Jcl:WI |
body weight |
control condition |
Akiyama S, et al., Biosci Biotechnol Biochem. 2009 Dec;73(12):2779-82. doi: 10.1271/bbb.90576. Epub 2009 Dec 7. |
body mass |
male |
52 days
| 6 |
|
|
190.46 |
g |
14.37 |
35.2 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103908 |
2884 |
WKY |
body weight |
streptozotocin (60 mg/kg) |
Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. |
body mass |
male |
156 days
| 10 |
|
|
259.65 |
g |
18.96 |
59.96 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99108 |
2219 |
WKY |
body weight |
streptozotocin (60 mg/kg) then gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (40000000000 null) |
Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. |
body mass |
male |
156 days
| 10 |
|
|
261.43 |
g |
21.34 |
67.48 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99109 |
2219 |
WKY |
body weight |
streptozotocin (60 mg/kg) then benazepril (10 mg/kg/d) |
Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. |
body mass |
male |
156 days
| 10 |
|
|
287.24 |
g |
20.18 |
63.81 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99111 |
2219 |
SD |
body weight |
left nephrectomy (for 56 days) then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (5 mg/kg) then puromycin (40 mg/kg) |
Ma LJ, et al., Kidney Int. 2004 Jan;65(1):106-15. |
body mass |
male |
0 days
| 9 |
|
|
308.0 |
g |
10.0 |
30.0 |
body weighing method |
0.0 |
unx |
56 |
days |
|
|
|
|
98933 |
2179 |
SD |
body weight |
left nephrectomy (for 28 days) then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (0.5 mg/kg) then puromycin (40 mg/kg) |
Ma LJ, et al., Kidney Int. 2004 Jan;65(1):106-15. |
body mass |
male |
0 days
| 7 |
|
|
296.0 |
g |
11.0 |
29.1 |
body weighing method |
0.0 |
unx |
28 |
days |
|
|
|
|
98931 |
2179 |
SD |
body weight |
left nephrectomy (for 56 days) then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (0.5 mg/kg) then puromycin (40 mg/kg) |
Ma LJ, et al., Kidney Int. 2004 Jan;65(1):106-15. |
body mass |
male |
0 days
| 7 |
|
|
386.0 |
g |
7.0 |
18.52 |
body weighing method |
0.0 |
unx |
56 |
days |
|
|
|
|
98934 |
2179 |
SS-Renem1Mcwi-/- |
body weight |
controlled sodium content diet (0.4 %) (for 49 days) |
Moreno C, et al., Hypertension. 2011 Mar;57(3):614-9. doi: 10.1161/HYPERTENSIONAHA.110.163840. Epub 2011 Jan 17. |
body mass |
male |
70 days
| 8 |
|
|
220.5 |
g |
10.7 |
30.26 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
98192 |
2038 |
SD |
body weight |
streptozotocin (60 mg/kg) then insulin then Moexipril (30-35 mg/kg/d) (for 112 days) |
Perico N, et al., J Am Soc Nephrol. 1994 Oct;5(4):1139-46. |
body mass |
male |
0 days
| 8 |
|
|
563.0 |
g |
12.37 |
35.0 |
body weighing method |
0.0 |
stz |
154 |
days |
|
|
|
|
99891 |
2358 |
LH/Mav |
body weight |
perindopril (0.04 mg/kg/d) (for 98 days) |
Egan EJ, et al., Acta Pharmacol Sin. 2008 Nov;29(11):1296-300. doi: 10.1111/j.1745-7254.2008.00862.x. |
body mass |
male |
112 days
| 6 |
|
|
372.0 |
g |
9.0 |
22.05 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102793 |
2723 |
MW |
body weight |
nephrectomy (for 28 days) then control condition |
Anderson S, et al., J Clin Invest. 1986 Jun;77(6):1993-2000. |
body mass |
male |
0 days
| 8 |
|
|
250.0 |
g |
3.0 |
8.49 |
body weighing method |
0.0 |
5/6 nephrectomy |
28 |
days |
|
|
|
|
100983 |
2561 |
GK/MolTac |
body weight |
control condition |
Keller AC, et al., J Cardiovasc Pharmacol. 2015 Feb;65(2):137-47. doi: 10.1097/FJC.0000000000000170. |
body mass |
male |
147 days
| 6 |
|
|
382.0 |
g |
13.0 |
31.84 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103981 |
2885 |
SR/NEisSlc |
body weight |
controlled sodium chloride content diet (8 %) (for 21 days) |
Yoshihara F, et al., Regul Pept. 2005 May 15;128(1):7-13. |
body mass |
male |
77 days
| 7 |
|
|
371.0 |
g |
4.54 |
12.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102409 |
2689 |
SS/NEisSlc |
body weight |
controlled sodium chloride content diet (8 %) (for 14 days) |
Yoshihara F, et al., Regul Pept. 2005 May 15;128(1):7-13. |
body mass |
male |
70 days
| 7 |
|
|
297.0 |
g |
5.29 |
14.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102408 |
2689 |
SS/JrHsd |
body weight |
gelled diet (200 g/kg/d) (for 8 days) then distilled water (for 6 days) |
Fenton RA, et al., Am J Physiol Renal Physiol. 2003 Jul;285(1):F143-51. Epub 2003 Apr 8. |
body mass |
male |
0 days
| 6 |
|
|
140.0 |
g |
3.1 |
7.59 |
body weighing method |
0.0 |
osmotic pump implant |
6 |
days |
|
|
|
|
102543 |
2691 |
SD |
body weight |
left anterior descending coronary artery occlusion (for 140 days) |
Lax CJ, et al., Clin Exp Pharmacol Physiol. 2004 Aug;31(8):512-7. |
body mass |
male |
189 days
| 10 |
|
|
568.3 |
g |
34.1 |
107.83 |
body weighing method |
0.0 |
lad occlusion |
140 |
days |
|
|
|
|
101077 |
2564 |
SD |
body weight |
sham surgical control condition (for 140 days) |
Lax CJ, et al., Clin Exp Pharmacol Physiol. 2004 Aug;31(8):512-7. |
body mass |
male |
189 days
| 6 |
|
|
532.2 |
g |
20.4 |
49.97 |
body weighing method |
0.0 |
sham lad occlusion |
140 |
days |
|
|
|
|
101078 |
2564 |
WF/Mol |
body weight |
controlled ramipril content drinking water (3 mg/kg/d) (for 8 days) then artificial aortocaval fistula (for 7 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 7 |
|
|
181.0 |
g |
3.0 |
7.94 |
body weighing method |
0.0 |
acf |
7 |
days |
|
|
|
|
101304 |
2585 |
WF/Mol |
body weight |
vehicle control condition then artificial aortocaval fistula (for 7 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 7 |
|
|
184.0 |
g |
3.0 |
7.94 |
body weighing method |
0.0 |
acf |
7 |
days |
|
|
|
|
101306 |
2585 |
WF/Mol |
body weight |
vehicle control condition then artificial aortocaval fistula (for 9 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 7 |
|
|
180.0 |
g |
2.0 |
5.29 |
body weighing method |
0.0 |
acf |
9 |
days |
|
|
|
|
101309 |
2585 |
WF/Mol |
body weight gain |
controlled ramipril content drinking water (3 mg/kg/d) (for 5 days) then sham surgical control condition (for 4 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 5 |
|
|
20.0 |
g |
2.0 |
4.47 |
body weighing method |
0.0 |
sham acf |
4 |
days |
|
change from surgery weight |
|
|
101323 |
2585 |
WF/Mol |
body weight gain |
vehicle control condition then sham surgical control condition (for 7 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 5 |
|
|
34.0 |
g |
2.0 |
4.47 |
body weighing method |
0.0 |
|
7 |
days |
|
change from surgery weight |
|
|
101329 |
2585 |
WF/Mol |
body weight gain |
vehicle control condition then artificial aortocaval fistula (for 7 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 5 |
|
|
12.0 |
g |
3.0 |
6.71 |
body weighing method |
0.0 |
acf |
7 |
days |
|
change from surgery weight |
|
|
101328 |
2585 |
WF/Mol |
body weight gain |
vehicle control condition then artificial aortocaval fistula (for 9 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 7 |
|
|
29.0 |
g |
3.0 |
7.94 |
body weighing method |
0.0 |
acf |
9 |
days |
|
change from surgery weight |
|
|
101331 |
2585 |
WF/Mol |
body weight gain |
vehicle control condition then artificial aortocaval fistula (for 4 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 7 |
|
|
-5.0 |
g |
2.0 |
5.29 |
body weighing method |
0.0 |
acf |
4 |
days |
|
change from surgery weight |
|
|
101338 |
2585 |
SS.ZUC-Leprfa-/-/Slc |
body weight |
bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
body mass |
female |
91 days
| 8 |
|
|
393.0 |
g |
6.0 |
16.97 |
body weighing method |
0.0 |
ovariectomy |
42 |
days |
|
|
|
|
101663 |
2622 |
SR/Hsd |
body weight gain |
artificial cerebrospinal fluid with 0.15 M sodium (4.4-4.6 ul/hr) (for 14 days) |
Huang BS, et al., Am J Physiol Heart Circ Physiol. 2005 Feb;288(2):H517-24. doi: 10.1152/ajpheart.00651.2004. Epub 2004 Sep 30. |
body mass |
male |
52 days-61 days |
0 |
|
|
65.0 |
g |
4.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
change from surgery weight (2wks) |
|
|
103214 |
2801 |
SS-Leprem2Mcwi |
body weight |
control condition |
McPherson KC, et al., Am J Physiol Renal Physiol. 2016 Oct 1;311(4):F793-F804. doi: 10.1152/ajprenal.00590.2015. Epub 2016 Jul 27. |
body mass |
male |
42 days
| 19 |
|
|
238.0 |
g |
8.0 |
34.87 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
100068 |
2418 |
SD |
body weight |
streptozotocin (60 mg/kg) then insulin |
Perico N, et al., J Am Soc Nephrol. 1994 Oct;5(4):1139-46. |
body mass |
male |
0 days
| 8 |
|
|
588.0 |
g |
27.58 |
78.0 |
body weighing method |
0.0 |
stz |
224 |
days |
|
|
|
|
99914 |
2358 |
SD |
body weight |
control condition |
Perico N, et al., J Am Soc Nephrol. 1994 Oct;5(4):1139-46. |
body mass |
male |
0 days
| 8 |
|
|
738.0 |
g |
27.93 |
79.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99916 |
2358 |
SD |
body weight |
streptozotocin (60 mg/kg) then insulin then Moexipril (30-35 mg/kg/d) (for 112 days) |
Perico N, et al., J Am Soc Nephrol. 1994 Oct;5(4):1139-46. |
body mass |
male |
0 days
| 8 |
|
|
570.0 |
g |
31.47 |
89.0 |
body weighing method |
0.0 |
stz |
224 |
days |
|
|
|
|
99915 |
2358 |
WKY |
body weight |
unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
body mass |
male |
0 days
| 8 |
|
|
215.0 |
g |
10.0 |
28.28 |
body weighing method |
0.0 |
unx |
28 |
days |
|
|
|
|
99936 |
2378 |
SR/NEisSlc |
body weight |
controlled sodium content diet (0.3 %) (for 91 days) |
Otsuka F, et al., Am J Physiol. 1998 Jun;274(6 Pt 2):R1797-806. |
body mass |
male |
91 days
| 6 |
|
|
405.0 |
g |
17.8 |
43.6 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
100698 |
2519 |
SD-Nfe2l2em1Mcwi+/+ |
body weight |
controlled sodium content diet (0.4 %) (between 70 and 84 days) |
Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4. |
body mass |
male |
56 days-70 days |
4 |
|
|
290.0 |
g |
11.1 |
22.2 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
100731 |
2520 |
MW |
body weight |
right nephrectomy (for 84 days) then angiotensin II receptor antagonist (20 mg/l) (for 28 days) |
Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55. |
body mass |
male |
0 days
| 7 |
|
|
284.7 |
g |
7.2 |
19.05 |
body weighing method |
0.0 |
~5/6 to 7/8 nephrectomy |
84 |
days |
|
|
|
|
100825 |
2523 |
MW |
body weight |
right nephrectomy (for 84 days) then enalapril (20 mg/kg/d) (for 28 days) |
Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55. |
body mass |
male |
0 days
| 9 |
|
|
299.6 |
g |
11.7 |
35.1 |
body weighing method |
0.0 |
~5/6 to 7/8 nephrectomy |
84 |
days |
|
|
|
|
100823 |
2523 |
SS.BN-(D13Rat25-RN34_13048990782)/Mcwi |
body weight |
control condition |
Stodola TJ, et al., Physiol Genomics. 2011 Jul 14;43(13):808-17. doi: 10.1152/physiolgenomics.00171.2010. Epub 2011 Apr 26. |
body mass |
male |
49 days-63 days |
14 |
|
|
260.7 |
g |
8.3 |
31.06 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99003 |
2198 |
SS.BN-(D13Hmgc64-RN34_13048990782)/Mcwi |
body weight |
common peroneal nerve direct electrical stimulation (3 V) (for 8 hours) |
Stodola TJ, et al., Physiol Genomics. 2011 Jul 14;43(13):808-17. doi: 10.1152/physiolgenomics.00171.2010. Epub 2011 Apr 26. |
body mass |
male |
56 days-70 days |
9 |
|
|
288.0 |
g |
7.6 |
22.8 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
98998 |
2198 |
SS/JrHsdMcwi |
body weight |
control condition |
Stodola TJ, et al., Physiol Genomics. 2011 Jul 14;43(13):808-17. doi: 10.1152/physiolgenomics.00171.2010. Epub 2011 Apr 26. |
body mass |
male |
49 days-63 days |
3 |
|
|
278.8 |
g |
3.0 |
5.2 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99015 |
2198 |
MHS |
body weight |
control condition |
Pugliese G, et al., Kidney Int. 2005 Apr;67(4):1440-52. doi: 10.1111/j.1523-1755.2005.00221.x. |
body mass |
male |
84 days
| 9 |
|
|
339.0 |
g |
10.67 |
32.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
104062 |
2907 |
MNS |
body weight |
streptozotocin (55 mg/kg) then insulin (4 IU/kg) (for 84 days) |
Pugliese G, et al., Kidney Int. 2005 Apr;67(4):1440-52. doi: 10.1111/j.1523-1755.2005.00221.x. |
body mass |
male |
168 days
| 8 |
|
|
370.0 |
g |
13.79 |
39.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
104065 |
2907 |
MNS |
body weight |
control condition |
Pugliese G, et al., Kidney Int. 2005 Apr;67(4):1440-52. doi: 10.1111/j.1523-1755.2005.00221.x. |
body mass |
male |
252 days
| 14 |
|
|
552.0 |
g |
6.41 |
24.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
104068 |
2907 |
MNS |
body weight |
standard diet |
Menini S, et al., J Hypertens. 2004 Nov;22(11):2185-92. |
body mass |
male |
270 days
| 10 |
|
|
565.2 |
g |
8.06 |
25.5 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
104195 |
2927 |
SS/JrHsdMcwi |
body weight |
vehicle control condition |
Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5. |
body mass |
male |
56 days
| 7 |
|
|
261.0 |
g |
6.0 |
15.87 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
106550 |
3032 |
SBH/Ygl |
body weight |
controlled sodium chloride content diet (0.65 %) (for 98 days) then streptozotocin (60 mg/kg) then insulin (10 ul) (for 42 days) |
Landau D, et al., J Endocrinol. 2008 Apr;197(1):75-83. doi: 10.1677/JOE-08-0040. |
body mass |
male |
98 days
| 7 |
|
|
223.0 |
g |
15.0 |
39.69 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
106702 |
3038 |
SBH/Ygl |
body weight |
deoxycorticosterone acetate (75 mg) (for 56 days) and controlled sodium content drinking water (1 %) (for 56 days) |
Rothermund L, et al., Eur J Pharmacol. 2003 May 16;468(3):209-16. doi: 10.1016/s0014-2999(03)01714-x. |
body mass |
male |
16 days
| 8 |
|
|
340.0 |
g |
8.9 |
25.17 |
body weighing method |
0.0 |
|
0 |
|
|
n=8-15 |
|
|
106644 |
3035 |
SHR/FubRkb |
fetal body weight |
control condition |
Schulte L, etal., J Hypertens. 2012 Oct;30(10):2031-8. doi: 10.1097/HJH.0b013e328356a60a. |
body mass |
not specified |
-6 days
| 10 |
|
|
0.18 |
g |
0.01 |
0.03 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109502 |
3145 |
LOU/MWsl |
change in body weight to initial body weight ratio |
rat IgM immunocytoma cells (1 x 10E4 cells) then doxorubicin (1 mg/kg) (for 10 days) |
van Hoesel QG, etal., Cancer Res. 1984 Sep;44(9):3698-705. |
body mass |
male |
105 days-115 days |
6 |
|
|
-8.1 |
% |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109575 |
3150 |
LOU/MWsl |
change in body weight to initial body weight ratio |
rat IgM immunocytoma cells (1 x 10E4 cells) then negatively charged liposome-entrapped doxorubicin (1 mg/kg) (for 28 days) |
van Hoesel QG, etal., Cancer Res. 1984 Sep;44(9):3698-705. |
body mass |
male |
105 days-133 days |
6 |
|
|
10.0 |
% |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109578 |
3150 |
LN/MavRrrcAek |
body weight to body length (nose to rump) ratio |
standard rat chow (for 84 days) |
Wang J, et al., Circ Cardiovasc Genet. 2015 Apr;8(2):316-26. doi: 10.1161/CIRCGENETICS.114.000520. Epub 2015 Jan 8. |
body mass |
male |
84 days
| 0 |
|
|
11.9 |
g/cm |
0.12 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
107399 |
3014 |
LN/MavRrrcAek |
maximum slope of body weight growth curve |
standard rat chow (for 98 days) then controlled sodium chloride content diet (4 %) (for 21 days) |
Wang J, et al., Circ Cardiovasc Genet. 2015 Apr;8(2):316-26. doi: 10.1161/CIRCGENETICS.114.000520. Epub 2015 Jan 8. |
body mass |
male |
21 days-126 days |
0 |
y=mx+c |
|
35.2 |
g/week |
0.52 |
|
body weighing method |
0.0 |
|
0 |
|
|
maximum slope of body weight growth curve (CMO:0003452) |
|
|
107403 |
3014 |
FHH/EurMcwiCrl |
body weight |
control condition |
Ulu N, etal., Am J Nephrol. 2009;30(3):209-17. doi: 10.1159/000218062. Epub 2009 May 5. |
body mass |
male |
182 days
| 14 |
|
|
375.0 |
g |
4.0 |
14.97 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109755 |
3153 |
GK/MolTac |
body weight |
control condition |
Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. |
body mass |
female |
240 days
| 11 |
|
|
280.0 |
g |
6.0 |
19.9 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
106894 |
3071 |
WKY/NMolTac |
body weight |
control condition |
Schrijvers BF, etal., Nephrol Dial Transplant. 2004 May;19(5):1092-7. doi: 10.1093/ndt/gfh107. Epub 2004 Feb 19. |
body mass |
female |
240 days
| 9 |
|
|
253.0 |
g |
4.0 |
12.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
106897 |
3071 |
SHRSP/A3NCrl |
body weight |
controlled sodium chloride content drinking water (1 %) (for 49 days) and controlled fat content diet (24.5 %) (for 49 days) then controlled GSK2181236A content diet (1 mg/kg/d) (for 42 days) |
Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. |
body mass |
male |
134 days-141 days |
10 |
|
|
338.0 |
g |
5.0 |
15.81 |
body weighing method |
0.0 |
|
0 |
|
|
HSFD +1.0 mg/kg/day GSK2181236A |
|
|
106962 |
3073 |
WAG/Rij |
body weight |
0.9% sodium chloride solution (1 ml) |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
female |
91 days-0 days |
2 |
|
|
200.0 |
g |
6.01 |
8.5 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
107015 |
3074 |
SHR/NHsd |
maximum body weight loss to initial body weight ratio |
arterial catheter implantation (for 1 days) |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
body mass |
male |
89 days-95 days |
10 |
|
|
4.5 |
% |
0.8 |
2.53 |
body weighing method |
0.0 |
arterial catheter implantation |
1 |
days |
|
|
|
|
107184 |
3077 |
F344/NHsd |
body weight |
control condition |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
body mass |
male |
88 days-94 days |
10 |
|
|
283.0 |
g |
8.0 |
25.3 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
107355 |
3077 |
DA/OlaHsd |
body weight |
control condition |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
body mass |
male |
88 days-94 days |
9 |
|
|
258.0 |
g |
6.0 |
18.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
107354 |
3077 |
SHRSP/A3NCrl |
body weight |
controlled sodium chloride content drinking water (1 %) (for 91 days) and controlled fat content diet (24.5 %) (for 91 days) then vehicle control condition (for 35 days) |
Lenhard SC, etal., J Pharmacol Exp Ther. 2003 Dec;307(3):939-46. doi: 10.1124/jpet.103.057398. Epub 2003 Oct 15. |
body mass |
male |
161 days-175 days |
6 |
|
|
307.0 |
g |
8.0 |
19.6 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
107382 |
3083 |
SHRSP/A3NCrl |
body weight |
control condition (for 91 days) |
Lenhard SC, etal., J Pharmacol Exp Ther. 2003 Dec;307(3):939-46. doi: 10.1124/jpet.103.057398. Epub 2003 Oct 15. |
body mass |
male |
161 days-175 days |
7 |
|
|
311.0 |
g |
4.0 |
10.58 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
107383 |
3083 |
MWF/FubRkb |
neonatal body weight |
control condition |
Rothermund L, etal., J Hypertens. 2006 Sep 24(9). |
body mass |
not specified |
7 days
| 0 |
|
|
13.4 |
g |
0.2 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108079 |
3115 |
HsdCpb:WU |
body weight |
control condition |
Szymanski MK, etal., Basic Res Cardiol. 2012 Mar;107(2):242. doi: 10.1007/s00395-011-0242-4. Epub 2012 Jan 19. |
body mass |
male |
84 days
| 5 |
|
|
386.0 |
g |
7.0 |
15.65 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108753 |
3130 |
WKY |
body weight |
unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
body mass |
male |
0 days
| 17 |
|
|
256.0 |
g |
5.0 |
20.62 |
body weighing method |
0.0 |
unx |
150 |
days |
|
|
|
|
107446 |
2378 |
MHS |
body weight |
control condition |
Capasso G, etal., Am J Physiol Renal Physiol. 2008 Aug;295(2):F556-67. doi: 10.1152/ajprenal.00340.2007. Epub 2008 May 14. |
body mass |
not specified |
85 days-87 days |
11 |
|
|
364.0 |
g |
5.0 |
16.58 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110139 |
3164 |
WKY |
body weight |
unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days) and bosentan (100 mg/kg/d) (for 136 days) |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
body mass |
male |
0 days
| 16 |
|
|
267.0 |
g |
9.0 |
36.0 |
body weighing method |
0.0 |
unx |
150 |
days |
|
|
|
|
107449 |
2378 |
MWF/Ztm |
body weight |
standard diet |
Remuzzi A, etal., Kidney Int. 1988 Oct;34(4):481-6. doi: 10.1038/ki.1988.206. |
body mass |
female |
126 days-153 days |
8 |
|
|
218.0 |
g |
3.89 |
11.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109198 |
3138 |
F344/NHsd |
volume of blood removed to total prehemorrhagic blood volume ratio |
arterial catheter implantation (for 1 days) then controlled hemorrhage (for 0.4 hours) |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
blood amount |
male |
89 days-95 days |
10 |
5.83 mL/100 g of body weight |
|
57.8 |
% |
0.4 |
1.26 |
body weighing method |
0.0 |
|
0 |
|
|
volume of blood removed to total prehemorrhagic blood volume ratio (CMO:0003663) |
|
|
109126 |
3077 |
LEW/Ztm |
body weight |
control condition |
Hackbarth H, etal., Ren Physiol. 1983;6(2):63-71. doi: 10.1159/000172882. |
body mass |
male |
45 days
| 5 |
|
|
178.9 |
g |
5.86 |
13.1 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109302 |
3137 |
PVG/OlaHsd |
maximum body weight loss to initial body weight ratio |
arterial catheter implantation (for 1 days) |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
body mass |
male |
89 days-95 days |
10 |
|
|
5.9 |
% |
1.0 |
3.16 |
body weighing method |
0.0 |
arterial catheter implantation |
1 |
days |
|
|
|
|
107180 |
3077 |
ACI/Eur |
maximum body weight loss to initial body weight ratio |
arterial catheter implantation (for 1 days) |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
body mass |
male |
89 days-95 days |
9 |
|
|
3.1 |
% |
0.9 |
2.7 |
body weighing method |
0.0 |
arterial catheter implantation |
1 |
days |
|
|
|
|
107171 |
3077 |
MWF/FubRkb |
body weight |
control condition |
Ijpelaar DH, etal., Am J Physiol Renal Physiol. 2008 Apr;294(4):F758-67. Epub 2008 Jan 16. |
body mass |
male |
58 days
| 5 |
|
|
241.28 |
g |
4.47 |
10.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109707 |
3152 |
Hsd:WI |
body weight |
control condition |
Rothermund L, etal., J Hypertens. 2006 Sep 24(9). |
body mass |
not specified |
100 days
| 0 |
|
|
376.0 |
g |
8.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108082 |
3115 |
HsdCpb:WU |
body weight |
left anterior descending coronary artery occlusion |
Szymanski MK, etal., Basic Res Cardiol. 2012 Mar;107(2):242. doi: 10.1007/s00395-011-0242-4. Epub 2012 Jan 19. |
body mass |
male |
175 days
| 6 |
|
|
466.0 |
g |
14.0 |
34.29 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108786 |
3130 |
MWF/Hsd |
body weight |
left anterior descending coronary artery occlusion |
Szymanski MK, etal., Basic Res Cardiol. 2012 Mar;107(2):242. doi: 10.1007/s00395-011-0242-4. Epub 2012 Jan 19. |
body mass |
male |
175 days
| 10 |
|
|
342.0 |
g |
8.0 |
25.3 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108789 |
3130 |
GK/MolTac |
body weight |
control condition |
Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. |
body mass |
male |
105 days
| 10 |
|
|
335.6 |
g |
5.2 |
16.44 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110730 |
3183 |
GK/MolTac |
body weight |
control condition |
Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. |
body mass |
male |
105 days
| 9 |
|
|
337.3 |
g |
7.8 |
23.4 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110731 |
3183 |
GK/MolTac |
body weight |
control condition |
Grong E, et al., J Endocrinol Invest. 2018 Jun;41(6):691-701. doi: 10.1007/s40618-017-0793-9. Epub 2017 Nov 22. |
body mass |
male |
119 days
| 8 |
|
|
343.0 |
g |
9.0 |
25.46 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110735 |
3183 |
SS/HsdMcwiCrl |
volume of blood removed to total prehemorrhagic blood volume ratio |
arterial catheter implantation (for 1 days) then controlled hemorrhage (for 0.4 hours) |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
blood amount |
male |
89 days-95 days |
8 |
5.83 mL/100 g of body weight |
|
56.5 |
% |
0.6 |
1.7 |
body weighing method |
|
|
0 |
|
|
volume of blood removed to total prehemorrhagic blood volume ratio (CMO:0003663) |
|
|
109130 |
3077 |
BN/Crl |
volume of blood removed to total prehemorrhagic blood volume ratio |
arterial catheter implantation (for 1 days) then controlled hemorrhage (for 0.4 hours) |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
blood amount |
male |
89 days-95 days |
10 |
5.83 mL/100 g of body weight |
|
56.5 |
% |
0.6 |
1.9 |
body weighing method |
|
|
0 |
|
|
volume of blood removed to total prehemorrhagic blood volume ratio (CMO:0003663) |
|
|
109133 |
3077 |
Crl:SD |
volume of blood removed to total prehemorrhagic blood volume ratio |
arterial catheter implantation (for 1 days) then controlled hemorrhage (for 0.4 hours) |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
blood amount |
male |
89 days-95 days |
11 |
5.83 mL/100 g of body weight |
|
56.8 |
% |
0.2 |
0.66 |
body weighing method |
|
|
0 |
|
|
volume of blood removed to total prehemorrhagic blood volume ratio (CMO:0003663) |
|
|
109134 |
3077 |
FHH/EurMcwiCrl |
volume of blood removed to total prehemorrhagic blood volume ratio |
arterial catheter implantation (for 1 days) then controlled hemorrhage (for 0.4 hours) |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
blood amount |
male |
89 days-95 days |
10 |
5.83 mL/100 g of body weight |
|
58.0 |
% |
0.5 |
1.58 |
body weighing method |
|
|
0 |
|
|
volume of blood removed to total prehemorrhagic blood volume ratio (CMO:0003663) |
|
|
109135 |
3077 |
F344/NHsd |
body weight |
0.9% sodium chloride solution (0.4 ml) |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
male |
56 days
| 2 |
|
|
200.0 |
g |
6.01 |
8.5 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
106984 |
3074 |
BDIX/Orl |
body weight |
azoxymethane (15 mg/kg) |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
female |
84 days
| 8 |
|
|
206.0 |
g |
3.18 |
9.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
106987 |
3074 |
F344/NHsd |
body weight |
azoxymethane (15 mg/kg) |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
female |
56 days
| 4 |
|
|
140.0 |
g |
6.8 |
13.6 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
106992 |
3074 |
WAG/Rij |
body weight |
azoxymethane (15 mg/kg) |
Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7. |
body mass |
female |
56 days
| 4 |
|
|
126.0 |
g |
3.9 |
7.8 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
body weight |
106994 |
3074 |
MWF/FubRkb |
body weight |
control condition |
Steireif C, etal., J Hypertens. 2013 Nov;31(11):2203-12; discussion 2212. doi: 10.1097/HJH.0b013e3283642384. |
body mass |
male |
84 days
| 10 |
|
|
302.6 |
g |
4.3 |
13.6 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109274 |
3141 |
LEW/SsNHsd |
body weight |
control condition |
Ulu N, etal., Am J Nephrol. 2009;30(3):209-17. doi: 10.1159/000218062. Epub 2009 May 5. |
body mass |
male |
182 days
| 12 |
|
|
415.0 |
g |
6.0 |
20.78 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109752 |
3153 |
ISIAH |
body weight |
control condition |
Ragaeva DS, et al., Physiol Behav. 2017 Jun 1;175:22-30. doi: 10.1016/j.physbeh.2017.03.026. Epub 2017 Mar 21. |
body mass |
male |
14 days
| 13 |
|
|
21.0 |
g |
1.8 |
6.49 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110673 |
3182 |
WAG/Nov |
body weight |
control condition |
Ragaeva DS, et al., Physiol Behav. 2017 Jun 1;175:22-30. doi: 10.1016/j.physbeh.2017.03.026. Epub 2017 Mar 21. |
body mass |
male |
7 days
| 15 |
|
|
11.9 |
g |
7.2 |
27.89 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110672 |
3182 |
BDIX/Nem |
fetal body weight |
trypan blue (60 mg/kg) |
Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. |
body mass |
male |
-1 days
| 49 |
|
|
2.84 |
g |
0.03 |
0.19 |
body weighing method |
0.0 |
|
12 |
days |
|
|
|
|
111222 |
3199 |
WM/Nem |
fetal body weight |
trypan blue (40 mg/kg) |
Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. |
body mass |
male |
-1 days
| 18 |
|
|
2.78 |
g |
0.16 |
0.68 |
body weighing method |
0.0 |
|
12 |
days |
|
|
|
|
111218 |
3199 |
WM/Nem |
fetal body weight |
trypan blue (120 mg/kg) |
Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. |
body mass |
male |
-1 days
| 24 |
|
|
2.43 |
g |
0.1 |
0.49 |
body weighing method |
0.0 |
|
12 |
days |
|
|
|
|
111220 |
3199 |
Crl:WI |
body weight |
control condition |
Fourny N, et al., Nutrients. 2019 Jan 6;11(1). pii: nu11010105. doi: 10.3390/nu11010105. |
body mass |
female |
270 days-300 days |
11 |
|
|
289.4 |
g |
6.6 |
21.89 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109873 |
3159 |
GK/Par |
body weight |
controlled resveratrol content drinking water (1 mg/kg/d) (for 56 days) |
Fourny N, et al., Nutrients. 2019 Jan 6;11(1). pii: nu11010105. doi: 10.3390/nu11010105. |
body mass |
female |
270 days-300 days |
8 |
|
|
269.7 |
g |
6.4 |
18.1 |
body weighing method |
0.0 |
|
0 |
|
56 days in drinking water |
|
|
|
109876 |
3159 |
BN/NHsdMcwi |
body weight |
control condition |
Nobrega MA, et al., Diabetes 2004 Mar;53(3):735-42. |
body mass |
male |
180 days
| 6 |
|
|
340.0 |
g |
18.0 |
44.09 |
body weighing method |
0.0 |
|
0 |
|
|
n=6-27 |
|
|
110590 |
3177 |
GK/Jpe |
body weight |
controlled cocoa butter content diet (7.5 null) (for 90 days) and controlled cholesterol content diet (1.25 null) (for 90 days) and soybean oil (2 ml/kg) (for 90 days) |
Sena CM, etal., Int J Mol Sci. 2018 Sep 11;19(9). pii: ijms19092706. doi: 10.3390/ijms19092706. |
body mass |
male |
540 days
| 7 |
|
|
428.8 |
g |
12.0 |
31.75 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110848 |
3193 |
GK/MolTac |
body weight |
anti-rh-VEGF165 monoclonal antibody (1 mg) (for 14 days) |
Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. |
body mass |
female |
70 days
| 10 |
|
|
212.0 |
g |
5.0 |
15.81 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110248 |
3168 |
GK/MolTac |
body weight |
control IgG monoclonal antibody (1 mg) (for 28 days) |
Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. |
body mass |
female |
84 days
| 9 |
|
|
230.0 |
g |
4.0 |
12.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110251 |
3168 |
GK/MolTac |
body weight |
anti-rh-VEGF165 monoclonal antibody (1 mg) (for 42 days) |
Schrijvers BF, et al., Horm Metab Res. 2005 Jan;37(1):21-5. doi: 10.1055/s-2005-861027. |
body mass |
female |
98 days
| 10 |
|
|
241.0 |
g |
5.0 |
15.81 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
110256 |
3168 |
COP/OlaHsd |
volume of blood removed to total prehemorrhagic blood volume ratio |
arterial catheter implantation (for 1 days) then controlled hemorrhage (for 0.4 hours) |
Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. |
blood amount |
male |
89 days-95 days |
10 |
5.83 mL/100 g of body weight |
|
57.1 |
% |
0.4 |
1.26 |
body weighing method |
|
|
0 |
|
|
|
|
|
109125 |
3077 |
SD-Myh7bem1Blar+/+ |
body weight |
control condition |
Chen P, etal., Sci China Life Sci. 2020 Sep;63(9):1347-1362. doi: 10.1007/s11427-019-1627-y. Epub 2020 Mar 17. |
body mass |
not specified |
84 days
| 0 |
|
|
307.6 |
g |
16.5 |
|
body weighing method |
0.0 |
|
0 |
|
|
SD-Myh7bem1Blar+/+ (RS:0005005) |
|
|
110827 |
3192 |
SHRSP/A3N |
body weight |
standard condition (for 126 days) |
Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. |
body mass |
male |
203 days-224 days |
10 |
|
|
341.0 |
g |
4.0 |
12.65 |
body weighing method |
0.0 |
|
0 |
|
|
standard rat chow |
|
|
107106 |
3075 |
LEW/Mol |
body weight |
controlled sodium chloride content diet (8 %) (for 56 days) |
Kreutz R, etal., J Hypertens. 2000 Jun;18(6):777-82. doi: 10.1097/00004872-200018060-00017. |
body mass |
female |
104 days
| 8 |
|
|
195.0 |
g |
1.7 |
4.81 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
108998 |
3134 |
MWF/Fub |
body weight |
controlled sodium chloride content diet (8 %) (for 56 days) |
Kreutz R, etal., J Hypertens. 2000 Jun;18(6):777-82. doi: 10.1097/00004872-200018060-00017. |
body mass |
female |
104 days
| 8 |
|
|
188.0 |
g |
1.6 |
4.53 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109002 |
3134 |
BDIX/OrlCrl |
body weight |
control condition |
Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. |
body mass |
male |
0 days
| 5 |
|
|
201.0 |
g |
5.81 |
13.0 |
body weighing method |
0.0 |
|
0 |
|
|
baseline group A |
|
|
111021 |
3195 |
WM/Nem |
fetal body weight |
trypan blue (40 mg/kg) |
Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. |
body mass |
female |
-1 days
| 28 |
|
|
2.55 |
g |
0.12 |
0.61 |
body weighing method |
0.0 |
|
12 |
days |
|
|
|
|
111227 |
3199 |
SHR/FubRkb |
body weight |
control condition |
Schulz A, etal., Physiol Genomics. 2010 Jun. |
body mass |
male |
84 days
| 0 |
|
|
248.0 |
g |
8.5 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
109034 |
3116 |
F344/NHsd |
body weight |
control condition |
Keele GR, etal., Obesity (Silver Spring). 2018 Jan;26(1):213-222. doi: 10.1002/oby.22075. Epub 2017 Nov 28. |
body mass |
male |
119 days
| 17 |
|
|
345.0 |
g |
11.63 |
47.95 |
body weighing method |
|
|
0 |
|
|
|
|
|
138398 |
3200 |
F344/NHsd |
nose to tail body mass index |
control condition |
Keele GR, etal., Obesity (Silver Spring). 2018 Jan;26(1):213-222. doi: 10.1002/oby.22075. Epub 2017 Nov 28. |
body mass |
male |
119 days
| 14 |
|
|
2.17 |
(g/cm2) x 10 |
0.05 |
0.2 |
body weighing method |
|
|
0 |
|
|
|
|
|
138400 |
3200 |
NMcwi:HS |
body weight |
control condition |
Keele GR, etal., Obesity (Silver Spring). 2018 Jan;26(1):213-222. doi: 10.1002/oby.22075. Epub 2017 Nov 28. |
body mass |
male |
119 days
| 741 |
|
|
337.56 |
g |
1.39 |
37.74 |
body weighing method |
|
|
0 |
|
|
|
|
|
138408 |
3200 |
WKY/NHsd |
nose to tail body mass index |
control condition |
Keele GR, etal., Obesity (Silver Spring). 2018 Jan;26(1):213-222. doi: 10.1002/oby.22075. Epub 2017 Nov 28. |
body mass |
male |
119 days
| 16 |
|
|
2.27 |
(g/cm2) x 10 |
0.04 |
0.15 |
body weighing method |
|
|
0 |
|
|
|
|
|
138415 |
3200 |
SS.SHR-(D9Mco72-D9Rat55)/Mco |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 25 and 28 days) |
Kumarasamy S, et al., Hypertens Res. 2011 Dec;34(12):1263-70. doi: 10.1038/hr.2011.116. Epub 2011 Aug 4. |
body mass |
not specified |
0 days
| 0 |
|
|
302.0 |
g |
2.88 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67528 |
749 |
SS.LEW-(D3Rat61-D3Wox1)/Ayd |
body weight |
controlled sodium content diet (2 %) (between 35 and 98 days) |
Duong C, et al., Mamm Genome 2006; 17(12): 1147-1161 |
body mass |
male |
98 days
| 5 |
|
|
399.0 |
g |
1.0 |
2.24 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12046 |
226 |
SS.LEW-(D8Rat56-D8Rat51)/Ayd |
body weight |
controlled sodium content diet (2 %) (between 35 and 98 days) |
Duong C, et al., Mamm Genome 2006; 17(12): 1147-1161 |
body mass |
male |
98 days
| 9 |
|
|
280.0 |
g |
9.0 |
27.0 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12057 |
226 |
SS.LEW-(D17Rat65-D17Chm2)/Ayd |
body weight |
controlled sodium content diet (2 %) (between 35 and 98 days) |
Duong C, et al., Mamm Genome 2006; 17(12): 1147-1161 |
body mass |
male |
98 days
| 5 |
|
|
387.0 |
g |
9.0 |
20.12 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12070 |
226 |
SS.SR-(D3Mco36-D3Mco46)/Jr |
body weight |
controlled sodium content diet (0.4 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 24 and 28 days) |
Lee SJ, et al., Genetics 2006 Dec;174(4):2203-13. |
body mass |
male |
70 days-72 days |
40 |
|
|
313.7 |
g |
2.6 |
16.44 |
body weighing method |
|
|
0 |
|
|
|
|
|
12281 |
237 |
SS.SR-(D3Mco36-D3Got159)/Jr |
body weight |
controlled sodium content diet (0.4 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 24 and 28 days) |
Lee SJ, et al., Genetics 2006 Dec;174(4):2203-13. |
body mass |
male |
70 days-72 days |
20 |
|
|
300.5 |
g |
2.0 |
8.94 |
body weighing method |
|
|
0 |
|
|
|
|
|
12286 |
237 |
SS/Jr |
body weight |
controlled sodium content diet (2 %) (between 24 and 27 days) |
Garrett MR, et al., Genome Res 1998 Jul;8(7):711-23 |
body mass |
not specified |
64 days-71 days |
19 |
|
|
299.0 |
g |
4.0 |
17.44 |
body weighing method |
0 |
|
0 |
|
|
|
|
4 rats per cage, 2 SR/Jr 2 LEW/NCrl |
64727 |
222 |
SS/JrSeac |
body weight |
controlled sodium content diet (0.3 %) (for 35 days) |
Fukushima K, et al., Nucl Med Biol. 2010 Nov;37(8):1005-12. Epub 2010 Sep 1. |
body mass |
not specified |
126 days
| 5 |
|
|
303.0 |
g |
14.31 |
32.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67255 |
733 |
LEW/OlaHsd |
body weight |
controlled olive oil content diet (5 %) (for 28 days) and controlled cholesterol content diet (2 %) (for 28 days) |
Bonne AC, et al., Arterioscler Thromb Vasc Biol 2002 Dec 1;22(12):2072-9. |
body mass |
female |
77 days
| 6 |
|
|
219.0 |
g |
4.9 |
12.0 |
body weighing method |
|
|
0 |
|
|
|
|
|
12612 |
271 |
BN.GK-(D2Wox49-D2Rat70)/Ox |
body weight |
control condition |
Wallace KJ, et al., Physiol Genomics 2004 Sep 16;19(1):1-10. Epub 2004 Jul 20. |
body mass |
male |
90 days
| 27 |
|
|
247.0 |
g |
4.0 |
20.78 |
body weighing method |
|
|
0 |
|
|
|
|
|
11299 |
69 |
BN.GK-(D2Wox49-D2Rat70)/Ox |
body weight |
control condition |
Wallace KJ, et al., Physiol Genomics 2004 Sep 16;19(1):1-10. Epub 2004 Jul 20. |
body mass |
female |
90 days
| 46 |
|
|
170.0 |
g |
2.0 |
13.56 |
body weighing method |
|
|
0 |
|
|
|
|
|
11304 |
69 |
F344/DuCrlCrlj |
body weight |
control condition |
Ogino Genom 2000 Nov 15;70(1):19-25. |
body mass |
male |
245 days-252 days |
15 |
|
|
404.4 |
g |
5.16 |
20.0 |
body weighing method |
|
|
0 |
|
|
|
|
|
11411 |
83 |
SHR |
body weight |
controlled sodium content diet (0.4 %) (for 122 days) then controlled sodium content diet (1.4 %) (for 210 days) |
Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81. |
body mass |
male |
360 days
| 4 |
|
|
254.0 |
g |
6.15 |
12.3 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
12574 |
268 |
BB.SHR-(D6Rat184-D6Rat3)/K |
body weight |
control condition |
Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. |
body mass |
male |
84 days
| 22 |
|
|
302.0 |
g |
4.9 |
23.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
12975 |
324 |
DRY |
body weight |
control condition |
Innes BA, et al., Hypertension 1998 Mar;31(3):741-6 |
body mass |
male |
140 days
| 35 |
|
|
346.0 |
g |
3.89 |
23.0 |
body weighing method |
|
|
0 |
|
|
|
|
|
11666 |
113 |
F344.OLETF-(D14Rat23-D14Rat12)/Tj |
body weight |
specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) |
Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. |
body mass |
male |
211 days
| 11 |
|
|
425.3 |
g |
5.3 |
17.58 |
body weighing method |
0.0 |
oral glucose |
0 |
min |
|
|
|
|
12797 |
311 |
F344/NHsd |
body weight |
control condition |
Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17. |
body mass |
male |
714 days-882 days |
5 |
|
|
429.1 |
g |
30.0 |
67.08 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84702 |
1599 |
SD |
body weight |
acetaminophen (250 mg/kg) (for 22 days) |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
male |
64 days-78 days |
6 |
|
|
244.0 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84768 |
1602 |
DA/Ztm |
maximum body weight loss to initial body weight ratio |
pristane (150 ul) |
Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. |
body mass |
both |
120 days-200 days |
17 |
|
|
14.1 |
% |
1.6 |
6.6 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
69804 |
1162 |
DA.PVG.1AV1-(D4Rat155-D4Rat84) |
maximum body weight loss to initial body weight ratio |
type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) |
Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. |
body mass |
both |
120 days-200 days |
14 |
|
|
2.8 |
% |
1.0 |
3.74 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
69799 |
1162 |
DA.PVG.1AV1-(D4Rat63-D4Rat203) |
maximum body weight loss to initial body weight ratio |
type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) |
Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. |
body mass |
both |
120 days-200 days |
10 |
|
|
14.6 |
% |
1.8 |
5.69 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
69810 |
1162 |
SS-Rag1em1Mcwi |
body weight |
controlled sodium content diet (4 %) (for 21 days) |
Mattson DL, et al., Am J Physiol Regul Integr Comp Physiol. 2013 Jan 30. |
body mass |
not specified |
84 days
| 0 |
|
|
400.0 |
g |
10.0 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
69206 |
1057 |
BB.SHR-(Gnal-D18Mit9)/K |
body weight |
control condition |
Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. |
body mass |
female |
84 days
| 10 |
|
|
206.0 |
g |
9.49 |
30.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
70098 |
324 |
BluHsd:LE |
body weight |
vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) |
Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26. |
body mass |
male |
70 days
| 8 |
|
|
345.8 |
g |
13.1 |
37.05 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
76140 |
1543 |
Crl:SD |
body weight gain |
controlled fructose content drinking water (5 %) (for 70 days) and controlled bisphenol A content drinking water (2.5 mg/l) (for 70 days) |
Ronn M, et al., Toxicology. 2013 Jan 7;303:125-32. doi: 10.1016/j.tox.2012.09.013. Epub 2012 Nov 8. |
body mass |
female |
35 days-105 days |
12 |
|
|
86.4 |
g |
4.01 |
13.9 |
body weighing method |
0.0 |
|
0 |
|
|
week one |
|
|
75761 |
1538 |
HanTac:WH |
body weight |
bisphenol A (50 mg/kg/d) (between 16 and 17 days) |
Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. |
body mass |
female |
16 days-17 days |
16 |
|
|
29.6 |
g |
1.33 |
5.3 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
96691 |
1559 |
WOKW/K |
body mass index (BMI) |
control condition |
Kovacs P, et al., Biochem Biophys Res Commun 2000 Mar 24;269(3):660-5. |
body mass |
not specified |
224 days
| 12 |
|
|
0.87 |
g/cm2 |
0.01 |
0.05 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
69110 |
1123 |
OLETF |
body weight |
control condition |
Kanemoto N, et al., Mamm Genome 1998 Jun;9(6):419-25 |
body mass |
male |
210 days
| 14 |
|
|
653.3 |
g |
6.3 |
23.57 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
68068 |
836 |
ACI/Eur |
body weight |
specific pathogen-free condition |
van Dijk SJ, et al., Nephron Exp Nephrol. 2006;104(3):e96-e102. Epub 2006 Jul 12. |
body mass |
not specified |
168 days-175 days |
12 |
|
|
309.0 |
g |
4.0 |
13.86 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
67903 |
832 |
ACI/Eur |
body weight |
unilateral nephrectomy |
van Dijk SJ, et al., Nephron Exp Nephrol. 2006;104(3):e96-e102. Epub 2006 Jul 12. |
body mass |
not specified |
168 days-175 days |
12 |
|
|
314.0 |
g |
3.0 |
10.39 |
body weighing method |
0.0 |
unilateral nephrectomy |
126 |
days |
|
|
|
|
67899 |
832 |
SHR/NHsd |
body weight |
control condition |
Garrett MR, et al., J Am Soc Nephrol 2003 May;14(5):1175-87 |
body mass |
male |
140 days-141 days |
6 |
|
|
375.0 |
g |
13.0 |
31.84 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65445 |
104 |
SS.SR-(D7Mco19-D7Mco7)/Jr |
body weight |
controlled sodium content diet (0.3 %) (between 10 and 12 days) |
Cicila GT, et al., Hypertension. 2009 Apr;53(4):725-32. Epub 2009 Mar 2. |
body mass |
male |
40 days-42 days |
19 |
|
|
150.2 |
g |
2.5 |
10.9 |
body weighing method |
0 |
|
0 |
|
|
|
|
|
65023 |
283 |
Iusm:P |
body weight |
control condition |
Alam I, etal., Alcohol Clin Exp Res. 2005 Oct;29(10):1769-76. doi: 10.1097/01.alc.0000183005.28502.4f. |
body mass |
male |
90 days
| 16 |
|
geometric mean |
492.12 |
g |
8.32 |
33.28 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
138484 |
3202 |
SD |
body weight |
control condition |
Venkatesan PS, et al., Biol Pharm Bull. 2014 Apr 5. |
body mass |
male |
50 days-64 days |
6 |
|
|
205.4 |
g |
|
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
84782 |
1602 |
SS/NEisSlc |
body weight |
controlled sodium content diet (8 %) (for 42 days) then 0.9% sodium chloride solution (0.3 ml) (for 42 days) |
Otsuka F, et al., Am J Physiol. 1998 Jun;274(6 Pt 2):R1797-806. |
body mass |
male |
91 days
| 12 |
|
|
347.6 |
g |
6.85 |
23.73 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
100696 |
2519 |
Crl:CD(SD) |
body weight |
standard diet then acetaminophen (300 mg/kg) (for 35 days) |
Kondo K, et al., J Toxicol Sci. 2012;37(5):911-29. |
body mass |
male |
105 days
| 8 |
|
|
477.0 |
g |
7.42 |
21.0 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
85531 |
1604 |
CrljJcl:SD |
body weight |
gestation (for 21 days) then lactation (for 7 days) |
Xu X, et al., Neurotoxicol Teratol. 2011 Jul-Aug;33(4):458-63. doi: 10.1016/j.ntt.2011.06.002. Epub 2011 Jun 17. |
body mass |
female |
0 days
| 6 |
|
|
261.98 |
g |
19.72 |
48.3 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
75903 |
1539 |
CrljJcl:SD |
body weight |
gestation (for 21 days) then controlled bisphenol A content drinking water (1 mg/l) (for 24 days) then lactation (for 14 days) |
Xu X, et al., Neurotoxicol Teratol. 2011 Jul-Aug;33(4):458-63. doi: 10.1016/j.ntt.2011.06.002. Epub 2011 Jun 17. |
body mass |
female |
0 days
| 8 |
|
|
257.34 |
g |
26.96 |
76.25 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
75919 |
1539 |
CrljJcl:SD |
body weight |
gestation (for 21 days) then controlled bisphenol A content drinking water (0.1 mg/l) (for 31 days) then lactation (for 21 days) |
Xu X, et al., Neurotoxicol Teratol. 2011 Jul-Aug;33(4):458-63. doi: 10.1016/j.ntt.2011.06.002. Epub 2011 Jun 17. |
body mass |
female |
0 days
| 8 |
|
|
260.19 |
g |
18.83 |
53.26 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
75915 |
1539 |
SS/JrHsd |
body weight |
controlled sodium chloride content diet (0.4 %) (for 14 days) then bilateral ovariectomy then 17 beta-estradiol (10 ug/d) (for 14 days) |
Zheng W, et al., Am J Physiol Heart Circ Physiol. 2008 Apr;294(4):H1508-13. doi: 10.1152/ajpheart.01322.2007. Epub 2008 Feb 1. |
body mass |
female |
0 days
| 0 |
|
|
211.0 |
g |
4.6 |
|
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
102193 |
2681 |
F344.OLETF-(D5Rat166-D5Rat90)/Tj |
body weight |
control condition |
Kotoh J, et al., J Vet Med Sci. 2016 Aug 11. |
body mass |
male |
175 days
| 8 |
|
|
400.67 |
g |
5.22 |
14.76 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
98032 |
1978 |
WKY |
body weight |
controlled in utero environment (100 % of calories) (for 22 days) |
Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. |
body mass |
not specified |
1 days
| 26 |
|
|
6.64 |
g |
0.14 |
0.71 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99073 |
2218 |
SD-Tg(Ren2)27 |
body weight |
control condition (for 0 hours) |
Cerutti C, et al., Physiol Genomics. 2006 Nov 27;27(3):295-308. doi: 10.1152/physiolgenomics.00318.2005. Epub 2006 Aug 1. |
body mass |
male |
84 days
| 6 |
|
|
326.0 |
g |
11.0 |
26.94 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103475 |
2826 |
WKY/NCrl |
body weight |
control condition |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
body mass |
male |
140 days
| 6 |
|
|
436.0 |
g |
6.0 |
14.7 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103486 |
2827 |
Iusm:HAD1 |
body weight |
control condition |
Alam I, etal., Alcohol Clin Exp Res. 2005 Oct;29(10):1769-76. doi: 10.1097/01.alc.0000183005.28502.4f. |
body mass |
male |
90 days
| 16 |
|
geometric mean |
301.11 |
g |
12.74 |
50.96 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
138486 |
3202 |
Iusm:NP |
body weight |
control condition |
Alam I, etal., Alcohol Clin Exp Res. 2005 Oct;29(10):1769-76. doi: 10.1097/01.alc.0000183005.28502.4f. |
body mass |
male |
120 days
| 16 |
|
geometric mean |
663.12 |
g |
9.28 |
37.12 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
138513 |
3202 |
Iusm:LAD2 |
body weight |
control condition |
Alam I, etal., Alcohol Clin Exp Res. 2005 Oct;29(10):1769-76. doi: 10.1097/01.alc.0000183005.28502.4f. |
body mass |
male |
120 days
| 16 |
|
geometric mean |
332.0 |
g |
6.44 |
25.76 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
138517 |
3202 |
SS-Nppbem2Mcwi-/- |
body weight |
gene transfer of the rat natriuretic peptide B gene using an adenovirus vector (100000000000 PFU) |
Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11. |
body mass |
male |
168 days
| 6 |
|
|
397.0 |
g |
18.0 |
44.09 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
99759 |
2319 |
SD |
body weight |
unilateral nephrectomy (between 12 and 14 days) |
Greene EL, et al., J Clin Invest. 1996 Aug 15;98(4):1063-8. |
body mass |
male |
0 days
| 11 |
|
|
277.0 |
g |
8.14 |
27.0 |
body weighing method |
0.0 |
unx |
13 |
days |
|
|
|
|
101536 |
2602 |
SD |
body weight |
unilateral nephrectomy (for 28 days) |
Greene EL, et al., J Clin Invest. 1996 Aug 15;98(4):1063-8. |
body mass |
male |
0 days
| 7 |
|
|
309.0 |
g |
18.9 |
50.0 |
body weighing method |
0.0 |
unx |
28 |
days |
|
|
|
|
101572 |
2602 |
SD |
body weight |
sham surgical control condition (for 2 days) |
Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. |
body mass |
male |
0 days
| 6 |
|
|
282.0 |
g |
16.0 |
39.19 |
body weighing method |
1.0 |
sham ACF |
2 |
days |
|
|
|
|
98774 |
2160 |
Hsd:WI |
change in body weight to body weight ratio |
bisphenol A (250 mg/kg/d) (for 91 days) |
Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796. |
body mass |
male |
119 days-126 days |
6 |
|
|
215.9 |
% |
15.19 |
37.2 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
76067 |
1545 |
GK/Jcl |
body weight |
control condition |
Akiyama S, et al., Biosci Biotechnol Biochem. 2009 Dec;73(12):2779-82. doi: 10.1271/bbb.90576. Epub 2009 Dec 7. |
body mass |
male |
24 days
| 6 |
|
|
179.97 |
g |
1.82 |
4.46 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
103909 |
2884 |
SD |
body weight |
left nephrectomy (for 28 days) then puromycin (100 mg/kg) then anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) then puromycin (40 mg/kg) |
Ma LJ, et al., Kidney Int. 2004 Jan;65(1):106-15. |
body mass |
male |
0 days
| 7 |
|
|
301.0 |
g |
5.0 |
13.23 |
body weighing method |
0.0 |
unx |
28 |
days |
|
|
|
|
98929 |
2179 |
SD |
body weight |
left nephrectomy (for 56 days) then puromycin (100 mg/kg) then anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) then puromycin (40 mg/kg) |
Ma LJ, et al., Kidney Int. 2004 Jan;65(1):106-15. |
body mass |
male |
0 days
| 7 |
|
|
318.0 |
g |
15.0 |
39.69 |
body weighing method |
0.0 |
unx |
56 |
days |
|
|
|
|
98932 |
2179 |
SS/JrHsd |
body weight |
gelled diet (200 g/kg/d) (for 8 days) then distilled water |
Fenton RA, et al., Am J Physiol Renal Physiol. 2003 Jul;285(1):F143-51. Epub 2003 Apr 8. |
body mass |
male |
0 days
| 6 |
|
|
131.0 |
g |
2.5 |
6.12 |
body weighing method |
0.0 |
osmotic pump implant |
0 |
days |
|
|
|
|
102542 |
2691 |
WF/Mol |
body weight |
vehicle control condition then artificial aortocaval fistula (for 2 days) |
Wahlander H, et al., Acta Physiol Scand. 1999 Feb;165(2):143-54. |
body mass |
male |
0 days
| 8 |
|
|
202.0 |
g |
3.0 |
8.49 |
body weighing method |
0.0 |
acf |
2 |
days |
|
|
|
|
101312 |
2585 |
F344/StmMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
91 days
| 12 |
|
|
287.33 |
g |
2.98 |
10.33 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139572 |
3292 |
BN/NHsdMcwi |
body mass index (BMI) |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
91 days
| 10 |
|
|
0.51 |
g/cm2 |
0.01 |
0.02 |
body weighing method |
|
|
0 |
|
"weight scale, tape measure" |
Body Mass Index (BMI) |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139043 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 21 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
42 days
| 12 |
|
|
134.42 |
g |
3.71 |
12.86 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139757 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 42 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
63 days
| 12 |
|
|
207.75 |
g |
5.62 |
19.45 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139760 |
3292 |
BUF/MnaMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
14 days
| 10 |
|
|
24.32 |
g |
0.72 |
2.27 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139237 |
3292 |
WKY/NCrl |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
21 days
| 15 |
|
|
39.6 |
g |
1.51 |
5.84 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
140012 |
3292 |
WKY/NCrl |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 49 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
70 days
| 15 |
|
|
242.67 |
g |
3.04 |
11.78 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
140019 |
3292 |
BUF/MnaMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
91 days
| 11 |
|
|
341.45 |
g |
3.79 |
12.57 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139314 |
3292 |
WKY/NCrl |
body weight |
control condition (0 null) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
7 days
| 15 |
|
|
10.62 |
g |
0.32 |
1.22 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
140076 |
3292 |
WKY/NCrl |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 35 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
56 days
| 15 |
|
|
193.87 |
g |
3.49 |
13.53 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
140083 |
3292 |
BN/NHsdMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 21 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
42 days
| 11 |
|
|
124.27 |
g |
2.56 |
8.49 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139049 |
3292 |
ACI/EurMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
7 days
| 12 |
|
|
11.16 |
g |
0.29 |
1.01 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138742 |
3292 |
ACI/EurMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 14 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
35 days
| 12 |
|
|
87.17 |
g |
1.31 |
4.53 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138746 |
3292 |
ACI/EurMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 42 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
63 days
| 12 |
|
|
187.58 |
g |
1.75 |
6.05 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138750 |
3292 |
ACI/EurMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 56 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
77 days
| 12 |
|
|
204.33 |
g |
1.92 |
6.67 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138752 |
3292 |
ACI/EurMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 35 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
56 days
| 12 |
|
|
171.83 |
g |
1.62 |
5.61 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138749 |
3292 |
F344/StmMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 7 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
28 days
| 12 |
|
|
61.83 |
g |
2.39 |
8.28 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139497 |
3292 |
F344/StmMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 28 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
49 days
| 12 |
|
|
164.75 |
g |
3.79 |
13.14 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139500 |
3292 |
F344/StmMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 63 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
84 days
| 12 |
|
|
281.83 |
g |
3.21 |
11.11 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139505 |
3292 |
ACI/EurMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 28 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
49 days
| 13 |
|
|
145.0 |
g |
1.66 |
6.0 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138814 |
3292 |
BN/NHsdMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 28 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
49 days
| 10 |
|
|
153.7 |
g |
3.92 |
12.39 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138988 |
3292 |
BN/NHsdMcwi |
body mass index (BMI) |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
91 days
| 10 |
|
|
0.41 |
g/cm2 |
0.01 |
0.02 |
body weighing method |
|
|
0 |
|
"weight scale, tape measure" |
Body Mass Index (BMI) |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138927 |
3292 |
BN/NHsdMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 7 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
28 days
| 10 |
|
|
61.9 |
g |
1.8 |
5.7 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138931 |
3292 |
BN/NHsdMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 35 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
56 days
| 10 |
|
|
125.4 |
g |
1.78 |
5.62 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138935 |
3292 |
SD-Nfe2l2em1Mcwi-/- |
body weight |
controlled sodium chloride content diet (0.4 %) (between 70 and 84 days) then controlled sodium chloride content diet (4 %) (for 3 days) then angiotensin II (100 ng/kg/min) (for 3 days) |
Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4. |
body mass |
male |
62 days-76 days |
6 |
|
|
307.0 |
g |
11.5 |
28.17 |
body weighing method |
0.0 |
|
0 |
|
|
|
|
|
100736 |
2520 |
BN/NHsdMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
91 days
| 10 |
|
|
155.2 |
g |
2.68 |
8.48 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138940 |
3292 |
BN/NHsdMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 63 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
84 days
| 10 |
|
|
237.5 |
g |
3.55 |
11.24 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138993 |
3292 |
BN/NHsdMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
14 days
| 11 |
|
|
26.55 |
g |
0.62 |
2.07 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139045 |
3292 |
ACI/EurMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 21 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
42 days
| 11 |
|
|
93.91 |
g |
1.85 |
6.12 |
body weighing method |
|
|
0 |
|
|
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138684 |
3292 |
BUF/MnaMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
7 days
| 10 |
|
|
12.51 |
g |
0.48 |
1.52 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139107 |
3292 |
BUF/MnaMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 14 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
35 days
| 10 |
|
|
98.1 |
g |
1.25 |
3.96 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139111 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 42 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
63 days
| 11 |
|
|
135.82 |
g |
2.25 |
7.45 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139631 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 56 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
77 days
| 11 |
|
|
146.82 |
g |
2.55 |
8.45 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139633 |
3292 |
BUF/MnaMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 21 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
42 days
| 10 |
|
|
127.5 |
g |
1.99 |
6.29 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139178 |
3292 |
BUF/MnaMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 49 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
70 days
| 10 |
|
|
184.8 |
g |
2.79 |
8.83 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139182 |
3292 |
BUF/MnaMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 35 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
56 days
| 11 |
|
|
236.73 |
g |
2.79 |
9.25 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139309 |
3292 |
M520/NRrrcMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
14 days
| 9 |
|
|
24.58 |
g |
0.71 |
2.12 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139690 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 42 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
63 days
| 9 |
|
|
138.44 |
g |
2.74 |
8.23 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139697 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
91 days
| 9 |
|
|
156.0 |
g |
2.65 |
7.94 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139701 |
3292 |
F344/StmMcwi |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
21 days
| 12 |
|
|
38.58 |
g |
1.31 |
4.54 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139562 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 35 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
56 days
| 11 |
|
|
128.09 |
g |
2.22 |
7.35 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139630 |
3292 |
BUF/MnaMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 63 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
84 days
| 10 |
|
|
197.2 |
g |
3.0 |
9.5 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139184 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 28 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
49 days
| 9 |
|
|
117.0 |
g |
2.03 |
6.08 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139695 |
3292 |
F344/StmMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 14 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
35 days
| 9 |
|
|
86.11 |
g |
2.06 |
6.19 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139369 |
3292 |
F344/StmMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 49 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
70 days
| 9 |
|
|
153.44 |
g |
2.2 |
6.6 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139374 |
3292 |
WKY/NCrl |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
7 days
| 10 |
|
|
10.07 |
g |
0.56 |
1.77 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139881 |
3292 |
WKY/NCrl |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
91 days
| 10 |
|
|
199.7 |
g |
3.39 |
10.73 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139893 |
3292 |
WKY/NCrl |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 56 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
77 days
| 10 |
|
|
183.1 |
g |
2.89 |
9.15 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139891 |
3292 |
WKY/NCrl |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 49 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
70 days
| 10 |
|
|
171.6 |
g |
2.82 |
8.92 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139890 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 35 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
56 days
| 12 |
|
|
188.92 |
g |
4.79 |
16.6 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139759 |
3292 |
M520/NRrrcMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 56 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
77 days
| 12 |
|
|
228.83 |
g |
4.77 |
16.52 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
139828 |
3292 |
WKY/NCrl |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 7 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
28 days
| 10 |
|
|
62.1 |
g |
2.48 |
7.85 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139884 |
3292 |
WKY/NCrl |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 7 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
28 days
| 10 |
|
|
61.3 |
g |
2.57 |
8.12 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139950 |
3292 |
WKY/NCrl |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 63 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
84 days
| 10 |
|
|
193.3 |
g |
2.53 |
8.01 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139958 |
3292 |
WKY/NCrl |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 63 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
84 days
| 15 |
|
|
286.6 |
g |
3.44 |
13.31 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
140021 |
3292 |
WKY/NCrl |
body weight |
control condition |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
14 days
| 10 |
|
|
22.97 |
g |
0.68 |
2.14 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139948 |
3292 |
WKY/NCrl |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 56 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
77 days
| 10 |
|
|
183.3 |
g |
2.56 |
8.1 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139957 |
3292 |
WKY/NCrl |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 28 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
49 days
| 10 |
|
|
130.7 |
g |
2.39 |
7.54 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139953 |
3292 |
F344/StmMcwi |
body mass index (BMI) |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
91 days
| 9 |
|
|
0.44 |
g/cm2 |
0.0 |
0.01 |
body weighing method |
|
|
0 |
|
"weight scale, tape measure" |
Body Mass Index (BMI) |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139430 |
3292 |
BN/NHsdMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 21 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
42 days
| 10 |
|
|
99.7 |
g |
1.62 |
5.12 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138876 |
3292 |
BN/NHsdMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 28 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
49 days
| 10 |
|
|
112.5 |
g |
1.83 |
5.8 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138877 |
3292 |
F344/StmMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 35 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
56 days
| 9 |
|
|
132.56 |
g |
1.24 |
3.71 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139438 |
3292 |
BN/NHsdMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 56 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
77 days
| 10 |
|
|
143.0 |
g |
3.96 |
12.53 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138881 |
3292 |
BN/NHsdMcwi |
body weight |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 49 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
70 days
| 10 |
|
|
141.1 |
g |
1.79 |
5.67 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
138880 |
3292 |
F344/StmMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 42 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
63 days
| 9 |
|
|
141.44 |
g |
1.17 |
3.5 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139439 |
3292 |
F344/StmMcwi |
body weight |
controlled bisphenol F content drinking water (1.125 mg/l) (for 49 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
female |
70 days
| 9 |
|
|
149.89 |
g |
1.15 |
3.44 |
body weighing method |
|
|
0 |
|
weight scale |
Body weight |
Changed sex from F to female to standardize across records, 7-30-2024 |
|
139440 |
3292 |
ACI/EurMcwi |
body mass index (BMI) |
controlled ethanol content drinking water used as vehicle (0.1 %) (for 70 days) |
Wagner VA, etal., Toxicol Sci. 2023 Jun 28;194(1):84-100. doi: 10.1093/toxsci/kfad046. |
body mass |
male |
91 days
| 12 |
|
|
0.49 |
g/cm2 |
0.0 |
0.01 |
body weighing method |
|
|
0 |
|
"weight scale, tape measure" |
Body Mass Index (BMI) |
Changed sex from M to male to standardize across records, 7-30-2024 |
|
138807 |
3292 |